pemetrexed profile

pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

theonellamide A: from Theonella marine sponges; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	135410875
CHEMBL ID	225072
CHEBI ID	63616
SCHEMBL ID	7968
MeSH ID	M0227083
PubMed CID	45382315
CHEMBL ID	3908274
MeSH ID	M0227083

Synonym
nsc-698037
nsc698037
ly231514
alimta
ly-231514
pemetrexed disodium
alimta (tn)
2-{4-[2-(2-amino-4-oxo-4,7-dihydro-3h-pyrrolo[2,3-d]pyrimidin-5-yl)-ethyl]-benzoylamino}-pentanedioic acid
LYA ,
DB00642
1JUJ
l-glutamic acid,3-d]pyrimidin-5-yl]ethyl]benzoyl]-
alimta (tn) (lilly)
pemetrexed ,
pemetrexed [inn:ban]
n-(4-(2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
hsdb 7316
l-glutamic acid, n-(4-(2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-
NCGC00167517-01
137281-23-3
(2s)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
CHEMBL225072
pemetrexed (tn)
D07472
pemetrexed (inn)
chebi:63616 ,
us9422297, pemetrexed
bdbm50027656
ly-2315
A807228
n-[4-[2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid disodium salt;pemetrexed
NCGC00242485-01
n-[4-[2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid
n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid
n-[4-[2(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid
04q9aiz7no ,
unii-04q9aiz7no
premetrexed [common mis-spelling]
HY-10820
CS-1297
(s)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid
n-{4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-l-glutamic acid
n-(4-(2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-l-glutamic acid
pemfexy
l-glutamic acid, n-(4-(2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-
pemetrexed [hsdb]
pemetrexed [orange book]
pemetrexed [vandf]
pemetrexed [mi]
pemetrexed [who-dd]
pemetrexed [inn]
n-(p-(2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-l-glutamate
pemetrexed [ema epar]
AKOS015896253
S5971
n-(4-[2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl)-l-glutamic acid
n-[4-[2(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo [2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid
n-[4-[2-[2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl]ethyl]benzoyl]glutamic acid
WBXPDJSOTKVWSJ-ZDUSSCGKSA-N
SCHEMBL7968
AB01273937-01
(s)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid
J-502393
DTXSID2048329 ,
P2288
(2s)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
ly-231514 disodium hydrate
AC-1701
(s)-2-(4-(2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo-[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedioic acid
(2s)-2-{[4-(2-{2-amino-4-oxo-3h,4h,7h-pyrrolo[2,3-d]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioic acid
n-({4-[2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]phenyl}carbonyl)-l-glutamic acid
Q415220
n-[4-[2-(2-amino-3,4-dihydro-4-oxo-7h-pyrrolo[2,3-d]pyrimi-din-5-yl)ethyl]benzoyl]l-glutamic acid
1006872-74-7
AS-30680
NCGC00166414-11
l-glutamic acid, n-[4-[2-(2-amino-4,7-dihydro-4-oxo-3h-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-
AKOS016842348
pemetrexed- bio-x
BP164240
EN300-7396246
pemetrexedum
premetrexed (common mis-spelling)
multitargeted antifolate
dtxcid7028304
l-glutamic acid, n-(4-(2-(2-amino-4,7-dihydro-4-oxo-1h-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)
pemetrexed for injection
n-(4-(2-(2-amino-4-oxo-4,7-dihydro-1h-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoyl)-l-glutamic acid
theonellamide a
CHEMBL3908274

Excerpt	Reference	Relevance
" The LD50 occurred at 60- and 250-fold lower doses of LY231514 in DBA/2 and CD1 nu/nu mice, respectively, maintained on low folate diet compared to standard diet."	( Role of folic acid in modulating the toxicity and efficacy of the multitargeted antifolate, LY231514. Schultz, RM; Shih, C; Worzalla, JF, )	0.13
" No unexpected adverse events were noted."	( Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A, 2007)	0.34
" Many drugs have been used for the treatment of this disease, but there is little information about how predictive factors can be used to aid treatment response and anticipate toxic effects related to anticancer treatment in colorectal cancer."	( Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer. Pantano, F; Santini, D; Schiavon, G; Tonini, G; Vincenzi, B, 2008)	0.35
" Main adverse drug reactions of severity grade 3 or 4 were neutrophil count decreased (20."	( Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Adachi, S; Fujimoto, T; Fukuoka, M; Ichinose, Y; Kubota, K; Nakagawa, K; Nambu, Y; Nishiwaki, Y; Ohe, Y; Saijo, N; Tamura, T; Yamamoto, N, 2008)	0.35
"Addition of bevacizumab to various chemotherapy agents or erlotinib in patients with NSCLC and treated brain metastases seems to be safe and is associated with a low incidence of CNS hemorrhage."	( Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. Akerley, W; Compton, P; Huang, JE; Kolb, MM; Langer, CJ; Socinski, MA; Wang, L, 2009)	0.35
" Dermatitis acneiform, diarrhea, nausea, and vomiting were the most frequently reported adverse events with AZD6244, compared with fatigue, anemia, nausea, anorexia, and dermatitis acneiform with pemetrexed."	( A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. Cebotaru, CL; Ciuleanu, TE; Damyanov, D; Ganchev, H; Hainsworth, JD; Kanarev, V; Morris, C; Pover, G; Stella, P; Tzekova, V, 2010)	0.36
" At each cycle, adverse events were assessed, and concomitant medications, transfusions, and hospitalizations were recorded."	( Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer. Douillard, JY; Eckardt, J; Liepa, AM; Novello, S; O'Brien, M; Paz-Ares, L; Pimentel, FL; Simms, L; Visseren-Grul, C; von Pawel, J, 2010)	0.36
" The most frequent AEs were gastrointestinal adverse events, skin rash, fever and fatigue."	( [The efficacy and safety of pemetrexed as monotherapy for Chinese patients with advanced non-small cell lung cancer]. Li, LY; Wang, MZ; Zhang, L; Zhang, XT; Zhao, J; Zhong, W, 2010)	0.36
"The no observed adverse effect level of intrathecal administration of pemetrexed was 1 mg/kg in rats."	( Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. Ahn, JS; Ahn, MJ; Chung, JY; Im, B; Lee, SY; Nam, MH; Park, K; Suh, YL; Sun, JM, 2011)	0.37
" Safety and tolerability were evaluated by recording the incidence of adverse events (AE) according to Common Toxicity Criteria for AE (CTCAE)."	( A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. Chouaid, C; Morris, T; Nathan, F; Pemberton, K, 2011)	0.37
"Objective of this indirect economic comparison was to estimate and compare management costs of grade 3/4 adverse events (AEs) reported for first-line erlotinib or pemetrexed maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC)."	( Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain. Banz, K; Bischoff, H; Brunner, M; Chouaid, C; de Castro Carpeño, J; de Marinis, F; Grossi, F; Vergnenègre, A; Walzer, S, 2011)	0.37
" Taken together, the data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors."	( Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Eulitt, P; Fisher, PB; Grant, S; Hamed, HA; Hubbard, N; Moran, RG; Nephew, KP; Park, MA; Tang, Y; Tye, G; Yacoub, A, 2011)	0.37
" Taken together, the data suggest that premexetred and sorafenib act synergistically to enhance tumor killing via the promotion of a toxic form of autophagy that leads to activation of the intrinsic apoptosis pathway, and predict that combination treatment represents a future therapeutic option in the treatment of solid tumors."	( Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y, 2011)	0.37
" Pemetrexed was reasonably well tolerated with few severe adverse events reported."	( Efficacy and safety of pemetrexed maintenance therapy versus best supportive care in patients from East Asia with advanced, nonsquamous non-small cell lung cancer: an exploratory subgroup analysis of a global, randomized, phase 3 clinical trial. Belani, CP; Chen, YM; Kim, JH; Orlando, M; Peterson, P; Wu, YL; Yang, SH; Zhang, L, 2012)	0.38
" Rash (98/196 [50%] in the erlotinib group vs 10/213 [5%] in the chemotherapy group for all grades; nine [5%] vs none for grade 3 or 4) and diarrhoea (36 [18%] vs four [2%] for all grades; five [3%] vs none for grade 3 or 4) were the most common treatment-related adverse events with erlotinib, whereas alopecia (none vs 23 [11%] for all grades; none vs one [<1%] for grade 3/4) was the most common treatment-related adverse event with chemotherapy."	( Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study. Cicenas, S; Ciuleanu, T; Gonzalez, EE; Grigorescu, AC; Hillenbach, C; Johannsdottir, HK; Klughammer, B; Miliauskas, S; Stelmakh, L, 2012)	0.38
" The most common adverse reactions (incidence ≥ 20%) with single-agent use are fatigue, nausea, and anorexia."	( Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment. Katsenos, S; Panagou, C; Psara, A, 2013)	0.39
" However, it has been reported to have adverse interactions with nonsteroid anti-inflammatory drugs(NSAIDs)."	( [Adverse events during pemetrexed administration caused by concomitant nonsteroid anti-inflammatory therapy]. Hiraki, K; Inata, J; Iwamoto, Y; Kanehara, M; Kitaguchi, S; Matsumoto, S; Miyamori, S; Nakashima, K; Sakamoto, S; Sakata, Y, 2012)	0.38
"Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC)."	( [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer]. Cheng, G; Hu, C; Hu, X; Huang, C; Jiao, S; Li, K; Luo, R; Lv, W; Ouyang, X; Sun, Y; Wang, J; Wang, M; Wang, Y; Wang, Z; Zhang, S; Zheng, R, 2012)	0.38
" The rate of adverse reactions, including white blood cell reduction, lower platelet count, lower hemoglobin, and hair loss in the PP group was significantly lower than that in the GP group."	( [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer]. Cheng, G; Hu, C; Hu, X; Huang, C; Jiao, S; Li, K; Luo, R; Lv, W; Ouyang, X; Sun, Y; Wang, J; Wang, M; Wang, Y; Wang, Z; Zhang, S; Zheng, R, 2012)	0.38
"The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group."	( [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer]. Cheng, G; Hu, C; Hu, X; Huang, C; Jiao, S; Li, K; Luo, R; Lv, W; Ouyang, X; Sun, Y; Wang, J; Wang, M; Wang, Y; Wang, Z; Zhang, S; Zheng, R, 2012)	0.38
"Rash is a common side effect of pemetrexed(PEM)."	( [Effectiveness of steroids for the rash side effect of pemetrexed]. Ishikawa, H; Kobayashi, R; Ohashi, Y; Onishi, T; Shino, M; Suzuki, K; Yamamoto, N, 2013)	0.39
" In this study, we aimed to determine the risk factors for severe adverse events associated with pemetrexed administration."	( Analysis of risk factors for severe adverse events of chemotherapy with pemetrexed and comparison of adverse event occurrence according to renal function. Abe, K; Hiraki, K; Inata, J; Iwamoto, Y; Kanehara, M; Miyamori, S; Sakata, Y, 2013)	0.39
"To assess whether adjuvant chemotherapy alters pulmonary function and impacts on treatment-related adverse events."	( Impact and safety of adjuvant chemotherapy on pulmonary function in early stage non-small cell lung cancer. Eberhardt, W; Fischer, JR; Griesinger, F; Herth, FJ; Kreuter, M; Reinmuth, N; Thomas, M; Vansteenkiste, J; Zuna, I, 2014)	0.4
" The most frequent adverse reactions were: hematological, gastrointestinal and neurological."	( Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer. Bautista-Paloma, FJ; Cotrina-Luque, J; Flores-Moreno, S; Galván-Banqueri, M; Pérez-Moreno, MA; Villalba-Moreno, A, 2014)	0.4
" Multivariate analysis demonstrated that a heavy smoking history (40 or more pack-year smoking history) was an independent adverse prognostic factor for OS."	( Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. Ahn, JS; Ahn, MJ; Chang, W; Choi, MK; Chung, MP; Hong, JY; Jung, HA; Kim, M; Kim, S; Lee, SJ; Park, K; Park, S; Sun, JM, 2014)	0.4
" The incidence rate of adverse drug reactions(ADR)was 76."	( [Safety and effectiveness of pemetrexed in patients with non-small cell lung cancer in Japan - analysis of post-marketing surveillance]. Enatsu, S; Kaneko, N; Kobayashi, N; Nishiuma, S; Okubo, S; Taketsuna, M, 2014)	0.4
" Patients who received pemetrexed maintenance (median 4 cycles, range 1-44) following 4 cycles of pemetrexed-cisplatin exhibited a higher incidence of drug-related serious adverse events compared with JMDB patients (median 6 cycles of pemetrexed-cisplatin) (10."	( Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials. Chouaki, N; de Marinis, F; Dediu, M; Gridelli, C; John, W; Manegold, C; Paz-Ares, LG; Peterson, PM; Pujol, JL; San Antonio, B; Scagliotti, GV; Thomas, M; Visseren-Grul, C, 2014)	0.4
" Adverse events (by maximum Common Terminology Criteria for Adverse Events [CTCAE] grade) and QoL (EuroQol 5-dimensional [EQ-5D] scale) were assessed."	( Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamou Bidoli, P; Chouaki, N; Corral, J; de Marinis, F; Dediu, M; Gridelli, C; John, W; Paz-Ares, L; Pujol, JL; San Antonio, B; Thomas, M; Visseren-Grul, C; Zimmermann, A, 2014)	0.4
" Herein, we retrospectively investigated the background characteristics of patients with a creatinine clearance rate (Ccr) of<45 mL/min, who experienced severe adverse events due to pemetrexed."	( [Assessment of risk factors for adverse events due to pemetrexed in patients with reduced renal function]. Abe, K; Funaki, M; Hata, Y; Hiraki, K; Inata, J; Iwamoto, Y; Kanehara, M; Kono, M; Miura, S; Miyamori, S; Sakata, Y; Sugawara, T, 2014)	0.4
" The main side effect of pemetrexed is myelosuppression, which may be prevented by folinic acid supplementation."	( [Pemetrexed nephrotoxicity]. Izzedine, H, 2015)	0.42
" Therefore, the adverse events were mostly mild."	( [Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for Japanese patients with advanced non-squamous non-small-cell lung cancer -- a retrospective analysis]. Hayashi, M; Hoshino, T; Imaizumi, K; Isogai, S; Kato, A; Mieno, Y; Minezawa, T; Morikawa, S; Morishita, M; Nakanishi, T; Niwa, Y; Okamura, T; Okazawa, M; Takeyama, T; Uozu, S; Yamaguchi, T, 2015)	0.42
" These results suggest that encapsulation of PMX within "fluid" liposomes might represent a novel strategy to enhance the therapeutic efficacy of PMX while minimizing the side effect encountered by the non selective delivery of free PMX to various body tissues."	( Liposomal pemetrexed: formulation, characterization and in vitro cytotoxicity studies for effective management of malignant pleural mesothelioma. Elnahas, HM; Essam Eldin, N; Ishida, T; Mahdy, MA, 2015)	0.42
" We analyzed adverse effects, such as myelosuppression, rash, and diarrhea, after 1 cycle of pemetrexed therapy."	( [Safety of pemetrexed according to the duration of vitamin B12 and folic acid supplementation prior to the first dose of pemetrexed]. Chohnabayashi, N; Gotoh, K; Jinta, T; Kitamura, A; Koyama, K; Nishimura, N; Ohde, S; Okafuji, K; Takayama, S; Tomishima, Y; Tsuda, Y; Yagi, N, 2015)	0.42
" Five patients experienced at least 1 treatment-related Grade 3 adverse event."	( Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. Diefenbach, K; Gettinger, SN; Hellmann, MD; Lettieri, J; Rizvi, NA; Sturm, I; Trnkova, ZJ, 2015)	0.42
"Grade 3 or 4 neoadjuvant-related adverse events included fatigue (3 patients), neutropenia (3 patients), hypertension (1 patient)."	( [Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin  in Patients with IIIa Lung Adenocarcinoma]. Ou, W; Xu, P; Yuan, C; Zhang, S, 2015)	0.42
"The treatment modality of neoadjuvant Bev-PC appears to be safe and tolerant in patients with stage IIIa lung adenocarcinoma."	( [Safety of Neoadjuvant Bevacizumab plus Pemetrexed and Carboplatin  in Patients with IIIa Lung Adenocarcinoma]. Ou, W; Xu, P; Yuan, C; Zhang, S, 2015)	0.42
"Erlotinib appears to be a useful second-line option in PS0/1 patients with EGFR mutation-negative advanced non-squamous NSCLC given its mild adverse effects."	( Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. Fujita, S; Hata, A; Iwasaku, M; Katakami, N; Korogi, Y; Mori, M; Morita, S; Namba, Y; Nishino, K; Nishiyama, A; Okuyama, T; Otsuka, K; Takeshita, J; Uchida, J; Yoshioka, H, 2015)	0.42
" The two groups were compared in terms of median survival and adverse events to chemotherapy."	( The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma. Ak, G; Akarsu, M; Metintas, M; Metintas, S, 2015)	0.42
"The study indicates that platinum-based gemcitabine is effective and a safe schema in malignant pleural mesothelioma."	( The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma. Ak, G; Akarsu, M; Metintas, M; Metintas, S, 2015)	0.42
" Grade 3-4 adverse events included leukopenia (2/39), and neutropenia (3/39) in first-line therapy versus neutropenia (1/40) and thrombocytopenia (2/40) in second-line treatment."	( A retrospective analysis of efficacy and safety of adding bevacizumab to chemotherapy as first- and second-line therapy in advanced non-small-cell lung cancer (NSCLC). Chen, N; Fang, W; Hu, Z; Huang, J; Quan, R; Zhan, J; Zhang, H; Zhang, L; Zhou, T, 2016)	0.43
" Our results would aid clinicians to make decisions of coadministration drugs to avoid drug interaction-induced side effects for achievement of safe and appropriate chemotherapy with pemetrexed."	( Lansoprazole Exacerbates Pemetrexed-Mediated Hematologic Toxicity by Competitive Inhibition of Renal Basolateral Human Organic Anion Transporter 3. Enokiya, T; Fujimoto, H; Hamada, Y; Ikemura, K; Iwamoto, T; Kaya, C; Kobayashi, T; Muraki, Y; Nakahara, H; Okuda, M, 2016)	0.43
" Four important transporter genes are expressed in the kidney, including organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), ATP-binding cassette subfamily B member 1 (ABCB1), and ATP-binding cassette subfamily C member 2 (ABCC2), and genetic polymorphisms in these genes may alter the efficacy and adverse effects of platinum drugs."	( Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-sma Chen, J; Liu, JY; Liu, ZQ; Qian, CY; Wang, Y; Yin, JY; Zheng, Y; Zhou, HH, 2016)	0.43
" Areas covered: There is clinical evidence which suggsest that, like other chemotherapeutic agents, not all HGOS patients are equally responsive to antifolates and do not have the same susceptibility to experience adverse drug-related toxicities."	( Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma. Fanelli, M; Hattinger, CM; Picci, P; Serra, M; Tavanti, E; Vella, S, 2017)	0.46
" Select adverse events (those with a potential immunologic cause) of any grade were observed in six, four, six, and five patients in arms A, B, C, and D, respectively."	( Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N, 2016)	0.43
" A higher incidence of some adverse events was observed with onartuzumab versus placebo, including peripheral edema (30% vs."	( Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. Boyer, M; Braiteh, F; Cosgriff, T; De Braud, F; Hsu, J; Kaen, D; Kingsley, CD; Lawler, W; Lena, H; Lowe, T; Mekhail, T; Novello, S; Phan, S; Schütte, W; Wakelee, H; Zvirbule, Z, 2017)	0.46
" We collected patients´ baseline characteristics, diagnostic and treatment data, effectiveness variables (response to treatment with pemetrexed and overallsurvival) and main adverse reactions detected."	( Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System. Bautista-Paloma, FJ; Calleja-Hernández, MÁ; Cotrina-Luque, J; Flores-Moreno, S; Galván-Banqueri, M; Pérez-Moreno, MA, 2016)	0.43
" Main adverse reactions detected were asthenia, haematological reactions, gastrointestinal reactions and dermal o mucous toxicity."	( Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System. Bautista-Paloma, FJ; Calleja-Hernández, MÁ; Cotrina-Luque, J; Flores-Moreno, S; Galván-Banqueri, M; Pérez-Moreno, MA, 2016)	0.43
" Patient characteristics and incidence of adverse events (AEs) were described for each cohort."	( Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study. Chen, J; Chen, L; Goodloe, RJ; John, WJ; San Antonio, B; Yan, Y, 2017)	0.46
"This meta-analysis compared safety profiles (selected drug-related treatment-emergent adverse events [TEAEs]) of first-line pemetrexed plus carboplatin (PCb) area under the concentration-time curve 5 mg/min•mL (PCb5) or 6 mg/min•mL (PCb6), two widely used regimens in clinical practice for advanced non-squamous non-small cell lung cancer."	( Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies. Chen, J; John, WJ; Liu, J; Okamoto, I; Rodrigues-Pereira, J; San Antonio, B; Schuette, WH; Stinchcombe, TE; Zinner, RG, 2017)	0.46
"In a phase III study, maintenance pemetrexed showed superior survival over placebo (PARAMOUNT) for patients with advanced non-squamous non-small cell lung cancer (NSCLC) who completed 4 cycles of pemetrexed plus cisplatin (PC) induction therapy, with low incidence of treatment-emergent adverse events (TEAEs) generally associated with pemetrexed."	( Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies. Chen, J; de Marinis, F; Gridelli, C; Langer, CJ; Liu, J; Oton, AB; Paz-Ares, LG; Pujol, JL; San Antonio, B; Scagliotti, GV; Visseren-Grul, C; Wozniak, AJ, 2017)	0.46
"All 66 treated patients experienced at least one adverse event (AE)."	( A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-s Adjei, AA; Bahleda, R; Besse, B; Dy, GK; Ferte, C; Groen, HJM; Lin, W; Morrissey, K; Planchard, D; Schutzman, JL; Shankar, G; Soria, JC; Ware, J; Zhou, J, 2017)	0.46
" Pemetrexed is generally well tolerated, but individual-patient differences exist in severity of adverse events."	( Severity and predictive factors of adverse events in pemetrexed-containing chemotherapy for non-small cell lung cancer. Abe, T; Iwanaga, K; Kimura, S; Komiya, K; Matsunaga, H; Miyahara, T; Nakamura, T; Nakashima, C; Sueoka-Aragane, N; Ureshino, N, 2017)	0.46
" However, polymorphisms of MTHFR C677T were not significantly associated with other adverse events and clinical outcomes."	( Correlation Between Methylenetetrahydrofolate Reductase (MTHFR) C677T Polymorphisms and Pemetrexed Chemotherapy Efficacy/Toxicity in Non-Squamous Non-Small Cell Lung Cancer. Chen, L; Chen, X; Lan, G; Lin, L, 2017)	0.46
" Bevacizumab was administered at a dose of 100 mg intravenously once a week combined with one or two types of chemotherapeutic drugs until confirmed disease progression or an intolerable adverse event was observed."	( Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer. Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C, 2018)	0.48
" The most common hematological adverse events were neutropenia, anemia, and thrombocytopenia."	( Analysis of the activity and safety of weekly low-dose bevacizumab-based regimens in heavily pretreated patients with metastatic breast cancer. Chen, J; Fan, Y; Hong, R; Ma, F; Ou, K; Sang, D; Wang, J; Xu, B; Yuan, P; Zhai, X; Zhao, C, 2018)	0.48
"Recombinant human endostatin (rh-endostatin) plus standard chemotherapy in advanced non-small cell lung cancer (NSCLC) patients has shown improved efficacy; however, it is unclear whether it is effective and safe when added to pemetrexed/cisplatin and used as maintenance therapy."	( Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy. He, X; Jin, J; Pi, J; Shi, Y; Zhou, S; Zuo, L, 2018)	0.48
"032) or in the incidence of drug-related or grade 3-4 adverse events."	( Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy. He, X; Jin, J; Pi, J; Shi, Y; Zhou, S; Zuo, L, 2018)	0.48
" Some studies have suggested that concomitant drugs may be the risk factors for severe adverse events."	( Effects of proton pump inhibitors on severe haematotoxicity induced after first course of pemetrexed/carboplatin combination chemotherapy. Araki, R; Hamamoto, T; Keira, T; Masuda, Y; Tanaka, T; Yamada, H, 2019)	0.51
" Adverse events were recorded."	( Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. Germonpré, P; Van den Wyngaert, T, 2019)	0.51
"9%) of patients due to adverse events, which were treatment related in 7%."	( Second-line erlotinib after failure of pemetrexed-containing chemotherapy in advanced non-small cell lung cancer (NSCLC): Real-world effectiveness, safety and tolerability. Germonpré, P; Van den Wyngaert, T, 2019)	0.51
" No unexpected severe adverse events or treatment-related deaths occurred."	( Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer. Fujiwara, Y; Goto, Y; Horinouchi, H; Kanda, S; Nokihara, H; Ohe, Y; Tamura, T; Yamamoto, N; Yamamoto, T, 2020)	0.56
" This review aims to describe the underlying mechanisms of the renal adverse effects caused by chemotherapy and ICI therapy, leading to a suggested diagnostic and treatment algorithm on the basis of clinical, laboratory, radiographic, and pathologic parameters."	( Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC. Aerts, JGJV; Cornelissen, R; Dumoulin, DW; van Gelder, T; Vansteenkiste, J; Visser, S; von der Thusen, J, 2020)	0.56
" As it is primarily eliminated by renal excretion, adequate renal function is essential to prevent toxic exposure."	( Cumulative pemetrexed dose increases the risk of nephrotoxicity. Biesma, B; Boosman, RJ; Burger, DM; de Rouw, N; Derijks, HJ; Hilbrands, LB; Ter Heine, R; van de Bruinhorst, H; van den Heuvel, MM, 2020)	0.56
"Search the online electronic databases on comparison the effectiveness and adverse effects of pemetrexed versus gefitinib in therapy outcomes of pre-treated NSCLC to September 2019."	( A meta-analysis of the safety and effectiveness of pemetrexed compared with gefitinib for pre-treated advanced or metastatic NSCLC. Chen, W; Li, F; Li, S; Li, Y; Lu, X; Zheng, D, 2020)	0.56
" The incidence of grade 3 or higher adverse events was 61."	( Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). Bi, M; Cang, S; Chen, G; Cheng, Y; Fang, J; Feng, J; Han, B; He, Z; Li, B; Li, J; Li, W; Lu, Y; Ma, R; Mei, X; Ren, X; Song, Y; Wang, L; Wang, S; Wang, Y; Wang, Z; Xie, C; Yang, N; Yang, Y; Yang, Z; Yu, Q; Yu, Z; Zhang, L; Zhang, W; Zhang, Y; Zhao, Y; Zhou, H; Zhou, J; Zhou, R; Zhu, D, 2020)	0.56
" Bevacizumab plus cisplatin/pemetrexed has been shown to be safe and effective in non-small cell lung cancer, however, there are no efficacy or safety data in Japanese patients with MPM treated with this regimen."	( Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study. Hayashi, M; Hirabayashi, M; Hirano, K; Kondo, M; Kuribayashi, K; Morise, M; Nakano, T; Tada, Y; Tanaka, M, 2021)	0.62
"Eligible patients (n = 7) received bevacizumab plus cisplatin/pemetrexed (up to six cycles), then single-agent bevacizumab until disease progression or onset of unacceptable adverse events (AEs), according to the 3+3 design analogy."	( Bevacizumab plus cisplatin/pemetrexed then bevacizumab alone for unresectable malignant pleural mesothelioma: A Japanese safety study. Hayashi, M; Hirabayashi, M; Hirano, K; Kondo, M; Kuribayashi, K; Morise, M; Nakano, T; Tada, Y; Tanaka, M, 2021)	0.62
" For patients with evacuated third-space fluid, these adverse effects were nullified."	( Haematological toxicity of pemetrexed in patients with metastatic non-squamous non-small cell carcinoma of lung with third-space fluid. Cheong, TF; Chiang, KY; Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC, 2021)	0.62
" We present two cases of RION that happened in seemingly safe radiation doses."	( Necrosis of the optic nerve and chiasm with safe radiation doses: Report of two rare cases. Abri Aghdam, K; Aghajani, A; Khosravi Farsani, M; Moghadasi, M; Soltan Sanjari, M, 2022)	0.72
"The primary endpoint was the 1-year survival rate, with secondary endpoints of response rate (RR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse event rate."	( Efficacy and safety of carboplatin and pemetrexed followed by maintenance with pemetrexed for elderly patients with advanced non-squamous non-small cell lung cancer: A single-arm, open-label, multicenter, phase II study. Hara, Y; Kaneko, T; Kobayashi, N; Manabe, S; Miyazawa, N; Murakami, S; Nishikawa, M; Saito, H; Shinkai, M; Shinoda, M; Tomaru, K, 2021)	0.62
"This post hoc analysis assessed the safety of pemetrexed and platinum in combination with pembrolizumab, including time-to-onset and time-to-resolution of all-cause any-grade and grade ≥3 adverse events (AEs) and renal AEs."	( Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. Aerts, J; Gadgeel, SM; Garon, EB; Kim, JS; Muehlenbein, CE; Peterson, P; Rizzo, MT, 2021)	0.62
" These results support the safe use of the KEYNOTE-189 regimen in clinical practice."	( Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. Aerts, J; Gadgeel, SM; Garon, EB; Kim, JS; Muehlenbein, CE; Peterson, P; Rizzo, MT, 2021)	0.62
"A monocentric comparative before/after study was carried out in an oncology day hospital to evaluate the efficacy of Safe Infusion Devices in reducing drug exposure compared to usual infusion practices."	( Evaluation of a safe infusion device on reducing occupational exposure of nurses to antineoplastic drugs: a comparative prospective study. Contamoins-1. Blanc, E; Bouleftour, W; Forges, F; Guitton, J; Hugues, M; Macé, A; Macron, C; Menguy, S; Raymond, B; Simoëns, X; Tinquaut, F, 2021)	0.62
"3% of contaminated samples while Safe Infusion Devices to a rate of 15%: Safe Infusion Devices reduced the risk of gloves contamination by 85% in multivariate analysis (Odds ratio = 0."	( Evaluation of a safe infusion device on reducing occupational exposure of nurses to antineoplastic drugs: a comparative prospective study. Contamoins-1. Blanc, E; Bouleftour, W; Forges, F; Guitton, J; Hugues, M; Macé, A; Macron, C; Menguy, S; Raymond, B; Simoëns, X; Tinquaut, F, 2021)	0.62
"Despite the current practice of using neutral solvent-purged infusers, the occupational exposure remains high for nurses and Safe Infusion Devices significantly reduced this risk of exposure."	( Evaluation of a safe infusion device on reducing occupational exposure of nurses to antineoplastic drugs: a comparative prospective study. Contamoins-1. Blanc, E; Bouleftour, W; Forges, F; Guitton, J; Hugues, M; Macé, A; Macron, C; Menguy, S; Raymond, B; Simoëns, X; Tinquaut, F, 2021)	0.62
" Treatment response, European Organization for Research and Treatment of Cancer QoL Questionnaire-Core 30 (EORTC QLQ-C30), progression-free survival (PFS), overall survival (OS), and adverse events were assessed during the follow-up."	( Drug-eluting bead bronchial arterial chemoembolization vs. chemotherapy in treating advanced non-small cell lung cancer: comparison of treatment efficacy, safety and quality of life. Bao, PT; Lin, H; Liu, XF; Mu, M; Pan, P; Tian, FF; Wang, Q; Zhang, R; Zhao, WG, 2021)	0.62
" Furthermore, two groups all exhibited mild and tolerable adverse events."	( Drug-eluting bead bronchial arterial chemoembolization vs. chemotherapy in treating advanced non-small cell lung cancer: comparison of treatment efficacy, safety and quality of life. Bao, PT; Lin, H; Liu, XF; Mu, M; Pan, P; Tian, FF; Wang, Q; Zhang, R; Zhao, WG, 2021)	0.62
" Overall survival and adverse events (AEs) were evaluated as secondary end points."	( Efficacy and Safety of Intrathecal Pemetrexed Combined With Dexamethasone for Treating Tyrosine Kinase Inhibitor-Failed Leptomeningeal Metastases From EGFR-Mutant NSCLC-a Prospective, Open-Label, Single-Arm Phase 1/2 Clinical Trial (Unique Identifier: Chi Du, Y; Fan, C; Gao, F; Gao, N; Huang, D; Jiang, Q; Jiang, Z; Jin, Y; Li, L; Lv, Y; Shen, W; Shi, T; Song, X; Teng, C; Wei, L; Xin, T; Zhao, Q; Zhao, X, 2021)	0.62
" The endpoints were progression-free survival (PFS), overall survival (OS) and adverse events (AEs)."	( The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials. Fang, Z; Liu, M; Liu, Q; Luo, N; Wei, Y; Yi, F; Zhang, W; Zhang, X, 2022)	0.72
" Regarding adverse events (AEs), the Bev+Pem group exhibited an increased occurrence of anaemia, fatigue, thrombocytopenia and anorexia."	( The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials. Fang, Z; Liu, M; Liu, Q; Luo, N; Wei, Y; Yi, F; Zhang, W; Zhang, X, 2022)	0.72
" OS and treatment-emergent adverse events (TEAEs) were analyzed in both groups by treatment duration."	( Overall Survival and Safety With Pemetrexed/Platinum ± Anti-VEGF Followed by Pemetrexed ± Anti-VEGF Maintenance in Advanced Nonsquamous Non-Small-Cell Lung Cancer: A Pooled Analysis of 4 Randomized Studies. Garon, EB; Kim, JS; Peterson, P; Rizzo, MT, 2022)	0.72
" Safety was assessed by adverse events (AEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)."	( Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. Cao, S; Han, B; Ling, X; Wang, H; Xu, J; Zhang, B; Zhang, X; Zhong, H; Zhong, R, 2022)	0.72
" In consideration of safety, the most frequent adverse events were peripheral neuropathy (37."	( Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients. Bao, Q; Chen, Y; Deng, R; Fu, Y; He, Y; Huang, M; Li, C; Liu, M; Liu, Y; Lv, J; Lv, Z; Miao, Y; Wang, F; Wang, L; Wang, Q; Zhang, C; Zhang, T; Zhang, W; Zhang, Z; Zhao, X; Zhou, H, 2022)	0.72
"Camrelizumab plus CP chemotherapy achieves favourable efficacy and tolerable adverse events in advanced lung adenocarcinoma patients."	( Efficacy, safety and prognostic factors of camrelizumab plus carboplatin and pemetrexed chemotherapy in advanced lung adenocarcinoma patients. Bao, Q; Chen, Y; Deng, R; Fu, Y; He, Y; Huang, M; Li, C; Liu, M; Liu, Y; Lv, J; Lv, Z; Miao, Y; Wang, F; Wang, L; Wang, Q; Zhang, C; Zhang, T; Zhang, W; Zhang, Z; Zhao, X; Zhou, H, 2022)	0.72
" However, its development is still restricted by low targeting, high dose and toxic side effects."	( A multimodal Metal-Organic framework based on unsaturated metal site for enhancing antitumor cytotoxicity through Chemo-Photodynamic therapy. Ding, Q; Li, B; Li, W; Liu, J; Muddassir, M; Ouyang, Q; Rao, C; Sakiyama, H; Xu, Z; Zhou, L, 2022)	0.72
" Moreover, the most common adverse events related to camrelizumab plus CP were fatigue (45."	( Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety. Cao, H; Lu, Y; Wei, W, 2022)	0.72
"Camrelizumab plus chemotherapy exhibits good efficacy and manageable adverse events in treating advanced non-squamous NSCLC patients."	( Camrelizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: Treatment response, survival pattern, and safety. Cao, H; Lu, Y; Wei, W, 2022)	0.72
" Among the various adverse events, renal toxicity can be a relevant safety issue."	( Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience. Aprile, M; Ardizzoni, A; Borelli, G; Busutti, M; Campus, A; Croci Chiocchini, AL; De Giglio, A; Di Federico, A; Gelsomino, F; Grandinetti, V; La Manna, G; Melotti, B; Sperandi, F; Vischini, G, 2022)	0.72
"Renal toxicity represents a challenging adverse event that could negatively impact outcomes of metastatic nonsquamous NSCLC patients receiving CT/ICI demanding a multidisciplinary approach."	( Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience. Aprile, M; Ardizzoni, A; Borelli, G; Busutti, M; Campus, A; Croci Chiocchini, AL; De Giglio, A; Di Federico, A; Gelsomino, F; Grandinetti, V; La Manna, G; Melotti, B; Sperandi, F; Vischini, G, 2022)	0.72
"6%) had a grade 3 or 4 treatment-related adverse event (AE), and one (1."	( Final results of DIADEM, a phase II study to investigate the efficacy and safety of durvalumab in advanced pretreated malignant pleural mesothelioma. Belletti, M; Bono, F; Bonomi, M; Canova, S; Carlucci, L; Ceresoli, GL; Cortinovis, DL; D'Aveni, A; De Angelis, A; De Simone, I; Galli, F; Gelsomino, F; Grosso, F; Mencoboni, M; Pasello, G; Perrino, M; Rulli, E; Zucali, PA, 2022)	0.72
" Patients who experienced toxicity of grade 3 or 4 according to the Common Terminology Criteria for Adverse Events v5."	( Predictive factors associated with pemetrexed acute toxicity. Arrondeau, J; Batista, R; Blanchet, B; Bonnet, M; Boudou-Rouquette, P; Goldwasser, F; Jouinot, A; Seif, V; Thomas-Schoemann, A; Vidal, M; Villeminey, C; Wislez, M, 2023)	0.91

Excerpt	Reference	Relevance
" infusion over 10 minutes for 5 days, repeated every 3 weeks, was conducted to evaluate the maximum tolerated dose, pharmacokinetic profile, and antitumor activity of the drug using this schedule."	( A phase I and pharmacokinetic study of LY231514, the multitargeted antifolate. Abrahams, T; Adams, L; Bailey, NP; Calvert, AH; Cassidy, J; Kaye, SB; Lind, MJ; McCarthy, S; McDonald, AC; Siddiqui, N; Twelves, CJ; Vasey, PA; Walling, J; Woodworth, JR, 1998)	0.3
" Plasma concentration-time data were analyzed by nonlinear mixed-effect modeling using NONMEM to estimate pemetrexed disodium pharmacokinetic parameters (mean, and between- and within-patient variability) as well as relationships between the pharmacokinetic parameters and various patient-specific factors (demographic and physiologic data)."	( Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Johnson, RD; Lalonde, RL; Ouellet, D; Periclou, AP; Woodworth, JR, 2000)	0.31
" In conclusion, population pharmacokinetic modeling revealed relationships between pharmacokinetic parameters and various patient specific factors."	( Population pharmacokinetics of pemetrexed disodium (ALIMTA) in patients with cancer. Johnson, RD; Lalonde, RL; Ouellet, D; Periclou, AP; Woodworth, JR, 2000)	0.31
" The half-life of MTA in the peritoneal fluid after intraperitoneal infusion was approximately 2 hours."	( Multi-targeted antifolate (MTA): pharmacokinetics of intraperitoneal administration in a rat model. Pestieau, SR; Stuart, OA; Sugarbaker, PH, 2000)	0.31
"This phase I and pharmacokinetic study of pemetrexed in combination with oxaliplatin was performed to determine the maximum tolerated dose (MTD), and to evaluate safety and pharmacokinetics in patients with metastatic solid tumors."	( Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Bozec, L; Campone, M; Delaloge, S; Fumoleau, P; Gamelin, E; Latz, JE; Misset, JL, 2004)	0.32
" Pharmacokinetic analyses of plasma gemcitabine and pemetrexed concentrations were performed."	( A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Dy, GK; Erlichman, C; Goldberg, RM; Hanson, LJ; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA; Suri, A, 2005)	0.33
" There was no pharmacokinetic interaction between the two drugs."	( A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors. Adjei, AA; Alberts, SR; Atherton, PJ; Burch, PA; Dy, GK; Erlichman, C; Goldberg, RM; Hanson, LJ; Pitot, HC; Reid, JM; Rubin, J; Sloan, JA; Suri, A, 2005)	0.33
"The objectives of these analyses were to (1) develop a semimechanistic-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model to describe neutropenic response to pemetrexed and to (2) identify influential covariates with respect to pharmacodynamic response."	( A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Ghosh, A; Johnson, RD; Karlsson, MO; Latz, JE; Rusthoven, JJ, 2006)	0.33
"The objectives of these population pharmacokinetic analyses were to (1) assess the overall disposition of pemetrexed, (2) characterize between-patient and within-patient variability and identify influential covariates with respect to pemetrexed pharmacokinetics; and, (3) provide individual empirical Bayesian estimates of pharmacokinetic parameters for use in a subsequent pharmacokinetic/pharmacodynamic evaluation of neutropenia following pemetrexed administration."	( Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Chaudhary, A; Ghosh, A; Johnson, RD; Latz, JE, 2006)	0.33
"Data from 287 patients who received 441 cycles without folic acid or vitamin B12 supplementation during participation in one of ten phase II cancer trials were evaluated by population pharmacokinetic analysis using NONMEM."	( Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Chaudhary, A; Ghosh, A; Johnson, RD; Latz, JE, 2006)	0.33
" Since pharmacodynamic analyses have shown that AUC and not C (max) is the primary determinant of neutropenic response to pemetrexed, this suggests that dose adjustments based on renal function, rather than body surface area, might be considered for pemetrexed."	( Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Chaudhary, A; Ghosh, A; Johnson, RD; Latz, JE, 2006)	0.33
"Pemetrexed disappearance from plasma was best described by a two compartment model with a mean distribution half-life of 13."	( Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates. Ames, MM; Blaney, SM; Dauser, R; McGovern, RM; McGuffey, L; Nuchtern, J; Reid, JM; Stapleton, SL; Thompson, PA, 2007)	0.34
" The study also sought to detect major pharmacokinetic drug-drug interactions between these agents and preliminary evidence of antitumor activity in patients with advanced solid malignancies."	( A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. Beeram, M; Chu, Q; De Bono, J; Forouzesh, B; Hammond, LA; Hong, S; John, W; Latz, JE; Nguyen, B; Rowinsky, EK; Schwartz, G, 2007)	0.34
" No major pharmacokinetic interactions between the agents were evident."	( A phase I and pharmacokinetic study of pemetrexed plus irinotecan in patients with advanced solid malignancies. Beeram, M; Chu, Q; De Bono, J; Forouzesh, B; Hammond, LA; Hong, S; John, W; Latz, JE; Nguyen, B; Rowinsky, EK; Schwartz, G, 2007)	0.34
"We report results of a phase I trial and pharmacokinetic study of pemetrexed (LY231514) in children and adolescents with refractory solid tumors."	( Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. Adamson, PC; Ames, MM; Blaney, SM; Ingle, AM; Krailo, M; Malempati, S; McGovern, R; Melemed, AS; Nicholson, HS; Reid, JM; Safgren, S; Stork, LC, 2007)	0.34
" Pharmacokinetic studies were performed during the first course of treatment."	( Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group. Adamson, PC; Ames, MM; Blaney, SM; Ingle, AM; Krailo, M; Malempati, S; McGovern, R; Melemed, AS; Nicholson, HS; Reid, JM; Safgren, S; Stork, LC, 2007)	0.34
"The purpose of this study was to investigate the utility of plasma pharmacokinetic and pharmacodynamic measures including plasma deoxynucleosides, homocysteine and methylmalonic acid concentrations in understanding the time course and extent of the inhibition of thymidylate synthase (TS) by pemetrexed in the context of a phase I/II combination study with vinorelbine."	( Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules. Clarke, SJ; Li, KM; Rivory, LP, 2007)	0.34
" The pemetrexed pharmacokinetic results were consistent with those from previous single-agent pemetrexed studies and a previous study of pemetrexed in combination with cisplatin."	( Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients. Ciuleanu, T; Darstein, CL; Latz, JE; Musib, LC; Specenier, PM; Vermorken, JB, 2009)	0.35
" As Cmax is a determinant of pemetrexed toxicity, intrapleural administration might offer a means of widening the effective therapeutic index of the drug by improving tolerability."	( Intrapleural administration of pemetrexed: a pharmacokinetic study in an animal model. Astoul, P; Bouvenot, J; Coltel, N; Devictor-Pierre, B; Fraticelli, A; Greillier, L; Lamarche, G; Monjanel-Mouterde, S, 2009)	0.35
" Pharmacodynamic separation by intermittent delivery of epidermal growth factor receptor tyrosine kinase inhibitors with chemotherapy may increase efficacy by overcoming hypothesized antagonism."	( Intermittent erlotinib in combination with pemetrexed: phase I schedules designed to achieve pharmacodynamic separation. Beckett, L; Davies, AM; Gandara, DR; Ho, C; Lara, PN; Lau, D; Perkins, N; Scudder, SA, 2009)	0.35
"This article focuses on all of the currently published pharmacokinetic data of pemetrexed reviewing a number of different scenarios and patient populations."	( Pharmacokinetic evaluation of pemetrexed. Sørensen, JB, 2011)	0.37
" The pharmacokinetic study showed a significant inverse correlation between the AUC of pemetrexed and the creatinine clearance."	( Dose escalation and pharmacokinetic study of carboplatin plus pemetrexed for elderly patients with advanced nonsquamous non-small-cell lung cancer: Kumamoto thoracic oncology study group trial 1002. Akaike, K; Fujii, S; Hamada, A; Hirosako, S; Iriki, T; Kishi, H; Kohrogi, H; Nakamura, K; Notsute, D; Saeki, S; Sakata, S; Saruwatari, K; Sasaki, J; Sato, R; Tanaka, H, 2015)	0.42
" The in vitro to in vivo extrapolation approach used in this work was developed to predict possible drug-drug interactions (DDIs) that may occur after coadministration of pemetrexed and nonsteroidal anti-inflammatory drugs (NSAIDs), and it included in vitro assays, risk assessment models, and physiologically based pharmacokinetic (PBPK) models."	( Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. Bacon, JA; Hall, SD; Higgins, JW; Hillgren, KM; Kim, RB; Pak, YA; Posada, MM; Schneck, KB; Tirona, RG, 2015)	0.42
" Regorafenib had acceptable tolerability and minor pharmacokinetic interactions in combination with standard doses of cisplatin and pemetrexed in patients with advanced nsNSCLCs."	( Preliminary Safety, Pharmacokinetics, and Efficacy of Regorafenib, Cisplatin, and Pemetrexed in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancers. Diefenbach, K; Gettinger, SN; Hellmann, MD; Lettieri, J; Rizvi, NA; Sturm, I; Trnkova, ZJ, 2015)	0.42
"In patients with unselected or EGFR wild-type advanced nonsquamous NSCLC, pharmacodynamic separation of pemetrexed and intercalated erlotinib had promising antitumor activity without new safety concerns."	( Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Bathini, VG; Beckett, LA; Gajavelli, S; Gandara, DR; Gucalp, R; Haigentz, M; Kim, M; Lara, PN; Li, T; Pasquinelli, PB; Perez-Soler, R; Piperdi, B; Sreedhara, M; Walsh, WV; Wen, H; Xie, X; Zhou, K, 2017)	0.46
"The pharmacokinetic target was an area under the concentration-time curve (AUC) of 123-205 mg·h/L."	( Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. Agterhuis, DE; Burger, DM; Croes, S; de Rouw, N; Derijks, HJ; Dingemans, AM; Posthuma, R; Schoenmaekers, JJAO; Ter Heine, R, 2019)	0.51
" Serial samples of cerebrospinal fluid (CSF) and plasma were obtained for pharmacokinetic studies."	( Safety, Pharmacokinetic and Clinical Activity of Intrathecal Chemotherapy With Pemetrexed via the Ommaya Reservoir for Leptomeningeal Metastases From Lung Adenocarcinoma: A Prospective Phase I Study. Jiang, C; Li, H; Lin, Y; Liu, X; Qian, X; Xie, Y; Yin, Z; Yu, T; Zheng, S, 2023)	0.91
" Pharmacokinetic analysis showed that using Ommaya reservoirs, higher pemetrexed concentrations and prolonged half-lives were achieved in the CSF compared with lumbar puncture (LP)."	( Safety, Pharmacokinetic and Clinical Activity of Intrathecal Chemotherapy With Pemetrexed via the Ommaya Reservoir for Leptomeningeal Metastases From Lung Adenocarcinoma: A Prospective Phase I Study. Jiang, C; Li, H; Lin, Y; Liu, X; Qian, X; Xie, Y; Yin, Z; Yu, T; Zheng, S, 2023)	0.91

Excerpt	Reference	Relevance
" This study was designed to (1) determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of MTA combined with cisplatin; (2) determine a recommended dose for phase II studies; and (3) collect anecdotal information on the antitumor activity of MTA combined with cisplatin."	( Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. Blatter, J; Depenbrock, H; Dumez, H; Hanauske, AR; Johnson, RD; Thödtmann, R; van Oosterom, A, 1999)	0.3
" Therefore, we evaluated the anti-proliferative potential of MTA combined with drugs known to exert therapeutic activity against colon cancer, including 5-fluorouracil, oxaliplatin, and SN38, the active metabolite of irinotecan."	( Pemetrexed disodium combined with oxaliplatin, SN38, or 5-fluorouracil, based on the quantitation of drug interactions in human HT29 colon cancer cells. Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Louvet, C; Raymond, E; Tournigand, C, 2002)	0.31
" Several phase I/II trials of pemetrexed as a single agent or in combination with a platinum drug have demonstrated considerable activity in mesothelioma."	( Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma. Green, MR; Meyer, ML; Suwanrusme, H, 2004)	0.32
"This phase I and pharmacokinetic study of pemetrexed in combination with oxaliplatin was performed to determine the maximum tolerated dose (MTD), and to evaluate safety and pharmacokinetics in patients with metastatic solid tumors."	( Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Bozec, L; Campone, M; Delaloge, S; Fumoleau, P; Gamelin, E; Latz, JE; Misset, JL, 2004)	0.32
" In this study, we investigated the anticancer activity of BGC9331 either alone or combined with 5-fluorouracil (5-FU), MTA (multi-target antifolate), oxali-platin and SN-38, the active metabolite of the topoisomerase I inhibitor CPT-11."	( Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independen André, T; Coudray, AM; De Gramont, A; Faivre, S; Gespach, C; Kornprobst, M; Larsen, AK; Louvet, C; Raymond, E; Tournigand, C, 2005)	0.33
"Patients received pemetrexed 500 mg/m2 alone or in combination with cisplatin 75 mg/m2 once every 21 days for > or = 6 cycles."	( Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Ashland, J; Belani, CP; Jänne, PA; Keohan, ML; Mintzer, DM; Monberg, MJ; Obasaju, CK; Polikoff, JA; Ross, HJ; Taylor, L; Wozniak, AJ; Ye, Z, 2005)	0.33
" Pemetrexed is the first and only chemotherapy agent that has been granted a marketing approval for use in combination with cisplatin for the treatment of chemo-naïve patients with unresectable MPM."	( Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Dickson, R; Dodd, S; Dundar, Y; Green, J; Walley, T, 2007)	0.34
"To examine evidence on the clinical effectiveness of pemetrexed disodium used in combination with cisplatin for the treatment of unresectable malignant pleural mesothelioma in chemotherapy naïve patients compared with other cytotoxic agents used alone or in combination, or supportive care."	( Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Dickson, R; Dodd, S; Dundar, Y; Green, J; Walley, T, 2007)	0.34
"Pemetrexed disodium in combination with cisplatin and with folic acid and vitamin B(12 )supplementation may improve survival when used in combination with cisplatin in good performance status patients."	( Pemetrexed disodium in combination with cisplatin versus other cytotoxic agents or supportive care for the treatment of malignant pleural mesothelioma. Dickson, R; Dodd, S; Dundar, Y; Green, J; Walley, T, 2007)	0.34
" In the present trial we investigated pemetrexed in combination with paclitaxel as front-line treatment in advanced or metastatic NSCLC."	( Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial. Dimitroulis, J; Karaindros, D; Katis, C; Koutandos, J; Stathopoulos, GP; Stathopoulos, J; Toubis, M, 2007)	0.34
" Patients were treated every 21 days with pemetrexed 500 mg/m alone (n = 91) or in combination with cisplatin 75 mg/m (n = 96) for a maximum of six cycles."	( Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. Belani, CP; Jänne, PA; Keohan, ML; Mintzer, DM; Monberg, MJ; Obasaju, CK; Polikoff, JA; Ross, HJ; Wozniak, AJ; Ye, Z, 2006)	0.33
"The data from this EAP study suggest that patients with previously treated MPM can benefit from treatment with pemetrexed alone or in combination with cisplatin."	( Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program. Belani, CP; Jänne, PA; Keohan, ML; Mintzer, DM; Monberg, MJ; Obasaju, CK; Polikoff, JA; Ross, HJ; Wozniak, AJ; Ye, Z, 2006)	0.33
" The schedule was pemetrexed 500 mg/m(2) in combination with carboplatin area under the curve 5, every 21 days."	( Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Aitini, E; Alabiso, O; Botta, M; Buosi, R; Carbone, R; Castagneto, B; Degiovanni, D; Galbusera, V; Giaretto, L; Mencoboni, M; Muzio, A; Piccolini, E; Rebella, L; Serra, M; Spigno, F, 2008)	0.35
"Pemetrexed in combination with cisplatin (Pem/Cis) is used globally for the treatment of malignant pleural mesothelioma (MPM)."	( Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients. Adachi, S; Fukuoka, M; Gemba, K; Hida, T; Ichinose, Y; Kunitoh, H; Nakagawa, K; Nambu, Y; Saijo, N; Shinkai, T; Yamazaki, K, 2008)	0.35
" Limited pharmacokinetic profiling of PTK787/ZK222584 revealed no evidence of drug-drug interactions."	( A phase I trial of PTK787/ZK222584 in combination with pemetrexed and cisplatin in patients with advanced solid tumors. Berg, W; Freeman, B; Manno, P; Sharma, S; Symanowski, J; Turner, J; Vogelzang, N, 2009)	0.35
"This clinical trial assessed the efficacy of pemetrexed combined with oxaliplatin (PEMOX) in patients with advanced gastric cancer (AGC)."	( Pemetrexed in combination with oxaliplatin as a first-line therapy for advanced gastric cancer: a multi-institutional phase II study. Amoroso, V; Bajetta, E; Barone, C; Cascinu, S; Celio, L; Cetto, GL; Di Costanzo, F; La Torre, I; Labianca, R; Pinotti, G; Sternberg, CN, 2009)	0.35
" The goal of this study was to evaluate the anticancer effect of a histone deacetylase inhibitor, valproate, on mesothelioma cells in combination with pemetrexed and cisplatin, the usual first-line regimen of chemotherapy for this tumor."	( Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Burny, A; Delvenne, P; Grigoriu, B; Hubert, P; Mascaux, C; Scherpereel, A; Vandermeers, F; Willems, L, 2009)	0.35
" As expected, valproate alone or combined with pemetrexed and cisplatin triggers hyperacetylation of histone H3."	( Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Burny, A; Delvenne, P; Grigoriu, B; Hubert, P; Mascaux, C; Scherpereel, A; Vandermeers, F; Willems, L, 2009)	0.35
"These observations support the potential additional efficacy of valproate in combination with pemetrexed and cisplatin for treatment of malignant mesothelioma."	( Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Burny, A; Delvenne, P; Grigoriu, B; Hubert, P; Mascaux, C; Scherpereel, A; Vandermeers, F; Willems, L, 2009)	0.35
") in combination with pemetrexed."	( Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Giaccone, G; Graefe, T; Hanauske, AR; Kuenen, B; Lahn, M; McNealy, P; Musib, LC; Thornton, D; Weigang-Köhler, K; Yilmaz, E, 2009)	0.35
" This review outlines the current preclinical and clinical studies using pemetrexed in combination with targeted agents in advanced NSCLC."	( The role of pemetrexed combined with targeted agents for non-small cell lung cancer. Jassem, J; Konopa, K, 2010)	0.36
" Twenty-three patients experiencing progression following 6 months after concluding platinum-based chemotherapy were managed with second-line treatment with carboplatin combined with gemcitabine or pemetrexed."	( High response of second-line chemotherapy with pemetrexed or gemcitabine combined with carboplatin in patients with non-small-cell lung cancer experiencing progression following 6 months after concluding platinum-based chemotherapy. Arrieta, O; Astorga, A; Flores-Estrada, D; Martinez-Barrera, L; Michel Ortega, RM; Pachuca, D; Villarreal-Garza, C, 2011)	0.37
"An oral daily dose of 500 mg enzastaurin was administered once daily (QD) or twice daily (BID) in combination with 500 mg/m pemetrexed on day 1 in repeated 21-day cycles."	( A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer. Baldwin, JR; Koshiji, M; Kunitoh, H; Murakami, H; Nakamura, Y; Nokihara, H; Ohe, Y; Shukuya, T; Takahashi, T; Tamura, T; Tanai, C; Yamamoto, N, 2010)	0.36
"Both schedules of enzastaurin in combination with pemetrexed were well tolerated and clinically active in patients with advanced non-small cell lung cancer."	( A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer. Baldwin, JR; Koshiji, M; Kunitoh, H; Murakami, H; Nakamura, Y; Nokihara, H; Ohe, Y; Shukuya, T; Takahashi, T; Tamura, T; Tanai, C; Yamamoto, N, 2010)	0.36
" In this study, using an intrathoracic murine model of malignant mesothelioma (MM), we provide evidence suggesting that Treg blockade could enhance survival when combined with pemetrexed in established tumor."	( Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma. Anraku, M; de Perrot, M; Johnston, MR; Keshavjee, S; Tagawa, T; Wu, L; Yun, Z; Zhang, L, 2010)	0.36
"A phase I trial escalating doses of sorafenib in combination with fixed doses of PE (Arm A) or CbP (Arm B) was performed using a 3-patient cohort design to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT); DLT were assessed in the first cycle."	( A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM, 2011)	0.37
"The MTD of sorafenib was 200 mg BID continuously in combination with carboplatin (AUC of 5) and pemetrexed 500 mg/m² every 3 weeks."	( A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM, 2011)	0.37
"This phase I study evaluated the safety, tolerability, preliminary antitumor activity, and pharmacokinetic interaction of weekly topotecan (days 1 and 8) in combination with pemetrexed (day 1 only) in patients with advanced solid tumors."	( A phase I study of weekly topotecan in combination with pemetrexed in patients with advanced malignancies. Burris, HA; Greco, FA; Infante, JR; Jewell, RC; Jones, SF; Spigel, DR; Thompson, DS, 2010)	0.36
" We have performed a feasibility study to investigate the safety of sunitinib in combination with pemetrexed for treatment of advanced refractory solid tumors."	( Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Fumita, S; Hashimoto, J; Ichikawa, Y; Kimura, N; Miyazaki, M; Nakagawa, K; Ohki, E; Okamoto, I; Shimizu, T; Takeda, M; Terashima, M; Tsurutani, J, 2012)	0.38
"5 mg/day) or a 2-weeks-on, 1-week-off treatment schedule (50 mg/day, Schedule 2/1) in combination with pemetrexed at 500 mg/m(2) on day 1 of repeated 21-day cycles."	( Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Fumita, S; Hashimoto, J; Ichikawa, Y; Kimura, N; Miyazaki, M; Nakagawa, K; Ohki, E; Okamoto, I; Shimizu, T; Takeda, M; Terashima, M; Tsurutani, J, 2012)	0.38
" Pharmacokinetic analysis did not reveal any substantial drug-drug interaction."	( Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Fumita, S; Hashimoto, J; Ichikawa, Y; Kimura, N; Miyazaki, M; Nakagawa, K; Ohki, E; Okamoto, I; Shimizu, T; Takeda, M; Terashima, M; Tsurutani, J, 2012)	0.38
"This study evaluated overall survival (OS) of patients with advanced non-squamous NSCLC following treatment with the specific endothelin A receptor antagonist, zibotentan in combination with pemetrexed compared with pemetrexed monotherapy."	( A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. Chouaid, C; Morris, T; Nathan, F; Pemberton, K, 2011)	0.37
"In this double-blinded, placebo-controlled study, patients with advanced NSCLC with non-squamous histology who had failed first-line platinum-based chemotherapy were randomized to receive either once-daily zibotentan 10 mg in combination with 3-weekly pemetrexed 500 mg/m(2) or placebo plus 3-weekly pemetrexed 500 mg/m(2)."	( A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. Chouaid, C; Morris, T; Nathan, F; Pemberton, K, 2011)	0.37
"There was no survival signal in patients with NSCLC following treatment with zibotentan in combination with pemetrexed."	( A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer. Chouaid, C; Morris, T; Nathan, F; Pemberton, K, 2011)	0.37
" The aim of this study is to evaluate the efficacy and side effects of pemetrexed combined with cisplatin/carboplatin in the treatment of advanced recurrent or metastasis NSCLC."	( [Pemetrexed combined with cisplatin or carboplatin regimen in the treatment of advanced recurrent or metastasis non-small cell lung cancer: analysis of 63 cases]. Li, J; Li, X; Liu, J; Shang, L; Wang, W; Wen, F, 2011)	0.37
"Pemetrexed combined with cisplatin/carboplatin is effective and feasible for advanced recurrent or metastasis NSCLC."	( [Pemetrexed combined with cisplatin or carboplatin regimen in the treatment of advanced recurrent or metastasis non-small cell lung cancer: analysis of 63 cases]. Li, J; Li, X; Liu, J; Shang, L; Wang, W; Wen, F, 2011)	0.37
" A Bayesian dose-escalation model was used to determine the feasible doses of daily or weekly everolimus combined with pemetrexed (500 mg/m q3w)."	( Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a phase I study using a novel, adaptive Bayesian dose-escalation model. Anrys, B; Boyer, M; Di Scala, L; Dimitrijevic, S; Laack, E; Miller, N; Petrovic, K; Pylvaenaeinen, I; Solomon, B; Vansteenkiste, J; Wolf, J, 2011)	0.37
" The aim of this study is to compare the efficacies and safeties of pemetrexed alone with pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma to provide evidences for combination therapy."	( [Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma]. Gao, Z; Han, B; Jiang, L; Jiang, Y; Liu, Y; Wang, X, 2011)	0.37
"From January 2009 to February 2011, 83 patients with stage IV lung adenocarcinoma received pemetrexed alone (single agent arm, n=47) or pemetrexed combined with oxaliplatin (combination arm, n=36) as salvage therapy."	( [Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma]. Gao, Z; Han, B; Jiang, L; Jiang, Y; Liu, Y; Wang, X, 2011)	0.37
"For salvage therapy, pemetrexed combined with oxaliplatin is tolerable in stage IV lung adenocarcinoma patients with good PS scores."	( [Pemetrexed alone versus pemetrexed combined with oxaliplatin as salvage therapy in stage IV lung adenocarcinoma]. Gao, Z; Han, B; Jiang, L; Jiang, Y; Liu, Y; Wang, X, 2011)	0.37
" No significant drug-drug interactions were identified."	( A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Blais, N; Camidge, DR; Canil, C; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; McWilliam, M; Ruiz-Garcia, A; Thall, A; Tye, L; Zhang, K, 2012)	0.38
" Pemetrexed in combination with carboplatin has been shown to be feasible in a phase I study in PSOC."	( A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Alvarez, AM; Bauknecht, T; Ghatage, P; Look, KY; Manouchehrpour, S; Oskay-Öezcelik, G; Sehouli, J; Szczylik, C; Zimmermann, A, 2012)	0.38
" Defining the platinum-based combination with the best therapeutic index would require a prospective phase III study."	( A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer. Alvarez, AM; Bauknecht, T; Ghatage, P; Look, KY; Manouchehrpour, S; Oskay-Öezcelik, G; Sehouli, J; Szczylik, C; Zimmermann, A, 2012)	0.38
" This phase II study aimed at evaluating its use in combination with cisplatin for recurrent or metastatic nasopharyngeal carcinoma (NPC)."	( A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma. Chan, L; Lee, AW; Ng, WT; Shum, T; Yau, TK; Yeung, MW, 2012)	0.38
" Pemetrexed has shown single-agent activity in SCCHN and in combination with cisplatin for other tumors."	( Pemetrexed in combination with cisplatin versus cisplatin monotherapy in patients with recurrent or metastatic head and neck cancer: final results of a randomized, double-blind, placebo-controlled, phase 3 study. Chang, SC; Frimodt-Moller, B; Hitt, R; Hong, RL; Hossain, AM; Koustenis, A; Licitra, L; Mezei, K; Reuter, C; Russo, F; Sahoo, TP; Shin, DM; Urba, S; van Herpen, CM, 2012)	0.38
"Pemetrexed has radiosensitizing potential when evaluated in vitro in combination with platinum-containing compounds and radiation."	( Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer. Enatsu, S; Funai, J; Kubota, K; Nihei, K; Niho, S; Ohe, Y; Sekiguchi, R; Sekine, I; Sumi, M; Tamura, T, 2013)	0.39
"Expected toxicities from concurrent chemoradiation were not worsened with concurrent TRT at a total dose of 66 Gy combined with pemetrexed in Japanese patients with locally advanced (LA) nonsquamous NSCLC."	( Dose-escalation study of thoracic radiotherapy in combination with pemetrexed plus Cisplatin followed by pemetrexed consolidation therapy in Japanese patients with locally advanced nonsquamous non-small-cell lung cancer. Enatsu, S; Funai, J; Kubota, K; Nihei, K; Niho, S; Ohe, Y; Sekiguchi, R; Sekine, I; Sumi, M; Tamura, T, 2013)	0.39
"To evaluate the safety, pharmacokinetics (PKs), and pharmacodynamics of aflibercept, and to identify the recommended phase II dose (RP2D) of aflibercept in combination with pemetrexed and cisplatin."	( A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Colevas, AD; Diaz-Padilla, I; Gao, B; Lawson, EB; Leighl, NB; Lisano, J; Liu, L; Neal, JW; Razak, AR; San Pedro-Salcedo, M; Shepherd, FA; Siu, LL; Thibault, A; Wakelee, HA, 2012)	0.38
"Aflibercept was administered at escalating doses of 2, 4, or 6 mg kg(-1) in combination with fixed doses of pemetrexed (500 mg m(-2)) plus cisplatin (75 mg m(-2)) every 3 weeks."	( A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Colevas, AD; Diaz-Padilla, I; Gao, B; Lawson, EB; Leighl, NB; Lisano, J; Liu, L; Neal, JW; Razak, AR; San Pedro-Salcedo, M; Shepherd, FA; Siu, LL; Thibault, A; Wakelee, HA, 2012)	0.38
" The RP2D of aflibercept was 6 mg kg(-1), to be administered intravenously every 3 weeks in combination with pemetrexed and cisplatin."	( A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Colevas, AD; Diaz-Padilla, I; Gao, B; Lawson, EB; Leighl, NB; Lisano, J; Liu, L; Neal, JW; Razak, AR; San Pedro-Salcedo, M; Shepherd, FA; Siu, LL; Thibault, A; Wakelee, HA, 2012)	0.38
"Due to the various inter-individual differences in the biological characteristics of tumor cells, as well as issues on the efficacy, adverse reactions, and defects of existing drugs, we compared the clinical efficacy and toxicity of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced non-small cell lung cancer (NSCLC)."	( [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer]. Cheng, G; Hu, C; Hu, X; Huang, C; Jiao, S; Li, K; Luo, R; Lv, W; Ouyang, X; Sun, Y; Wang, J; Wang, M; Wang, Y; Wang, Z; Zhang, S; Zheng, R, 2012)	0.38
"251 patients were randomly divided into pemetrexed combined with cisplatin group (PP group) with 127 cases and gemcitabine combined with cisplatin group (GP group) with 124 cases."	( [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer]. Cheng, G; Hu, C; Hu, X; Huang, C; Jiao, S; Li, K; Luo, R; Lv, W; Ouyang, X; Sun, Y; Wang, J; Wang, M; Wang, Y; Wang, Z; Zhang, S; Zheng, R, 2012)	0.38
"The clinical efficacy of pemetrexed and gemcitabine combined with cisplatin for the treatment of previously untreated advanced NSCLC was roughly the same, but the adverse reactions decreased significantly in the PP group compared with those in the GP group."	( [Efficacy and toxicity of pemetrexed or gemcitabine combined with cisplatin in the treatment of patients with advanced non-small cell lung cancer]. Cheng, G; Hu, C; Hu, X; Huang, C; Jiao, S; Li, K; Luo, R; Lv, W; Ouyang, X; Sun, Y; Wang, J; Wang, M; Wang, Y; Wang, Z; Zhang, S; Zheng, R, 2012)	0.38
" There were no clinically significant drug-drug interactions."	( Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Doebele, RC; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K, 2013)	0.39
" Its activity on brain metastases makes pemetrexed attractive in combination with whole-brain radiation therapy (WBRT), but it could also potentially increase toxicity."	( First assessment of whole-brain radiation therapy combined with pemetrexed-based chemotherapy in non-small-cell lung carcinoma: data on safety and efficacy. Bauduceau, O; Ceccaldi, B; Chargari, C; Dulou, R; Fournel, P; Guy, JB; Jacob, J; Le Moulec, S; Magné, N; Moriceau, G; Moussaid, Y; Pacaut, C; Rivoirard, R; Védrine, L, 2013)	0.39
"5%) alone, or combined with distant metastases (48."	( Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Chang, SC; Dietz, A; Gauler, TC; Hamid, O; Hossain, AM; Licitra, L; Lopez-Picazo, JM; Stöhlmacher-Williams, J; Vermorken, JB, 2013)	0.39
"To observe the clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer (NSCLC)."	( [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer]. Shi, X; Yu, XM; Zhang, YP; Zhao, J, 2013)	0.39
" Thus, pemetrexed combined with carboplatin is an effective chemotherapeutic regimen for advanced NSCLC in elderly patients."	( [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer]. Shi, X; Yu, XM; Zhang, YP; Zhao, J, 2013)	0.39
" Pharmacokinetic data revealed no clinically significant drug-drug interactions."	( Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K, 2013)	0.39
" Application of (177)Lu-EC0800 with PMXther resulted in a two- to four-fold enhanced tumor growth delay and a prolonged survival of KB and IGROV-1 tumor-bearing mice, as compared to the combination with PMXsubther or untreated control mice."	( 177Lu-EC0800 combined with the antifolate pemetrexed: preclinical pilot study of folate receptor targeted radionuclide tumor therapy. Haller, S; Leamon, CP; Müller, C; Reber, J, 2013)	0.39
"To investigate the efficacy and safety of Javanica oil emulsion injection (Yadanzi®) combined with pemetrexed and platinum (PP) for treating patients with advanced lung cancer."	( Phase II study on Javanica oil emulsion injection (Yadanzi®) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, L; Xu, X, 2013)	0.39
"Javanica oil emulsion injection combined with chemotherapy could be considered as a safe and effective regimen in treating patients with advanced lung adenocarcinoma."	( Phase II study on Javanica oil emulsion injection (Yadanzi®) combined with chemotherapy in treating patients with advanced lung adenocarcinoma. Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; Xiang, J; Xu, L; Xu, X, 2013)	0.39
"This study evaluated the efficacy and safety of ziv-aflibercept in combination with cisplatin and pemetrexed in non-small cell lung cancer (NSCLC)."	( A phase II multicentre study of ziv-aflibercept in combination with cisplatin and pemetrexed in patients with previously untreated advanced/metastatic non-squamous non-small cell lung cancer. Adjei, AA; Brahmer, JR; Chen, H; Dicioccio, AT; Gao, B; Jotte, RM; Kuo, CJ; Leighl, NB; Liu, L; Modiano, MR; Neal, JW; Riess, JW; Rigas, JR; Wakelee, HA, 2014)	0.4
"This randomized open-label phase II study evaluated the efficacy, safety, and tolerability of pazopanib in combination with pemetrexed compared with the standard cisplatin/pemetrexed doublet in patients with previously untreated, advanced, nonsquamous non-small-cell lung cancer."	( An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. Besse, B; Bosquee, L; Chouaid, C; Felip, E; Lechevalier, T; Lianes-Barragán, P; Mellemgaard, A; Ottesen, LH; Paul, EM; Reck, M; Ruiz-Soto, R; Scagliotti, GV; Sigal, E; von Pawel, J, 2013)	0.39
" Although most patients eligible for surgery undergo cytoreductive surgery in combination with hyperthermic intraperitoneal chemotherapy, the role of perioperative systemic chemotherapy still remains undefined."	( Complete pathological response to neoadjuvant pemetrexed/cisplatin in combination with regional hyperthermia in a patient with sarcomatoid peritoneal mesothelioma. Albertsmeier, M; Angele, MK; Boeck, S; Graser, A; Haas, M; Heinemann, V; Kruger, S; Lindner, LH; Reu, S; Sotlar, K; Stemmler, HJ, 2014)	0.4
" This study was conducted to elucidate the safety and efficacy of palliative chemotherapy with gemcitabine or pemetrexed, both in combination with a platinum agent in NSCLC patients with ILD."	( Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. Ahn, JS; Ahn, MJ; Chang, W; Choi, MK; Chung, MP; Hong, JY; Jung, HA; Kim, M; Kim, S; Lee, SJ; Park, K; Park, S; Sun, JM, 2014)	0.4
"Patients with advanced or recurrent NSCLC and ILD who received gemcitabine or pemetrexed in combination with a platinum agent as first-line chemotherapy were retrospectively analyzed."	( Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. Ahn, JS; Ahn, MJ; Chang, W; Choi, MK; Chung, MP; Hong, JY; Jung, HA; Kim, M; Kim, S; Lee, SJ; Park, K; Park, S; Sun, JM, 2014)	0.4
"Our results suggest that gemcitabine or pemetrexed in combination with platinum agents could be a feasible option for advanced NSCLC with ILD with some risk of AE-ILD or early death."	( Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. Ahn, JS; Ahn, MJ; Chang, W; Choi, MK; Chung, MP; Hong, JY; Jung, HA; Kim, M; Kim, S; Lee, SJ; Park, K; Park, S; Sun, JM, 2014)	0.4
" The aim of this study was to investigate the antitumor activity of recombinant human Apo2L/TRAIL (dulanermin) in combination with chemotherapy in MPM in vitro and in vivo."	( Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma. Cavallari, I; Ciminale, V; Favaretto, A; Marulli, G; Nannini, N; Pasello, G; Rea, F; Schiavon, M; Silic-Benussi, M; Urso, L, 2014)	0.4
"In the present studies, we employed a panel of MPM cell lines to test the antitumor activity of recombinant human Apo2L/TRAIL (T) in combination with carboplatin and pemetrexed (CP) in vitro and SCID mice."	( Synergistic antitumor activity of recombinant human Apo2L/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with carboplatin and pemetrexed in malignant pleural mesothelioma. Cavallari, I; Ciminale, V; Favaretto, A; Marulli, G; Nannini, N; Pasello, G; Rea, F; Schiavon, M; Silic-Benussi, M; Urso, L, 2014)	0.4
" LY2603618 administered in combination with pemetrexed and cisplatin demonstrated an acceptable safety profile."	( Preclinical analyses and phase I evaluation of LY2603618 administered in combination with pemetrexed and cisplatin in patients with advanced cancer. Barnard, D; Calles, A; Calvo, E; Chen, VJ; Diaz, HB; Dickgreber, N; Huber, L; Hynes, SM; Iversen, P; Kays, L; Kumm, E; Lin, AB; Marshall, M; Merzoug, FF; Ohnmacht, U; Sebastian, M; Voss, B; Wehler, T, 2014)	0.4
" Erlotinib combined with pemetrexed/cisplatin may be effective in the treatment of LM in EGFR mutation patients after gefitinib failure."	( Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure. Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M, 2015)	0.42
"The primary objective of this study was to determine the safety and maximum tolerated dose (MTD) of the antimesothelin immunotoxin SS1(dsFv)PE38 (SS1P) (a recombinant antimesothelin immunotoxin consisting of a murine antimesothelin variable antibody fragment [Fv] linked to PE38, a truncated portion of Pseudomonas exotoxin A) in combination with pemetrexed and cisplatin in chemotherapy-naive patients with advanced malignant pleural mesothelioma (MPM)."	( Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen Hassan, R; Hollevoet, K; Kreitman, RJ; Ling, A; Miettinen, M; Pastan, I; Sharon, E; Steinberg, SM; Thomas, A; Zhang, J, 2014)	0.4
"SS1P given with pemetrexed and cisplatin is safe and well tolerated and exhibits significant antitumor activity in patients with unresectable, advanced pleural mesothelioma."	( Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen Hassan, R; Hollevoet, K; Kreitman, RJ; Ling, A; Miettinen, M; Pastan, I; Sharon, E; Steinberg, SM; Thomas, A; Zhang, J, 2014)	0.4
"In a 3 + 3 dose-escalation design, patients were given intravenous pemetrexed (500 mg/m(2)) on day 1 of a 21-day cycle (maximum 6 cycles), combined with continuous daily oral afatinib (schedule A [SA]; starting dose 30 mg, escalation to 50 mg) or pulsed-dose daily oral afatinib (schedule B [SB]; starting dose 50 mg, escalation to 70 mg) on days 1-6 of each 21-day cycle."	( A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Chand, VK; Chu, QS; Hirte, HW; Hotte, SJ; Sangha, R; Schnell, D; Sergenson, G, 2014)	0.4
"Continuous- or pulsed-dose afatinib combined with pemetrexed exhibited a manageable safety profile."	( A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Chand, VK; Chu, QS; Hirte, HW; Hotte, SJ; Sangha, R; Schnell, D; Sergenson, G, 2014)	0.4
"Fifty-nine mesothelioma patients (31 men with a median age of 62 years) treated in first-line chemotherapy with platinum in combination with pemetrexed or pemetrexed monotherapy were enrolled."	( Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients. Dyszkiewicz, W; Kalinka-Warzocha, E; Knetki-Wróblewska, M; Kowalski, DM; Krawczyk, P; Krzakowski, M; Kucharczyk, T; Milanowski, J; Powrózek, T; Ramlau, R; Winiarczyk, K, 2014)	0.4
" This phase 2 study investigated ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in advanced/metastatic NSCLC."	( Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Alexandris, E; Bonomi, P; Bustin, F; Camidge, DR; Cao, D; Doebele, RC; Eakle, J; Goldschmidt, J; Reck, M; Spigel, D; Tehfe, M; Thomas, S; Verma, S; Yurasov, S, 2015)	0.42
"The primary endpoint of significant prolongation of PFS was not met; however, ramucirumab showed evidence of clinical activity in combination with pemetrexed and platinum in nonsquamous NSCLC patients."	( Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Alexandris, E; Bonomi, P; Bustin, F; Camidge, DR; Cao, D; Doebele, RC; Eakle, J; Goldschmidt, J; Reck, M; Spigel, D; Tehfe, M; Thomas, S; Verma, S; Yurasov, S, 2015)	0.42
" Docetaxel 75 mg/m(2) or pemetrexed 500 mg/m(2) once every 21 days per the investigator was administered with apricoxib or placebo 400 mg once per day."	( Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. de Mayolo, JA; Edelman, MJ; Evans, TL; Feliciano, J; Fidler, MJ; Keresztes, R; Medeiros, M; Otterson, G; Rogers, JS; Sanborn, RE; Schneider, BJ; Sequist, LV; Tan, MT; Yang, Y; Zaknoen, SL, 2015)	0.42
" Fifteen patients were enrolled in a dose escalation of eribulin mesylate in combination with pemetrexed (E+P)."	( An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. Bondarenko, I; Dave, H; Freeman, A; Hodge, JP; Huber, B; Lieberman, R; Shelton, MJ; Shparyk, Y; Vynnychenko, I; Waller, CF, 2015)	0.42
" The in vitro to in vivo extrapolation approach used in this work was developed to predict possible drug-drug interactions (DDIs) that may occur after coadministration of pemetrexed and nonsteroidal anti-inflammatory drugs (NSAIDs), and it included in vitro assays, risk assessment models, and physiologically based pharmacokinetic (PBPK) models."	( Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. Bacon, JA; Hall, SD; Higgins, JW; Hillgren, KM; Kim, RB; Pak, YA; Posada, MM; Schneck, KB; Tirona, RG, 2015)	0.42
" Thus, we examined the feasibility of using thoracic radiotherapy combined with concurrent full-dose pemetrexed as the first-line treatment for advanced nonsquamous NSCLC patients."	( Full-dose pemetrexed plus cisplatin combined with concurrent thoracic radiotherapy for previously untreated advanced nonsquamous non-small cell lung cancer. Cai, XW; Feng, W; Fu, XL; Liu, Q; Xue, MC; Yu, W; Zhang, Q; Zhu, ZF, 2015)	0.42
" This randomized, phase II trial (n [ 143) investigated volasertib monotherapy or in combination with pemetrexed compared with pemetrexed monotherapy in patients with NSCLC whose disease had progressed after previous platinum-based chemotherapy."	( A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. Blais, N; Chu, Q; Ellis, PM; Gu, Y; Hirsh, V; Leighl, NB; Liu, D; Pilz, K; Reaume, MN; Sadrolhefazi, B; Wierzbicki, R, 2015)	0.42
" Pharmacokinetics analyses showed no drug-drug interactions between volasertib and pemetrexed."	( A Randomized, Open-Label Phase II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. Blais, N; Chu, Q; Ellis, PM; Gu, Y; Hirsh, V; Leighl, NB; Liu, D; Pilz, K; Reaume, MN; Sadrolhefazi, B; Wierzbicki, R, 2015)	0.42
" The objective of this phase 1 dose de-escalation trial was to estimate the minimum tolerated dose of [6R]-MTHF to be used in combination with pemetrexed 500 mg/m(2) in the neoadjuvant treatment of patients with rectal cancer."	( Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer. Björkqvist, H; Carlsson, G; Derwinger, K; Gibson, F; Gustavsson, B; Kurlberg, G; Odin, E; Swartling, T, 2015)	0.42
"Adult patients (≥18 years) with resectable rectal adenocarcinoma were allocated to [6R]-MTHF doses of 500, 100, 50, and 10 mg/m(2) in combination with pemetrexed 500 mg/m(2)."	( Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer. Björkqvist, H; Carlsson, G; Derwinger, K; Gibson, F; Gustavsson, B; Kurlberg, G; Odin, E; Swartling, T, 2015)	0.42
"The results of this phase 1 study indicate that the estimated minimum tolerated dose of [6R]-MTHF was 100 mg/m(2) once weekly in combination with pemetrexed 500 mg/m(2)."	( Phase 1 dose de-escalation trial of the endogenous folate [6R]-5,10-methylene tetrahydrofolate in combination with fixed-dose pemetrexed as neoadjuvant therapy in patients with resectable rectal cancer. Björkqvist, H; Carlsson, G; Derwinger, K; Gibson, F; Gustavsson, B; Kurlberg, G; Odin, E; Swartling, T, 2015)	0.42
"LY2090314 (LY) is a glycogen synthase kinase 3 inhibitor with preclinical efficacy in xenograft models when combined with platinum regimens."	( A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin. Brail, LH; Burris, HA; Chow, KH; Cooksey, JF; Farrington, DL; Gray, JE; Infante, JR; Jackson, KA; Jones, SF; Simon, GR; Yeo, A; Zamek-Gliszczynski, MJ, 2015)	0.42
"To study the effectiveness of human recombinant endostatin injection (Endostar®) combined with cisplatin doublets in treating advanced non-small cell lung cancer (NSCLC), and to evaluate outcome by CT perfusion imaging."	( Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging. Chen, SQ; Cui, FB; Gao, EY; Jiang, BQ; Li, M; Shu, RB; Sun, P; Tang, W; Wang, H; Zhang, FL; Zhang, Y, 2015)	0.42
"The response rate with Endostar® administered 4 days before chemotherapy and combined with chemotherapy from day 5 in group A was better than Endostar® combined with chemotherapy from the first day, and CT perfusion imaging could be a reasonable method for evaluation of patient outcomes."	( Human Recombinant Endostatin Combined with Cisplatin Based Doublets in Treating Patients with Advanced NSCLC and Evaluation by CT Perfusion Imaging. Chen, SQ; Cui, FB; Gao, EY; Jiang, BQ; Li, M; Shu, RB; Sun, P; Tang, W; Wang, H; Zhang, FL; Zhang, Y, 2015)	0.42
"This open-label, phase I, dose-escalation part of a phase I/II study evaluated the safety, pharmacokinetics, and preliminary efficacy of nintedanib, a triple angiokinase inhibitor, combined with pemetrexed in Japanese patients with advanced non-small cell lung cancer (NSCLC) after first-line chemotherapy."	( Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer. Daga, H; Goto, K; Kaiser, R; Kaneda, H; Konishi, K; Miyazaki, M; Nakagawa, K; Okada, H; Okamoto, I; Sarashina, A; Takeda, K; Tanaka, T; Ueda, S; Yoh, K, 2015)	0.42
"We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC)."	( A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer. Chouaid, C; Engel-Riedel, W; Fischer, JR; Mazières, J; Nguyen, T; Reck, M; Ripoche, V; Schmid-Bindert, G; Schuette, W; Soldatenkova, V; Stöhlmacher, J; Vinolas, N; Visseren-Grul, C; Wolf, M, 2015)	0.42
" Safety and PK of LY2603618 in combination with pemetrexed were favorable."	( Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer. Boyd, TE; Hynes, SM; Kang, JH; Kim, SW; Lin, AB; Lin, J; Myrand, SP; Novello, S; Park, K; Pinder-Schenck, M; Richards, DA; Rosenberg, R; Scagliotti, G; Smith, D; Smyth, EN; Su, WC; Wijayawardana, S, 2016)	0.43
" CheckMate 012, a phase I, multicohort study, was conducted to explore the safety and efficacy of nivolumab as monotherapy or combined with current standard therapies in first-line advanced NSCLC."	( Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. Antonia, S; Borghaei, H; Brahmer, JR; Chen, AC; Chow, LQ; Gerber, DE; Gettinger, S; Goldman, JW; Harbison, CT; Hellmann, MD; Juergens, RA; Laurie, SA; Nathan, FE; Rizvi, NA; Shen, Y; Shepherd, FA, 2016)	0.43
" This single-center phase Ib study investigated the tolerability, safety, and pharmacokinetics of nivolumab combined with standard chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC)."	( Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study. Fujiwara, Y; Goto, K; Horinouchi, H; Hozumi, H; Kanda, S; Kitazono, S; Kubo, E; Mizugaki, H; Nokihara, H; Shiraishi, H; Sunami, K; Tamura, T; Tanaka, A; Utsumi, H; Yamamoto, N, 2016)	0.43
"Patients with untreated stage IIIB/IV non-squamous NSCLC, stratified by MET diagnostic status, were randomized to receive onartuzumab (15 mg/kg intravenously every 3 weeks) or placebo in combination with either paclitaxel/platinum/bevacizumab (bevacizumab cohort), or in combination with platinum/pemetrexed (pemetrexed cohort) with maintenance bevacizumab or pemetrexed and onartuzumab/placebo as appropriate."	( Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. Boyer, M; Braiteh, F; Cosgriff, T; De Braud, F; Hsu, J; Kaen, D; Kingsley, CD; Lawler, W; Lena, H; Lowe, T; Mekhail, T; Novello, S; Phan, S; Schütte, W; Wakelee, H; Zvirbule, Z, 2017)	0.46
"Onartuzumab does not appear to provide any additional clinical benefit when given in combination with current first-line standard-of-care chemotherapy for non-squamous NSCLC."	( Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer. Boyer, M; Braiteh, F; Cosgriff, T; De Braud, F; Hsu, J; Kaen, D; Kingsley, CD; Lawler, W; Lena, H; Lowe, T; Mekhail, T; Novello, S; Phan, S; Schütte, W; Wakelee, H; Zvirbule, Z, 2017)	0.46
" The primary end point established the maximum tolerated dose in combination with cisplatin-pemetrexed in a dose deescalation scheme."	( Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). Gandara, DR; Kalemkerian, GP; Kelly, K; Moon, J; Redman, MW; Tsao, AS; Vogelzang, NJ; Wistuba, II, 2017)	0.46
"Cediranib combined with cisplatin-pemetrexed has a reasonable toxicity profile and preliminary promising efficacy."	( Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). Gandara, DR; Kalemkerian, GP; Kelly, K; Moon, J; Redman, MW; Tsao, AS; Vogelzang, NJ; Wistuba, II, 2017)	0.46
" Chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer were enrolled in a dose-escalation study (standard 3 + 3 design) of SASP in combination with cisplatin and pemetrexed."	( Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. Fujita, A; Harada, T; Hirai, F; Imamura, CK; Inada, M; Iwama, E; Kishimoto, J; Mushiroda, T; Nagano, O; Nakanishi, Y; Nosaki, K; Ogata, H; Okamoto, I; Otsubo, K; Ozeki, T; Sakata, S; Saya, H; Seto, T; Suina, K; Takenoyama, M; Toyokawa, G; Tsuchihashi, K, 2017)	0.46
" This study aimed to evaluate the pan-PI3K inhibitor pictilisib in combination with first-line treatment regimens that were the standard of care at the time of study, in patients with NSCLC."	( A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-s Adjei, AA; Bahleda, R; Besse, B; Dy, GK; Ferte, C; Groen, HJM; Lin, W; Morrissey, K; Planchard, D; Schutzman, JL; Shankar, G; Soria, JC; Ware, J; Zhou, J, 2017)	0.46
"To evaluate the clinical effectiveness of pemetrexed combined with cisplatin for the first-line chemotherapy of patients with advanced non-small-cell lung cancer (NSCLC) and maintenance treatment."	( Clinical effectiveness of pemetrexed combined with cisplatin chemotherapy for advanced and maintenance treatment for patients with non-small-cell lung cancer. Chen, WH; Dai, HP; Gan, YL; Xu, HY; Zhu, YM, 2018)	0.48
"240 advanced NSCLC patients were randomly divided into either a control group (treated with gemcitabine combined with cisplatin) or an observation group (treated with pemetrexed combined with cisplatin)."	( Clinical effectiveness of pemetrexed combined with cisplatin chemotherapy for advanced and maintenance treatment for patients with non-small-cell lung cancer. Chen, WH; Dai, HP; Gan, YL; Xu, HY; Zhu, YM, 2018)	0.48
"Pemetrexed combined with cisplatin was both safe and efficacious for the first-line chemotherapy of NSCLC patients at a progressive stage and for maintenance treatment."	( Clinical effectiveness of pemetrexed combined with cisplatin chemotherapy for advanced and maintenance treatment for patients with non-small-cell lung cancer. Chen, WH; Dai, HP; Gan, YL; Xu, HY; Zhu, YM, 2018)	0.48
" Methods Patients were administered escalating twice daily doses of vatalanib in combination with pemetrexed disodium in 21-day cycles."	( A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors. Adjei, AA; Lim, VS; Molina, J; Satele, D; Wang, F; Yin, J, 2019)	0.51
"We describe a phase Ib clinical trial evaluating treatment with BI1361849 combined with local radiation in 26 stage IV NSCLC patients with partial response (PR)/stable disease (SD) after standard first-line therapy."	( Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. Alt, J; Bischoff, H; Cathomas, R; Doener, F; Fotin-Mleczek, M; Früh, M; Geißler, M; Gnad-Vogt, U; Griesinger, F; Hilbe, W; Hipp, MM; Hong, HS; Kallen, KJ; Klinkhardt, U; Koch, SD; Muth, A; Pall, G; Papachristofilou, A; Pless, M; Scheel, B; Schröder, A; Sebastian, M; Seibel, T; Stosnach, C; Wehler, T; Weiss, C; Zippelius, A, 2019)	0.51
" One patient had a partial response in combination with pemetrexed maintenance, and 46."	( Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. Alt, J; Bischoff, H; Cathomas, R; Doener, F; Fotin-Mleczek, M; Früh, M; Geißler, M; Gnad-Vogt, U; Griesinger, F; Hilbe, W; Hipp, MM; Hong, HS; Kallen, KJ; Klinkhardt, U; Koch, SD; Muth, A; Pall, G; Papachristofilou, A; Pless, M; Scheel, B; Schröder, A; Sebastian, M; Seibel, T; Stosnach, C; Wehler, T; Weiss, C; Zippelius, A, 2019)	0.51
" The aim of this study is to investigate the efficacy of pemetrexed combined with platinum chemotherapy in patients with HER2-mutant and HER2 wild-type lung adenocarcinoma."	( [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung  Adenocarcinoma]. Li, B; Li, P; Li, X; Shen, S; Shi, Y; Zhang, F, 2019)	0.51
"HER2-mutant lung adenocarcinoma patients with first-line pemetrexed combined with platinum chemotherapy have greater clinical benefit than HER2 wild-type patients."	( [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung  Adenocarcinoma]. Li, B; Li, P; Li, X; Shen, S; Shi, Y; Zhang, F, 2019)	0.51
" Conclusion At 15 mg/kg weekly, GSK3052230 was well tolerated in combination with pemetrexed/cisplatin and durable responses were observed."	( A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Baker-Neblett, K; Bellovin, DI; DeYoung, MP; Dómine, M; Fennell, DA; Gadgeel, S; Kindler, HL; Kostorov, V; Levchenko, E; López, PG; Mitrica, I; Morgensztern, D; Orlov, S; Schellens, JHM; Trigo, J; van Brummelen, EMJ; Vansteenkiste, JF; Vasquez, J; Viteri, S; Wang, X; Yan, L; Zauderer, MG, 2020)	0.56
" In this study, we evaluated whether MWA combined with chemotherapy could improve progression-free survival (PFS) of patients with stage IV lung adenocarcinoma compared with chemotherapy alone."	( Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone. Li, C; Shao, JB; Sun, ZG; Wang, J; Zhang, N; Zhu, LM, 2019)	0.51
"A total of 49 patients were enrolled into the study; 21 patients accepted MWA therapy combined with chemotherapy, 28 patients accepted only chemotherapy."	( Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone. Li, C; Shao, JB; Sun, ZG; Wang, J; Zhang, N; Zhu, LM, 2019)	0.51
" Cox multivariate regression demonstrated that MWA combined with chemotherapy was the independent factor for both the PFS and TTLP."	( Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone. Li, C; Shao, JB; Sun, ZG; Wang, J; Zhang, N; Zhu, LM, 2019)	0.51
"MWA, as a topical treatment method, when combined with chemotherapy improved the PFS and TTLP of patients with stage IV lung adenocarcinoma."	( Microwave ablation combined with chemotherapy improved progression free survival of IV stage lung adenocarcinoma patients compared with chemotherapy alone. Li, C; Shao, JB; Sun, ZG; Wang, J; Zhang, N; Zhu, LM, 2019)	0.51
"Antiangiogenic agents combined with chemotherapy have efficacy in the treatment of unresectable malignant pleural mesothelioma (MPM)."	( Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). Box-Noriega, B; Fossella, FV; Gadgeel, S; Gandara, DR; Heymach, JV; Hueftle, JG; Kelly, K; Lu, C; Miao, J; Redman, MW; Tsao, AS; Velasco, MR; Vogelzang, NJ; Wistuba, II, 2019)	0.51
" The efficacy was significantly improved after lobaplatin combined with pemetrexed, temozolomide and bevacizumab."	( Chemotherapy combined with bevacizumab for the treatment of advanced lung adenocarcinoma cancer harboring EGFR-ANXA2, EGFR-RAD51, ATR and BRCA2 mutations: A case report. Cheng, Y; Huang, Z; Li, H; Liu, J; Liu, Y; Zhang, S; Zhong, R, 2020)	0.56
"To study the treatment of advanced lung adenocarcinoma in the elderly with pemetrexed combined with platinum drugs."	( Study on the treatment of advanced lung adenocarcinoma in the elderly with pemetrexed combined with platinum drugs. Ba, X; Bian, L; Han, J; Zhao, G, 2019)	0.51
" This study aimed to investigate VEGFA messenger RNA expression in patients with EGFR mutation, and to further compare the efficacy of bevacizumab combined with platinum-based chemotherapy between EGFR-mutant and wild-type patients."	( Potential Benefits of Bevacizumab Combined With Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer Patients With EGFR Mutation. Gen, S; Hase, T; Hasegawa, Y; Hashimoto, N; Kodama, Y; Matsui, A; Miyazawa, A; Morise, M; Sato, M; Tamiya, Y; Tanaka, I, 2020)	0.56
" The patients in MPC group were treated with microwave ablation (MWA) combined with PC while patients in MGC group were given MWA combined with gemcitabine plus cisplatin (GC)."	( Comparative clinical study on microwave ablation combined with gemcitabine and cisplatin or combined with pemetrexed and cisplatin in treatment of advanced NSCLC. Feng, Y; Wang, L; Wu, Y; Zhang, Y; Zhou, Y, 2020)	0.56
"We utilized syngeneic mouse models of MPM and lung cancer and assessed the therapeutic effects of anti-PD-1 antibody and its combination with cisplatin (CDDP) and pemetrexed (PEM)."	( Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells. Goto, H; Hanibuchi, M; Ishizawa, K; Kishuku, M; Koyama, K; Kozai, H; Mitsuhashi, A; Nishioka, Y; Ogawa, H; Ogino, H; Otsuka, K; Saijo, A; Tobiume, M; Yoneda, H, 2020)	0.56
"For patients with advanced non-small-cell lung cancer and gradual progression who are EGFR-T790M mutation negative after initial EGFR-TKI therapy, EGFR-TKI combined with chemotherapy confers longer PFS and overall survival than sequential EGFR-TKI and chemotherapy does."	( EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study. Chang, Q; Chu, T; Han, B; Lou, Y; Lv, M; Qian, J; Qiang, H; Teng, J; Xu, J; Zhang, Y; Zhao, Y; Zhong, R, 2021)	0.62
"This phase 2 study explored tislelizumab, an anti-PD-1 antibody, in combination with platinum-based chemotherapy as first-line treatment of advanced lung cancer."	( A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. Cheng, Y; Cui, J; Leaw, SJ; Liu, Z; Ma, X; Ma, Y; Ma, Z; Shu, Y; Tan, W; Wang, J; Wang, Z; Wu, Y; Zhang, Y; Zhao, J, 2020)	0.56
" All patients received tislelizumab 200 mg in combination with 4-6 cycles of platinum-doublet."	( A Phase 2 Study of Tislelizumab in Combination With Platinum-Based Chemotherapy as First-line Treatment for Advanced Lung Cancer in Chinese Patients. Cheng, Y; Cui, J; Leaw, SJ; Liu, Z; Ma, X; Ma, Y; Ma, Z; Shu, Y; Tan, W; Wang, J; Wang, Z; Wu, Y; Zhang, Y; Zhao, J, 2020)	0.56
"This is the first study to explore the efficacy and safety of osimertinib combined with platinum-based chemotherapy in previously untreated NSCLC patients with EGFR-sensitizing mutations."	( A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). Asahina, H; Isobe, T; Kagamu, H; Kikuchi, T; Kobayashi, K; Maemondo, M; Morita, S; Oizumi, S; Okamoto, I; Seike, M; Sugio, K; Takahashi, K; Tanaka, K, 2021)	0.62
"This post hoc analysis assessed the safety of pemetrexed and platinum in combination with pembrolizumab, including time-to-onset and time-to-resolution of all-cause any-grade and grade ≥3 adverse events (AEs) and renal AEs."	( Safety of pemetrexed plus platinum in combination with pembrolizumab for metastatic nonsquamous non-small cell lung cancer: A post hoc analysis of KEYNOTE-189. Aerts, J; Gadgeel, SM; Garon, EB; Kim, JS; Muehlenbein, CE; Peterson, P; Rizzo, MT, 2021)	0.62
" To assess the optimal choice of first-line and maintenance treatment regimens, we performed a meta-analysis of prospective randomized controlled clinical trials (RCTs) of patients with NS-NSCLC on bevacizumab combined with chemotherapy."	( Clinical option of pemetrexed-based versus paclitaxel-based first-line chemotherapeutic regimens in combination with bevacizumab for advanced non-squamous non-small-cell lung cancer and optimal maintenance therapy: evidence from a meta-analysis of randomi Cao, R; Guo, YJ; Han, CB; Huang, LT; Jing, W; Ma, J; Song, J; Sun, L; Wang, YR; Zhang, SL; Zhang, XY; Zhao, JZ, 2021)	0.62
"When the patients of advanced non-squamous non-small cell lung cancer (NSCLC) have achieved remission by induction therapy, it is controversial that combination with bevacizumab is used as maintenance therapy."	( Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: A systematic review and meta-analysis. Hong, L; Kong, Y; Xu, J; Xu, X, 2021)	0.62
" The application of combination with bevacizumab, pemetrexed was studied in clinical trials of maintenance treatment for advanced NSCLC."	( Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: A systematic review and meta-analysis. Hong, L; Kong, Y; Xu, J; Xu, X, 2021)	0.62
" Compared with bevacizumab and pemetrexed, PFS of combination with bevacizumab was significantly improved (hazard ratio [HR] = 0."	( Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: A systematic review and meta-analysis. Hong, L; Kong, Y; Xu, J; Xu, X, 2021)	0.62
"PFS was significantly improved in patients with advanced non-squamous NSCLC who use bevacizumab combination with single-agent as maintenance treatment, but it does not translate into the advantages of OS; compared with bevacizumab, no PFS and OS benefits were found."	( Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: A systematic review and meta-analysis. Hong, L; Kong, Y; Xu, J; Xu, X, 2021)	0.62
" This study aimed to explore the real-world use of anti-diabetic agent metformin in combination with pemetrexed-based platinum doublets in a first-line setting."	( Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. Chang, GR; Chen, CM; Chen, W; Chong, KY; Cidem, A; Lin, CH; Staniczek, T; Tsai, YT; Wang, JL; Yen, CC, 2021)	0.62
" However, the clinical significance of immune checkpoint inhibitors combined with chemotherapy in elderly patients with NSCLC has not yet been fully understood."	( Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. Chihara, Y; Goto, Y; Hibino, M; Hiranuma, O; Iwasaku, M; Kaneko, Y; Kijima, T; Morimoto, K; Morimoto, Y; Nakao, A; Takayama, K; Takeda, T; Takeshita, M; Takumi, C; Uchino, J; Yamada, T; Yamaguchi, H; Yokoi, T, 2021)	0.62
"Pemetrexed (800 mg day 1), cis-platinum (40 mg day 1-3) combined with bevacizumab (400 mg day 1) every 3 weeks were administered to the patient."	( Erlotinib combined with bevacizumab and chemotherapy in first line osimertinib-resistant NSCLC patient with leptomeningeal metastasis: A case report. Li, M; Luo, N; Qi, Y; Wang, M; Zhu, F, 2021)	0.62
"Our prospective, open-label, single-arm phase II study investigated the safety and efficacy of DCVAC/LuCa (dendritic cell vaccines for lung cancer) combined with standard carboplatin/pemetrexed in advanced non-squamous (nsq) non-small-cell lung cancer (NSCLC)."	( Safety and efficacy of dendritic cell-based immunotherapy (DCVAC/LuCa) combined with carboplatin/pemetrexed for patients with advanced non-squamous non-small-cell lung cancer without oncogenic drivers. Cao, S; Han, B; Ling, X; Wang, H; Xu, J; Zhang, B; Zhang, X; Zhong, H; Zhong, R, 2022)	0.72
"We aimed to study the activity of chemotherapy in combination with pembrolizumab as first-line treatment in patients with stage IV ERBB2-mutated NSCLC."	( Pembrolizumab in Combination with Chemotherapy in Patients with ERBB2-Mutated Non-Small Cell Lung Cancer. Abu Rous, F; Gadgeel, S; Gutta, R; Halmos, B; Li, P, 2022)	0.72
" We hypothesize that Src kinase inhibitors, including Bosutinib, may exhibit clinical synergy in combination with the antifolate drug pemetrexed."	( A Phase I Study of the Non-Receptor Kinase Inhibitor Bosutinib in Combination with Pemetrexed in Patients with Selected Metastatic Solid Tumors. Karim, NA; Khaled, A; Morris, JC; Patel, N; Pulliam, S; Shoukier, M; Ullah, A; Wang, H, 2022)	0.72
" Chemotherapy of pemetrexed and cisplatin combined with antiangiogenic therapy of bevacizumab is recommended as the first-line regimen by guidelines."	( Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma. Guo, W; Huang, X; Liang, J; Lv, Y; Zhang, D, 2022)	0.72
"He received firstly pemetrexed combined with platinum and bevacizumab, which barely curbed disease progression; When the first line treatment failed, he was switched to tislelizumab combined with anlotinib."	( Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma. Guo, W; Huang, X; Liang, J; Lv, Y; Zhang, D, 2022)	0.72
"Tislelizumab combined with anlotinib significantly relieved his clinical symptoms, and imaging examination further validated the improvement."	( Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma. Guo, W; Huang, X; Liang, J; Lv, Y; Zhang, D, 2022)	0.72
"The case firstly demonstrated the efficacy of tislelizumab combined with anlotinib in the second-line management of MPM."	( Tislelizumab combined with anlotinib in the second-line treatment of malignant pleural mesothelioma. Guo, W; Huang, X; Liang, J; Lv, Y; Zhang, D, 2022)	0.72
" Patients in each group were randomly treated with EGFR-tyrosine kinase inhibitor (TKI) monotherapy or EGFR-TKI combined with pemetrexed in a ratio of 1:1."	( EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study. Feng, W; Gu, W; He, M; Li, M; Li, Z; Liang, J; Lu, Y; Shi, X; Wang, F; Yang, S; Ye, Z; You, D; Zhang, H, 2023)	0.91
" There were no significant differences in PFS between patients with and without concomitant and between patients received TKI monotherapy and TKI combined with pemetrexed (p=0."	( EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-mutated NSCLC: A Prospective, Randomized, Exploratory Study. Feng, W; Gu, W; He, M; Li, M; Li, Z; Liang, J; Lu, Y; Shi, X; Wang, F; Yang, S; Ye, Z; You, D; Zhang, H, 2023)	0.91
"Chemotherapy, in combination with immune checkpoint blockade (ICB) targeting to programmed death-1 (PD-1) or its ligand PD-L1, is one of the first-line treatments for patients with advanced non-small-cell lung cancer (NSCLC)."	( Pemetrexed combined with dual immune checkpoint blockade enhances cytotoxic T lymphocytes against lung cancer. Chen, MC; Chiu, SC; Cho, DY; Huang, SW; Hung, MY; Jan, CI; Li, YH; Pan, CM, 2023)	0.91
"The Atezo-Brain study evaluated atezolizumab combined with chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) with untreated brain metastases, a population traditionally excluded from trials."	( Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05). Blasco, A; Bruna, J; De Castro, J; Estival, A; Felip, E; Guirado, M; Huidobro, G; Juan, O; López, R; Massutí, B; Mosquera, J; Nadal, E; Navarro, V; Pereira, E; Rodríguez-Abreu, D; Simó, M; Sullivan, I; Vilariño, N, 2023)	0.91

Excerpt	Reference	Relevance
"The LUX-Lung 3 study investigated the efficacy of chemotherapy compared with afatinib, a selective, orally bioavailable ErbB family blocker that irreversibly blocks signaling from epidermal growth factor receptor (EGFR/ErbB1), human epidermal growth factor receptor 2 (HER2/ErbB2), and ErbB4 and has wide-spectrum preclinical activity against EGFR mutations."	( Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Bennouna, J; Boyer, M; Geater, SL; Gorbunova, V; Hirsh, V; Kato, T; Lee, KH; Massey, D; Mok, T; O'Byrne, K; Orlov, S; Schuler, M; Sequist, LV; Shah, R; Shahidi, M; Su, WC; Tsai, CM; Yamamoto, N; Yang, JC; Zazulina, V, 2013)	0.39
" In mice xenografted with NCI-H2228 cells expressing EML4-ALK, orally administered ASP3026 was well absorbed in tumor tissues, reaching concentrations >10-fold higher than those in plasma, and induced tumor regression with a wide therapeutic margin between efficacious and toxic doses."	( The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice. Doihara, H; Furutani, T; Fushiki, H; Konagai, S; Kondoh, Y; Kudoh, M; Kuromitsu, S; Mori, K; Mori, M; Saito, R; Sakagami, H; Shimada, I; Shindou, N; Soga, T; Ueno, Y, 2014)	0.4
" However, effective delivery of drugs in combination at the tumor site is marred by low bioavailability and systemic toxicity of individual drugs."	( Synergistic activity of combination therapy with PEGylated pemetrexed and gemcitabine for an effective cancer treatment. Sahoo, SK; Vandana, M, 2015)	0.42
" The oral administration of drug complex in rats revealed high bioavailability (22."	( Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer. Alam, F; Byun, Y; Choi, JU; Jeon, OC; Lee, DS; Lee, S; Maharjan, R; Mahmud, F; Park, J; Park, JW, 2018)	0.48
" Therefore, the oral bioavailability of HP-beta-CD/PMX/DCK/P188-NE in rats was evaluated as 26."	( Enhanced oral absorption of pemetrexed by ion-pairing complex formation with deoxycholic acid derivative and multiple nanoemulsion formulations: preparation, characterization, and in vivo oral bioavailability and anticancer effect. Byun, Y; Choi, JU; Pangeni, R; Panthi, VK; Park, JW, 2018)	0.48
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" This resulted in a 282% improvement in oral bioavailability in rats."	( Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity. Byun, Y; Chang, KY; Choi, JU; Jha, SK; Kang, SH; Maharjan, R; Pangeni, R; Park, JW; Subedi, L, 2021)	0.62

Excerpt	Relevance	Reference
" The 3-weekly dosing schedule was chosen for phase II evaluation."	( Clinical studies with MTA. Calvert, AH; Walling, JM, 1998)	0.3
" The every three week dosing schedule has proven to be convenient and easy to administer and the clinical toxicities of LY231514 seem to be well tolerated."	( Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Chen, VJ; Habeck, LL; Mendelsohn, LG; Schultz, RM; Shih, C, 1998)	0.3
" Three dosing schedules have been investigated in the phase I setting: daily x5 every 21 days, weekly x4 every 42 days, and once every 21 days."	( Overview of phase I trials of multitargeted antifolate (MTA, LY231514). Rinaldi, DA, 1999)	0.3
" The present data suggest the potential clinical efficacy of combining Alimta administration with radiotherapy for Alimta-sensitive cells and indicate that further testing needs to be conducted to optimize the dosing schedule to enhance the interaction between the therapeutic agents."	( Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation. Mauceri, HJ; Salloum, RM; Seetharam, S; Vokes, EE; Weichselbaum, RR, 2001)	0.31
" The marked improvement in toxicity and tolerance with vitamin supplementation suggests the need to reexamine optimal dosing in pemetrexed combination schedules."	( Pemetrexed in advanced colorectal cancer. de Gramont, A; Louvet, C, 2004)	0.32
" Ongoing and future studies will establish optimal dosing regimens of pemetrexed and potential benefits of vitamin supplementation in the settings of metastatic breast cancer and gynecologic malignancies."	( Phase II studies of pemetrexed in metastatic breast and gynecologic cancers. Smith, I, 2004)	0.32
" Additional studies are needed to define appropriate dosing for renally impaired patients receiving higher dose pemetrexed with vitamin supplementation."	( Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. Baker, SD; Chaudhary, AK; Chaudhuri, T; Goetz, A; Hammond, LA; Johnson, RD; Latz, JE; Mita, AC; Molpus, K; Patnaik, A; Rowinsky, EK; Sandler, A; Simms, L; Sweeney, CJ; Takimoto, CH; Tolcher, AW; Villalona-Calero, M, 2006)	0.33
"Pemetrexed (500 mg/m(2)) with vitamin supplementation is well tolerated and requires no dosage adjustment when coadministered with aspirin (in patients with CrCl > or =60 mL/min) or ibuprofen (in patients with CrCl > or =80 mL/min)."	( Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer. Baker, SD; Battiato, L; Chaudhary, AK; Chaudhuri, T; Cleverly, A; Fife, K; Krull, JH; Latz, JE; Mita, AC; Murry, DJ; Rowinsky, EK; Sandler, A; Sweeney, CJ; Takimoto, CH, 2006)	0.33
" Finally, dosing and administration are reviewed, including appropriate premedication."	( Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy. Shah, SR; Stanford, BL; Villela, LR, 2006)	0.33
" No clear dose-response relationship could be established."	( Use of pemetrexed in breast cancer. Dittrich, C, 2006)	0.33
" Pemetrexed dosing was 500 mg/m and carboplatin was AUC (area under the curve) 5 once every 3 weeks."	( Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. Perell, K; Sundstrøm, S; Sørensen, JB; Thielsen, AK, 2007)	0.34
"Chemonaive patients with stage IIIB/IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 to 2 received either 500 mg/m2 of pemetrexed (day 1, every 3 weeks) for eight cycles, or the same dosage of pemetrexed for cycles 1 and 2 and then 1200 mg/m2 of gemcitabine (days 1 and 8, every 3 weeks) for cycles 3 and 4 (repeated once for a total of eight cycles)."	( Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: a multicenter, randomized, phase II trial. Caffo, O; Favaretto, A; Gregorc, V; Gridelli, C; Kaukel, E; Manegold, C; Martoni, A; Migliorino, MR; Müller, TR; Muñoz, M; Peterson, P; Reck, M; Rossi, A; Russo, F; Schmittel, A, 2007)	0.34
" At level 1, 4/6 patients experienced DLTs; dosing decreased to level 0 and 4/5 patients experienced DLTs."	( Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium. Atienza, D; Awasthi, S; Berry, W; Delaune, R; Deutsch, M; Dien, PY; Gregory, TF; Hood, K; Hutson, TE; Ilegbodu, D; Kolodziej, MJ; Mull, S; Muscato, JJ; Nicol, S; Raju, RN; Ruxer, RL; Vukelja, S, 2008)	0.35
"This phase III randomized trial compared pemetrexed 500 mg/m(2) (P500) with pemetrexed 900 mg/m(2) (P900) to determine whether higher dosing benefits non-small-cell lung cancer (NSCLC) patients as second-line therapy."	( A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer. Cullen, MH; Fischer, JR; Iscoe, N; Joy, AA; Novello, S; Peterson, P; Sörenson, S; Visseren-Grul, CM; Zatloukal, P; Zereu, M, 2008)	0.35
"The Pem/Cis combination provides promising activity and an acceptable safety profile for chemonaive Japanese MPM patients with the same recommend dosage and schedule used in rest of the world."	( Efficacy and safety of pemetrexed in combination with cisplatin for malignant pleural mesothelioma: a phase I/II study in Japanese patients. Adachi, S; Fukuoka, M; Gemba, K; Hida, T; Ichinose, Y; Kunitoh, H; Nakagawa, K; Nambu, Y; Saijo, N; Shinkai, T; Yamazaki, K, 2008)	0.35
" We defined each agent's clinical potency index (CPI) as the AUC achieved with standard pediatric dosing regimens divided by the in vitro IC50."	( Clinical potency of methotrexate, aminopterin, talotrexin and pemetrexed in childhood leukemias. Adamson, PC; Norris, RE, 2010)	0.36
" This review summarizes the background, scientific rationale and early clinical data in support of intercalation of intermittent erlotinib dosing with pemetrexed as a means of achieving pharmacodynamic separation."	( Intercalation of erlotinib and pemetrexed in the treatment of non-small cell lung cancer. Gandara, DR; Lara, PN; Li, T; Mack, PC; Perez-Soler, R, 2010)	0.36
" Hematologic toxicities limiting day 8 gemcitabine dosing were observed in the first 20 patients, prompting a protocol amendment to evaluate pemetrexed 500 mg/m2 followed by gemcitabine 1500 mg/m2 on day 1 of a 14-day cycle."	( A phase II trial of pemetrexed and gemcitabine in patients with metastatic breast cancer who have received prior taxane therapy. Elias, AD; Gralow, J; Muscato, J; Neubauer, M; O'Shaughnessy, JA; Orlando, M; Pippen, J; Shonukan, O; Stokoe, C; Vaughn, LG; Wang, Y, 2010)	0.36
" The enzastaurin dosing regimen (QD or BID) had no effect on pemetrexed pharmacokinetics."	( A phase I study of enzastaurin combined with pemetrexed in advanced non-small cell lung cancer. Baldwin, JR; Koshiji, M; Kunitoh, H; Murakami, H; Nakamura, Y; Nokihara, H; Ohe, Y; Shukuya, T; Takahashi, T; Tamura, T; Tanai, C; Yamamoto, N, 2010)	0.36
"Sunitinib was administered once daily on a continuous daily dosing (CDD) schedule (37."	( Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Fumita, S; Hashimoto, J; Ichikawa, Y; Kimura, N; Miyazaki, M; Nakagawa, K; Ohki, E; Okamoto, I; Shimizu, T; Takeda, M; Terashima, M; Tsurutani, J, 2012)	0.38
" Treatment durations and dosing were derived from randomized controlled trials, FDA labeling, and National Comprehensive Cancer Network guidelines."	( Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer. Carlson, JJ; Reyes, C; Veenstra, DL; Wong, WB, 2011)	0.37
"Using a 3 + 3 dose-escalation design, patients received oral sunitinib qd by continuous daily dosing (CDD schedule; 37."	( A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Blais, N; Camidge, DR; Canil, C; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; McWilliam, M; Ruiz-Garcia, A; Thall, A; Tye, L; Zhang, K, 2012)	0.38
" The antitumor activity, different dosing sequences, and dosing regimens of TH-302 in combination with commonly used conventional chemotherapeutics were investigated in human tumor xenograft models."	( TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y, 2012)	0.38
" Simultaneous administration of TH-302 and chemotherapeutics increased toxicity versus schedules with dosing separations."	( TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Ahluwalia, D; Ammons, WS; Baker, AF; Cranmer, LD; Curd, JG; Duan, JX; Ferraro, D; Hart, CP; Liu, Q; Matteucci, MD; Sun, JD; Wang, J; Wang, Y, 2012)	0.38
" Both groups had one patient who reduced dosage because of myelosuppression (grade IV)."	( [Effects of EGFR-TKIs on sequential pemetrexed for advanced pulmonary adenocarcinoma]. Gao, Z; Han, B; Jiang, L; Jiang, Y; Liu, Y; Wang, X, 2012)	0.38
" One patient dosed at 4 mg kg(-1) experienced grade 3 hypophosphatemia (dose-limiting toxicity; DLT), which prompted a cohort expansion."	( A phase I dose-escalation study of aflibercept administered in combination with pemetrexed and cisplatin in patients with advanced solid tumours. Colevas, AD; Diaz-Padilla, I; Gao, B; Lawson, EB; Leighl, NB; Lisano, J; Liu, L; Neal, JW; Razak, AR; San Pedro-Salcedo, M; Shepherd, FA; Siu, LL; Thibault, A; Wakelee, HA, 2012)	0.38
" Pemetrexed was given at the dosage of 500 mg/m(2) on day 1, with folic acid and vitamin B12 supplementation, each cycle repeated every 3 weeks."	( Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy. Huang, P; Huang, Y; Wang, F; Wu, J; Zhang, L; Zhang, Y; Zhao, L, 2012)	0.38
"5 or 50 mg) qd on a continuous daily dosing (CDD) schedule or Schedule 2/1 (2 weeks on, 1 week off treatment) plus pemetrexed (400 or 500 mg/m(2) IV) and cisplatin (75 mg/m(2) IV) q3w up to 6 cycles."	( Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Doebele, RC; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K, 2013)	0.39
" Double dosage of gefitinib (500 mg per day) together with pemetrexed were given as the second-line therapy after the patient developed new brain lesions and leptomeningeal metastasis during the maintenance therapy of gefitinib."	( Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib. Fang, X; Hu, Y; Li, M; Ma, S; Shen, H; Tan, C; Yuan, Y, 2012)	0.38
" However, the dosage and period of medication was not fully verified."	( [Effectiveness of steroids for the rash side effect of pemetrexed]. Ishikawa, H; Kobayashi, R; Ohashi, Y; Onishi, T; Shino, M; Suzuki, K; Yamamoto, N, 2013)	0.39
" Decreasing the price or adjusting the dosage of pemetrexed may be a better option for meeting the treatment demands of Chinese patients."	( Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system. Chen, G; Li, J; Ouyang, L; Peng, L; Tan, C; Wan, X; Wang, S; Zeng, X; Zhao, Z, 2013)	0.39
"In this phase I dose-escalation study, patients received oral sunitinib on a continuous daily dosing (CDD) schedule (37."	( Sunitinib combined with pemetrexed and carboplatin in patients with advanced solid malignancies--results of a phase I dose-escalation study. Blais, N; Camidge, DR; Chao, RC; Chow, LQ; Diab, SG; Jonker, DJ; Laurie, SA; Ruiz-Garcia, A; Soulières, D; Thall, A; Zhang, K, 2013)	0.39
" Pulsed dosing conferred no apparent safety or dose advantage."	( A phase I, dose-escalation trial of continuous- and pulsed-dose afatinib combined with pemetrexed in patients with advanced solid tumors. Chand, VK; Chu, QS; Hirte, HW; Hotte, SJ; Sangha, R; Schnell, D; Sergenson, G, 2014)	0.4
"During phase Ib, E+P was tolerated only at a markedly lower dosing intensity relative to the eribulin monotherapy regimen approved for breast cancer and used in phase II studies of NSCLC."	( An open-label, multicenter, randomized phase Ib/II study of eribulin mesylate administered in combination with pemetrexed versus pemetrexed alone as second-line therapy in patients with advanced nonsquamous non-small-cell lung cancer. Bondarenko, I; Dave, H; Freeman, A; Hodge, JP; Huber, B; Lieberman, R; Shelton, MJ; Shparyk, Y; Vynnychenko, I; Waller, CF, 2015)	0.42
" Targeted therapies do not require any adjustment of the dosage in case of moderate or severe renal insufficiency but adapting the doses of biphosphonates to renal function is necessary."	( [Impact of lung cancer treatments on renal function]. Belaiche, S; Couraud, S; Moro-Sibilot, D; Sakhri, L; Toffart, AC, 2014)	0.4
" In addition, the homocysteine blood concentration just before the first cycle dosage of pemetrexed was significantly elevated relative to the 2-3 cycle."	( Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy. Hosomi, Y; Nagamata, M; Nakahara, Y; Okamura, T; Okuma, Y; Shimokawa, T; Sunami, K; Takagi, Y; Takahashi, S; Watanabe, K; Yomota, M, 2016)	0.43
"2% completed their planned dosage within a 9-week feasibility time frame."	( Reduced folate and serum vitamin metabolites in patients with rectal carcinoma: an open-label feasibility study of pemetrexed with folic acid and vitamin B12 supplementation. Björkqvist, HG; Carlsson, GU; Gustavsson, BG; Kurlberg, GK; Odin, EA; Stoffregen, CC; Tångefjord, MT, 2016)	0.43
" Because dosing delays and modifications were associated with the MTD, the recommended phase II dose was declared to be pemetrexed 500 mg/m2 every 14 days with oral sorafenib 400 mg given twice daily on days 1-5."	( Phase I study of pemetrexed with sorafenib in advanced solid tumors. Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W, 2016)	0.43
" Cohort B involved a modified schedule of sorafenib dosing on days 1-5 of each 14-day pemetrexed cycle."	( Phase I study of pemetrexed with sorafenib in advanced solid tumors. Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W, 2016)	0.43
" Pemetrexed was added to vinflunine dosed at 280 mg/m2 on day 1 of a 21-day cycle."	( Combined treatment with pemetrexed and vinflunine in patients with metastatic urothelial cell carcinoma after prior platinum-containing chemotherapy - results of an exploratory phase I study. Agerbæk, M; Pappot, H; Ullén, A; von der Maase, H, 2018)	0.48
"This study has identified a truncated dosing regimen and recommended phase II dose of demcizumab (5 mg/kg q3-weekly ×4) for subsequent clinical evaluation in combination with standard carboplatin and pemetrexed chemotherapy."	( Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC. Harris, DL; Hidalgo, M; Hughes, BGM; Jameson, MB; Kapoun, AM; Kotasek, D; Markman, B; McKeage, MJ; Millward, MJ; Stagg, RJ; Xu, L, 2018)	0.48
" Furthermore, the combination index and dose reduction index values indicated that the cSBL + pemetrexed combination showed the highest synergism, and thus potential for reducing dosage of each drug, compared with the other combinations, including the existing pemetrexed + cisplatin regimen."	( Sialic acid-binding lectin from bullfrog eggs inhibits human malignant mesothelioma cell growth in vitro and in vivo. Hara, A; Hosono, M; Satoh, T; Sugawara, S; Tatsuta, T, 2018)	0.48
" One-month toxicity study confirmed that daily dosing of oral pemetrexed is safe by investigating apoptosis in the gut tissues from mice."	( Oral pemetrexed facilitates low-dose metronomic therapy and enhances antitumor efficacy in lung cancer. Alam, F; Byun, Y; Choi, JU; Jeon, OC; Lee, DS; Lee, S; Maharjan, R; Mahmud, F; Park, J; Park, JW, 2018)	0.48
" In patients administered maintenance treatment, rh-endostatin plus pemetrexed was associated with prolonged PFS compared to single-agent pemetrexed when PFS was calculated from first dosing (13."	( Efficacy and safety of rh-endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh-endostatin plus pemetrexed maintenance in non-small cell lung cancer: A retrospective comparison with standard chemotherapy. He, X; Jin, J; Pi, J; Shi, Y; Zhou, S; Zuo, L, 2018)	0.48
" Dosing is based on body surface are (BSA), while renal function is the only determinant for exposure and thus toxicity."	( Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. Agterhuis, DE; Burger, DM; Croes, S; de Rouw, N; Derijks, HJ; Dingemans, AM; Posthuma, R; Schoenmaekers, JJAO; Ter Heine, R, 2019)	0.51
"Altogether, we showed that pharmacokinetically-guided dosing of pemetrexed may be a feasible strategy for patients with lung cancer and renal impairment."	( Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis. Agterhuis, DE; Burger, DM; Croes, S; de Rouw, N; Derijks, HJ; Dingemans, AM; Posthuma, R; Schoenmaekers, JJAO; Ter Heine, R, 2019)	0.51
" Results 36 patients were dosed at 10, 15, and 20 mg/kg doses of GSK3052230."	( A phase Ib study of GSK3052230, an FGF ligand trap in combination with pemetrexed and cisplatin in patients with malignant pleural mesothelioma. Baker-Neblett, K; Bellovin, DI; DeYoung, MP; Dómine, M; Fennell, DA; Gadgeel, S; Kindler, HL; Kostorov, V; Levchenko, E; López, PG; Mitrica, I; Morgensztern, D; Orlov, S; Schellens, JHM; Trigo, J; van Brummelen, EMJ; Vansteenkiste, JF; Vasquez, J; Viteri, S; Wang, X; Yan, L; Zauderer, MG, 2020)	0.56
" Intrathecal chemotherapy is the mainstay of treatment for NSCLC patients with LM, but the optimal drug, administration route and mode, and dosage remain unclear."	( [Use of Ommaya Reservoirs to Deliver Pemetrexed in Leptomeningeal Metastasis from Non-small Cell Lung Cancer: A Case Report and Review of the Literature]. Guo, A; Huang, M; Li, H; Lin, Y; Yin, Z, 2019)	0.51
" Although dosing is based on body surface area (BSA), large interindividual variability in pemetrexed plasma concentrations is observed."	( A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions. Aerts, JGJV; Burger, DM; de Rouw, N; Derijks, HJ; Koolen, SLW; Ter Heine, R; van den Heuvel, MM; Visser, S, 2020)	0.56
" Binimetinib 30 mg BID (dose level 1 [DL1]) or 45 mg BID (dose level 2 [DL2]) was given with standard doses of carboplatin and pemetrexed using an intermittent dosing schedule."	( A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. Albaba, H; Arif, S; Bradbury, PA; Chan, M; Chen, EX; Effendi, S; Fung, AS; Gill, S; Graham, DM; Law, JH; Le, LW; Leighl, NB; Pisters, KM; Rothenstein, J; Sawczak, M; Stockley, TL; Trinkaus, M; Zawisza, D; Zhang, T; Zurawska, U, 2021)	0.62
"In this study, we developed oral pemetrexed (PMX) for metronomic dosing to enhance antitumor immunity."	( Metronomic delivery of orally available pemetrexed-incorporated colloidal dispersions for boosting tumor-specific immunity. Byun, Y; Chang, KY; Choi, JU; Jha, SK; Kang, SH; Maharjan, R; Pangeni, R; Park, JW; Subedi, L, 2021)	0.62
" We postulate that individualized dosing reduces the incidence of neutropenia."	( The Pharmacoeconomic Benefits of Pemetrexed Dose Individualization in Patients With Lung Cancer. Boosman, RJ; Burger, DM; de Boer, M; de Rouw, N; Derijks, HJ; Frederix, GWJ; Lieverse, JE; Ter Heine, R; van den Heuvel, MM, 2022)	0.72
" The use of a low test dosing of cytotoxic drugs may aid in dose individualization without causing harm."	( Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof-of-concept study. Boosman, RJ; Burgers, JA; de Rouw, N; Huitema, ADR; Ter Heine, R, 2023)	0.91
"We show that test dosing of pemetrexed is feasible, but there seems no added value for a low test dosing in the dose individualization of pemetrexed."	( Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof-of-concept study. Boosman, RJ; Burgers, JA; de Rouw, N; Huitema, ADR; Ter Heine, R, 2023)	0.91
" Optimized dosing of pemetrexed based on renal function instead of body surface area (BSA) is hypothesized to reduce pharmacokinetic variability in systemic exposure and could therefore improve treatment outcomes."	( Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial. Biesma, B; Boosman, RJ; Burger, DM; Burgers, JA; Croes, S; de Rouw, N; Derijks, HJ; Dingemans, AC; Dumoulin, DW; Hendriks, LEL; Huitema, ADR; Mathijssen, RHJ; Piet, B; Pruis, MA; Ter Heine, R; van den Heuvel, MM, 2023)	0.91
"A multicenter randomized (1:1) controlled trial was performed to assess superiority of optimized dosing versus BSA-based dosing in patients who were eligible for pemetrexed-based chemotherapy."	( Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial. Biesma, B; Boosman, RJ; Burger, DM; Burgers, JA; Croes, S; de Rouw, N; Derijks, HJ; Dingemans, AC; Dumoulin, DW; Hendriks, LEL; Huitema, ADR; Mathijssen, RHJ; Piet, B; Pruis, MA; Ter Heine, R; van den Heuvel, MM, 2023)	0.91
" The AUC of pemetrexed was similar between the optimized dosing arm (n = 37) and the standard of care arm (n = 44) (155 mg × h/L vs 160 mg × h/L (p = 0."	( Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial. Biesma, B; Boosman, RJ; Burger, DM; Burgers, JA; Croes, S; de Rouw, N; Derijks, HJ; Dingemans, AC; Dumoulin, DW; Hendriks, LEL; Huitema, ADR; Mathijssen, RHJ; Piet, B; Pruis, MA; Ter Heine, R; van den Heuvel, MM, 2023)	0.91
"We could not show superiority of optimized dosing of pemetrexed in patients with an adequate renal function does not show added value on the attainment of a pharmacokinetic endpoint, safety, nor QoL compared to standard of care dosing."	( Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial. Biesma, B; Boosman, RJ; Burger, DM; Burgers, JA; Croes, S; de Rouw, N; Derijks, HJ; Dingemans, AC; Dumoulin, DW; Hendriks, LEL; Huitema, ADR; Mathijssen, RHJ; Piet, B; Pruis, MA; Ter Heine, R; van den Heuvel, MM, 2023)	0.91
" Timely and individualized selection of the hormone dosage is essential for the treatment of immunotherapy-induced multisystem irAEs."	( Adverse reactions and efficacy of camrelizumab in patients with lung adenocarcinoma with high PD-L1 expression: A case report. Liu, X; Wang, Z; Wei, T, 2023)	0.91

Role	Description
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
antimetabolite	A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
EC 2.1.1.45 (thymidylate synthase) inhibitor	An EC 2.1.1.* (methyltransferases) inhibitor that interferes with the action of thymidylate synthase (EC 2.1.1.45).
EC 1.5.1.3 (dihydrofolate reductase) inhibitor	An EC 1.5.1.* (oxidoreductase acting on donor CH-NH group, NAD(+) or NADP(+) as acceptor) inhibitor that interferes with the action of dihydrofolate reductase (EC 1.5.1.3).
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor	An EC 2.1.2.* (hydroxymethyl-, formyl- and related transferases) inhibitor that interferes with the action of phosphoribosylglycinamide formyltransferase (EC 2.1.2.2).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
pyrrolopyrimidine
N-acyl-L-glutamic acid	Any optically active N-acylglutamic acid having L-configuration.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
EWS/FLI fusion protein	Homo sapiens (human)	Potency	0.3903	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
tyrosine-protein kinase Yes	Homo sapiens (human)	Potency	38.7088	0.0000	5.0182	79.2586	AID686947
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, Thymidylate Synthase	Escherichia coli	Ki	0.1090	0.1090	0.1090	0.1090	AID977610
Chain A, Thymidylate Synthase	Homo sapiens (human)	Ki	0.1090	0.1090	0.1090	0.1090	AID977610
Chain A, Thymidylate Synthase	Escherichia coli	Ki	0.1090	0.1090	0.1090	0.1090	AID977610
Thymidylate synthase	Escherichia coli	IC50 (µMol)	122.2385	0.0190	2.5896	10.0000	AID211439; AID211442; AID211446; AID240801; AID241657; AID260014; AID282387; AID282575; AID282789; AID312254; AID341439; AID391733; AID422633
Thymidylate synthase	Escherichia coli LF82	IC50 (µMol)	76.0000	0.0230	0.0355	0.0480	AID613094
Dihydrofolate reductase	Homo sapiens (human)	IC50 (µMol)	7.6762	0.0006	0.8726	7.3000	AID1663358; AID1663359; AID240641; AID241717; AID260039; AID282388; AID282571; AID282785; AID312256; AID341462; AID391734; AID422635; AID457195; AID56945; AID56964; AID56978; AID613096
Dihydrofolate reductase	Homo sapiens (human)	Ki	0.0071	0.0000	0.3756	4.9000	AID1894189; AID238926; AID513675
Dihydrofolate reductase	Mus musculus (house mouse)	Ki	0.5600	0.0000	0.2171	3.9000	AID57444
Dihydrofolate reductase	Lacticaseibacillus casei	IC50 (µMol)	173.0750	0.0013	0.2696	4.9000	AID241776; AID282573; AID57739; AID57759
Thymidylate synthase	Lacticaseibacillus casei	IC50 (µMol)	29.0000	0.0090	1.9324	8.8000	AID211645; AID211799; AID241751; AID282576
Thymidylate synthase	Lacticaseibacillus casei	Ki	0.5500	0.0100	1.6550	9.3900	AID212843
Thymidylate synthase	Homo sapiens (human)	IC50 (µMol)	15.8118	0.0066	2.0637	9.5000	AID1439756; AID1501141; AID1763184; AID212126; AID212157; AID212297; AID212301; AID240604; AID241683; AID260013; AID282386; AID282574; AID282788; AID312253; AID341428; AID391732; AID422632; AID457192; AID476562; AID613093; AID671163; AID740238
Thymidylate synthase	Homo sapiens (human)	Ki	0.1142	0.0001	0.3435	3.0000	AID1894188; AID238909; AID513674
Thymidylate synthase	Mus musculus (house mouse)	Ki	0.3400	0.0034	1.7375	9.3000	AID212657
Dihydrofolate reductase	Escherichia coli K-12	IC50 (µMol)	383.5250	0.0015	0.5512	6.8000	AID241682; AID282389; AID282572; AID282786; AID341469; AID391736; AID422636; AID457196; AID57235; AID57240; AID57243; AID613097
Folate receptor beta	Homo sapiens (human)	IC50 (µMol)	0.2585	0.0220	0.2658	0.8630	AID1164835; AID1164836; AID1380194; AID1380199; AID1512995; AID1512999
Folate receptor alpha	Homo sapiens (human)	IC50 (µMol)	0.2417	0.0150	0.1964	0.8940	AID1164833; AID1164834; AID1197480; AID1380197; AID1380198; AID1512994
Dihydrofolate reductase	Pneumocystis carinii	IC50 (µMol)	230.0000	0.0006	0.5476	6.2000	AID55842
Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)	IC50 (µMol)	5.0285	0.0058	0.3122	3.0000	AID1197489; AID1501141; AID1513009; AID349815; AID362438; AID459869
Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)	Ki	0.6112	0.0060	0.2592	1.0000	AID1252445; AID1631997; AID1894190; AID513677
Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)	IC50 (µMol)	0.0700	0.0100	0.2600	0.7000	AID1501141
Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)	Ki	200.0000	0.4000	0.6400	0.8800	AID1709484
Reduced folate transporter	Homo sapiens (human)	IC50 (µMol)	0.0928	0.0007	0.0501	0.1380	AID1164831; AID1197478; AID1380195; AID1512992; AID1512997
Thymidylate synthase	Rattus norvegicus (Norway rat)	IC50 (µMol)	20.0000	0.3600	0.5400	0.9000	AID212677
Bifunctional dihydrofolate reductase-thymidylate synthase	Toxoplasma gondii	IC50 (µMol)	2.4780	0.0006	1.0428	10.0000	AID282787; AID282790; AID341451; AID341470; AID391735; AID391737; AID422634; AID422637; AID457194; AID457197; AID56187; AID56327; AID613095; AID613098; AID671165
Trifunctional purine biosynthetic protein adenosine-3	Mus musculus (house mouse)	IC50 (µMol)	20.0000	0.7800	0.7800	0.7800	AID349814; AID362437; AID459868
Proton-coupled folate transporter	Homo sapiens (human)	IC50 (µMol)	0.0229	0.0083	0.0612	0.1210	AID1164837; AID1197481; AID1380200; AID1512996; AID1512998
Proton-coupled folate transporter	Homo sapiens (human)	Ki	0.6776	0.0940	0.6776	2.5400	AID1380212; AID1513003; AID1631995; AID459865; AID459866; AID695098; AID695099
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Proton-coupled folate transporter	Homo sapiens (human)	K	0.1570	0.0440	0.1570	0.2700	AID1252439; AID1252440
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
tetrahydrobiopterin biosynthetic process	Dihydrofolate reductase	Homo sapiens (human)
one-carbon metabolic process	Dihydrofolate reductase	Homo sapiens (human)
negative regulation of translation	Dihydrofolate reductase	Homo sapiens (human)
axon regeneration	Dihydrofolate reductase	Homo sapiens (human)
response to methotrexate	Dihydrofolate reductase	Homo sapiens (human)
dihydrofolate metabolic process	Dihydrofolate reductase	Homo sapiens (human)
tetrahydrofolate metabolic process	Dihydrofolate reductase	Homo sapiens (human)
tetrahydrofolate biosynthetic process	Dihydrofolate reductase	Homo sapiens (human)
folic acid metabolic process	Dihydrofolate reductase	Homo sapiens (human)
positive regulation of nitric-oxide synthase activity	Dihydrofolate reductase	Homo sapiens (human)
regulation of removal of superoxide radicals	Dihydrofolate reductase	Homo sapiens (human)
dTMP biosynthetic process	Thymidylate synthase	Homo sapiens (human)
dTTP biosynthetic process	Thymidylate synthase	Homo sapiens (human)
circadian rhythm	Thymidylate synthase	Homo sapiens (human)
response to xenobiotic stimulus	Thymidylate synthase	Homo sapiens (human)
response to toxic substance	Thymidylate synthase	Homo sapiens (human)
negative regulation of translation	Thymidylate synthase	Homo sapiens (human)
uracil metabolic process	Thymidylate synthase	Homo sapiens (human)
methylation	Thymidylate synthase	Homo sapiens (human)
response to progesterone	Thymidylate synthase	Homo sapiens (human)
response to vitamin A	Thymidylate synthase	Homo sapiens (human)
response to cytokine	Thymidylate synthase	Homo sapiens (human)
tetrahydrofolate interconversion	Thymidylate synthase	Homo sapiens (human)
response to ethanol	Thymidylate synthase	Homo sapiens (human)
response to organophosphorus	Thymidylate synthase	Homo sapiens (human)
developmental growth	Thymidylate synthase	Homo sapiens (human)
cartilage development	Thymidylate synthase	Homo sapiens (human)
response to glucocorticoid	Thymidylate synthase	Homo sapiens (human)
response to folic acid	Thymidylate synthase	Homo sapiens (human)
intestinal epithelial cell maturation	Thymidylate synthase	Homo sapiens (human)
DNA biosynthetic process	Thymidylate synthase	Homo sapiens (human)
liver regeneration	Thymidylate synthase	Homo sapiens (human)
10-formyltetrahydrofolate biosynthetic process	Dihydrofolate reductase	Escherichia coli K-12
response to xenobiotic stimulus	Dihydrofolate reductase	Escherichia coli K-12
folic acid biosynthetic process	Dihydrofolate reductase	Escherichia coli K-12
one-carbon metabolic process	Dihydrofolate reductase	Escherichia coli K-12
response to methotrexate	Dihydrofolate reductase	Escherichia coli K-12
tetrahydrofolate biosynthetic process	Dihydrofolate reductase	Escherichia coli K-12
response to antibiotic	Dihydrofolate reductase	Escherichia coli K-12
dihydrofolate metabolic process	Dihydrofolate reductase	Escherichia coli K-12
folic acid metabolic process	Dihydrofolate reductase	Escherichia coli K-12
monocyte chemotaxis	Folate receptor beta	Homo sapiens (human)
inflammatory response	Folate receptor beta	Homo sapiens (human)
positive regulation of cell population proliferation	Folate receptor beta	Homo sapiens (human)
folic acid transport	Folate receptor beta	Homo sapiens (human)
cellular response to folic acid	Folate receptor beta	Homo sapiens (human)
cell adhesion	Folate receptor beta	Homo sapiens (human)
sperm-egg recognition	Folate receptor beta	Homo sapiens (human)
fusion of sperm to egg plasma membrane involved in single fertilization	Folate receptor beta	Homo sapiens (human)
heart looping	Folate receptor alpha	Homo sapiens (human)
neural crest cell migration involved in heart formation	Folate receptor alpha	Homo sapiens (human)
cardiac neural crest cell migration involved in outflow tract morphogenesis	Folate receptor alpha	Homo sapiens (human)
receptor-mediated endocytosis	Folate receptor alpha	Homo sapiens (human)
folic acid transport	Folate receptor alpha	Homo sapiens (human)
regulation of transforming growth factor beta receptor signaling pathway	Folate receptor alpha	Homo sapiens (human)
axon regeneration	Folate receptor alpha	Homo sapiens (human)
folic acid metabolic process	Folate receptor alpha	Homo sapiens (human)
regulation of canonical Wnt signaling pathway	Folate receptor alpha	Homo sapiens (human)
pharyngeal arch artery morphogenesis	Folate receptor alpha	Homo sapiens (human)
anterior neural tube closure	Folate receptor alpha	Homo sapiens (human)
cellular response to folic acid	Folate receptor alpha	Homo sapiens (human)
cell adhesion	Folate receptor alpha	Homo sapiens (human)
fusion of sperm to egg plasma membrane involved in single fertilization	Folate receptor alpha	Homo sapiens (human)
sperm-egg recognition	Folate receptor alpha	Homo sapiens (human)
brainstem development	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
GMP biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
'de novo' IMP biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
glycine metabolic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
purine ribonucleoside monophosphate biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
response to organic substance	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
response to inorganic substance	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
cerebellum development	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
cerebral cortex development	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
'de novo' AMP biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
tetrahydrofolate biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
'de novo' XMP biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
purine nucleotide biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
adenine biosynthetic process	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
brainstem development	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
nucleobase-containing compound metabolic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
GMP biosynthetic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
'de novo' IMP biosynthetic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
response to inorganic substance	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
cerebellum development	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
cerebral cortex development	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
animal organ regeneration	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
'de novo' AMP biosynthetic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
dihydrofolate metabolic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
tetrahydrofolate biosynthetic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
'de novo' XMP biosynthetic process	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
cellular response to interleukin-7	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
dTMP biosynthetic process	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
glycine metabolic process	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
L-serine metabolic process	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
L-serine catabolic process	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
purine nucleobase biosynthetic process	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
negative regulation of translation	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
tetrahydrofolate interconversion	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
tetrahydrofolate metabolic process	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
folic acid metabolic process	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
protein homotetramerization	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
cellular response to tetrahydrofolate	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
cellular response to leukemia inhibitory factor	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
glycine biosynthetic process from serine	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
carnitine biosynthetic process	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
xenobiotic transmembrane transport	Reduced folate transporter	Homo sapiens (human)
female pregnancy	Reduced folate transporter	Homo sapiens (human)
organic anion transport	Reduced folate transporter	Homo sapiens (human)
folic acid transport	Reduced folate transporter	Homo sapiens (human)
folic acid metabolic process	Reduced folate transporter	Homo sapiens (human)
methotrexate transport	Reduced folate transporter	Homo sapiens (human)
monoatomic anion transmembrane transport	Reduced folate transporter	Homo sapiens (human)
folate transmembrane transport	Reduced folate transporter	Homo sapiens (human)
cyclic-GMP-AMP transmembrane import across plasma membrane	Reduced folate transporter	Homo sapiens (human)
positive regulation of cGAS/STING signaling pathway	Reduced folate transporter	Homo sapiens (human)
transport across blood-brain barrier	Reduced folate transporter	Homo sapiens (human)
folate import across plasma membrane	Reduced folate transporter	Homo sapiens (human)
intracellular iron ion homeostasis	Proton-coupled folate transporter	Homo sapiens (human)
folic acid transport	Proton-coupled folate transporter	Homo sapiens (human)
heme transport	Proton-coupled folate transporter	Homo sapiens (human)
heme metabolic process	Proton-coupled folate transporter	Homo sapiens (human)
folic acid metabolic process	Proton-coupled folate transporter	Homo sapiens (human)
methotrexate transport	Proton-coupled folate transporter	Homo sapiens (human)
intestinal folate absorption	Proton-coupled folate transporter	Homo sapiens (human)
folate transmembrane transport	Proton-coupled folate transporter	Homo sapiens (human)
proton transmembrane transport	Proton-coupled folate transporter	Homo sapiens (human)
folate import across plasma membrane	Proton-coupled folate transporter	Homo sapiens (human)
transmembrane transport	Proton-coupled folate transporter	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
mRNA regulatory element binding translation repressor activity	Dihydrofolate reductase	Homo sapiens (human)
mRNA binding	Dihydrofolate reductase	Homo sapiens (human)
dihydrofolate reductase activity	Dihydrofolate reductase	Homo sapiens (human)
folic acid binding	Dihydrofolate reductase	Homo sapiens (human)
NADPH binding	Dihydrofolate reductase	Homo sapiens (human)
sequence-specific mRNA binding	Dihydrofolate reductase	Homo sapiens (human)
NADP binding	Dihydrofolate reductase	Homo sapiens (human)
mRNA regulatory element binding translation repressor activity	Thymidylate synthase	Homo sapiens (human)
thymidylate synthase activity	Thymidylate synthase	Homo sapiens (human)
folic acid binding	Thymidylate synthase	Homo sapiens (human)
protein homodimerization activity	Thymidylate synthase	Homo sapiens (human)
sequence-specific mRNA binding	Thymidylate synthase	Homo sapiens (human)
dihydrofolate reductase activity	Dihydrofolate reductase	Escherichia coli K-12
protein binding	Dihydrofolate reductase	Escherichia coli K-12
folic acid binding	Dihydrofolate reductase	Escherichia coli K-12
oxidoreductase activity	Dihydrofolate reductase	Escherichia coli K-12
NADP binding	Dihydrofolate reductase	Escherichia coli K-12
methotrexate binding	Dihydrofolate reductase	Escherichia coli K-12
dihydrofolic acid binding	Dihydrofolate reductase	Escherichia coli K-12
NADP+ binding	Dihydrofolate reductase	Escherichia coli K-12
NADPH binding	Dihydrofolate reductase	Escherichia coli K-12
folic acid binding	Folate receptor beta	Homo sapiens (human)
folic acid receptor activity	Folate receptor beta	Homo sapiens (human)
signaling receptor activity	Folate receptor beta	Homo sapiens (human)
protein binding	Folate receptor alpha	Homo sapiens (human)
folic acid binding	Folate receptor alpha	Homo sapiens (human)
folic acid receptor activity	Folate receptor alpha	Homo sapiens (human)
signaling receptor activity	Folate receptor alpha	Homo sapiens (human)
phosphoribosylamine-glycine ligase activity	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
phosphoribosylformylglycinamidine cyclo-ligase activity	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
phosphoribosylglycinamide formyltransferase activity	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
ATP binding	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
metal ion binding	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
IMP cyclohydrolase activity	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
protein homodimerization activity	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
cadherin binding	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
phosphoribosylaminoimidazolecarboxamide formyltransferase activity	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
mRNA regulatory element binding translation repressor activity	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
glycine hydroxymethyltransferase activity	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
protein binding	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
pyridoxal phosphate binding	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
small molecule binding	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
identical protein binding	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
protein homodimerization activity	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
mRNA 5'-UTR binding	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
serine binding	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
aldehyde-lyase activity	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
organic anion transmembrane transporter activity	Reduced folate transporter	Homo sapiens (human)
folic acid transmembrane transporter activity	Reduced folate transporter	Homo sapiens (human)
folate:monoatomic anion antiporter activity	Reduced folate transporter	Homo sapiens (human)
antiporter activity	Reduced folate transporter	Homo sapiens (human)
methotrexate transmembrane transporter activity	Reduced folate transporter	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Reduced folate transporter	Homo sapiens (human)
2',3'-cyclic GMP-AMP binding	Reduced folate transporter	Homo sapiens (human)
cyclic-GMP-AMP transmembrane transporter activity	Reduced folate transporter	Homo sapiens (human)
folic acid binding	Reduced folate transporter	Homo sapiens (human)
heme transmembrane transporter activity	Proton-coupled folate transporter	Homo sapiens (human)
folic acid binding	Proton-coupled folate transporter	Homo sapiens (human)
folic acid transmembrane transporter activity	Proton-coupled folate transporter	Homo sapiens (human)
proton transmembrane transporter activity	Proton-coupled folate transporter	Homo sapiens (human)
heme transmembrane transporter activity	Proton-coupled folate transporter	Homo sapiens (human)
symporter activity	Proton-coupled folate transporter	Homo sapiens (human)
methotrexate transmembrane transporter activity	Proton-coupled folate transporter	Homo sapiens (human)
folic acid:proton symporter activity	Proton-coupled folate transporter	Homo sapiens (human)
transmembrane transporter activity	Proton-coupled folate transporter	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
mitochondrion	Dihydrofolate reductase	Homo sapiens (human)
cytosol	Dihydrofolate reductase	Homo sapiens (human)
mitochondrion	Dihydrofolate reductase	Homo sapiens (human)
cytosol	Dihydrofolate reductase	Mus musculus (house mouse)
nucleus	Thymidylate synthase	Homo sapiens (human)
cytoplasm	Thymidylate synthase	Homo sapiens (human)
mitochondrion	Thymidylate synthase	Homo sapiens (human)
mitochondrial inner membrane	Thymidylate synthase	Homo sapiens (human)
mitochondrial matrix	Thymidylate synthase	Homo sapiens (human)
cytosol	Thymidylate synthase	Homo sapiens (human)
mitochondrion	Thymidylate synthase	Homo sapiens (human)
cytosol	Thymidylate synthase	Homo sapiens (human)
cytosol	Dihydrofolate reductase	Escherichia coli K-12
cytosol	Dihydrofolate reductase	Escherichia coli K-12
extracellular region	Folate receptor beta	Homo sapiens (human)
plasma membrane	Folate receptor beta	Homo sapiens (human)
external side of plasma membrane	Folate receptor beta	Homo sapiens (human)
cell surface	Folate receptor beta	Homo sapiens (human)
external side of plasma membrane	Folate receptor beta	Homo sapiens (human)
Golgi membrane	Folate receptor alpha	Homo sapiens (human)
endosome	Folate receptor alpha	Homo sapiens (human)
endoplasmic reticulum membrane	Folate receptor alpha	Homo sapiens (human)
plasma membrane	Folate receptor alpha	Homo sapiens (human)
external side of plasma membrane	Folate receptor alpha	Homo sapiens (human)
cell surface	Folate receptor alpha	Homo sapiens (human)
ER to Golgi transport vesicle membrane	Folate receptor alpha	Homo sapiens (human)
membrane	Folate receptor alpha	Homo sapiens (human)
basolateral plasma membrane	Folate receptor alpha	Homo sapiens (human)
apical plasma membrane	Folate receptor alpha	Homo sapiens (human)
transport vesicle	Folate receptor alpha	Homo sapiens (human)
clathrin-coated vesicle	Folate receptor alpha	Homo sapiens (human)
brush border membrane	Folate receptor alpha	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment membrane	Folate receptor alpha	Homo sapiens (human)
extracellular exosome	Folate receptor alpha	Homo sapiens (human)
nucleus	Folate receptor alpha	Homo sapiens (human)
external side of plasma membrane	Folate receptor alpha	Homo sapiens (human)
cytosol	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
cytosol	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
extracellular exosome	Trifunctional purine biosynthetic protein adenosine-3	Homo sapiens (human)
cytosol	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
plasma membrane	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
membrane	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
extracellular exosome	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
cytosol	Bifunctional purine biosynthesis protein ATIC	Homo sapiens (human)
nucleoplasm	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
cytosol	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
extracellular exosome	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
mitochondrion	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
nucleus	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
cytoplasm	Serine hydroxymethyltransferase, cytosolic	Homo sapiens (human)
plasma membrane	Reduced folate transporter	Homo sapiens (human)
basolateral plasma membrane	Reduced folate transporter	Homo sapiens (human)
apical plasma membrane	Reduced folate transporter	Homo sapiens (human)
brush border membrane	Reduced folate transporter	Homo sapiens (human)
basolateral plasma membrane	Reduced folate transporter	Homo sapiens (human)
plasma membrane	Reduced folate transporter	Homo sapiens (human)
apical plasma membrane	Reduced folate transporter	Homo sapiens (human)
plasma membrane	Proton-coupled folate transporter	Homo sapiens (human)
basolateral plasma membrane	Proton-coupled folate transporter	Homo sapiens (human)
cytoplasm	Proton-coupled folate transporter	Homo sapiens (human)
endosome	Proton-coupled folate transporter	Homo sapiens (human)
plasma membrane	Proton-coupled folate transporter	Homo sapiens (human)
cell surface	Proton-coupled folate transporter	Homo sapiens (human)
endosome membrane	Proton-coupled folate transporter	Homo sapiens (human)
basolateral plasma membrane	Proton-coupled folate transporter	Homo sapiens (human)
apical plasma membrane	Proton-coupled folate transporter	Homo sapiens (human)
brush border membrane	Proton-coupled folate transporter	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855	NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854	NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS	2023	Disease models & mechanisms, 03-01, Volume: 16, Issue:3	In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1562587	Antiproliferative activity against human KB cells in presence of thymidine	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID1380219	Toxicity in folate-deficient diet fed ICR SCID mouse assessed as body weight loss at 8.1 mg/kg, iv administered every 2 days for 4 times starting on day 3 measured twice per week	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID1513013	Anticlonogenic activity against human IGROV1 cells incubated for 24 hrs followed by compound wash out and measured after 10 days by methylene blue staining-based assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1501142	Antiproliferative activity against human SW620 cells in folate free medium after 72 hrs in presence of leucovorin by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID1398150	Effect on HSP90 protein expression in human IGROV1 cells by Western blot analysis	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth.
AID282574	Inhibition of human recombinant thymidylate synthase	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID671164	Inhibition of Escherichia coli thymidylate synthase	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
AID1513017	Antiproliferative activity against FRalpha knockout human IGROV1 KD4 cells after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1709484	Inhibition of human full length N-terminal His-tagged ATIC expressed in Chinese Hamster MTXRII-OuaR2-4 R2 cells assessed as reduction in THF formation using 10-CHOTHF as substrate by spectrophotometric method	2021	Bioorganic & medicinal chemistry, 05-01, Volume: 37	Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor
AID1236755	Antiproliferative activity against human HeLa cells at 100 ug/ml after 72 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID1198264	Cytotoxicity against human A549 cells assessed as growth inhibition after 72 hrs by MTT assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1062557	Cytotoxicity against chinese hamster R2 cells after 96 hrs by CellTitre-Blue fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1894190	Inhibition of GARFT (unknown origin) assessed as inhibition constant	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1501167	Induction of apoptosis in human KB cells assessed as early apoptotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 16.9%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID1197482	Cytotoxicity against PCFT-deficient Chinese hamster R2(VC) cells assessed as growth inhibition after 96 hrs by CellTiter-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
AID1512992	Binding affinity to human RFC expressed in Chinese hamster PC43-10 cells assessed as antiproliferative activity measured as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID605429	Growth inhibition of human A549 cells assessed as cell growth at 6.4 uM after 72 hrs by fluorometric microculture cytotoxicity assay in presence of 100 uM hypoxanthine relative to untreated control	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes.
AID621181	Inhibition of GARFTase in chinese hamster R2 cells expressing human PCFT assessed as incorporation of [14C]glycine into [14C]formyl GAR in the presence of 4 uM azaserine	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1360133	Selectivity index, ratio of CC50 for human HTB125 cells to IC50 for human A549 cells	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID341472	Selectivity for sToxoplasma gondii dihydrofolate reductase over human dihydrofolate reductase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID621123	Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID422633	Inhibition of Escherichia coli thymidylate synthase	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
AID341470	Inhibition of Toxoplasma gondii dihydrofolate reductase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID1062556	Cytotoxicity against chinese hamster RT16 cells expressing human FRalpha after 96 hrs by CellTitre-Blue fluorescence assay in presence of folic acid	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID621127	Antiproliferative activity against chinese hamster D4 cells expressing human FRbeta assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID391738	Selectivity ratio of IC50 for human recombinant DHFR to IC50 for Toxoplasma gondii DHFR	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.
AID72867	Compound was evaluated for the inhibitory activity against GAR transformylase purified from mouse L1210 cells	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.
AID1562580	Cytotoxicity against HUVEC assessed as reduction in cell viability after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID1236756	Antiproliferative activity against human T47D cells at 100 ug/ml after 24 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID1513004	Inhibition of human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as reduction in [3H]MTX uptake at pH 5.5 at 1 uM measured over 2 mins relative to control	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1053455	Growth inhibition of Chinese hamster PC43-10 cells after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID99486	Compound was evaluated for the half-maximal inhibition against mouse L1210 leukemic cell growth	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.
AID362437	Inhibition of mouse recombinant GARFTase	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1631997	Inhibition of recombinant N-terminal 6His-tagged human GARFTase assessed as formation of 5,8-dideazafolate from 10-formyl-5,8-dideazafolic acid measured at every 15 seconds over 20 min by spectrophotometric analysis	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesi
AID1380209	Inhibition of [3H]MTX uptake at human PCFT expressed in Chinese hamster R2/PCFT4 cells at 10 uM at pH 5.5 by scintillation counting method relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID1252421	Selectivity ratio of IC50 for human RFC expressed in Chinese hamster PC43-10 cells assessed as cell growth inhibition to IC50 for human FRalpha expressed in Chinese hamster RT16 cells assessed as cell growth inhibition	2015	Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17	6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
AID221803	Compound was evaluated for the half-maximal inhibition against human CCRF-CEM lymphoblastic leukemic cell growth	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.
AID1164833	Inhibition of FRalpha (unknown origin) expressed in Chinese hamster RT16 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID238926	Inhibition of recombinant human dihydrofolate reductase done at 37 degree C in pH 7.4 with compound	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID1198282	Cell cycle arrest in human KB cells assessed as accumulation at G2 phase at 1 uM after 96 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 34%)	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
AID1663358	Inhibition of DHFR in human KB cells expressing RFC/FRalpha/PCFT assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID613093	Inhibition of human TS assessed as oxidation of tetrahydrofolate to dihydrofolate after 2 to 12 mins by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1219361	Ratio of efflux clearance to clearance in brain measured in mouse at 0.3 uCi/ml by in vitro brain slice uptake technique	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID57243	Inhibitory concentration against isolated Escherichia coli Dihydrofolate reductase	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID1062535	Induction of apoptosis in human KB cells assessed as late apoptotic cells at 1 uM after 96 hrs by Annexin V-FITC/7-AAD staining-based flow cytometry (Rvb = 2.09%)	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID459864	Displacement of [3H]folic acid from human FRbeta expressed in Chinese hamster D4 cells relative to unlabeled folic acid	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID1380197	Binding affinity to human FR-alpha receptor expressed in Chinese hamster RT16 cells assessed as antiproliferative activity measured as reduction in cell viability after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID1380201	Growth inhibition of Chinese hamster R2(VC) cells after 96 hrs celltiter-blue assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID1562573	Antiproliferative activity against human KB cells assessed as reduction in cell viability after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID391734	Inhibition of human recombinant DHFR	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.
AID1513000	Selectivity ratio of IC50 for human RFC2 expressed in human HeLa R1-11 cells to IC50 for human PCFT4 expressed in human HeLa R1-11 cells	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1062530	Inhibition of AICARFTase in human KB cells assessed as phosphorylated AMPK at 1 uM after 48 hrs by Western blot analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID56327	Inhibitory concentration against isolated Toxoplasma gondii DHFR (dihydrofolate reductase)	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID1053449	Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID621169	Induction of current in human PCFT expressed in xenopus oocyte at 5 uM at holding potential -90 mV by voltage clamp assay	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID312258	Inhibition of Toxoplasma gondii DHFR	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1501147	Inhibition of thymidylate synthase in human KB cells assessed as reduction in cell proliferation at 1 to 10 nM after 72 hrs in presence of excess of thymidine by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1501168	Induction of apoptosis in human KB cells assessed as late apoptotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 5.5%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID1219357	Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence of 50 mM unlabelled compou	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1513019	Antiproliferative activity against human A2780 cells after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1297310	Cell cycle arrest in human SW620 cells assessed as accumulation at G1 phase at 10 uM after 96 hrs by propidium iodide staining based flow cytometry in presence of leucovorin (Rvb = 62.4 %)	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID312253	Inhibition of human thymidylate synthase	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1631978	Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue fluorescence analysis	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesi
AID1219372	Brain efflux index in Mrp2 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 60 mins	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1164831	Inhibition of RFC (unknown origin) expressed in Chinese hamster PC43-10 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
AID1562574	Antiproliferative activity against human SW620 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID362421	Antiproliferative activity against human RFC expressing Chinese hamster PC43-10 cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1663361	Inhibition of DHFR in human KB cells expressing RFC/FRalpha/PCFT assessed as reduction in cell growth after 96 hrs in presence of AICA by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID1631991	Inhibition of [3H]MTX uptake at human PCFT expressed in Chinese hamster R2/PCFT4 cells at 1 and 10 uM and pH 5.5 measured after 5 mins	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesi
AID1219362	Efflux clearance mouse brain measured per gm of tissue at 0.3 uCi/ml by in vitro brain slice uptake technique	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1062547	Cytotoxicity against human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTitre-Blue fluorescence assay in presence of adenosine/AICA/thymidine	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1236749	Antiproliferative activity against African green monkey Vero cells at 100 ug/ml after 72 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID1501149	Inhibition of TS/AICARFTase/GARFTase in human KB cells assessed as reduction in cell proliferation at 1 to 10 nM after 72 hrs in presence of excess of thymidine and adenosine by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID459868	Inhibition of mouse recombinant GARFtase assessed as FGAR formation by spectrophotometry	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID362423	Antiproliferative activity against human FRalpha expressing Chinese hamster RT16 cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1197478	Binding affinity to human RFC expressed in Chinese hamster PC43-10 cells assessed as cell growth inhibition after 96 hrs by CellTiter-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
AID1252445	Inhibition of human recombinant His-tagged GARFTase assessed as formation of 5,8-dideazafolate from 10-formyl-5,80-dideazafolic acid measured every 15 secs over 20 mins by spectrophotometric analysis	2015	Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17	6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
AID1562590	Antiproliferative activity against human KB cells in presence of AICA and thymidine	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID1252437	Cellular uptake in PCFT-null Chinese hamster R2 cells at 0.5 uM at 37 degC at pH 5.5 measured over 2 mins	2015	Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17	6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
AID282573	Inhibition of Lactobacillus casei DHFR	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID212301	Inhibitory concentration against isolated Thymidylate synthase	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID341451	Inhibition of Toxoplasma gondii thymidylate synthase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID22930	First-order rate constant of the compound	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.
AID1297295	Antiproliferative activity against human SW620 cells after 72 hrs by MTT assay in presence of leucovorin	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID422634	Inhibition of Toxoplasma gondii thymidylate synthase	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID595567	Mixed-type inhibition of human recombinant Serine hydroxymethyltransferase, cytosolic measured by Y-axes intercepts of mixed-type inhibition against compound concentration by spectrophotometry	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed.
AID362422	Antiproliferative activity against human RFC expressing Chinese hamster R2 cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID621135	Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as inhibition of colony formation after 10 to 14 days	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID282790	Inhibition of Toxoplasma gondii thymidylate synthase	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofol
AID341469	Inhibition of Escherichia coli dihydrofolate reductase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID1360131	Selectivity index, ratio of CC50 for human IOSE80 cells to IC50 for human A549 cells	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID1236750	Antiproliferative activity against human A549 cells at 100 ug/ml after 24 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID422638	Ratio of IC50 for human recombinant dihydrofolate reductase to IC50 for Toxoplasma gondii dihydrofolate reductase	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
AID1562595	Cell cycle arrest in human KB cells assessed as accumulation at G2 phase at 10 uM after 96 hrs by RNase-1 A/propidium iodide staining-based flow cytometric analysis (Rvb = 9.06%)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID513677	Inhibition of GARFT	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs.
AID1198283	Cell cycle arrest in human KB cells assessed as accumulation at G1 phase at 1 uM after 96 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 52.4%)	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
AID621170	Inhibition of human PCFT-mediated [3H]MTX uptake ectopically expressed in chinese hamster R2 cells at 10 uM at pH 5.5 to 7.2	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1853730	Induction of hTS expression in human IGROV-1 cells assessed as fold increase at 5 uM measured after 48 hrs by immunoblot quantitative analysis	2021	Journal of medicinal chemistry, 03-25, Volume: 64, Issue:6	Folic Acid-Peptide Conjugates Combine Selective Cancer Cell Internalization with Thymidylate Synthase Dimer Interface Targeting.
AID1512999	Binding affinity to human FR2 expressed in human HeLa R1-11 cells assessed as antiproliferative activity measured as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID241717	Inhibition of human dihydrofolate reductase at 37 degree C pH 7.4	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID1197483	Antiproliferative activity against human KB cells expressing RFC/FRalpha/PCFT after 96 hrs by CellTiter-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
AID1252438	Binding affinity to human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as increase in intracellular drug transport at 0.5 uM at 37 degC at pH 5.5 measured over 5 mins in presence of AGF94	2015	Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17	6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
AID1219374	Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence of 1 mM unlabelled compoun	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1236758	Antiproliferative activity against human T47D cells at 100 ug/ml after 72 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID1663356	Inhibition of DHFR in Chinese Hamster D4 cells expressing human FRbeta assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID1252440	Binding affinity to human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as intracellular drug transport rate at 37 degC at pH 6.8 measured over 2 mins by Lineweaver-Burk plot analysis	2015	Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17	6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
AID1513006	Inhibition of human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as reduction in [3H]MTX uptake at pH 5.5 at 1 to 10 uM measured over 2 mins	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID621131	Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1439757	Inhibition of Escherichia coli thymidylate synthase using dUMP/(6R,S)-tetrahydrofolate as substrate/co-factor by spectrophotometric method	2017	Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7	Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
AID1197481	Binding affinity to human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as cell growth inhibition after 96 hrs by CellTiter-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
AID459867	Displacement of [3H]MTX from human RFC expressed in Chinese hamster PC43-10 cells at 10 uM	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID1062549	Displacement of [3H]folic acid from human FRalpha expressed in chinese hamster RT16 cells after 15 mins by scintillation counting analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1219353	Drug uptake in mouse brain ipsilateral cerebrum assessed as radiolabelled compound after 30 mins at 0.1 uM, intracerebral microinjection in presence 100 mM benzylpenicillin OAT inhibitor	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID282788	Inhibition of human thymidylate synthase	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofol
AID241682	Inhibition of Escherichia coli dihydrofolate reductase at 37 degree C pH 7.4	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID1380203	Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs in presence of folic acid by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID1164834	Inhibition of FRalpha (unknown origin) expressed in Chinese hamster RT16 cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
AID1197479	Cytotoxicity against RFC-deficient Chinese hamster R2 cells assessed as growth inhibition after 96 hrs by CellTiter-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
AID312259	Selectivity ratio of IC50 for Toxoplasma gondii DHFR over IC50 for human recombinant DHFR	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1918193	Dissociation constant, pKa of the compound	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1297306	Inhibition of GARFTase/AICARFTase in human SW620 cells assessed as growth inhibition coincubated with adenosine	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID1297301	Inhibition of AICARFTase in human SW620 cells assessed as growth inhibition coincubated with AICA	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID1252423	Selectivity ratio of IC50 for human RFC expressed in Chinese hamster PC43-10 cells assessed as cell growth inhibition to IC50 for human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as cell growth inhibition	2015	Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17	6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
AID1219375	Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence of 50 mM unlabelled compou	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID621176	Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as growth inhibition in the presence of 10 uM thymidine and 320 uM AICA	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1398149	Effect on DHFR protein expression in human IGROV1 cells by Western blot analysis	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth.
AID1198267	Inhibition of thymidylate synthase in human KB cells assessed as cell growth inhibition in presence of 10 uM thymidine	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
AID1164832	Cytotoxicity against Chinese hamster R2 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
AID1198263	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by MTT assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
AID241683	Inhibition of human thymidylate synthetase at 37 degree C pH 7.4	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID613096	Inhibition of human DHFR by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1297300	Inhibition of thymidylate synthase/AICARFTase in human SW620 cells assessed as growth inhibition coincubated with AICA and thymine	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID56945	Compound was evaluated as inhibitor of human Dihydrofolate reductase	2003	Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4	Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and
AID476564	Inhibition of Toxoplasma gondii thymidylate synthase	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
AID260039	Inhibition of recombinant human DHFR	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1).
AID260013	Inhibition of recombinant human TS	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1).
AID1360123	Antiproliferative activity against human SGC7901 cells after 24 hrs by MTT assay	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID1894189	Inhibition of DHFR (unknown origin) assessed as inhibition constant	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID621122	Antiproliferative activity against chinese hamster PC43-10 expressing human RFC assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1360132	Selectivity index, ratio of CC50 for human GES1 cells to IC50 for human A549 cells	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID1062539	Cell cycle arrest in human KB cells assessed as accumulation at G1/G0 phase at 1 uM after 96 hrs by propidium iodide staining-based flow cytometry (Rvb = 67.4%)	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1501141	Inhibition of TS/AICARFTase/GARFTase in human KB cells assessed as reduction in cell proliferation in folate free medium after 72 hrs in presence of leucovorin by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID595565	Binding affinity to human recombinant Serine hydroxymethyltransferase, cytosolic by isothermal titration calorimetry	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1062532	Inhibition of GARFTase in human KB cells assessed as incorporation of [14C]-glycine into [14C]-formyl GAR incubated 30 mins prior to [14C]-glycine addition measured after 16 hrs by radiometric assay in presence of azaserin	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1562594	Cell cycle arrest in human KB cells assessed as accumulation at S phase at 10 uM after 96 hrs by RNase-1 A/propidium iodide staining-based flow cytometric analysis (Rvb = 48.26%)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID422637	Inhibition of Toxoplasma gondii dihydrofolate reductase	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
AID1219352	Drug uptake in mouse brain ipsilateral cerebrum assessed as radiolabelled compound after 30 mins at 0.1 uM, intracerebral microinjection in presence 100 mM probenecid OAT inhibitor	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID595566	Competitive inhibition of human recombinant Serine hydroxymethyltransferase, cytosolic by spectrophotometry	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed.
AID621130	Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID595568	Inhibition of human recombinant Serine hydroxymethyltransferase, cytosolic measured by slope intercepts of mixed-type inhibition against compound concentration by spectrophotometry	2011	European journal of medicinal chemistry, May, Volume: 46, Issue:5	In silico and in vitro validation of serine hydroxymethyltransferase as a chemotherapeutic target of the antifolate drug pemetrexed.
AID1219355	Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins relative to wild type	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID56978	Inhibitory concentration against isolated human Dihydrofolate reductase	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID1380200	Binding affinity to human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as antiproliferative activity measured as reduction in cell viability after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID362425	Antiproliferative activity against human FRbeta expressing Chinese hamster D4 cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1219371	Brain efflux index in wild type mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1512994	Binding affinity to human FRalpha expressed in Chinese hamster RT16 cells assessed as antiproliferative activity measured as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1219370	Drug uptake in mouse brain ipsilateral cerebrum assessed as radiolabelled compound after 30 mins at 0.1 uM, intracerebral microinjection in presence of 50 mM unlabelled compound	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID282572	Inhibition of Escherichia coli DHFR	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID240883	Inhibitory concentration against Escherichia coli dihydrofolate reductase	2005	Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9	Novel 2-amino-4-oxo-5-arylthio-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase.
AID282388	Inhibition of human DHFR	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
AID613098	Inhibition of Toxoplasma gondii DHFR by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1512993	Antiproliferative activity in Chinese hamster R2 cells deficient in RFC, PCFT, and FRalpha assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1197490	Inhibition of AICARFTase in human KB cells expressing RFC/FRalpha/PCFT assessed as increase in ZAM level at 1 uM after 48 hrs by anion-exchange HPLC analysis relative to control	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
AID476562	Inhibition of human thymidylate synthase	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
AID1501148	Inhibition of AICARFTase/GARFTase in human KB cells assessed as reduction in cell proliferation at 1 to 10 nM after 72 hrs in presence of excess of adenosine by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID1053451	Growth inhibition of Chinese hamster D4 cells after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1164836	Inhibition of FRbeta (unknown origin) expressed in Chinese hamster D4 cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
AID1360122	Antiproliferative activity against human OVCAR3 cells after 24 hrs by MTT assay	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID1236757	Antiproliferative activity against human T47D cells at 100 ug/ml after 48 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID1164839	Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
AID212657	Compound was evaluated for competitive inhibition of recombinant mouse thymidylate synthase	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.
AID1062558	Cytotoxicity against chinese hamster PC43-10 cells expressing human RFC after 96 hrs by CellTitre-Blue fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID211446	Inhibitory concentration against isolated Escherichia coli Thymidylate synthase	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID341471	Selectivity for Escherichia coli dihydrofolate reductase over human dihydrofolate reductase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID391733	Inhibition of Escherichia coli thymidylate synthase	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.
AID282789	Inhibition of Escherichia coli thymidylate synthase	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofol
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID241776	Inhibition of Lactobacillus casei dihydrofolate reductase at 37 degree C pH 7.4	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID671163	Inhibition of human thymidylate synthase	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
AID1219363	Elimination rate constant mouse brain at 0.3 uCi/ml	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID282386	Inhibition of human thymidylate synthase	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
AID1219358	Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence 100 mM probenecid OAT inhi	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID341428	Inhibition of human thymidylate synthase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID1380199	Binding affinity to human FR-beta receptor expressed in Chinese hamster D4 cells assessed as antiproliferative activity measured as reduction in cell viability after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID1513016	Antiproliferative activity against FRalpha knockout human IGROV1 KD10 cells after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1380195	Binding affinity to human RFC expressed in Chinese hamster PC43-10 cells assessed as antiproliferative activity measured as reduction in cell viability after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID260046	Inhibition of DHFR from Escherichia coli	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1).
AID282787	Inhibition of Toxoplasma gondii DHFR	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofol
AID1663359	Inhibition of DHFR in human KB cells expressing RFC/FRalpha/PCFT assessed as reduction in cell growth after 96 hrs in presence of folic acid by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID1398148	Effect on TS protein expression in human IGROV1 cells by Western blot analysis	2018	Journal of medicinal chemistry, 08-23, Volume: 61, Issue:16	Conformational Propensity and Biological Studies of Proline Mutated LR Peptides Inhibiting Human Thymidylate Synthase and Ovarian Cancer Cell Growth.
AID477295	Octanol-water partition coefficient, log P of the compound	2010	European journal of medicinal chemistry, Apr, Volume: 45, Issue:4	QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID282786	Inhibition of Escherichia coli DHFR	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofol
AID1062533	Induction of apoptosis in human KB cells assessed as viable cells at 1 uM after 96 hrs by Annexin V-FITC/7-AAD staining-based flow cytometry (RVB = 89.6%)	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1663353	Inhibition of DHFR in Chinese Hamster MTXRII-OuaR2-4/FRalpha-null R2 cells assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID241657	Inhibition of Escherichia coli thymidylate synthetase at 37 degree C pH 7.4	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID238909	Inhibition of human thymidylate synthetase at 37 degree C pH 7.4	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID1062555	Cytotoxicity against chinese hamster RT16 cells expressing human FRalpha after 96 hrs by CellTitre-Blue fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID621128	Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1663362	Inhibition of DHFR in human KB cells expressing RFC/FRalpha/PCFT assessed as reduction in cell growth after 96 hrs in presence of thymidine by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID1219373	Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID459863	Displacement of [3H]folic acid from human FRalpha expressed in Chinese hamster RT16 cells relative to unlabeled folic acid	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID459869	Inhibition of GARFtase in human KB cells assessed as [14C]glycine incorporation in to [14C]FGAR in folate free RPMI medium with 2 nM LCV by in-situassay	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID341462	Inhibition of human dihydrofolate reductase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID621175	Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as growth inhibition at <50 nM in the presence of 10 uM thymidine	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID422635	Inhibition of human recombinant dihydrofolate reductase	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
AID1197489	Inhibition of GARFTase in human KB cells expressing RFC/FRalpha/PCFT assessed as incorporation of [U-14C]-glycine into [14C]-formyl glycinamide ribonucleotide incubated for 1 hr followed by [U-14C]-glycine addition measured after 16 hrs	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
AID1631995	Inhibition of [3H]MTX uptake at human PCFT expressed in Chinese hamster R2/PCFT4 cells at pH 5.5 measured after 5 mins by Dixon plot analysis	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Tumor Targeting with Novel 6-Substituted Pyrrolo [2,3-d] Pyrimidine Antifolates with Heteroatom Bridge Substitutions via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesi
AID1562583	Inhibition of colony formation in human KB cells at 100 nM after 10 to 14 days by methylene blue staining based assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID1252439	Binding affinity to human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as intracellular drug transport rate at 37 degC at pH 5.5 measured over 2 mins by Lineweaver-Burk plot analysis	2015	Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17	6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
AID1219354	Brain efflux index in Mrp2 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 60 mins relative to wild type	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1219368	Drug uptake in mouse brain ipsilateral cerebrum assessed as radiolabelled compound after 30 mins at 0.1 uM, intracerebral microinjection	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1164840	Cytotoxicity against human KB cells assessed as cell growth inhibition incubated up to 96 hrs in presence of 200 nM folic acid by Celltiter-blue cell viability assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
AID1562588	Antiproliferative activity against human KB cells in presence of adenosine	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID362430	Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1663354	Inhibition of DHFR in Chinese Hamster PC43-10 cells expressing human RFC assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID1219367	Elimination half life in mouse brain at 10 nCi/ml, icv	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID391736	Inhibition of Escherichia coli DHFR	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.
AID1062537	Cell cycle arrest in human KB cells assessed as accumulation at G2/M phase at 1 uM after 96 hrs by propidium iodide staining-based flow cytometry (Rvb = 13.2%)	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1062538	Cell cycle arrest in human KB cells assessed as accumulation at S phase at 1 uM after 96 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.9%)	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1663355	Inhibition of DHFR in Chinese Hamster RT16 cells expressing human FRalpha assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID1053447	Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID1360125	Antiproliferative activity against human A549 cells at 0.512 uM after 24 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID1053452	Growth inhibition of Chinese hamster RT16 cells after 96 hrs by CellTiter-blue assay in presence of folic acid	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID770036	Inhibition of Cryptosporidium hominis thymidylate synthase	2013	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 23, Issue:19	Substituted pyrrolo[2,3-d]pyrimidines as Cryptosporidium hominis thymidylate synthase inhibitors.
AID605430	Growth inhibition of human A549 cells assessed as cell growth at 6.4 uM after 72 hrs by fluorometric microculture cytotoxicity assay in presence of 20 uM thymidine relative to untreated control	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes.
AID513674	Inhibition of thymine synthase	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs.
AID349814	Inhibition of mouse recombinant GARFTase	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transpo
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1062542	Cytotoxicity against human KB cells expressing human RFC/FRalpha/PCFT assessed as depletion of ATP pools at 1 uM after 24 hrs by ion-pair HPLC analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1894188	Inhibition of thymidylate synthase (unknown origin) assessed as inhibition constant	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1236754	Antiproliferative activity against human HeLa cells at 100 ug/ml after 48 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID240801	Inhibitory concentration against Escherichia coli thymidylate synthase	2005	Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9	Novel 2-amino-4-oxo-5-arylthio-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase.
AID1236752	Antiproliferative activity against human A549 cells at 100 ug/ml after 72 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID1380194	Binding affinity to human FR-beta receptor expressed in Chinese hamster D4 cells assessed as antiproliferative activity measured as reduction in cell viability after 96 hrs in presence of folic acid by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID362426	Antiproliferative activity against human FRbeta expressing Chinese hamster D4 cells in presence of folic acid	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1062553	Cytotoxicity against chinese hamster R2(VC) cells after 96 hrs by CellTitre-Blue fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID312256	Inhibition of human recombinant DHFR	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID457194	Inhibition of Toxoplasma gondii TS at 30 degC under pH 7.4 by spectrophotometry	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1360126	Antiproliferative activity against human A549 cells at 1.28 uM after 24 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID1501162	Cell cycle arrest in human KB cells assessed as accumulation at G1 phase at 10 uM after 96 hrs by propidium iodide staining based flow cytometry (Rvb = 54.75%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID211799	Inhibitory concentration against isolated Lactobacillus casei Thymidylate synthase	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID1380196	Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID459866	Displacement of [3H]MTX from human PCFT expressed in Chinese hamster R2 cells at pH 5.5 by Dixon plot	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID1360130	Selectivity index, ratio of CC50 for HPAEpiC to IC50 for human A549 cells	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID1380211	Inhibition of [3H]MTX uptake at human PCFT expressed in Chinese hamster R2/PCFT4 cells at 10 uM at pH 6.8 by scintillation counting method relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID312255	Inhibition of Toxoplasma gondii thymidylate synthase	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID613094	Inhibition of Escherichia coli TS assessed as oxidation of tetrahydrofolate to dihydrofolate after 2 to 12 mins by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1763184	Inhibition of human thymidylate synthase expressed in Escherichia coli using 6R,S-tetrahydrofolate and dUMP as substrate by spectrophotometric analysis	2021	Bioorganic & medicinal chemistry, 05-15, Volume: 38	Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1512995	Binding affinity to human FRbeta expressed in Chinese hamster D4 cells assessed as antiproliferative activity measured as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1360129	Antiproliferative activity against human A549 cells at 20 uM after 24 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID282387	Inhibition of Escherichia coli thymidylate synthase	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
AID1198265	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
AID1219366	Drug elimination in mouse brain at 10 nCi/ml, icv	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1198281	Cell cycle arrest in human KB cells assessed as accumulation at S phase at 1 uM after 96 hrs by propidium iodide staining-based flow cytometric analysis (Rvb = 13.6%)	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
AID740237	Inhibition of Escherichia coli thymidylate synthase by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents.
AID282571	Inhibition of human recombinant DHFR	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID1297309	Cell cycle arrest in human SW620 cells assessed as accumulation at G2 phase at 10 uM after 96 hrs by propidium iodide staining based flow cytometry in presence of leucovorin (Rvb = 10.3 %)	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID1501161	Cell cycle arrest in human KB cells assessed as accumulation at G2 phase at 10 uM after 96 hrs by propidium iodide staining based flow cytometry (Rvb = 9.59%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID621180	Decrease in intracellular ATP concentration in chinese hamster R2 cells expressing human PCFT at 1 uM after 24 hrs by HPLC relative to control at pH 6.8	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1053448	Growth inhibition of Chinese hamster R2(VC) cells after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID1198269	Inhibition of GARFTase/AICARFTase in human KB cells assessed as cell growth inhibition in presence of 10 uM thymidine and 60 uM adenosine	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
AID1380212	Inhibition of [3H]MTX uptake at human PCFT expressed in Chinese hamster R2/PCFT4 cells at pH 5.5 measured after 2 mins by Dixon plot analysis	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID57444	Binding affinity against dihydrofolate reductase	1994	Journal of medicinal chemistry, May-27, Volume: 37, Issue:11	Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID1513009	Inhibition of GARFTase in human IGROV1 cells assessed as decrease in incorporation of [14C(U)glycine into [14C]formyl GAR formation after 24 hrs	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1236747	Antiproliferative activity against African green monkey Vero cells at 100 ug/ml after 24 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID1053453	Growth inhibition of Chinese hamster RT16 cells after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID621136	Inhibition of human RFC-mediated [3H]MTX uptake in chinese hamster PC43-10 cells at 10 uM after 2 mins relative to control	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1663363	Inhibition of DHFR in human KB cells expressing RFC/FRalpha/PCFT assessed as reduction in cell growth after 96 hrs in presence of glycine by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID362429	Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID312257	Inhibition of Escherichia coli DHFR	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID671165	Inhibition of Toxoplasma gondii thymidylate synthase	2012	Bioorganic & medicinal chemistry, Jul-15, Volume: 20, Issue:14	Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
AID212126	Inhibitory activity against recombinant Pneumocystis carinii TS	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
AID57759	Inhibitory concentration against isolated Lactobacillus casei Dihydrofolate reductase	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID457193	Inhibition of Escherichia coli TS at 30 degC under pH 7.4 by spectrophotometry	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1360128	Antiproliferative activity against human A549 cells at 8 uM after 24 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID211645	Compound was evaluated as inhibitor of Lactobacillus casei thymidylate synthase	2003	Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4	Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID605431	Growth inhibition of human A549 cells assessed as cell growth at 6.4 uM after 72 hrs by fluorometric microculture cytotoxicity assay in presence of 100 uM hypoxanthine and 20 uM thymidine relative to untreated control	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes.
AID211439	Compound was evaluated as inhibitor of Escherichia coli thymidylate synthase	2003	Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4	Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1062524	Cell cycle arrest in human KB cells assessed as accumulation at G1/G0 phase at 1 uM after 48 hrs by propidium iodide staining-based flow cytometry relative to control	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1236748	Antiproliferative activity against African green monkey Vero cells at 100 ug/ml after 48 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID1512998	Binding affinity to human PCFT4 expressed in human HeLa R1-11 cells assessed as antiproliferative activity measured as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1062527	Inhibition of AICARFTase in human KB cells assessed as accumulation of ZMP after 48 hrs by HPLC analysis	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID362440	Induction of apoptotic activity in human KB cells at 1 uM after 24 hrs	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID695098	Inhibition of [3H]MTX transport at human PCFT expressed in Chinese hamster R2 cells at pH 5.5 by Dixon plot	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter
AID513675	Inhibition of DHFR	2010	Journal of medicinal chemistry, Sep-23, Volume: 53, Issue:18	Novel approaches for targeting thymidylate synthase to overcome the resistance and toxicity of anticancer drugs.
AID1062546	Cytotoxicity against human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTitre-Blue fluorescence assay in presence of thymidine/adenosine	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID613095	Inhibition of Toxoplasma gondii TS assessed as oxidation of tetrahydrofolate to dihydrofolate after 2 to 12 mins by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1236751	Antiproliferative activity against human A549 cells at 100 ug/ml after 48 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID362428	Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID476563	Inhibition of Escherichia coli thymidylate synthase	2010	Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4	Single agents with designed combination chemotherapy potential: synthesis and evaluation of substituted pyrimido[4,5-b]indoles as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
AID1513005	Inhibition of human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as reduction in [3H]MTX uptake at pH 5.5 at 10 uM measured over 2 mins relative to control	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1062534	Induction of apoptosis in human KB cells assessed as necrotic cells at 1 uM after 96 hrs by Annexin V-FITC/7-AAD staining-based flow cytometry (RVB = 7.80%)	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID240604	Inhibitory concentration against human thymidylate synthase	2005	Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9	Novel 2-amino-4-oxo-5-arylthio-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase.
AID1380217	Antitumor activity against human IGROV1 cells xenografted in folate-deficient diet ICR SCID mouse assessed as tumor growth delay time at 8.1 mg/kg, iv administered every 2 days for 4 times starting on day 3 measured twice per week	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID457197	Inhibition of Toxoplasma gondii DHFR at 30 degC under pH 7.4 by spectrophotometry	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID422632	Inhibition of human thymidylate synthase	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
AID1513018	Antiproliferative activity against human IGROV1 cells harboring non targeted control shRNA sequence after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1197480	Binding affinity to human FRalpha expressed in Chinese hamster RT16 cells assessed as cell growth inhibition after 96 hrs by CellTiter-Blue assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.
AID1164837	Inhibition of PCFT (unknown origin) expressed in Chinese hamster R2/PCFT4 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
AID211442	Inhibitory activity against Escherichia coli thymidylate synthase	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
AID1501169	Induction of apoptosis in human KB cells assessed as necrotic cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 3%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID1198268	Inhibition of GARFTase/AICARFTase in human KB cells assessed as cell growth inhibition in presence of 320 uM AICA	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
AID349815	Inhibition of GARFTase in human KB cells assessed as inhibition of incorporation of [14C]glycine into [14C]formyl GAR after 30 mins in presence of azaserine	2009	Journal of medicinal chemistry, May-14, Volume: 52, Issue:9	Synthesis and biological activity of a novel series of 6-substituted thieno[2,3-d]pyrimidine antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors over the reduced folate carrier and proton-coupled folate transpo
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1380202	Antiproliferative activity against human KB cells expressing human RFC/FR-alpha/PCFT assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID1380210	Inhibition of [3H]MTX uptake at human PCFT expressed in Chinese hamster R2/PCFT4 cells at 1 uM at pH 6.8 by scintillation counting method relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID695100	Ratio of Ki for human PCFT at pH 6.8 to Ki for human PCFT at pH 5.5 by [3H]MTX transport assay	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter
AID1219360	Volume of distribution in mouse brain per gm of tissue at 0.3 uCi/ml after 1 to 2 hrs by in vitro brain slice uptake technique	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID56187	Inhibitory activity against Toxoplasma gondii dihydrofolate reductase	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
AID1053450	Growth inhibition of Chinese hamster D4 cells after 96 hrs by CellTiter-blue assay in presence of folic acid	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID422636	Inhibition of Escherichia coli dihydrofolate reductase	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Design, synthesis, and X-ray crystal structure of classical and nonclassical 2-amino-4-oxo-5-substituted-6-ethylthieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors and as potential antitumor agents.
AID695099	Inhibition of [3H]MTX transport at human PCFT expressed in Chinese hamster R2 cells at pH 6.8 by Dixon plot	2012	Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4	Synthesis and biological activity of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl regioisomers as inhibitors of de novo purine biosynthesis with selectivity for cellular uptake by high affinity folate receptors and the proton-coupled folate transporter
AID1512996	Binding affinity to human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as antiproliferative activity measured as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1360124	Antiproliferative activity against human MDA-MB-231 cells after 24 hrs by MTT assay	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID621125	Antiproliferative activity against chinese hamster RT16 cells expressing human FRalpha assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID212297	Inhibitory activity against human thymidylate synthase	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
AID621129	Antiproliferative activity against chinese hamster R2(VC) cells expressing human PCFT assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID312254	Inhibition of Escherichia coli thymidylate synthase	2008	Journal of medicinal chemistry, Jan-10, Volume: 51, Issue:1	Design, synthesis, and biological evaluation of classical and nonclassical 2-amino-4-oxo-5-substituted-6-methylpyrrolo[3,2-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1513033	Inhibition of human RFC2 expressed in human HeLa R1-11 cells assessed as reduction in [3H]MTX uptake at pH 7.2 at 1 uM measured over 2 mins relative to control	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1501143	Antiproliferative activity against human MCF7 cells in folate free medium after 72 hrs in presence of leucovorin by MTT assay	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID621177	Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as growth inhibition in the presence of 60 uM adenosine	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1663357	Inhibition of DHFR in Chinese Hamster MTXRII-OuaR2-4 R2 cells expressing human PCFT assessed as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID1062554	Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1663360	Inhibition of DHFR in human KB cells expressing RFC/FRalpha/PCFT assessed as reduction in cell growth after 96 hrs in presence of adenosine by Cell-Titer Blue assay	2020	Bioorganic & medicinal chemistry, 06-15, Volume: 28, Issue:12	Design, synthesis and biological evaluation of novel pyrrolo[2,3-d]pyrimidine as tumor-targeting agents with selectivity for tumor uptake by high affinity folate receptors over the reduced folate carrier.
AID282389	Inhibition of Escherichia coli DHFR	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Benzoyl ring halogenated classical 2-amino-6-methyl-3,4-dihydro-4-oxo-5-substituted thiobenzoyl-7H-pyrrolo[2,3-d]pyrimidine antifolates as inhibitors of thymidylate synthase and as antitumor agents.
AID241751	Inhibition of Lactobacillus casei thymidylate synthetase at 37 degree C pH 7.4	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	Synthesis of classical, four-carbon bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID621133	Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID362433	Inhibition of human RFC-mediated [3H]MTX transport in Chinese hamster PC43-10 cells at 10 uM	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID57235	Compound was evaluated as inhibitor of Escherichia coli Dihydrofolate reductase	2003	Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4	Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and
AID1297305	Inhibition of thymidylate synthase in human SW620 cells assessed as growth inhibition coincubated with thymidine	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID621178	Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as growth inhibition in the presence of 60 uM adenosine and 10 uM thymidine	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1562596	Cell cycle arrest in human KB cells assessed as accumulation at G1 phase at 10 uM after 96 hrs by RNase-1 A/propidium iodide staining-based flow cytometric analysis (Rvb = 42.69%)	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID605432	Growth inhibition of human A549 cells assessed as cell growth at 6.4 uM after 72 hrs by fluorometric microculture cytotoxicity assay relative to untreated control	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes.
AID740238	Inhibition of human thymidylate synthase by spectrophotometric analysis	2013	Bioorganic & medicinal chemistry, Apr-15, Volume: 21, Issue:8	Novel 1,3,4-oxadiazole thioether derivatives targeting thymidylate synthase as dual anticancer/antimicrobial agents.
AID1297308	Cell cycle arrest in human SW620 cells assessed as accumulation at S phase at 10 uM after 96 hrs by propidium iodide staining based flow cytometry in presence of leucovorin (Rvb = 27.3 %)	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID18269	Km was determined	1992	Journal of medicinal chemistry, Nov-13, Volume: 35, Issue:23	A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.
AID1198266	Inhibition of GARFTase/AICARFTase in human KB cells assessed as cell growth inhibition in presence of 60 uM adenosine	2015	European journal of medicinal chemistry, Mar-26, Volume: 93	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidines as potential nonclassical antifolates targeting both thymidylate and purine nucleotide biosynthesis.
AID457196	Inhibition of Escherichia coli DHFR at 30 degC under pH 7.4 by spectrophotometry	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1053446	Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID457195	Inhibition of human DHFR at 30 degC under pH 7.4 by spectrophotometry	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1164838	Cytotoxicity against Chinese hamster R2 cells expressing empty vector assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
AID391735	Inhibition of Toxoplasma gondii thymidylate synthase	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.
AID1219376	Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence 100 mM probenecid OAT inhi	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1918194	Lipophilicity, log D of the compound	2022	Journal of medicinal chemistry, 11-10, Volume: 65, Issue:21	Identification of Organic Anion Transporter 2 Inhibitors: Screening, Structure-Based Analysis, and Clinical Drug Interaction Risk Assessment.
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID282576	Inhibition of Lactobacillus casei thymidylate synthase	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID1360127	Antiproliferative activity against human A549 cells at 3.2 uM after 24 hrs by MTT assay relative to control	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID1513003	Inhibition of human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as reduction in [3H]MTX uptake at pH 5.5 measured over 2 mins by Dixon plot analysis	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1501160	Cell cycle arrest in human KB cells assessed as accumulation at S phase at 10 uM after 96 hrs by propidium iodide staining based flow cytometry (Rvb = 35.66%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID457192	Inhibition of human thymidylate synthase at 30 degC under pH 7.4 by spectrophotometry	2010	Bioorganic & medicinal chemistry, Jan-15, Volume: 18, Issue:2	2,4-Diamino-5-methyl-6-substituted arylthio-furo[2,3-d]pyrimidines as novel classical and nonclassical antifolates as potential dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1297294	Antiproliferative activity against human KB cells after 72 hrs by MTT assay in presence of leucovorin	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1062536	Induction of apoptosis in human KB cells assessed as early apoptotic cells at 1 uM after 96 hrs by Annexin V-FITC/7-AAD staining-based flow cytometry (Rvb = 0.485%)	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID362427	Antiproliferative activity against human RFC and FRalpha expressing human KB cells	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1513020	Antiproliferative activity against wild type human IGROV1 cells after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID212157	Compound was evaluated as inhibitor of human thymidylate synthase	2003	Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4	Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and
AID391732	Inhibition of human thymidylate synthase	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.
AID1164835	Inhibition of FRbeta (unknown origin) expressed in Chinese hamster D4 cells assessed as cell growth inhibition incubated up to 96 hrs by Celltiter-blue cell viability assay	2014	Journal of medicinal chemistry, Oct-09, Volume: 57, Issue:19	Structure-activity profiles of novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolates with modified amino acids for cellular uptake by folate receptors α and β and the proton-coupled folate transporter.
AID1062540	Cell cycle arrest in human KB cells assessed as accumulation at sub-G1 phase at 1 uM after 96 hrs by propidium iodide staining-based flow cytometry (Rvb = 3.5%)	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1513015	Selectivity ratio of IC50 for human IGROV1 cells harboring non targeted control shRNA sequence to IC50 for FRalpha knockout human IGROV1 KD4 cells	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID362424	Antiproliferative activity against human FRalpha expressing Chinese hamster RT16 cells in presence of folic acid	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID1297296	Antiproliferative activity against human A549 cells after 72 hrs by MTT assay in presence of leucovorin	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID1219351	Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence 100 mM benzylpenicillin OA	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1562575	Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 72 hrs by MTT assay	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID1236753	Antiproliferative activity against human HeLa cells at 100 ug/ml after 24 hrs by BrdUrd incorporation assay	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis, structure elucidation and identification of antiproliferative activities of a novel class of thiophene bioisosteres bearing the privileged 7,8-dihydroimidazo[2,1-c][1,2,4]triazin-4(6H)-one scaffold.
AID1512997	Binding affinity to human RFC2 expressed in human HeLa R1-11 cells assessed as antiproliferative activity measured as reduction in cell growth after 96 hrs by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID260014	Inhibition of TS from Escherichia coli	2006	Journal of medicinal chemistry, Feb-09, Volume: 49, Issue:3	Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1).
AID362438	Inhibition of GARFTase in human KB cells assessed as inhibition of [14C]glycine incorporation into [14C]formylGAR in presence of azaserine	2008	Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16	Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity.
AID613097	Inhibition of Escherichia coli DHFR by spectrophotometry	2011	Bioorganic & medicinal chemistry, Jun-01, Volume: 19, Issue:11	Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors.
AID1501166	Induction of apoptosis in human KB cells assessed as live cells at 10 uM after 48 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 74.6%)	2017	European journal of medicinal chemistry, Oct-20, Volume: 139	Novel 6-substituted benzoyl and non-benzoyl straight chain pyrrolo[2,3-d]pyrimidines as potential antitumor agents with multitargeted inhibition of TS, GARFTase and AICARFTase.
AID459865	Displacement of [3H]MTX from human PCFT expressed in Chinese hamster R2 cells at pH 6.8 by Dixon plot	2010	Journal of medicinal chemistry, Feb-11, Volume: 53, Issue:3	Synthesis and antitumor activity of a novel series of 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitors of purine biosynthesis with selectivity for high affinity folate receptors and the proton-coupled folate transporter over the reduc
AID282575	Inhibition of Escherichia coli thymidylate synthase	2004	Journal of medicinal chemistry, Dec-30, Volume: 47, Issue:27	Synthesis of classical, three-carbon-bridged 5-substituted furo[2,3-d]pyrimidine and 6-substituted pyrrolo[2,3-d]pyrimidine analogues as antifolates.
AID1219359	Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence 100 mM benzylpenicillin OA	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1380208	Inhibition of [3H]MTX uptake at human PCFT expressed in Chinese hamster R2/PCFT4 cells at 1 uM at pH 5.5 by scintillation counting method relative to control	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID57739	Compound was evaluated as inhibitor of Lactobacillus casei Dihydrofolate reductase	2003	Journal of medicinal chemistry, Feb-13, Volume: 46, Issue:4	Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and
AID1513014	Selectivity ratio of IC50 for human IGROV1 cells harboring non targeted control shRNA sequence to IC50 for FRalpha knockout human IGROV1 KD10 cells	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID1380198	Binding affinity to human FR-alpha receptor expressed in Chinese hamster RT16 cells assessed as antiproliferative activity measured as reduction in cell viability after 96 hrs in presence of folic acid by Cell-Titer Blue assay	2018	Journal of medicinal chemistry, 03-08, Volume: 61, Issue:5	Tumor Targeting with Novel Pyridyl 6-Substituted Pyrrolo[2,3- d]Pyrimidine Antifolates via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of De Novo Purine Nucleotide Biosynthesis.
AID1219369	Drug uptake in mouse brain ipsilateral cerebrum assessed as radiolabelled compound after 30 mins at 0.1 uM, intracerebral microinjection in presence of 1 mM unlabelled compound	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1562589	Antiproliferative activity against human KB cells in presence of AICA	2019	European journal of medicinal chemistry, Sep-15, Volume: 178	Targeting dihydrofolate reductase: Design, synthesis and biological evaluation of novel 6-substituted pyrrolo[2,3-d]pyrimidines as nonclassical antifolates and as potential antitumor agents.
AID621124	Antiproliferative activity against chinese hamster RT16 cells expressing human FRalpha assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1439756	Inhibition of human thymidylate synthase using dUMP/(6R,S)-tetrahydrofolate as substrate/co-factor by spectrophotometric method	2017	Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7	Synthesis and evaluation of 5-(arylthio)-9H-pyrimido[4,5-b]indole-2,4-diamines as receptor tyrosine kinase and thymidylate synthase inhibitors and as antitumor agents.
AID1053454	Growth inhibition of Chinese hamster MTXRII-OuaR2-4 cells after 96 hrs by CellTiter-blue assay	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis.
AID1513002	Inhibition of human RFC2 expressed in human HeLa R1-11 cells assessed as reduction in [3H]MTX uptake at pH 7.2 at 10 uM measured over 2 mins relative to control	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID282785	Inhibition of human DHFR	2005	Journal of medicinal chemistry, Nov-17, Volume: 48, Issue:23	Synthesis of N-{4-[(2,4-diamino-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid and N-{4-[(2-amino-4-oxo-5-methyl-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)thio]benzoyl}-L-glutamic acid as dual inhibitors of dihydrofol
AID57240	Inhibitory activity against recombinant Escherichia coli dihydrofolate reductase	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
AID1297307	Inhibition of thymidylate synthase/GARFTase/AICARFTase in human SW620 cells assessed as growth inhibition coincubated with thymidine and adenosine	2016	European journal of medicinal chemistry, Jun-10, Volume: 115	Design, synthesis and biological evaluation of 6-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of TS and AICARFTase and as potential antitumor agents.
AID1062552	Cytotoxicity against human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTitre-Blue fluorescence assay	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID212843	Binding affinity against TS	1994	Journal of medicinal chemistry, May-27, Volume: 37, Issue:11	Synthesis and antitumor activities of novel 6-5 fused ring heterocycle antifolates: N-[4-[omega-(2-amino-4-substituted-6,7-dihydrocyclopenta [d]pyrimidin-5-yl)alkyl]benzoyl]-L-glutamic acids.
AID621132	Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID391737	Inhibition of Toxoplasma gondii DHFR	2008	Journal of medicinal chemistry, Sep-25, Volume: 51, Issue:18	Potent dual thymidylate synthase and dihydrofolate reductase inhibitors: classical and nonclassical 2-amino-4-oxo-5-arylthio-substituted-6-methylthieno[2,3-d]pyrimidine antifolates.
AID1709483	Inhibition of human full length N-terminal His-tagged GARFTase expressed in Chinese Hamster MTXRII-OuaR2-4 R2 cells assessed as reduction in THF formation using 10-CHOTHF as substrate by spectrophotometric method	2021	Bioorganic & medicinal chemistry, 05-01, Volume: 37	Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor
AID621126	Antiproliferative activity against chinese hamster D4 cells expressing human FRbeta assessed as reduction of viable cells after 96 hrs	2011	Journal of medicinal chemistry, Oct-27, Volume: 54, Issue:20	Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-gl
AID240641	Inhibitory concentration against human dihydrofolate reductase	2005	Bioorganic & medicinal chemistry letters, May-02, Volume: 15, Issue:9	Novel 2-amino-4-oxo-5-arylthio-substituted-pyrrolo[2,3-d]pyrimidines as nonclassical antifolate inhibitors of thymidylate synthase.
AID1513001	Selectivity ratio of IC50 for human RFC2 expressed in human HeLa R1-11 cells to IC50 for human FR2 expressed in human HeLa R1-11 cells	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	Fluorine-Substituted Pyrrolo[2,3- d]Pyrimidine Analogues with Tumor Targeting via Cellular Uptake by Folate Receptor α and the Proton-Coupled Folate Transporter and Inhibition of de Novo Purine Nucleotide Biosynthesis.
AID212677	Inhibitory concentration against isolated rat thymidylate synthase	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID1360121	Antiproliferative activity against human A549 cells after 24 hrs by MTT assay	2018	European journal of medicinal chemistry, Jun-25, Volume: 154	Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs.
AID341439	Inhibition of Escherichia coli thymidylate synthase	2008	Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15	The effect of 5-alkyl modification on the biological activity of pyrrolo[2,3-d]pyrimidine containing classical and nonclassical antifolates as inhibitors of dihydrofolate reductase and as antitumor and/or antiopportunistic infection agents.
AID55842	Inhibitory concentration against isolated Pneumocystis carinii DHFR (Dihydrofolate reductase)	2000	Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21	Design, synthesis, and X-ray crystal structure of a potent dual inhibitor of thymidylate synthase and dihydrofolate reductase as an antitumor agent.
AID1062551	Cytotoxicity against human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTitre-Blue fluorescence assay in presence of folic acid	2013	Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24	Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implic
AID1252436	Binding affinity to human PCFT expressed in Chinese hamster R2/PCFT4 cells assessed as intracellular drug level at 0.5 uM at 37 degC at pH 5.5 measured over 5 mins	2015	Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17	6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
AID56964	Inhibitory activity against human dihydrofolate reductase	2001	Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12	Synthesis, antifolate, and antitumor activities of classical and nonclassical 2-amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines.
AID1219356	Brain efflux index in Bcrp1 deficient mouse assessed as transport of compound from ipsilateral cerebrum to the circulating blood across the blood-brain barrier at 10 nCi/ml, intracerebral microinjection after 30 mins in presence of 1 mM unlabelled compoun	2013	Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 41, Issue:3	Brain efflux index to investigate the influence of active efflux on brain distribution of pemetrexed and methotrexate.
AID1252422	Selectivity ratio of IC50 for human RFC expressed in Chinese hamster PC43-10 cells assessed as cell growth inhibition to IC50 for human FRbeta expressed in Chinese hamster D4 cells assessed as cell growth inhibition	2015	Journal of medicinal chemistry, Sep-10, Volume: 58, Issue:17	6-Substituted Pyrrolo[2,3-d]pyrimidine Thienoyl Regioisomers as Targeted Antifolates for Folate Receptor α and the Proton-Coupled Folate Transporter in Human Tumors.
AID977610	Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB	2001	Journal of molecular biology, Nov-02, Volume: 313, Issue:4	Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases.
AID1811	Experimentally measured binding affinity data derived from PDB	2001	Journal of molecular biology, Nov-02, Volume: 313, Issue:4	Multi-targeted antifolates aimed at avoiding drug resistance form covalent closed inhibitory complexes with human and Escherichia coli thymidylate synthases.
AID1321673	Antifungal activity against amphotericin-B resistant Candida albicans ATCC 90873 assessed as growth inhibition using alamar blue staining measured after 14 to 16 hrs by microdilution assay
AID1321696	Binding affinity to cholesterol containing POPC large unilamellar vescicle in pH 7.4 phosphate buffer by SPR analysis
AID1321677	Diffusion coefficient of the compound in 4:1 ratio of DMSO-d6/D2O solvent system at 1.2 mM and 25 degC by 1H NMR DOSY spectroscopy
AID1321691	Binding affinity to sodium dodecyl sulphate-d25 micelles at 200 uM by 1H NMR DOSY spectroscopy
AID1321694	Induction of membrane damage in POPC/cholesterol GUV model assessed as membrane curvature at 20 uM after 13 to 55 mins by TNM-DCCH staining based confocal microscopic analysis
AID1321679	Aqueous diffusion coefficient of the compound in 98:2 ratio of D2O/H2O solvent system at 1.2 mM and 25 degC by 1H NMR DOSY spectroscopy
AID1321674	Antifungal activity against Trichophyton assessed as growth inhibition using alamar blue staining measured after 14 to 16 hrs by microdilution assay
AID1321681	Binding affinity to sodium dodecyl sulphate-d25 micelles assessed as reduction in compound 1H resonance line broadening at compound:Mn2+ ratio of 2:3 to 10:1 by 1H NMR DOSY spectroscopy
AID1321672	Antifungal activity against wild-type Candida albicans ATCC 32354 assessed as growth inhibition using alamar blue staining measured after 14 to 16 hrs by microdilution assay
AID1321675	Antifungal activity against Aspergillus assessed as growth inhibition using alamar blue staining measured after 14 to 16 hrs by microdilution assay
AID1321693	Binding affinity to cholesterol free DMPC-d54/DHPC-d22 bicelles assessed as amide proton signals measured at 200 uM by 1H NMR spectroscopy
AID1321686	Binding affinity to cholesterol containing DMPC-d54/DHPC-d22 bicelles assessed as fluorescence intensity measured at ratio of 2:10 Mn2+ to compound by 1H NMR spectroscopy relative to control

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	46 (1.91)	18.2507
2000's	521 (21.58)	29.6817
2010's	1424 (58.99)	24.3611
2020's	423 (17.52)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	657 (26.61%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	362 (14.66%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	288 (11.66%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	28 (1.13%)	0.25%
Observational	0 (0.00%)	0.25%
Other	1,134 (45.93%)	84.16%
Other	5 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (964)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 1 Dose-Escalation Study to Examine the Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer [NCT00415636]	Phase 1	31 participants (Actual)	Interventional	2007-01-31	Completed
A Single-Arm, Multicenter, Open-Label, Phase 2 Study of Pemetrexed/Cisplatin Chemotherapy for Patients With Metastatic/Recurrent Soft Tissue Sarcoma in 4- Independent Histologic Subtypes [NCT04605770]	Phase 2	164 participants (Anticipated)	Interventional	2020-12-22	Recruiting
A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants With Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated With Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study) [NCT05096663]	Phase 2/Phase 3	82 participants (Actual)	Interventional	2022-03-15	Active, not recruiting
A Phase 3, Randomized, Global Trial of Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) [NCT03348904]	Phase 3	2 participants (Actual)	Interventional	2017-12-27	Terminated(stopped due to Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention.)
Phase II, Randomized, Open-Label Trial of Biweekly Pemetrexed Plus Gemcitabine vs. Pemetrexed or Pemetrexed Plus Carboplatin in Relapsed Non Small Cell Lung Cancer After Neoadjuvant or Adjuvant Chemotherapy [NCT00356525]	Phase 2	41 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to Stopped early due to low enrollment)
Phase I/II Trial of Gemcitabine/Pemetrexed Combination in Patients With Advanced Cutaneous T-Cell Lymphoma [NCT00369629]	Phase 1	14 participants (Actual)	Interventional	2006-08-28	Terminated(stopped due to This was planned as a phase I/II study originally, but due to a lack of funding, the phase II portion was never conducted.)
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer [NCT01143974]	Phase 4	28 participants (Actual)	Interventional	2010-06-30	Completed
Phase II Study of Pemetrexed Monotherapy in Patients With Platinum-resistant Squamous Cell Carcinoma of Head and Neck [NCT01333696]	Phase 2	32 participants (Anticipated)	Interventional	2011-04-30	Recruiting
A Phase I/Ib Study of MEK162, a MEK Inhibitor, in Combination With Carboplatin and Pemetrexed in Patients With Non-squamous Carcinoma of the Lung [NCT02185690]	Phase 1	13 participants (Actual)	Interventional	2018-01-11	Completed
A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult With Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study [NCT06096844]	Phase 3	304 participants (Anticipated)	Interventional	2024-02-16	Not yet recruiting
A Randomized, Open-Label, Multicenter, Phase 2, Umbrella Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations With and Without Chemotherapy as Neoad [NCT05577702]	Phase 2	120 participants (Anticipated)	Interventional	2023-02-15	Recruiting
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After O [NCT04988295]	Phase 3	776 participants (Actual)	Interventional	2021-11-17	Active, not recruiting
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer [NCT04538664]	Phase 3	308 participants (Actual)	Interventional	2020-10-13	Active, not recruiting
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC [NCT04092283]	Phase 3	660 participants (Anticipated)	Interventional	2020-04-29	Active, not recruiting
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advan [NCT04077463]	Phase 1	460 participants (Anticipated)	Interventional	2019-09-04	Recruiting
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer [NCT02609776]	Phase 1	751 participants (Actual)	Interventional	2016-05-24	Active, not recruiting
A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma [NCT01064648]	Phase 1/Phase 2	117 participants (Actual)	Interventional	2010-03-15	Active, not recruiting
Open-label, Phase 2 Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metast [NCT05849246]	Phase 2	130 participants (Anticipated)	Interventional	2023-05-30	Not yet recruiting
Phase II Study of Concurrent Cisplatin/Pemetrexed and RT Followed by Docetaxel in Stage III NSCLC (Non Small Cell Lung Cancer) [NCT00301808]	Phase 2	29 participants (Actual)	Interventional	2005-11-30	Completed
Study of Atezolizumab in Combination With Carboplatin + Paclitaxel +Bevacizumab vs With Pemetrexed + Cisplatin or Carboplatin With Stage IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER With EGFR(+) or ALK(+) [NCT03991403]	Phase 3	228 participants (Actual)	Interventional	2019-08-27	Active, not recruiting
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer [NCT03366766]	Phase 2	14 participants (Actual)	Interventional	2017-12-20	Completed
A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed ny Adjuvant ALIMTA/Cisplatin [NCT00165503]	Phase 2	16 participants (Actual)	Interventional	2004-04-30	Terminated(stopped due to lack of acurral)
Pembrolizumab Plus Bevacizumab and Chemotherapy as First-Line Treatment for Advanced or Metastatic Non-Squamous NSCLC Patients With EGFR Exon 20 Insertion Mutation: An Open-Label, Single-Arm, Phase II Trial [NCT05751187]	Phase 2	54 participants (Anticipated)	Interventional	2023-06-27	Recruiting
A Pilot Window-of-opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma [NCT02707666]	Phase 1	15 participants (Anticipated)	Interventional	2016-02-25	Recruiting
Phase I Dose Escalation Trial of Biweekly Alimta (With Vitamin Supplementation) in Combination With Taxotere in Advanced Solid Tumor Patients [NCT01172028]	Phase 1	33 participants (Actual)	Interventional	2005-09-30	Completed
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) [NCT01383148]	Phase 2/Phase 3	222 participants (Actual)	Interventional	2012-04-30	Terminated
Induction Pemetrexed and Cisplatin Followed by Pemetrexed as Maintenance vs Carboplatin-paclitaxel and Bevacizumab Followed by Bevacizumab as Maintenance:Multicenter Randomized Phase III Study in Patients With Advanced Non-Squamous Non Small-cell Lung Can [NCT01303926]	Phase 3	118 participants (Anticipated)	Interventional	2010-01-31	Active, not recruiting
Clinical and Radiographic Comparison of RetroMTA, OrthoMTA And Ferric Sulfate for Pulpotomy in Primary Molars [NCT03718676]		32 participants (Actual)	Interventional	2017-06-02	Completed
A Multicenter Phase II Trial of Neoadjuvant JS001, or JS001 in Combination With Chemotherapy in Resectable NSCLC. [NCT03623776]	Phase 2	80 participants (Anticipated)	Interventional	2019-02-01	Active, not recruiting
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response [NCT03655834]	Phase 4	10 participants (Actual)	Interventional	2019-02-01	Completed
Bevacizumab, Pemetrexed and Cisplatin, or Erlotinib and Bevacizumab for Advanced Non-Squamous NSCLC Stratified by EGFR Mutation Status. A Multicenter Phase II Trial Including Biopsy at Progression (BIO-PRO Trial). [NCT01116219]	Phase 2	149 participants (Anticipated)	Interventional	2010-06-30	Completed
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors: a Single Arm Phase 2 Study [NCT03647956]	Phase 2	40 participants (Anticipated)	Interventional	2018-10-01	Recruiting
A Phase II Study of Pemetrexed in Recurrent Cervical Adenocarcinomas [NCT02868892]	Phase 2	6 participants (Actual)	Interventional	2015-07-31	Terminated(stopped due to departure of PI from institution and poor population for study participation)
A Phase Ib/II Multicenter, Randomized, Open Label Trial to Compare Tepotinib (MSC2156119J) Combined With Gefitinib Versus Chemotherapy as Second-Line Treatment in Subjects With MET Positive, Locally Advanced or Metastatic NSCLC Harboring EGFR Mutation and [NCT01982955]	Phase 1/Phase 2	88 participants (Actual)	Interventional	2013-12-23	Completed
A Multicenter Phase II Trial of Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Patients With Unresectable Stage III Non-Small Cell Lung Cancer [NCT03872661]	Phase 2	36 participants (Anticipated)	Interventional	2019-03-01	Recruiting
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Sm [NCT03976323]	Phase 3	1,005 participants (Actual)	Interventional	2019-06-28	Active, not recruiting
Assessment of Bone Healing After MTA and PRF Application in Periapical Lesions By Using CBCT [NCT03743987]		36 participants (Actual)	Interventional	2016-12-20	Completed
A Phase 2 Study of Icotinib With Concurrent Radiotherapy vs. Pemetrexed+ Carboplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor ( EGFR) Mutation [NCT02407366]	Phase 2	80 participants (Anticipated)	Interventional	2014-12-31	Recruiting
A Randomized Open-Label Phase III Trial of Pembrolizumab Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer [NCT02142738]	Phase 3	305 participants (Actual)	Interventional	2014-08-25	Completed
Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma [NCT02399566]	Phase 4	300 participants (Anticipated)	Interventional	2015-05-31	Not yet recruiting
Exploiting Metformin Plus/Minus Cyclic Fasting Mimicking Diet (FMD) to Improve the Efficacy of First Line Chemo-immunotherapy in Advanced LKB1-inactive Lung Adenocarcinoma [NCT03709147]	Phase 2	64 participants (Anticipated)	Interventional	2018-10-30	Recruiting
A Phase II Trial of Pemetrexed and Cisplatin or Carboplatin in Combination With TTFields (150 kHz) as First-line Treatment in Malignant Pleural Mesothelioma [NCT02397928]	Phase 2	82 participants (Actual)	Interventional	2015-02-28	Completed
A Randomized, Double-blind, Multicenter Phase III Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer [NCT04439890]	Phase 3	369 participants (Anticipated)	Interventional	2019-08-08	Recruiting
SAMSUNG MEDICAL CENTER [NCT03110484]	Phase 2	44 participants (Anticipated)	Interventional	2021-07-09	Recruiting
Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE) [NCT05742607]	Phase 2	70 participants (Anticipated)	Interventional	2023-06-23	Recruiting
A Phase 3 Study to Evaluate Zimberelimab (AB122) Combined With AB154 in Front-Line, PD-L1-High, Locally Advanced or Metastatic Non-Small Cell Lung Cancer [NCT04736173]	Phase 3	750 participants (Anticipated)	Interventional	2021-02-08	Recruiting
Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer [NCT03307785]	Phase 1	58 participants (Actual)	Interventional	2017-10-12	Active, not recruiting
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) [NCT03085914]	Phase 1/Phase 2	70 participants (Actual)	Interventional	2017-05-02	Completed
A Phase I Trial of Preoperative Carboplatin or Cisplatin and Pemetrexed With Thoracic Radiation Therapy Followed by Lobectomy in Resectable Stage III Patients With Non-Squamous Non Small Cell Lung Cancer (NSCLC) [NCT01373463]	Phase 1	48 participants (Actual)	Interventional	2011-05-31	Terminated(stopped due to Investigator left site)
The Safety and Efficacy of Rh-Endostatin (Endostar®) Continuous Intravenous Infusion in Combination With Docetaxel/Carboplatin or Pemetrexed/Carboplatin (DC/PC) Regimens for Untreated Stage IIIB/IV Non-small-cell Lung Cancer (NSCLC) [NCT03706703]	Phase 2	50 participants (Anticipated)	Interventional	2018-10-01	Recruiting
A Multicenter Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab Followed By Pemetrexed and Bevacizumab Maintenance Therapy in Patients With a Light or Never Smoking History [NCT01344824]	Phase 2	38 participants (Actual)	Interventional	2010-03-31	Completed
A Phase I/II Study of Anlotinib Combined With Platinum-based Chemotherapy as the First-line Treatment of Patients With Locally Advanced or Advanced Non-Small Cell Lung Cancer [NCT03636685]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2018-08-15	Not yet recruiting
A Randomized Phase II Study of Anlotinib Combined With Pemetrexed and Cisplatin in First Treatment for Advanced Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Negative Mutations [NCT03671538]		62 participants (Anticipated)	Interventional	2018-10-01	Not yet recruiting
Chemotherapy Plus Pembrolizumab After Progression With Previous PD-1/PD-L1 Inhibitors in Patients With Advanced Non-small Cell Lung Cancer: Placebo-controlled Randomized Phase II Study [NCT03656094]	Phase 2	98 participants (Anticipated)	Interventional	2018-11-01	Recruiting
A Phase 2 Study of Pemetrexed Versus Pemetrexed Plus Erlotinib in Second-Line Treatment in Patients With Nonsquamous NSCLC [NCT00447057]	Phase 2	204 participants (Actual)	Interventional	2007-03-31	Completed
Randomized Phase II Trial Evaluating the Optimal Sequencing of PD-1 Inhibition With Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in Patients With Chemotherapy Naive Stage IV Non-small Cell Lung Cancer [NCT02591615]	Phase 2	91 participants (Actual)	Interventional	2016-03-31	Completed
Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study [NCT02588781]	Phase 2	23 participants (Actual)	Interventional	2015-10-31	Active, not recruiting
A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors [NCT02124148]	Phase 1	167 participants (Actual)	Interventional	2014-06-18	Completed
Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) [NCT04158141]	Phase 3	16 participants (Actual)	Interventional	2020-01-29	Terminated(stopped due to Permanent Administrative Closure)
A Phase 1, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability Pharmacokinetics Immunogenicity, and Antitumor Activity of MEDI5752 in Subjects With Advanced Solid Tumors. [NCT03530397]	Phase 1	396 participants (Anticipated)	Interventional	2018-04-24	Recruiting
A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer [NCT01828099]	Phase 3	376 participants (Actual)	Interventional	2013-07-09	Active, not recruiting
A Phase III, Randomized, Double-blinded, Multicenter Study of AK105 Combined With Carboplatin and Pemetrexed vs Placebo Combined With Carboplatin and Pemetrexed as First-line Therapy in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer [NCT03866980]	Phase 3	164 participants (Actual)	Interventional	2018-11-27	Active, not recruiting
A Pilot Study: Phase II Study of Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer [NCT01336543]	Phase 2	0 participants (Actual)	Interventional	2011-03-31	Withdrawn(stopped due to Low accrual, small patient population at center.)
Dose Climbing Trial of Anlotinib Plus Pemetrexed/Docetaxel in the Second-line Treatment of Advanced Gene Negative Non-squamous Non-small Cell Lung Cancer [NCT03566576]		18 participants (Anticipated)	Interventional	2018-07-01	Not yet recruiting
A Randomized, Multicenter, Open-Label Phase 3 Study of Pemetrexed-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Pemetrexed-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cance [NCT00982111]	Phase 3	633 participants (Actual)	Interventional	2009-11-02	Completed
The Efficacy and Safety of Osimertinib Plus Carboplatin and Pemetrexed Versus Osimertinib Monotherapy in Metastatic EGFRm NSCLC Patients With EGFRm Persistence in ctDNA at 3 Weeks After 1L Osimertinib: A Multicenter, Randomized Controlled Study [NCT04769388]	Phase 2	150 participants (Anticipated)	Interventional	2021-12-28	Recruiting
Anlotinib-based Combination as First-line Treatment in Advanced Non-small Cell Lung Cancer: a Single Center, Three Arms and Exploratory Study [NCT03628521]	Phase 1	80 participants (Anticipated)	Interventional	2018-07-20	Recruiting
Study of Sintilimab Combined With Anlotinib and Platinum-Containing Dual-Agent Chemotherapy as First Line Therapy in Malignant Pleural Mesothelioma: A Single Arm, Open-label, Prospective Phase II Trial [NCT05188859]	Phase 2	29 participants (Anticipated)	Interventional	2022-01-31	Not yet recruiting
The Efficacy and Safety of Aumolertinib Combined Ommaya Reservoir Intrathecal Chemotherapy With Pemetrexed for Leptomeningeal Metastasis From EGFR-mutated NSCLC and Investigate the Efficacy Prognostic Value of Dynamic Changes of cfDNA [NCT05810350]	Phase 2	40 participants (Anticipated)	Interventional	2023-01-01	Recruiting
An Open-label, Randomized, Multi-center, Phase III Clinical Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelial Cancer Previously Treated With [NCT05754853]	Phase 3	290 participants (Anticipated)	Interventional	2023-04-06	Recruiting
Recombinant Human Endostatin in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial [NCT05574998]	Phase 2	100 participants (Anticipated)	Interventional	2021-02-01	Recruiting
A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma [NCT02039674]	Phase 1/Phase 2	267 participants (Actual)	Interventional	2014-02-21	Completed
Randomized Phase II Trial of Single Agent Chemotherapy Plus Nivolumab or Single Agent Chemotherapy Alone in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor [NCT03041181]	Phase 2	3 participants (Actual)	Interventional	2017-01-27	Terminated(stopped due to Funder decision - lack of accrual)
A Phase II Trial of Oxaliplatin and Pemetrexed in Hormone Refractory Prostate Cancer [NCT01338792]	Phase 2	47 participants (Actual)	Interventional	2006-06-30	Completed
EGFR Tyrosine Kinase Inhibitor Combined With Concurrent or Sequential Chemotherapy for Advanced Lung Cancer Patients of Gradual Progression After First-line EGFR-TKI Therapy: a Randomized Controlled Study [NCT03544814]	Phase 2	99 participants (Actual)	Interventional	2015-01-01	Completed
Combination of Chemotherapy and Gefitinib as First-line Treatment of Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomised Controlled Trial [NCT02148380]		121 participants (Actual)	Interventional	2014-05-31	Completed
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies [NCT04993677]	Phase 2	77 participants (Actual)	Interventional	2021-10-06	Active, not recruiting
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Can [NCT02542293]	Phase 3	953 participants (Actual)	Interventional	2015-11-03	Active, not recruiting
A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel, Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel, as Neoadjuvant Treatment for Early Breast Cancer [NCT00149214]	Phase 2	257 participants (Actual)	Interventional	2005-09-30	Completed
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors [NCT01301716]	Phase 1	75 participants (Actual)	Interventional	2011-09-30	Completed
A Phase I Study of OSI-906 in Combination With Pemetrexed in Advanced Solid Tumor Malignancies [NCT01567384]	Phase 1	0 participants (Actual)	Interventional	2012-05-31	Withdrawn(stopped due to The sponsor withdrew support for the study before any patients were enrolled.)
Anlotinib Combined With Pemetrexed And Carboplatin Followed by Maintenance Therapy With Anlotinib Plus Pemetrexed as the First-line Treatment in Patients With Advanced Nonsquamous NSCLC [NCT03790228]	Phase 1	43 participants (Anticipated)	Interventional	2019-03-22	Recruiting
Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer [NCT03777124]	Phase 2	230 participants (Anticipated)	Interventional	2019-02-28	Not yet recruiting
Study of Anlotinib Combined With Pemetrexed as the Second-line Treatment in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer (ALTER-L025) [NCT03778138]	Phase 2	51 participants (Anticipated)	Interventional	2019-01-01	Recruiting
A Phase II Trial of Pemetrexed in Combination With Gemcitabine as First Line Treatment in Extensive-Stage Small Cell Lung Carcinoma [NCT00129974]	Phase 2	1 participants (Actual)	Interventional	2005-08-31	Terminated(stopped due to failure to accrue)
Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations Who Did Not Progress After Pemetrexed in Combination With Platinum-based Chemotherapy:a Single-arm, Open, [NCT03992885]	Phase 3	70 participants (Anticipated)	Interventional	2019-07-01	Recruiting
A Phase II Trial to Investigate Genetic Markers of Response to Pembrolizumab (MK-3475, SCH 900475) Combined With Chemotherapy as a First-line Treatment for Non-Small Cell Lung Cancer (KEYNOTE-782) [NCT03664024]	Phase 2	118 participants (Actual)	Interventional	2018-10-30	Completed
Study of Pemetrexed Disodium Plus Cisplatin as First-line Therapy in Patients With Advanced Non-squamous Cell Lung Cancer: a Phase IIA Pharmacogenomic Trial [NCT01088906]	Phase 2	57 participants (Actual)	Interventional	2010-01-31	Terminated(stopped due to No safety reasons. Low recruitment.)
Randomized Phase III Study of Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer After Platinum-Based Therapy [NCT00095199]	Phase 3	939 participants (Actual)	Interventional	2005-01-31	Completed
Randomized, Phase II, Open-Label Controlled Study of Two Different Doses and Schedules of EMD 72000 (Matuzumab) in Combination With Pemetrexed, or Pemetrexed Alone, as Second-Line Treatment for Stage IIIB/IV Non-Small Cell Lung Cancer and Progressive Dise [NCT00111839]	Phase 2	150 participants (Actual)	Interventional	2005-05-31	Completed
Phase III Open Label First Line Therapy Study of Tislelizumab With Chemotherapy Versus Chemotherapy in Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(NSCLC) [NCT03663205]	Phase 3	334 participants (Actual)	Interventional	2018-07-23	Completed
Phase 2 Study of Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-squamous Non-small Cell Lung Cancer With PD-L1 Tumor Proportion Score of Less Than 50%: CJLSG1901 [NCT04396457]	Phase 2	50 participants (Anticipated)	Interventional	2020-05-25	Active, not recruiting
A Phase II, Prospective, Single Arm Trial of Cadonilimab in Combination With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma [NCT05930665]	Phase 2	38 participants (Anticipated)	Interventional	2023-07-31	Not yet recruiting
Phase II Trial of Standard Platinum Doublet Chemotherapy + Various Proton Beam Therapy (PBT) Doses in Order to Determine the Optimal Dose of PBT for Unresectable Stage 2/3 Non-Small Cell Lung Cancer [NCT03132532]	Phase 2	18 participants (Actual)	Interventional	2017-07-31	Active, not recruiting
A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma [NCT02899299]	Phase 3	605 participants (Actual)	Interventional	2016-11-29	Completed
Phase I Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin (ADIAtezoPemCarbo) (iTRAP Study) [NCT03498222]	Phase 1	0 participants (Actual)	Interventional	2018-06-01	Withdrawn(stopped due to Funder and IMP manufacturer withdrew support)
A PHASE II STUDY Of ADJUVANT CHEMOTHERAPY After SURGERY For STAGE I Lung ADENOCARCINOMA PATIENTS With MICROPAPILLARY COMPONENT More Than Or EQUAL To 20% [NCT03351842]	Phase 2	460 participants (Anticipated)	Interventional	2017-09-01	Recruiting
Almonertinib Alone Versus Almonertinib Plus Chemotherapy as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive With Concomitant Non-EGFR Driver Gene Mutation Positive, Locally Advanced or Metastatic Non-Small C [NCT04500704]	Phase 3	166 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
A Randomized, Open-label, Phase II Study of Maintaining Pan-ERBB Blockade Following Platinum-based Induction Chemotherapy in Patients With EGFR Mutated, Metastatic Non-small-cell Lung Cancer Progressing After Treatment With Afatinib as First EGFR-targetin [NCT02488694]	Phase 2	4 participants (Actual)	Interventional	2015-11-30	Terminated(stopped due to unsufficient recruitment)
Phase II Study of Tislelizumab Plus Pemetrexed in Patients With Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS) [NCT05253118]	Phase 2	28 participants (Anticipated)	Interventional	2022-08-18	Recruiting
A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients With PDL-1 of 1%-49% [NCT04856176]	Phase 2	83 participants (Anticipated)	Interventional	2022-01-03	Recruiting
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) [NCT03800134]	Phase 3	826 participants (Actual)	Interventional	2018-12-06	Active, not recruiting
"A Study on theFuzhengTherapy Promoted Immune Reconstitution to Improve the Survival of Early-stage Lung Cancer After Surgical Operation" [NCT02603003]	Phase 1	218 participants (Actual)	Interventional	2015-06-30	Completed
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response [NCT03655821]	Phase 4	81 participants (Actual)	Interventional	2019-02-01	Terminated(stopped due to 81 patients included, difficult inclusion and full inclusion would not change the results)
A Factorial Study Comparing Pemetrexed With Gemcitabine and Testing the Efficacy of the Addition of Cisplatin in Elderly Patients With Non Squamous Advanced, Metastatic or Recurrent NSCLC. [NCT01656551]	Phase 3	232 participants (Actual)	Interventional	2012-08-31	Active, not recruiting
The Prognosis Study of Postoperative Non-small-cell Lung Cancer Patients Treated Precisely With the Integrated Traditional Chinese and Western Medicine Based on CTC Detection [NCT03269162]	Phase 3	144 participants (Anticipated)	Interventional	2016-09-30	Active, not recruiting
A Study in Cancer Patients to Evaluate the Ability of LY2603618 to Act as an Inhibitor of CYP2D6 Using Desipramine as a Probe Substrate [NCT01358968]	Phase 1	20 participants (Actual)	Interventional	2011-06-30	Completed
A Phase 1/2 Study of Apatinib in Combination With AP(Pemetrexed/Cisplatin) or AC(Pemetrexed/Carboplatin) as First-line Chemotherapy for Advanced Epidermal Growth Factor Receptor(EGFR) Wild Type Non-squamous Non-small Cell Lung Cancer [NCT03201146]	Phase 1/Phase 2	48 participants (Anticipated)	Interventional	2017-06-27	Recruiting
A Multicenter, Open-Label, Phase Ib/II Study of AK119 and AK112 With or Without Chemotherapy in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Who Have Failed to Epidermal Growth Factor Receptor Tyrosine K [NCT05636267]	Phase 1/Phase 2	114 participants (Anticipated)	Interventional	2023-02-10	Recruiting
A Phase 1/2, Open-Label, Multicenter Study to Investigate the Safety and Preliminary Efficacy of Combined Bempegaldesleukin (NKTR-214) and Pembrolizumab With or Without Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors [NCT03138889]	Phase 1/Phase 2	162 participants (Actual)	Interventional	2017-06-09	Terminated(stopped due to Sponsor decision)
Personalized Therapy for Esophagogastric Cancer Using Thymidylate Synthase Genetic Markers [NCT02296671]	Phase 2	0 participants (Actual)	Interventional	2015-02-28	Withdrawn(stopped due to Was unable to accrue any patients)
Neoadjuvant Icotinib With Chemotherapy for Resectable Stage II-IIIB N2 EGFR Mutation-positive Lung Adenocarcinoma: A Phase II Study [NCT05132985]	Phase 2	45 participants (Anticipated)	Interventional	2022-01-01	Not yet recruiting
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study [NCT05692999]	Phase 3	1,166 participants (Anticipated)	Interventional	2023-03-20	Recruiting
Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung Adenocarcinoma [NCT00903292]		52 participants (Anticipated)	Interventional	2009-03-31	Recruiting
A Randomized, Open-Label, Dose Escalation Study of Bevacizumab With Ambulatory Blood Pressure Monitoring in Previously Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer [NCT01063283]		20 participants (Actual)	Interventional	2010-03-31	Completed
A Single Armed Phase ⅡStudy of Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation [NCT02737774]	Phase 2	60 participants (Anticipated)	Interventional	2016-04-13	Active, not recruiting
Chemotherapy in KRAS Mutated Chemotherapy Naive Non-small Cell Lung Cancer Patients: a Phase III Study Comparing Cisplatin-pemetrexed With Carboplatin-paclitaxel-bevacizumab: NVALT 22 [NCT02743923]	Phase 3	203 participants (Actual)	Interventional	2016-04-30	Active, not recruiting
Phase II Trial of Combination Pemetrexed (Alimta) and Carboplatin (Paraplatin) in Platinum Sensitive Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Carcinoma [NCT01001910]	Phase 2	22 participants (Actual)	Interventional	2008-07-31	Completed
A Phase I Study of INCB024360 (Epacadostat) Alone, INCB024360 in Combination With Pembrolizumab (MK-3475), and INCB024360 and Pembrolizumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors (KEYNOTE-434) [NCT02862457]	Phase 1	34 participants (Actual)	Interventional	2016-08-23	Completed
An Open-Label, Phase 1B Study of NEO-PV-01 With Pembrolizumab Plus Chemotherapy in Patients With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer [NCT03380871]	Phase 1	38 participants (Actual)	Interventional	2018-05-04	Completed
A Single-Arm Phase II Clinical Trial of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma [NCT03376737]	Phase 2	120 participants (Anticipated)	Interventional	2017-10-12	Recruiting
Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE) [NCT04892953]	Phase 2	51 participants (Anticipated)	Interventional	2021-07-07	Recruiting
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042) [NCT03850444]	Phase 3	262 participants (Actual)	Interventional	2016-08-01	Completed
A Phase II Trial to Assess the Safety, Immunological Activity of TroVax® Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma [NCT01569919]	Phase 2	26 participants (Anticipated)	Interventional	2012-12-31	Recruiting
BRIDGE Trial: Phase II Trial of durvalumaB and chemotheRapy Induction Followed by Durvalumab and Radiotherapy in larGe volumE Stage III NSCLC [NCT04765709]	Phase 2	10 participants (Actual)	Interventional	2021-09-24	Active, not recruiting
High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases [NCT02284490]	Phase 2	25 participants (Anticipated)	Interventional	2014-11-30	Not yet recruiting
A Multi-Regional, Randomized, Double-blind, Phase 3 Study of the Efficacy and Safety of Sintilimab Plus Chemotherapy vs Placebo Plus Chemotherapy Before Surgery and Sintilimab vs Placebo After Surgery for Resectable Non-small Cell Lung Cancer [NCT05116462]	Phase 3	800 participants (Anticipated)	Interventional	2021-11-11	Not yet recruiting
A Randomized Phase II Trial Of Pemetrexed With Or Without PF-3512676 For The Treatment Of Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer After Failure Of One Prior Chemotherapy Regimen For Advanced Disease [NCT00321308]	Phase 2	36 participants (Actual)	Interventional	2006-09-30	Terminated(stopped due to See Termination Reason in Detailed Description.)
A Phase II Study of Pemetrexed in Children With Recurrent Malignancies [NCT00520936]	Phase 2	72 participants (Actual)	Interventional	2007-09-30	Completed
A Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC) (MAGELLAN) [NCT03819465]	Phase 1	175 participants (Actual)	Interventional	2018-12-27	Active, not recruiting
Furmonertinib Combined With Cisplatin/Pemetrexed as Neoadjuvant Therapy in EGFR Mutated Stage IIIA-IIIB Resectable Non-small Cell Lung Cancer (FORESEE): a Prospective, Open-label, Single-arm, Phase 2 Study [NCT05430802]	Phase 2	40 participants (Anticipated)	Interventional	2022-02-24	Recruiting
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial [NCT05891080]	Phase 2	124 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
Pevonedistat as a Single Agent and in Combination With Chemotherapy in Patients With Malignant Mesothelioma [NCT03319537]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2017-10-05	Completed
Clinical Study to Evaluate the Efficacy, Safety and Tolerability of Savolitinib + Osimertinib Versus Pemetrexed + Platinum in Treatment of Patients With NSCLC With MET Amplification [NCT05015608]	Phase 3	250 participants (Anticipated)	Interventional	2021-11-22	Recruiting
Early Positron Emission Tomography as a Predictor of Response in Neoadjuvant Chemotherapy for Non-Small Cell Lung Cancer [NCT00227539]	Phase 2	25 participants (Actual)	Interventional	2005-07-31	Completed
Pemetrexed in Maintenance in Patients With Impaired Renal Function: Randomized Phase 4 Multicenter Study Comparing 2 Dose Calculation Strategies (PKAPIR) [NCT03607149]	Phase 4	11 participants (Actual)	Interventional	2017-04-06	Completed
A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment for Advanced Non-Small Cell Lung Cancer [NCT00102804]	Phase 3	663 participants (Actual)	Interventional	2005-03-31	Completed
A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC [NCT06161441]	Phase 2	180 participants (Anticipated)	Interventional	2024-03-05	Not yet recruiting
Phase II Study of Pemetrexed and Pembrolizumab in Recurrent and/or Metastatic Salivary Gland Malignancies [NCT04895735]	Phase 2	45 participants (Anticipated)	Interventional	2021-07-23	Recruiting
A Phase 1/2, Dose Escalation, Dose Expansion, and Dose Optimization Study of the Safety, Tolerability, and Anti-tumor Activity of SAR444881 Administered Alone and in Combination With Pembrolizumab, Cetuximab and/or Chemotherapy in Participants With Advanc [NCT04717375]	Phase 1/Phase 2	456 participants (Anticipated)	Interventional	2021-04-11	Recruiting
A Randomized, Double Blind, Phase 3 Study of Platinum-Based Chemotherapy With or Without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer (POD1UM-304) [NCT04205812]	Phase 3	583 participants (Actual)	Interventional	2020-09-27	Active, not recruiting
An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer ( [NCT02477826]	Phase 3	2,748 participants (Actual)	Interventional	2015-08-05	Active, not recruiting
Pemetrexed Monochemotherapy in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer. A Pilot Study to Define the Best Dosing Schedule for a Planned Phase II Randomized Trial [NCT00370292]	Phase 2	19 participants (Actual)	Interventional	2006-09-30	Completed
Phase I Clinical Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Combination With Pemetrexed and Cisplatin in Patients With Advanced Cancer [NCT00106626]	Phase 1	52 participants (Actual)	Interventional	2005-08-31	Completed
Study of Thalidomide With First-line Chemotherapy and as Maintenance Treatment of Advanced Nonsquamous NSCLC With Epidermal Growth Factor Receptor Wild-Type or Unknown Mutation Status: A Multicenter, Randomized, Prospective Clinical Trial [NCT03062800]	Phase 2	232 participants (Anticipated)	Interventional	2016-12-31	Recruiting
Clinical Research of S-1 Versus Pemetrexed in the Maintenance Treatment of Advanced Non-squamous Non-small Cell Lung Cancer [NCT03700333]	Phase 3	120 participants (Anticipated)	Interventional	2018-10-20	Not yet recruiting
A Phase II/III Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma [NCT02784171]	Phase 2/Phase 3	520 participants (Actual)	Interventional	2016-11-11	Active, not recruiting
A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES [NCT03317496]	Phase 1/Phase 2	67 participants (Actual)	Interventional	2017-12-21	Terminated(stopped due to The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).)
ICARuS II (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multicenter, Randomized Phase II Trial of Normothermic Intraperitoneal Chemotherapy and Intravenous Chemotherapy After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemother [NCT06057935]	Phase 2	64 participants (Anticipated)	Interventional	2023-09-21	Recruiting
A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors [NCT04956640]	Phase 1	400 participants (Anticipated)	Interventional	2021-07-19	Recruiting
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic [NCT02453282]	Phase 3	1,118 participants (Actual)	Interventional	2015-07-21	Active, not recruiting
A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy. [NCT03944772]	Phase 2	250 participants (Anticipated)	Interventional	2019-06-25	Active, not recruiting
Phase II Trial of Pemetrexed-Based Induction Chemotherapy Followed by Concomitant Chemoradiotherapy in Previously Irradiated Head and Neck Cancer Patients [NCT01172470]	Phase 2	34 participants (Actual)	Interventional	2005-06-30	Completed
The Prospective,Multicenter,Randomized Controlled Clinical Study of the Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC） [NCT02076477]	Phase 3	420 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Research on the Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via Digital Droplet PCR (ddPCR) From Peripheral Blood in NSCLC Patients [NCT05458726]	Phase 2	80 participants (Anticipated)	Interventional	2020-09-15	Recruiting
A Randomized,Open-label, Multi-Center, Phase II Clinical Trial to Assess the Efficacy and Safety of SHR-1210± SHR-1020 Versus Physician's Choice Chemotherapy in the Treatment of Recurrent or Metastatic Cervical Cancer Patients [NCT04680988]	Phase 2	194 participants (Actual)	Interventional	2021-04-05	Active, not recruiting
Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma [NCT02518802]	Phase 3	220 participants (Anticipated)	Interventional	2015-01-31	Recruiting
A Phase II Trial of AMG 102 in Combination With Pemetrexed and Cisplatin in Patients With Malignant Pleural Mesothelioma [NCT01105390]	Phase 2	0 participants (Actual)	Interventional	2010-04-30	Withdrawn(stopped due to withdrawn)
A Phase I Open Label Study of Continuous Oral Treatment With BIBF 1120 Together With Pemetrexed in Previously Treated Patients With Non-small Cell Lung Cancer [NCT02182102]	Phase 1	26 participants (Actual)	Interventional	2005-09-30	Completed
The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab for Patients With Advanced Non-squamous Non-small Cell Lung Cancer [NCT02200354]	Phase 2	20 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to inclusion speed)
A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer [NCT03134872]	Phase 3	419 participants (Actual)	Interventional	2017-05-12	Completed
Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma [NCT05185544]		50 participants (Anticipated)	Observational	2022-01-01	Not yet recruiting
Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor Activating Mutation [NCT04470076]	Phase 2	30 participants (Anticipated)	Interventional	2020-07-10	Not yet recruiting
A Randomized, Open-Label, Multicenter Phase 3 Study to Evaluate SKB264 Monotherapy Versus Pemetrexed in Combination With Platinum in Patients With Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutation Who Have Failed to [NCT05870319]	Phase 3	356 participants (Anticipated)	Interventional	2023-06-26	Recruiting
Phase 3, Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Combined With Osimertinib vs Platinum-Based Chemotherapy in Subjects With c-Met Overexpressing (OE) EGFR Mutant, Locally Advanced/Metastatic Non-Squamous NSCLC A [NCT06093503]	Phase 3	250 participants (Anticipated)	Interventional	2024-05-31	Not yet recruiting
A Single Arm, Phase 2 Study of Amivantamab, Lazertinib and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers (NSCLCs) With EGFR Mutations [NCT05299125]	Phase 2	49 participants (Anticipated)	Interventional	2023-05-24	Recruiting
An Open-label, Dose-escalation, Phase I/II Study to Assess the Safety, the Tolerability, the Immunogenicity and the Preliminary Clinical Activity of the Therapeutic Cancer Vaccine, PDC*lung01, Associated or Not With Anti-PD-1 Treatment in Patients With No [NCT03970746]	Phase 1/Phase 2	73 participants (Actual)	Interventional	2019-09-10	Active, not recruiting
Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin [NCT02535312]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2016-03-08	Active, not recruiting
A Three Arm, Randomized, Double-Blind, Multicenter, Phase 3 Study of HLX10(Anti-PD-1 Antibody) in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04(Avastin Biosimilar) Compared With Carboplatin+Pemetrexed in 1L Stage IIIB/IIIC or IV N [NCT03952403]	Phase 3	643 participants (Actual)	Interventional	2019-12-02	Active, not recruiting
A Phase 1b, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0482 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors. [NCT03918278]	Phase 1	230 participants (Anticipated)	Interventional	2019-06-19	Active, not recruiting
A Randomized Phase I/II Study of Standard Chemotherapy (Cisplatin and Pemetrexed) With or Without Axitinib in Patients With Malignant Mesothelioma: Interim Biopsy Analysis to Determine Efficacy [NCT01211275]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2009-05-22	Completed
A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma [NCT01353482]	Phase 1/Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to UCL CTC were informed by Merck Sharp & Dohme on 22.08.11 that support for the trial had been withdrawn in light of results from another trial with trial drug.)
Immunotherapy in Lung Cancer: Which Treatment After Immunotherapy Cessation: A Prospective Registry From the European Lung Cancer Working Party [NCT04465942]		300 participants (Anticipated)	Observational [Patient Registry]	2020-06-26	Recruiting
A Phase II Study of Pembrolizumab Plus Platinum and Pemetrexed as First Line Therapy in Advanced Non-squamous Non-small Cell Lung Cancer Patients With EGFR Exon 21 Point Mutation and Programmed Cell Death Ligand 1 Expression [NCT06142617]	Phase 2	37 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol [NCT03737994]	Phase 2	10 participants (Actual)	Interventional	2019-07-25	Active, not recruiting
A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-Pd-L1 Antibody) in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Patients Who Are Chemotherapy-Naive and Have Stage [NCT02657434]	Phase 3	578 participants (Actual)	Interventional	2016-04-30	Completed
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC) [NCT00324805]	Phase 3	1,501 participants (Actual)	Interventional	2007-06-01	Active, not recruiting
A Phase 1b Combination Study of INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) [NCT03920839]	Phase 1	0 participants (Actual)	Interventional	2019-07-15	Withdrawn(stopped due to As of November 4, 2019 the study was halted prematurely and will not resume.)
Intrathecal-pemetrexed Combined With Concurrent Involved-field Radiotherapy for Leptomeningeal Metastasis From Solid Tumor: a Phase I/II Clinical Trial [NCT03507244]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2018-04-12	Completed
A Phase 2 Open-label Single-arm Study to Evaluate the Combination of Pembrolizumab, Lenvatinib and Chemotherapy in Non-small Cell Lung Cancer (NSCLC) Harbouring Targetable Mutation and Failed Standard Tyrosine Kinase Inhibitors [NCT04989322]	Phase 2	46 participants (Anticipated)	Interventional	2021-10-05	Recruiting
Chemotherapy Combination With Local Radiotherapy and rhGM-CSF for Oligometastatic Stage IV NSCLC Patients Without Progression After First-line Chemotherapy: a Prospective Randomized Controlled Study [NCT03489616]		45 participants (Anticipated)	Interventional	2018-01-15	Recruiting
Phase I Clinical Trial of Ixabepilone and Pemetrexed in Advanced Solid Tumors [NCT01170871]	Phase 1	0 participants (Actual)	Interventional		Withdrawn(stopped due to Sponsor withdrew support)
A Randomized, Multicenter, Open-label Phase Ib/II Study of RO5083945 in Combination With Cisplatin and Gemcitabine/Pemetrexed Versus Cisplatin and Gemcitabine/Pemetrexed in Patients With Advanced or Recurrent Non Small Cell Lung Cancer Who Have Not Receiv [NCT01185847]	Phase 2	90 participants (Actual)	Interventional	2010-11-30	Completed
Phase II Study of Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations [NCT01109615]	Phase 2	40 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to Lacking effect of treatment)
An Open-Label, Phase I/Ib Dose Escalation Study to Assess the Safety and Tolerability of GSK1120212 in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel in Subjects With Advanced Solid T [NCT01192165]	Phase 1	169 participants (Actual)	Interventional	2010-09-14	Completed
Phase 2 Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small [NCT01192243]	Phase 2	68 participants (Anticipated)	Interventional	2009-12-31	Recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies [NCT05891171]	Phase 1	81 participants (Anticipated)	Interventional	2023-10-13	Recruiting
A Phase III Randomized, Controlled, Open-label, Multicenter, Global Study of Capmatinib in Combination With Osimertinib Versus Platinum - Pemetrexed Based Doublet Chemotherapy in Patients With Locally Advanced or Metastatic NSCLC Harboring EGFR Activating [NCT04816214]	Phase 3	6 participants (Actual)	Interventional	2021-09-22	Terminated(stopped due to Novartis decided to terminate the study based on a business consideration and not related with any safety concerns. Randomized part was not initiated)
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer [NCT04194944]	Phase 3	261 participants (Actual)	Interventional	2020-02-17	Active, not recruiting
Phase I Study of Cabozantinib in Combination With Pemetrexed in Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC), Urothelial Cancer and Advanced Malignant Mesothelioma [NCT04173338]	Phase 1	9 participants (Actual)	Interventional	2020-01-23	Terminated(stopped due to Closed by IRB on 3/28/22)
Randomized Multicenter Study to Compare the Effectiveness and Safety of Erlotinib and Pemetrexed as Maintenance Therapy of Advanced Non-Squamous Non-Small Cell Lung Cancer [NCT03460678]	Phase 4	9 participants (Actual)	Interventional	2018-02-28	Terminated(stopped due to Difficulty recruiting)
A Multicenter, Open Clinical Trial of Using TS Gene Polymorphism to Predict Effect in Patients of Advanced Lung Adenocarcinoma to Pemetrexed Combining With Cisplatin Regiment as First-line Treatment [NCT00940069]	Phase 2	60 participants (Actual)	Interventional	2009-03-31	Completed
Efficacy and Safety of Anlotinib Combined With Platinum Plus Pemetrexed in T790M Mutation Negative Metastastic Non-squamous Non-small-cell Lung Cancer After Progression on First-line EGFR TKI: a Phase II, Muti-center, Single Arm Study [NCT03706287]	Phase 1/Phase 2	62 participants (Anticipated)	Interventional	2018-12-06	Recruiting
A Phase II, Open-Label, Multi-Cohort Study to Investigate the Preliminary Antitumor Activity, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With Chemotherapy as First-Line Treatment in Chinese Subjects With Loca [NCT03432598]	Phase 2	54 participants (Actual)	Interventional	2017-08-24	Completed
A Study to Evaluate the Efficacy and Safety of Anlotinib Plus Pemetrexed as the 1-line Treatment of Patients With Platinum Intolerant Advanced Non-squamous NSCLC, With Pemetrexed Control. [NCT03768037]	Phase 4	106 participants (Anticipated)	Interventional	2018-11-26	Recruiting
A Prospective, Single-center, One-arm Clinical Study of Apatinib Combined With Chemotherapy for Patients Who Progressed After First Line EGFR-TKI Treatment Without T790M Mutation [NCT03758677]	Phase 2	30 participants (Anticipated)	Interventional	2020-08-01	Not yet recruiting
Alflutinib Versus Alflutinib Plus Chemotherapy for Nonesmall Cell Lung Cancer With EGFR (T790M)- Associated Resistance to Initial EGFR Inhibitor Treatment: An Open-label, Randomised Phase 2 Clinical Trial [NCT05209256]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2022-03-01	Not yet recruiting
International Multicenter Randomized Double-Blind Placebo-Controlled Clinical Trial Evaluating Efficacy and Safety Of BCD-100 in Combination With Pemetrexed+Cisplatin/Carboplatin Compared to Placebo in Combination With Pemetrexed+Cisplatin/Carboplatin as [NCT03912389]	Phase 3	292 participants (Anticipated)	Interventional	2019-06-01	Recruiting
A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer [NCT01282151]	Phase 3	148 participants (Actual)	Interventional	2011-07-31	Terminated(stopped due to Difficulty in recruitment due to approval of maintenance pemetrexed treatment)
Phase I Trial of Haploidentical Natural Killer (NK) Cells in Combination With Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) [NCT03366064]	Phase 1	5 participants (Actual)	Interventional	2017-11-09	Completed
"An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 Regorafenib, Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Nonsquamous Non-Small Cel [NCT01187615]	Phase 1	9 participants (Actual)	Interventional	2010-08-31	Terminated
A Phase III Study to Investigate the Differential Influence of Prior Chemotherapy on the Efficacy of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (IIIB, IV) With or Without EGFR Gene Mutation [NCT01204307]	Phase 2	101 participants (Actual)	Interventional	2010-01-31	Completed
A Single Arm, Phase II Clinical Trial of Orelabrutinib Combined With Pemetrexed in the Treatment for Patients With Relapsed/Refractory Central Nervous System Lymphoma [NCT05209620]	Phase 2	30 participants (Anticipated)	Interventional	2021-12-21	Recruiting
Efficacy and Safety of Pemetrexed Plus Cisplatin as Combination Chemotherapy for Post-operative Adenocarcinoma : Multi-center, Single Arm, Open-label, Phase Ⅱ Trial [NCT02498860]	Phase 2	106 participants (Actual)	Interventional	2015-09-01	Completed
Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open [NCT03792503]	Phase 4	20 participants (Anticipated)	Interventional	2019-02-28	Not yet recruiting
Phase I Trial of Cisplatin and Pemetrexed in Combination With Panobinostat in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer [NCT01336842]	Phase 1	23 participants (Actual)	Interventional	2011-04-30	Completed
A Phase II Study of Pemetrexed Plus Carboplatin Combined With Radiation in Patients With Inoperable Locally Advanced Non-small Cell Lung Cancer [NCT00886678]	Phase 2	63 participants (Anticipated)	Interventional	2008-07-31	Active, not recruiting
Efficacy and Safety Evaluation of Percutaneous Ommaya Capsule Injection of Autologous Bi-dimensional Specific T Cells in the Treatment of Glioma and in Combination With Pemetrexed in the Treatment of Brain/Meningeal Metastases [NCT05459441]	Early Phase 1	30 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Zanubrutinib With Pemetrexed for the Treatment of Relapsed/Refractory Primary and Secondary CNS Lymphomas: A Phase II Trial With a Safety Lead-In [NCT05681195]	Phase 2	15 participants (Anticipated)	Interventional	2023-09-27	Recruiting
Phase 1/2 Study of Pemetrexed Plus Cisplatin in Unresectable, Advanced Gastric Carcinoma. [NCT00320515]	Phase 1/Phase 2	89 participants (Actual)	Interventional	2004-03-31	Completed
A Randomized, Open-label, Phase II, 2-arm Multi-center Trial Comparing Maintenance Therapy With Pazopanib or Pemetrexed in Non-progressing Subjects With Metastatic Stage IVA and IVB Non-squamous Non-small Cell Lung Cancer (NSCLC) After Induction Therapy W [NCT01313663]	Phase 2	20 participants (Actual)	Interventional	2011-02-28	Terminated
A Multicenter Phase II Randomized Trial Of Immunotherapy Versus Chemotherapy Guided By Circulating Tumor DNA-Based Molecular Response On Patients With Metastatic NSCLC [NCT05715229]	Phase 2	108 participants (Anticipated)	Interventional	2023-09-29	Recruiting
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer [NCT04989283]	Phase 2	0 participants (Actual)	Interventional	2021-09-09	Withdrawn(stopped due to Due to no accrual)
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma [NCT03228537]	Phase 1	29 participants (Actual)	Interventional	2018-07-16	Active, not recruiting
A Randomized Ph 3 Study Comparing First-Line Pemetrexed/Cisplatin Followed by Gefitinib With Gefitinib Alone in East Asian Never Smoker or Light Ex-Smoker Patients With Locally Advanced or Metastatic Nonsquamous NSCLC [NCT01017874]	Phase 3	236 participants (Actual)	Interventional	2009-11-30	Completed
Phase 2 Study of Pemetrexed in Combination With Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [NCT01057589]	Phase 2	66 participants (Actual)	Interventional	2010-02-28	Completed
A Phase I/II Clinical Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma [NCT02347917]	Phase 1/Phase 2	28 participants (Actual)	Interventional	2015-02-28	Completed
A Phase I Study of the Treatment of Recurrent Primary or Secondary CNS Lymphoma With ALIMTA (Pemetrexed), a Novel Anti-Folate [NCT00916630]	Phase 1	18 participants (Actual)	Interventional	2009-01-31	Completed
Randomized, Open-Label, Phase 3 Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or I [NCT00762034]	Phase 3	939 participants (Actual)	Interventional	2008-12-31	Completed
An Open Label Phase Ib Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Maximum Tolerated Dose of Anetumab Ravtansine in Combination With Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 in Subjects With Mesothel [NCT02639091]	Phase 1	36 participants (Actual)	Interventional	2016-02-03	Completed
A Phase I Open Label Study of GSK3359609 Administered Alone and in Combination With Anticancer Agents in Subjects With Selected Advanced Solid Tumors [NCT02723955]	Phase 1	829 participants (Actual)	Interventional	2016-06-23	Completed
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer [NCT00698815]	Phase 2	130 participants (Actual)	Interventional	2008-04-15	Completed
Phase 3 Study of Pemetrexed, Cisplatin, and Radiotherapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiotherapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Patients With Unresectable, Locally Advanced, Stage I [NCT00686959]	Phase 3	598 participants (Actual)	Interventional	2008-09-30	Completed
Pilot Study of Pemetrexed for the Treatment of Chordoma [NCT03955042]	Phase 1	15 participants (Actual)	Interventional	2019-09-06	Completed
A Phase 2 Double-Blind Randomized Study of Oral Enzastaurin HCl Versus Placebo Concurrently With Pemetrexed (Alimta®) as Second-Line Therapy in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00530621]	Phase 2	160 participants (Actual)	Interventional	2007-09-30	Completed
Randomized Phase II Study of Pemetrexed Versus Pemetrexed and Carboplatin as Second Line Chemotherapy in Advanced Non-small-cell Lung Cancer (NSCLC). [NCT00786331]	Phase 2	230 participants (Anticipated)	Interventional	2007-07-31	Recruiting
A Multicenter, Randomized, Phase II Study of Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Advanced or Locally-advanced Osimertinib-resistant Non-squamous Non-small Cell Lung Cancer (ALTER-L031) [NCT04136535]	Phase 2	105 participants (Anticipated)	Interventional	2019-10-18	Not yet recruiting
A Phase II Study of Pemetrexed as Second-Line Treatment in Patients With Pancreatic Cancer Progressing Despite Therapy With Gemcitabine [NCT00864513]	Phase 2	17 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to At interim analysis the study did not meet the response criteria to continue)
A Randomized Phase II Study of Erlotinib Compared to Single Agent Chemotherapy-erlotinib Combination in Pretreated Patients With Advanced NSCLC (NVALT10 Study) [NCT00835471]	Phase 2	195 participants (Actual)	Interventional	2009-03-31	Completed
Open-label Study of Bevacizumab Maintenance Therapy (AVASTIN®) With or Without Pemetrexed After First-line Chemotherapy With Bevacizumab-cisplatin-pemetrexed in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC [NCT00961415]	Phase 3	376 participants (Actual)	Interventional	2009-08-31	Completed
Open-Label Single-Arm Phase 2 Study of Alimta in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Who Have Had Prior Platinum Based Chemotherapy [NCT00630149]	Phase 2	35 participants (Actual)	Interventional	2007-11-30	Completed
Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative [NCT02804646]	Phase 4	100 participants (Anticipated)	Interventional	2016-06-30	Recruiting
A Phase I/II Study Evaluating the Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer (Triumph-02) [NCT05978401]	Phase 1/Phase 2	152 participants (Anticipated)	Interventional	2023-08-10	Not yet recruiting
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated, MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung C [NCT05261399]	Phase 3	324 participants (Anticipated)	Interventional	2022-08-03	Recruiting
Pilot Study of Serial Plasma Genotyping to Guide the Adaptive Treatment of Advanced NSCLC Receiving First-line Pembrolizumab [NCT04166487]	Phase 2	40 participants (Actual)	Interventional	2020-01-13	Active, not recruiting
A Phase Ib Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens. [NCT01783197]	Phase 1	39 participants (Actual)	Interventional	2013-06-04	Completed
A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy. [NCT01708993]	Phase 2	166 participants (Actual)	Interventional	2012-12-10	Completed
An Open-Label, Multicenter Study of IBI308 in Subjects With Selected Advanced Solid Tumors [NCT02937116]	Phase 1	233 participants (Actual)	Interventional	2016-10-19	Completed
Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) [NCT02709512]	Phase 2/Phase 3	249 participants (Actual)	Interventional	2017-08-01	Completed
EGFR-TKI With Chemotherapy as First Line Treatment in Stage IIIB/IV NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism [NCT02859077]	Phase 3	100 participants (Anticipated)	Interventional	2016-08-31	Not yet recruiting
Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases [NCT02162537]	Phase 3	95 participants (Actual)	Interventional	2013-12-31	Terminated(stopped due to Slow inclusions due in part to a change in practices. The first chemotherapy become a standard for patients with NSCL with asymptomatic brain metastases.)
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Ce [NCT04265534]	Phase 2	40 participants (Actual)	Interventional	2020-07-24	Terminated(stopped due to Lack of Clinical Benefit)
A Randomized, Double-blinded, Phase III Study of Pemetrexed Plus Platinum Chemotherapy With or Without Sintilimab (IBI308) in First Line Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (Orient-11) [NCT03607539]	Phase 3	397 participants (Actual)	Interventional	2018-08-23	Completed
Almonertinib Alone Versus Almonertinib Plus Chemotherapy as First-Line Treatment in Locally Advanced Or Metastatic NSCLC Patients With Concomitant EGFR and Tumor Suppressor Gene Mutation: A Multicenter, Open-Label, Randomized, Controlled Phase III Study ( [NCT04500717]	Phase 3	460 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
A Single-Arm Phase 2 Study to Investigate Bintrafusp Alfa With Platinum-Pemetrexed for TKI-Resistant EGFR-Mutant NSCLC [NCT04971187]	Phase 2	3 participants (Actual)	Interventional	2021-06-30	Terminated(stopped due to PI Request)
Four Versus Six Cycles of Pemetrexed/Platinum as a First Line Treatment of Malignant Pleural Mesothelioma; a Randomized Phase II Study [NCT02497053]	Phase 2	70 participants (Anticipated)	Interventional	2015-06-30	Recruiting
A Phase II Study to Evaluate Camrelizumab With Pemetrexed / Carboplatin in Patients With Brain Metastases of Driven Gene-negative, Non-squamous Non-small Cell Lung Cancer [NCT04211090]	Phase 2	45 participants (Actual)	Interventional	2020-01-15	Active, not recruiting
Chemotherapy in Combination With Erlotinib, or Sequential Chemotherapy for Erlotinib for Treatment, EGFR - TKI Resistance of EGFR Mutations in Patients With NSCLC Randomized Controlled Phase II Clinical Study [NCT02037997]	Phase 2	80 participants (Anticipated)	Interventional	2013-12-31	Recruiting
Master Protocol: A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination With Investigational Agents With or Without Chemotherapy in Patients With Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer [NCT05635708]	Phase 2	200 participants (Anticipated)	Interventional	2023-03-07	Recruiting
Phase I/II Clinical Trial of Intrathecal Pemetrexed as First Line Intrathecal Chemotherapy in Patients With Leptomeningeal Metastasis [NCT05289908]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2022-02-21	Active, not recruiting
A Phase III, Randomized, Double-Blind Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) [NCT04194203]	Phase 3	304 participants (Actual)	Interventional	2020-04-09	Active, not recruiting
KEYMAKER-U01 Substudy 1: A Phase 2, Umbrella Study With Rolling Arms of Investigational Agents With Pembrolizumab in Combination With Chemotherapy in Treatment-Naive Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [NCT04165070]	Phase 2	360 participants (Anticipated)	Interventional	2019-12-19	Active, not recruiting
A Phase III, Randomized, Double-blind Trial of Platinum Doublet Chemotherapy +/-Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (NSCLC) (KEYNO [NCT03425643]	Phase 3	797 participants (Actual)	Interventional	2018-04-24	Active, not recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung) [NCT03337698]	Phase 1/Phase 2	470 participants (Anticipated)	Interventional	2018-01-02	Recruiting
A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, as a Single Agent and as Combination Therapy in Patients With Advanced Solid Malignancies and Expansion in Select Malignancies [NCT02922764]	Phase 1	150 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Combination of Induction Durvalumab and Tremelimumab Alone Versus Durvalumab and Tremelimumab With Chemotherapy for Potentially Resectable Pleural Mesothelioma [NCT05932199]	Phase 1/Phase 2	52 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
Randomized Phase III Study of Maintenance Therapy With Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC [NCT01107626]	Phase 3	1,516 participants (Actual)	Interventional	2010-10-25	Completed
Erlotinib Treatment Beyond Progression in EGFR Mutant or Patients Who Have Responded EGFR TKI in Stage IIIB/IV NSCLC [NCT02064491]	Phase 2	18 participants (Actual)	Interventional	2014-02-28	Completed
An Open-label, Randomized, Phase III, Multicenter Clinical Trial Comparing the Efficacy and Safety of Individualized Intraperitoneal and System Chemotherapy Versus System Chemotherapy as First-line Chemotherapy for Advanced Gastric Cancer [NCT03061058]	Phase 3	240 participants (Anticipated)	Interventional	2013-04-01	Recruiting
A Phase III, Open-Label, Randomized Multicenter Study to Compare AC0010 and Pemetrexed/Cisplatin in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI [NCT03058094]	Phase 3	0 participants (Actual)	Interventional	2018-12-31	Withdrawn(stopped due to Considiering to change the Chemotherapy into Gefitinib)
Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed After First - Line Induction Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer: A Prospective, Open, Single Arm Clinical Study [NCT03190239]	Phase 2	20 participants (Anticipated)	Interventional	2017-07-15	Not yet recruiting
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) [NCT04846634]	Phase 2	90 participants (Anticipated)	Interventional	2021-08-31	Not yet recruiting
A Randomized, Multicenter,Open-label Phase II Study is to Evaluate the Effects of Chemotherapy and Sintilimab or in Combination With Autologous Cytokine-induced Killer Cell Immunotherapy in Patients With Stage IV Non-small-cell Lung Cancer [NCT04836728]	Phase 2	156 participants (Anticipated)	Interventional	2021-04-01	Not yet recruiting
A Phase 1b/2, Open-label, Randomized Study of Vudalimab in Combination With Chemotherapy or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced Non-small Cell Lung Cancer [NCT06173505]	Phase 1/Phase 2	168 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal [NCT05502237]	Phase 3	720 participants (Anticipated)	Interventional	2022-10-12	Recruiting
A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment [NCT05184712]	Phase 3	470 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma [NCT05001880]	Phase 2	66 participants (Anticipated)	Interventional	2022-03-22	Recruiting
Phase I Study of Osimertinib+Bevacizumab+Carboplatin and Pemetrexed for Untreated Patients With EGFR Mutation Advanced Non-squamous Non-Small Cell Lung Cancer With Concomitant Mutations. [NCT05507606]	Phase 2	50 participants (Anticipated)	Interventional	2021-08-01	Recruiting
An Open Label, Dose Escalation Followed by Dose Expansion, Safety and Tolerability Trial of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Subjects With Solid Malignant Tumors [NCT03267316]	Phase 1/Phase 2	167 participants (Actual)	Interventional	2017-09-19	Active, not recruiting
"A Phase II Trial of Celecoxib Plus Chemotherapy [Docetaxel or Pemetrexed] in Patients With Previously Treated, COX Dependent Recurrent Non-Small Cell Lung Cancer" [NCT00520845]	Phase 2	23 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to slow accrual)
Phase II Study of Concurrent Carboplatin, Pemetrexed, and Radiotherapy for Limited Stage of Small Cell Lung Cancer [NCT00494026]	Phase 2	4 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Study stopped early based on interim results of another trial, showing inferior activity of pemetrexed/carboplatin compared to etoposide/carboplatin in SCLC.)
Phase II Trial of Pemetrexed in Second Line Advanced/Metastatic Osteosarcomas [NCT00523419]	Phase 2	32 participants (Actual)	Interventional	2007-09-30	Completed
Phase II Trial of ALIMTA in Relapsed Small Cell Lung Cancer [NCT00191750]	Phase 2	80 participants	Interventional	2004-07-31	Completed
A Phase I, Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6918 Administered Daily as a Single Agent and in Combination Treatment in Adult Patients With Refractory Solid Malignancies [NCT00733031]	Phase 1	75 participants (Anticipated)	Interventional	2008-08-31	Terminated(stopped due to PK results demonstrate low and variable plasma concentrations so that achieving therapeutic concentrations is unlikely.)
Phase II Trial: Efficacy and Toxicity of Induction Pemetrexed (ALIMTA) and Oxaliplatin (ELOXATIN) in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma [NCT00503997]	Phase 2	42 participants (Actual)	Interventional	2006-12-31	Completed
Pemetrexed Plus Bevacizumab in Pretreated, Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC) [NCT00741221]	Phase 2	50 participants (Actual)	Interventional	2008-06-30	Completed
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients With Advanced or Metastatic Solid Tumors Including EGFR-mutated Non-Small Cell Lung Cancer [NCT05498428]	Phase 2	390 participants (Anticipated)	Interventional	2022-11-11	Recruiting
A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsqu [NCT04716933]	Phase 3	201 participants (Actual)	Interventional	2019-11-05	Active, not recruiting
Open-label, Phase 2 Study of Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) Combined With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With CEACAM5 Positive Exp [NCT04524689]	Phase 2	215 participants (Anticipated)	Interventional	2020-10-26	Recruiting
A Phase III, Open-label, Randomized Study of Osimertinib With or Without Platinum Plus Pemetrexed Chemo, as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation Positive, Locally Advanced or Metastatic Non-small Cell Lung [NCT04035486]	Phase 3	587 participants (Actual)	Interventional	2019-07-02	Active, not recruiting
A Limited Access Phase II Trial of Pemetrexed (Alimta, LY231514) (NSC #698037) in Combination With Cisplatin (NSC #119875) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix [NCT00691301]	Phase 2	55 participants (Actual)	Interventional	2008-09-30	Completed
Phase 2 Study of ALIMTA® (Pemetrexed) Plus Cisplatin as First-Line Treatment of Gastric Cancer [NCT00415168]	Phase 2	53 participants (Actual)	Interventional	2006-12-31	Completed
Phase II Prospective Study Evaluating the Role of Directed Cisplatin Based Chemo With Either Vinorelbine or Pemetrexed for the Adj Tx of Early Stage NSCLC in Patients Using Genomic Expression Profiles of Chemo Sensitivity to Guide Therapy [NCT00545948]	Phase 2	31 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to Study terminated due to reproducibility issues with genomics prediction model.)
Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer [NCT00989690]	Phase 3	275 participants (Anticipated)	Interventional	2008-02-29	Recruiting
"A Phase 2 Trial of Pemetrexed and Cisplatin Followed Sequentially by Gefitinib Versus Pemetrexed and Cisplatin in Asian Never Smoker Patients With Advanced Non-Small Cell Lung Cancer" [NCT00409006]	Phase 2	70 participants (Actual)	Interventional	2007-02-28	Completed
A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma [NCT00998166]	Phase 2	4 participants (Actual)	Interventional	2007-06-30	Terminated(stopped due to Poor enrollment)
Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer [NCT00222729]	Phase 2	42 participants (Actual)	Interventional	2005-11-30	Completed
A Phase 1 Dose-Finding Study Of The Anti-Angiogenesis Agent, AG-013736, In Combinations Of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, Gemcitabine/Cisplatin and Pemetrexed/Cisplatin In Patients With Advanced Solid Tumors [NCT00454649]	Phase 1	102 participants (Actual)	Interventional	2005-12-31	Completed
CHAMP - An Open-label, Randomised, Multicentre, Phase II Clinical Study of Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Stage IIIB or IV Primary Nonsquamous Non-small Cell Lung Cancer, With [NCT01088620]	Phase 2	134 participants (Anticipated)	Interventional	2010-04-30	Suspended(stopped due to the DSMB stopped the trial due to unacceptable side effects in the experimental arm which has not yet been verified)
A Phase 2 Clinical Trial:Low -Dose-bevacizumab and Pemetrexed Versus Treatment of Physician's Choice in Metastatic HER2-negative Breast Cancer Patients After Failure of Taxanes and Anthracycline-containing Regimens [NCT02829008]	Phase 2	120 participants (Anticipated)	Interventional	2016-04-30	Active, not recruiting
A Phase II First-Line Study of a Combination of Pemetrexed, Carboplatin and Bevacizumab in Advanced Nonsquamous NSCLC Evaluating Efficacy and Tolerability in Elderly Patients (Age ≥ 70 Yrs) With Good Performance Status (PS < 2) [NCT00798603]	Phase 2	65 participants (Actual)	Interventional	2008-12-31	Completed
Pilot Study of Pembrolizumab Combined With Pemetrexed or Abemaciclib for the Treatment of Patients With High Grade Glioma [NCT04220892]	Early Phase 1	0 participants (Actual)	Interventional	2020-07-08	Withdrawn(stopped due to One of the study drugs will no longer be supplied by manufacturer and the pembrolizumab + abemaciclib study arm is removed due to toxicity seen in other trials.)
Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging With Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC [NCT02607423]	Phase 2	0 participants (Actual)	Interventional	2015-11-19	Withdrawn(stopped due to The study failed to meet its accrual targets.)
A Phase II Trial of Pemetrexed (Alimta [Registered Trademark]) Combined With Sirolimus (Rapamycin, Rapamune [Registered Trademark]) in Subjects With Relapsed or Refractory NSCLC [NCT00923273]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to Premature closure - investigator left the National Institutes of Health.)
A Phase II, Double-blind, Placebo Controlled, Randomised Study to Assess the Efficacy and Safety of ZD4054 (Zibotentan) in Combination With Pemetrexed (Alimta®) vs. Pemetrexed Alone in Patients With Non-small Cell Lung Cancer Who Have Failed One Prior Pla [NCT00745875]	Phase 2	66 participants (Actual)	Interventional	2008-08-31	Completed
A Randomized, Open-Label, Controlled, Multicenter Phase III Study of Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone Versus Platinum-based Chemotherapy for First-line Treatment in Subjects With PD-L1 Positive Relapsed or Advanced NSCLC [NCT04203485]	Phase 3	762 participants (Anticipated)	Interventional	2020-06-15	Not yet recruiting
A Single Arm,Open-label, Study of Fruquintinib Combined With Sintilimab and Chemotherapy in Patients With Unresectable or Metastatic Advanced Wild-type Genotype Non-squamous Non-small Cell Lung Cancer [NCT04956146]	Phase 2	46 participants (Anticipated)	Interventional	2022-02-02	Recruiting
Randomized Phase II Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients [NCT04470674]	Phase 2	0 participants (Actual)	Interventional	2021-04-06	Withdrawn(stopped due to Lack of Accrual)
A Phase I/II Study of VEGF-Antisense Oligonucleotide (VEGF-AS, Veglin) in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma [NCT00668499]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2008-04-30	Withdrawn(stopped due to Sponsor withdrew support)
A Phase I Study of Pazopanib in Combination With Either Erlotinib or Pemetrexed in Patients With Advanced Solid Tumors [NCT00619424]	Phase 1	58 participants (Actual)	Interventional	2007-11-15	Completed
A Randomized, Double-blind, Phase 2 Study of BMS-986315 and Nivolumab in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy as First-line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) [NCT06094296]	Phase 2	196 participants (Anticipated)	Interventional	2023-11-03	Not yet recruiting
A Global, Randomised, Phase 3, Open-label Study of REGN2810 (ANTI-PD 1 Antibody) Versus Platinum Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic PD L1+Non-small Cell Lung Cancer [NCT03088540]	Phase 3	712 participants (Actual)	Interventional	2017-05-29	Active, not recruiting
MTA vs CEM Pulpotomy in Young Permanent Molars With a Diagnosis of Irreversible Pulpitis: A Randomized Clinical Trial [NCT04243733]		40 participants (Anticipated)	Interventional	2018-10-10	Recruiting
An Exploratory, Prospective Phase II Study to Investigate Progression-Free Survival, Response and Overall Survival Seen With Pemetrexed/Cisplatin and the Role of Thymidylate Synthase Expression [NCT00887549]	Phase 2	70 participants (Actual)	Interventional	2009-04-30	Completed
Evaluation of the Efficacy of Er,Cr:YSGG Laser in Partial Pulpotomy Therapy of Permanent Immature Molar Teeth With Deep Dentin Caries [NCT04010929]		64 participants (Actual)	Interventional	2018-01-08	Completed
A Phase I/II Study Of The Docetaxel/Pemetrexed Combination As First Line Treatment In Patients With Advanced/Metastatic NSCLC [NCT00684099]	Phase 1/Phase 2	70 participants (Anticipated)	Interventional	2006-05-31	Completed
A Phase II Study of Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Docetaxel Consolidation in Patients With Inoperable Stage IIIA/B Squamous Cell Lung Cancer [NCT02787473]	Phase 2	54 participants (Anticipated)	Interventional	2016-10-31	Recruiting
A Phase 2 Study of Pemetrexed and Cisplatin Plus Cetuximab Followed by Pemetrexed and Cetuximab Maintenance Therapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB or IV) Other Than Predominantly Squamous Cell Histol [NCT00867009]	Phase 2	113 participants (Actual)	Interventional	2009-04-30	Completed
Phase II Study of Pemetrexed or Nab-paclitaxel With Pembrolizumab in Elderly (>/= 75 Years) Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT04754815]	Phase 2	0 participants (Actual)	Interventional	2021-04-01	Withdrawn(stopped due to Logistical challenges primarily due to COVID led to delay in starting the study and now is not felt to be clinically relevant.)
Pembrolizumab + Platinum Doublets Without Radiation for Patients With PD-L1 ≥50% Locally Advanced Non-small Cell Lung Cancer: a Multicenter Prospective Single Arm Phase II Study [NCT04153734]	Phase 2	21 participants (Anticipated)	Interventional	2019-12-01	Not yet recruiting
Randomized, Double-Blind, Placebo Controlled, Phase 2 Study of Pemetrexed and Cisplatin Plus Enzastaurin Versus Pemetrexed and Cisplatin Plus Placebo in Chemonaive Patients With Advanced, Unresectable, or Metastatic (Stage IIIB or IV) Nonsquamous Non-Smal [NCT00538681]	Phase 2	35 participants (Actual)	Interventional	2007-09-30	Terminated(stopped due to Terminated due to lack of efficacy demonstrated in relevant participant population in other clinical trials.)
An Open-label, Randomized, Phase I/II Trial Investigating the Safety and Efficacy of IO102 in Combination With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment for Patients With Metastatic Non-Small Cell Lung Cancer [NCT03562871]	Phase 1/Phase 2	109 participants (Actual)	Interventional	2018-08-22	Completed
An Open-label, Multi-center Phase Ib/III Study Evaluating the Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation [NCT05504278]	Phase 1	144 participants (Anticipated)	Interventional	2022-09-20	Recruiting
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC. [NCT03520686]	Phase 3	1,538 participants (Anticipated)	Interventional	2018-05-18	Active, not recruiting
A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer [NCT00529100]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2005-12-31	Completed
Phase II Combination of Pemetrexed and Oxaliplatin in Patients With Recurrent Non-Small Cell Lung Cancer After Failure to Platinum Based Adjuvant Chemotherapy [NCT00612677]	Phase 2	1 participants (Actual)	Interventional	2007-06-30	Terminated(stopped due to slow accrual - the 1 patient accrued did not go on treatment)
A Randomized Phase 3 Study Comparing Pemetrexed-Carboplatin With Docetaxel-Carboplatin as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00520676]	Phase 3	260 participants (Actual)	Interventional	2007-10-31	Completed
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or Pemetrexed) in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations [NCT06074588]	Phase 3	556 participants (Anticipated)	Interventional	2023-11-12	Recruiting
A Phase II, Randomized, Multicenter, Double-Blind, Controlled Study of Tobemstomig Plus Platinum-Based Chemotherapy Versus Pembrolizumab Plus Platinum-Based Chemotherapy in Patients With Previously Untreated Locally Advanced or Metastatic Non-Small Cell L [NCT05775289]	Phase 2	180 participants (Anticipated)	Interventional	2023-03-15	Recruiting
A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatm [NCT05722015]	Phase 3	339 participants (Anticipated)	Interventional	2023-02-14	Active, not recruiting
Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Loc [NCT05298423]	Phase 3	784 participants (Anticipated)	Interventional	2022-05-03	Recruiting
Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies. [NCT05059522]	Phase 3	262 participants (Anticipated)	Interventional	2021-09-29	Recruiting
A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Patients With Previously Untreated Locally Advanced Resectable Stage II [NCT04832854]	Phase 2	50 participants (Actual)	Interventional	2021-04-23	Active, not recruiting
An Open Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella B) [NCT03768063]	Phase 3	1,000 participants (Anticipated)	Interventional	2019-02-28	Recruiting
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon [NCT05668988]	Phase 3	320 participants (Anticipated)	Interventional	2022-12-13	Recruiting
Phase I/II Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations [NCT05241873]	Phase 1/Phase 2	332 participants (Anticipated)	Interventional	2022-03-04	Recruiting
An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04) [NCT05048797]	Phase 3	264 participants (Anticipated)	Interventional	2021-10-28	Recruiting
A Phase I/Ib Trial of Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC [NCT03177291]	Phase 1	48 participants (Actual)	Interventional	2017-09-26	Active, not recruiting
Safety and Efficacy of Anlotinib Hydrochloride Combined With Pemetrexed Plus Cisplatin/Carboplatin (AP) as First Line Treatment for Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer [NCT04012619]	Phase 1	8 participants (Actual)	Interventional	2019-04-30	Completed
Phase II Prospective Study Evaluating the Role of Personalized Chemotherapy Regimens for Chemo-Naive Select Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC) in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy [NCT00509366]	Phase 2	101 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Study terminated due to reproducibility issues with genomics prediction model.)
A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin in the First Line Therapy of Advanced NSCLC [NCT00402051]	Phase 2	133 participants (Actual)	Interventional	2006-11-30	Completed
Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer [NCT00454194]	Phase 2	110 participants (Actual)	Interventional	2007-09-30	Completed
A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients With Advanced Non-Small Cell Lung Cancer [NCT00456261]	Phase 2	110 participants (Actual)	Interventional	2007-03-31	Completed
Phase 1, Dose Escalation Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer [NCT00560573]	Phase 1	46 participants (Actual)	Interventional	2007-11-30	Completed
Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer With Osimertinib Third-line Rechallenge [NCT04335292]	Phase 2	200 participants (Anticipated)	Interventional	2021-01-06	Recruiting
A Phase II Study of ALIMTA® (Pemetrexed) and GEMZAR® (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer [NCT00383331]	Phase 2	19 participants (Actual)	Interventional	2007-02-28	Terminated(stopped due to Trial was stopped early due to low enrollment)
A Randomized Phase II Study of Two Chemotherapy Regimens, Pemetrexed-Carboplatin, and Gemcitabine-Vinorelbine, in Anthracycline and Taxanes Pretreated Advanced Breast Cancer Patients [NCT00325234]	Phase 2	135 participants (Actual)	Interventional	2006-06-30	Completed
A Randomized Phase 2 Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Chemotherapy in Patients With Completely Resected Stage Ib or II Non-Small Cell Lung Cancer [NCT00269152]	Phase 2	122 participants (Actual)	Interventional	2005-12-31	Completed
A Phase II Study of Pemetrexed Chemotherapy in Poor-Risk Patients With Advanced Head and Neck Cancer [NCT00293579]	Phase 2	5 participants (Actual)	Interventional	2006-02-28	Completed
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy [NCT04622007]	Phase 2	180 participants (Anticipated)	Interventional	2021-06-02	Recruiting
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors [NCT04083599]	Phase 1/Phase 2	1,287 participants (Anticipated)	Interventional	2019-09-17	Recruiting
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Sma [NCT03164616]	Phase 3	1,186 participants (Actual)	Interventional	2017-06-01	Active, not recruiting
Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors [NCT05298176]	Phase 2	21 participants (Anticipated)	Interventional	2022-01-04	Recruiting
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer [NCT05500092]	Phase 2	52 participants (Anticipated)	Interventional	2023-01-25	Recruiting
Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors. [NCT00703638]	Phase 1	16 participants (Actual)	Interventional	2008-05-31	Completed
Additional Chemotherapy for EGFRm Patients With the Continued Presence of Plasma ctDNA EGFRm at Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) [NCT05281406]	Phase 2	50 participants (Anticipated)	Interventional	2021-11-12	Recruiting
A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189) [NCT03950674]	Phase 3	40 participants (Actual)	Interventional	2016-02-22	Completed
A Randomized, Double-Blind, Phase III Study of Platinum+Pemetrexed Chemotherapy With or Without Pembrolizumab (MK-3475) in First Line Metastatic Non-squamous Non-small Cell Lung Cancer Subjects (KEYNOTE-189) [NCT02578680]	Phase 3	616 participants (Actual)	Interventional	2016-01-15	Completed
Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE) [NCT02595840]	Phase 2	4 participants (Actual)	Interventional	2015-11-25	Terminated(stopped due to Futility)
A Phase II Study of Concurrent Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer: Hoosier Oncology Group LUN08-129 [NCT00732303]	Phase 2	8 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to Study terminated due to withdrawal of pharmaceutical funding)
A Phase II Trial of Paclitaxel, Bevacizumab and Pemetrexed in Patients With Untreated, Advanced Non-Small Cell Lung Cancer Using Web-Based Data Collection, Patient Self-Reporting of Adverse Effects and Automated Response Assessment [NCT00807573]	Phase 2	44 participants (Actual)	Interventional	2008-12-31	Completed
Multicenter, Randomized, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Pemetrexed Therapy Compared to Placebo Plus Standard Pemetrexed Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cel [NCT00806819]	Phase 3	718 participants (Actual)	Interventional	2008-12-31	Completed
An Open-Label Clinical Trial of MORAb-009 in Combination With Pemetrexed and Cisplatin in Subjects With Mesothelioma [NCT00738582]	Phase 2	89 participants (Actual)	Interventional	2008-12-31	Completed
A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC) [NCT00589667]	Phase 2	26 participants (Actual)	Interventional	2006-09-30	Completed
An Open-label, Multicentre, Randomised Phase II Study of Pazopanib in Combination With Pemetrexed in First-line Treatment of Subjects With Predominantly Non-squamous Cell Stage IIIBwet/IV Non-small Cell Lung Cancer [NCT00871403]	Phase 2	107 participants (Actual)	Interventional	2009-07-31	Completed
Open Label Phase 1 Dose Finding Study of TRC102 in Combination With Pemetrexed in Patients With Advanced or Metastatic Solid Cancer for Whom Curative Therapy is Unavailable [NCT00692159]	Phase 1	28 participants (Actual)	Interventional	2008-06-30	Completed
MK-0646 IMPACT Study: MK-0646, Insulin Growth Factor 1 Receptor Antibody in Stage IIIB or IV Metastatic Non-Squamous Lung Cancer, Combined With Pemetrexed (Alimta) and Cisplatin, a Randomized Phase II Trial. [NCT00799240]	Phase 2	27 participants (Actual)	Interventional	2009-06-30	Completed
A Randomised Open-label Phase II Trial of BI 6727 Monotherapy and BI 6727 in Combination With Standard Dose Pemetrexed Compared to Pemetrexed Monotherapy in Second Line Non-small Cell Lung Cancer [NCT00824408]	Phase 2	143 participants (Actual)	Interventional	2009-03-31	Completed
A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma [NCT00794417]	Phase 1/Phase 2	60 participants (Actual)	Interventional	2008-11-30	Terminated
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer. [NCT00034489]	Phase 2	0 participants	Interventional		Completed
A Phase II Study of Erlotinib and Chemotherapy for Patients With Stage IB-IIIA NSCLC With EGFR Mutations (ECON) [NCT00577707]	Phase 2	9 participants (Actual)	Interventional	2007-11-30	Completed
Phase I/II Study of Concurrent Cisplatin, Pemetrexed, and Radiotherapy for Limited Stage Small Cell Lung Cancer [NCT00447421]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2007-02-28	Terminated(stopped due to Interim results of another trial showed inferior activity of treatment)
Stereotactic Radiosurgery and Systemic Dose Chemotherapy for Locally Advanced Lung Cancer (Protocol Number GK001) [NCT02568033]	Early Phase 1	22 participants (Anticipated)	Interventional	2013-10-31	Recruiting
Phase 1 Study Of Sunitinib (SU011248) In Combination With Pemetrexed In Patients With Advanced Solid Malignancies In Japan [NCT00732992]	Phase 1	12 participants (Actual)	Interventional	2008-08-31	Completed
Feasibility of Administering Adjuvant Chemotherapy of Pemetrexed Followed by Pemetrexed/Oxaliplatin Immediately Post-VATS in Patients With Completely Resected NSCLC [NCT00923637]	Phase 2	75 participants (Anticipated)	Interventional	2009-06-30	Recruiting
Systemic Chemotherapy Combined With Thoracic Cavity Perfusion of Recombinant Human Adenovirus Type 5 and Endostatin Injections Versus Cisplatin for Treatment Malignant Hydrothorax in Non Small Cell Lung Cancer (NSCLC) Patients: A Multi-center, Randomized, [NCT02579564]	Phase 3	134 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
A Multicenter, Double Blind, Randomized, Controlled Study of M7824 With Concurrent Chemoradiation Followed by M7824 Versus Concurrent Chemoradiation Plus Placebo Followed by Durvalumab in Participants With Unresectable Stage III Non-small Cell Lung Cancer [NCT03840902]	Phase 2	168 participants (Actual)	Interventional	2019-04-16	Terminated(stopped due to Based on recommendations by an external IDMC, Sponsor decided to discontinue this clinical study due to a low likelihood of achieving superiority in the efficacy endpoints versus standard of care.)
A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Advanced Non-Small-Cell Lung Cancer With Progressive Disease After Last Treatment With Im [NCT02654587]	Phase 3	363 participants (Anticipated)	Interventional	2016-02-29	Active, not recruiting
0822GCC Randomized, Double-Blind, Placebo-Controlled Multicenter Phase 2 Study of the Efficacy and Safety of Apricoxib in Combination With Either Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer Patients [NCT00771953]	Phase 2	109 participants (Actual)	Interventional	2008-11-30	Completed
Pilot Study to Determine Therapeutic Response of Pemetrexed (Alimta) in Recurrent or Progressive Primary Central Nervous System Lymphoma (PCNSL) by Establishing the Radiographic Response Rate Using Modified Macdonald Criteria [NCT00712062]	Phase 2	0 participants (Actual)	Interventional	2009-02-28	Withdrawn(stopped due to Lack of accrual)
Efficacy and Safety of Immune Checkpoint (PD-1) Inhibitor Combined With Pemetrexed Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC [NCT06132698]	Phase 2	17 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
A Study of Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed vs Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced NCSLC of Nonsquamous Histology [NCT00948675]	Phase 3	361 participants (Actual)	Interventional	2009-09-01	Completed
A Randomized, Double-blind, Multi-center, Phase III Clinical Study Assessing the Efficacy and Safety of Sintilimab ± IBI305 Combined With Pemetrexed and Cisplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous Non-small Cell Lung [NCT03802240]	Phase 3	492 participants (Actual)	Interventional	2019-07-11	Completed
Phase II Study of Neo-adjuvant Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Malignant Pleural Mesothelioma [NCT00895648]	Phase 2	6 participants (Actual)	Interventional	2009-01-31	Terminated(stopped due to low accrual due to competing study for same group of patients)
Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance：a Phase II,Muti-center, Single Arm Study [NCT04316351]	Phase 2	60 participants (Anticipated)	Interventional	2020-04-01	Recruiting
[NCT02795884]	Phase 3	0 participants (Actual)	Interventional	2016-06-30	Withdrawn(stopped due to Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim)
Advanced Non-small Cell Lung Cancer With Chinese Medicine Comprehensive Treatment Plan [NCT02777788]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2014-09-30	Active, not recruiting
Phase I Study of Concomitant Pemetrexed and CDDP Plus Radiation Therapy in Patients With Locally Advanced or Metastatic Esophageal or Gastroesophageal (GEJ) Carcinomas [NCT00701857]	Phase 1	10 participants (Actual)	Interventional	2008-02-29	Completed
Randomized Phase II Study of Pemetrexed Alone vs Pemetrexed Plus Cisplatin in Patients With EGFR Mutation-positive Advanced NSCLC After First Line EGFR-TKIs Failure [NCT02725918]	Phase 2	150 participants (Anticipated)	Interventional	2016-04-01	Recruiting
Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer (NSCLC) Alone and in Combination With Chemotherapy. [NCT02710396]	Phase 2	19 participants (Actual)	Interventional	2016-05-31	Terminated(stopped due to Frontline pembrolizumab approved in NSCLC as monotherapy and in combination with chemotherapy representing a new standard of care.)
A Phase 2 Study of Pemetrexed and Erlotinib for Metastatic Colorectal Cancer Refractory to Standard Chemotherapy [NCT02723578]	Phase 2	50 participants (Actual)	Interventional	2015-12-01	Completed
Phase II Study of Gemcitabine and Pemetrexed in Primary Unknown Adenocarcinoma [NCT00191503]	Phase 2	30 participants	Interventional	2005-01-31	Completed
Phase II Study of First-Line Therapy With Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer [NCT00193414]	Phase 2	72 participants (Actual)	Interventional	2005-05-31	Completed
Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer [NCT01020786]	Phase 4	109 participants (Actual)	Interventional	2009-11-30	Completed
A Phase II Trial With Pemetrexed Plus Cisplatin as First Line Chemotherapy for Advanced Non - Small Cell Lung Cancer (NSCLC) Patients With Measurable Asymptomatic Brain Metastasis (GFPC 07-01/METAL). [NCT00744900]	Phase 2	45 participants (Actual)	Interventional	2008-09-30	Completed
An Open Label Pilot Study of NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer [NCT00749346]	Phase 1/Phase 2	42 participants (Anticipated)	Interventional	2008-05-31	Completed
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma [NCT02879669]	Phase 1/Phase 2	31 participants (Actual)	Interventional	2016-06-30	Active, not recruiting
Pilot Study of the Feasibility of Intrapleural Photodynamic Therapy in a Multimodal Treatment Combining Extended Pleurectomy/Decortication, Adjuvant Chemotherapy and Prophylactic Radiotherapy in Patients With Malignant Pleural Mesothelioma [NCT02662504]	Phase 2	6 participants (Actual)	Interventional	2016-01-16	Completed
A Multicentre Randomised Phase III Trial Comparing Atezolizumab Plus Bevacizumab and Standard Chemotherapy Versus Bevacizumab and Standard Chemotherapy as First-line Treatment for Advanced Malignant Pleural Mesothelioma [NCT03762018]	Phase 3	401 participants (Actual)	Interventional	2019-04-30	Active, not recruiting
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) Chemotherapy Plus Cisplatin (or Carboplatin) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type [NCT02906150]	Phase 2	140 participants (Anticipated)	Interventional	2016-09-30	Not yet recruiting
A Randomized Phase 3 Trial of Alimta (Pemetrexed) and Carboplatin Versus Etoposide and Carboplatin in Extensive-Stage Small Cell Lung Cancer [NCT00363415]	Phase 3	908 participants (Actual)	Interventional	2006-08-31	Completed
A Multi-center, Randomized, Double-blind, Phase III Trial of SHR-1210 in Combination With Famitinib or Placebo Plus Chemotherapy in Subjects With Non-squamous Non-small-cell Lung Cancer. [NCT04619433]	Phase 3	560 participants (Anticipated)	Interventional	2021-02-01	Recruiting
An Exploratory Phase 2 Study of Pemetrexed/Cisplatin as Pre-operative Chemotherapy in the Treatment of Stage IIIAN2 Nonsquamous Non-Small Cell Lung Cancer [NCT01165021]	Phase 2	19 participants (Actual)	Interventional	2010-11-30	Completed
Phase III Study Comparing Maintenance With Pemetrexed or Gemcitabine to a Surveillance in Elderly Patients (70 Years Old and More) With a Advanced Non Small Cell Lung Cancer Controlled by Induction Chemotherapy. [NCT01850303]	Phase 3	632 participants (Actual)	Interventional	2013-05-16	Completed
An Extended Feasibility Phase I/II Study of Methylenetetrahydrofolate and Pemetrexed Single Agent, Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer [NCT01397305]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2011-04-14	Completed
A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment With Atezolizumab or Placebo in Combination With Platinum-Based Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB [NCT03456063]	Phase 3	453 participants (Actual)	Interventional	2018-04-24	Active, not recruiting
A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00087711]	Phase 3	1,713 participants (Actual)	Interventional	2004-07-31	Completed
A Randomized Phase II Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Non-squamous Non-small Cell Lung Cancer [NCT01401192]	Phase 2	304 participants (Anticipated)	Interventional	2011-07-31	Recruiting
Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence [NCT03380468]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2018-01-01	Recruiting
Pemetrexed and Platinum Use in the Neoadjuvant Setting for Resectable Stage II and IIIA Lung Adenocarcinoma [NCT02980991]	Phase 2	80 participants (Actual)	Interventional	2015-12-31	Completed
A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Ad [NCT00974584]	Phase 1	65 participants (Actual)	Interventional	2009-10-31	Completed
Phase 2 Randomized, Controlled, Open-label Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without EGFR Mutations [NCT00891579]	Phase 2	161 participants (Actual)	Interventional	2009-02-28	Completed
Chang Gung Memorial Hospital, Chang Gung University, College of Medicine, Taipei, Taiwan [NCT01004601]		179 participants (Actual)	Interventional	2005-03-31	Completed
A Phase II Trial of Carboplatin, Bevacizumab and Pemetrexed in Advanced Non-Small Cell Lung Cancer [NCT00614822]	Phase 2	50 participants (Actual)	Interventional	2007-11-30	Completed
A Randomized Phase 2 Study Comparing Pemetrexed Plus Best Supportive Care With Best Supportive Care as Maintenance, Following First-Line Treatment With Pemetrexed-Cisplatin, in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer [NCT00606021]	Phase 2	106 participants (Actual)	Interventional	2008-01-31	Completed
Pemetrexed With Simplified Folate and Dexamethasone Supplementation Versus Pemetrexed With Standard Supplementation as Second-line Chemotherapy for Patients With Non-squamous Non-small Cell Lung Cancer [NCT00609518]	Phase 2	111 participants (Actual)	Interventional	2008-02-29	Completed
A Randomised, Open-label, Phase III Study of BIBW 2992 Versus Chemotherapy as First-line Treatment for Patients With Stage IIIB or IV Adenocarcinoma of the Lung Harbouring an EGFR Activating Mutation [NCT00949650]	Phase 3	345 participants (Actual)	Interventional	2009-08-14	Completed
Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer [NCT00907179]	Phase 1	12 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..)
A Randomized Phase III Trial of Adjuvant Chemotherapy in Patients With Early Stage Non-Small Cell Lung Cancer Associated With Banking of Frozen Tumor Specimens and Collection of Gene Expression Profile Data [NCT00863512]	Phase 3	34 participants (Actual)	Interventional	2009-03-31	Terminated
Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma [NCT00868192]	Phase 2	38 participants (Actual)	Interventional	2008-05-31	Completed
A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck [NCT04107103]	Phase 2	20 participants (Anticipated)	Interventional	2020-03-19	Recruiting
A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Non-squamous Non-Small Cell Lung Cancer. [NCT00789373]	Phase 3	939 participants (Actual)	Interventional	2008-11-30	Completed
Phase 2 Trial of Pemetrexed (Alimta™) Combined With Paclitaxel in Patients With Recurrent/Advanced Follicular, Papillary or Anaplastic Thyroid Cancer [NCT00786552]	Phase 2	47 participants (Anticipated)	Interventional	2008-11-30	Recruiting
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations [NCT04129502]	Phase 3	354 participants (Actual)	Interventional	2020-01-10	Active, not recruiting
Randomized Phase II Trial, Comparing Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Plus Erlotinib to Standard of Care Chemotherapy (Pemetrexed or Docetaxel) Alone in EGFR TKI-Responsive Non-Small Cell Lung Cancer [NCT00660816]	Phase 2	46 participants (Actual)	Interventional	2008-01-31	Completed
Phase 1/1b Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors [NCT04047862]	Phase 1	542 participants (Anticipated)	Interventional	2019-08-26	Recruiting
A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors [NCT03564691]	Phase 1	442 participants (Anticipated)	Interventional	2018-07-11	Active, not recruiting
A Phase III, Multi-center, Randomized Trial of Pemetrexed and Gefitinib in Never-smoker and Adenocarcinoma Patients With Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy [NCT01066195]	Phase 3	129 participants (Anticipated)	Interventional	2008-05-31	Enrolling by invitation
Randomized Phase 2 Study Of Cisplatin/Pemetrexed With Or Without Axitinib (AG-013736) As First-Line Treatment For Patients With Non-Squamous Non-Small Cell Lung Cancer [NCT00768755]	Phase 1/Phase 2	180 participants (Actual)	Interventional	2009-01-31	Completed
A Phase 2 Study of ALIMTA in Solid Tumor Patients With Stable Third-Space Fluid [NCT00316225]	Phase 2	31 participants (Actual)	Interventional	2006-12-31	Completed
A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer [NCT03003962]	Phase 3	669 participants (Actual)	Interventional	2017-01-02	Active, not recruiting
Nedaplatin or Cisplatin Combined With Pemetrexed in the First Line Treatment of Advanced Adenocarcinoma：A Prospective Multi-center Phase III Randomized Controlled Trial [NCT02607592]	Phase 3	293 participants (Anticipated)	Interventional	2015-08-31	Recruiting
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study [NCT04115410]		4,724 participants (Anticipated)	Observational	2020-07-01	Not yet recruiting
Clinical and Radiographic Evaluation of Premixed Verses Powder / Liquid Bioceramic Mineral Trioxide Aggregate in Indirect Pulp Capping of Immature Permanent Mandibular Molars: A Randomized Clinical Trial [NCT05597553]		24 participants (Anticipated)	Interventional	2023-01-01	Not yet recruiting
Efficacy and Safety of Rh-endostatin（Endostar）Combined With Platinum-based Doublet Chemotherapy and Pembrolizumab as First Line Therapy in Patients With Advanced or Metastatic Non-small-cell Lung Cancer [NCT04094909]	Phase 2	186 participants (Anticipated)	Interventional	2020-02-06	Not yet recruiting
EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism [NCT03002844]	Phase 2	50 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients With Stage IIIB/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2 [NCT00892710]	Phase 2	172 participants (Actual)	Interventional	2009-06-30	Completed
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC [NCT01993810]	Phase 3	330 participants (Actual)	Interventional	2014-02-03	Active, not recruiting
A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer [NCT00006007]	Phase 2	59 participants (Actual)	Interventional	2000-12-31	Completed
Safety Confirmation Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma [NCT00386815]	Phase 2	20 participants	Interventional	2006-10-31	Completed
An Open-label, Multi-center, Phase II Umbrella Study to Assess Efficacy of Targeted Therapy or Immunotherapy Directed by Next Generation Sequencing (NGS) in Chinese Patients With Advanced NSCLC (TRUMP) [NCT03574402]	Phase 2	400 participants (Anticipated)	Interventional	2018-07-09	Recruiting
A Pharmacokinetic Study of Pemetrexed in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases [NCT00424242]	Early Phase 1	15 participants (Anticipated)	Interventional	2007-01-31	Completed
MARVEL: Marker Validation of Erlotinib in Lung Cancer- A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed Versus Erlotinib [NCT00738881]	Phase 3	23 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to Slow accrual)
Phase I Study Of SU011248 In Combination With Pemetrexed, Pemetrexed/Cisplatin And Pemetrexed/Carboplatin In Patients With Advanced Solid Malignancies [NCT00528619]	Phase 1	96 participants (Actual)	Interventional	2006-11-30	Completed
A Phase 1 Dose-Escalation and Phase 2 Randomized, Open-Label Study of Nivolumab and Veliparib in Combination With Platinum Doublet Chemotherapy in Subjects With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) [NCT02944396]	Phase 1	25 participants (Actual)	Interventional	2016-12-23	Completed
Performance Status and Influencing Factors During Second-Line Treatment With Pemetrexed in Patients With Stage III/IVNon Small Cell Lung Cancer [NCT00540241]		542 participants (Actual)	Observational	2007-09-30	Completed
Phase II Study of Single-Agent Alimta in the Treatment of Patients With Advanced and Metastatic Hepatoma [NCT00191412]	Phase 2	41 participants	Interventional	2005-01-31	Completed
Protocol H6Q-MC-S034(a) Randomized, Double-Blind, Phase 2 Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Chemonaive Patients With Stage IIIB or IV Non-Small Cell Lung Cancer [NCT00533429]	Phase 2	40 participants (Actual)	Interventional	2007-10-31	Completed
NGR014: Randomized Phase II Study of NGR-hTNF in Combination With Standard Chemotherapy Versus Standard Chemotherapy Alone in Previously Untreated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [NCT00994097]	Phase 2	121 participants (Actual)	Interventional	2009-07-31	Completed
Phase I Clinical Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the First-line Treatment of IIIB/IIIC/IV Non-Small Cell Lung Cancer [NCT03987867]	Phase 1	30 participants (Anticipated)	Interventional	2019-06-01	Recruiting
A Randomized Phase 3 Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Monotherapy in Patients With Recurrent or Metastatic Head and Neck Cancer [NCT00415194]	Phase 3	795 participants (Actual)	Interventional	2006-12-31	Completed
A Phase II Evaluation of Pemetrexed (Alimta, LY231514l, IND # 40061) in the Treatment of Recurrent or Persistent Platinum Resistant Ovarian or Primary Peritoneal Carcinoma [NCT00461786]	Phase 2	51 participants (Actual)	Interventional	2004-09-30	Completed
Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer [NCT00234052]	Phase 2	51 participants (Actual)	Interventional	2005-07-28	Completed
A Randomized Phase II Study of ALIMTA® (Pemetrexed) and GEMZAR® (Gemcitabine) Every 14 Days Versus Pemetrexed and Gemcitabine Every 21 Days in Advanced Non-Small Cell Lung Cancer [NCT00407550]	Phase 2	19 participants (Actual)	Interventional	2006-11-30	Completed
Phase 1/2 Study of Biweekly ALIMTA Plus Cisplatin in Patients With Locally, Advanced, Non-Resectable or Metastatic Urothelial Cancer [NCT00374868]	Phase 1/Phase 2	59 participants (Actual)	Interventional	2006-08-31	Completed
A Phase II Trial of Preoperative Radiation and Chemotherapy (Pemetrexed and Carboplatin) for Locally Advanced Esophageal Cancer [NCT00268437]	Phase 2	27 participants (Actual)	Interventional	2006-04-30	Terminated(stopped due to Trial closed early because, during an interim analysis, the primary endpoint fell short.)
Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy [NCT00380718]	Phase 4	33 participants (Actual)	Interventional	2006-11-30	Completed
A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma [NCT00377520]	Phase 2	27 participants (Actual)	Interventional	2006-09-30	Completed
Phase II Trial of Pemetrexed in Patients With Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) [NCT00265785]	Phase 2	27 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to Closed due to poor accrual)
INST 0601C: A Non-Randomized Phase II Protocol of Erlotinib for Patients With Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung [NCT00391586]	Phase 2	45 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to PI left institution.)
Phase 3 Study of Pemetrexed Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy [NCT00391274]	Phase 3	211 participants (Actual)	Interventional	2006-10-31	Completed
Phase II Study of Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib [NCT05948462]	Phase 2	0 participants (Actual)	Interventional	2023-11-30	Withdrawn(stopped due to Study withdrawn by pharmaceutical funding partner)
A Phase Ib/II, Open-Label, Multicenter Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib in Combination With Other Anti-Cancer Therapies in Patients With Previously Untreated Advanced Or Metastatic Non-Small Cell Lung Cancer With a [NCT05789082]	Phase 1/Phase 2	96 participants (Anticipated)	Interventional	2023-06-20	Recruiting
A Randomized, Double-Blind, Phase 3 Study of MK-7684A in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer [NCT05226598]	Phase 3	700 participants (Anticipated)	Interventional	2022-03-24	Active, not recruiting
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With Completely Resected Stage IB (Tumors Equal to or Larger Than 4cm) to Stage IIIA Anaplastic Lym [NCT03456076]	Phase 3	257 participants (Actual)	Interventional	2018-08-16	Active, not recruiting
Phase II Trial of Pemetrexed Plus Gemcitabine in Patients With Advanced Non-Clear Cell Renal Cell Cancer [NCT00491075]	Phase 2	16 participants (Actual)	Interventional	2005-12-31	Terminated(stopped due to Closed early for poor accrual.)
A Phase II Trial Pemetrexed Carboplatin as First Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC) in Elderly Patients [NCT00350792]	Phase 2	62 participants (Actual)	Interventional	2006-08-31	Completed
A Randomized, Open-label Phase II Study of Pemetrexed (Alimta) Plus Carboplatin With or Without Enzastaurin Hydrochloride, or Docetaxel Plus Carboplatin as First Line Treatment in Patients With Advanced Stage Non-small Cell Lung Cancer (NSCLC) [NCT00308750]	Phase 2	218 participants (Actual)	Interventional	2006-03-31	Completed
A Phase 1 and 2 Clinical Trial of ALIMTA® (Pemetrexed) in Combination With Carboplatin in Patients With Recurrent Ovarian or Primary Peritoneal Cancer [NCT00489359]	Phase 1/Phase 2	86 participants (Actual)	Interventional	2005-07-31	Completed
A Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors [NCT06116240]	Phase 1	135 participants (Anticipated)	Interventional	2022-09-02	Active, not recruiting
A Phase II Study of Treatment of Brain Metastases From Non-Small Cell Lung Cancer With Concurrent Whole Brain Radiation Therapy and Pemetrexed [NCT00280748]	Phase 2	10 participants (Actual)	Interventional	2005-05-31	Terminated(stopped due to Slow accrual)
A Phase II Study to Evaluate Activity and Toxicity of Gemcitabine in Combination With Pemetrexed Long Term Infusion in the Treatment of Pretreated Metastatic Colorectal Cancer Patients [NCT01909830]	Phase 2	18 participants (Actual)	Interventional	2012-07-31	Completed
A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients With Previously Untreat [NCT04619797]	Phase 2/Phase 3	542 participants (Actual)	Interventional	2020-12-14	Active, not recruiting
A Phase 3 Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First-line Intervention in Participants With Metastatic Nonsqu [NCT03829319]	Phase 3	761 participants (Actual)	Interventional	2019-03-25	Active, not recruiting
Phase II Trial of Pemetrexed Disodium and Carboplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer [NCT00227565]	Phase 2	50 participants (Actual)	Interventional	2006-02-28	Completed
A Phase 2, Open-label, Randomized, Parallel Group, Controlled Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus-Positive, Non-Squamous, Non-Small Cell Lung Carcinoma Following First-Line Inducti [NCT02531854]	Phase 2	0 participants (Actual)	Interventional	2018-12-31	Withdrawn(stopped due to Study was withdrawn per sponsor decision)
A Phase IB Study of Pembrolizumab in Combination With Pemetrexed and Oxaliplatin in Patients With Chemo-Refractory Metastatic Colorectal Cancer [NCT03626922]	Phase 1	33 participants (Anticipated)	Interventional	2019-05-15	Active, not recruiting
Multicenter Phase II Study of Pemetrexed/Cisplatin With or Without Bevacizumab in Patients With Brain Metastases From Non Squamous Non-small Cell Lung Cancer Harboring EGFR Wild Type [NCT01951482]	Phase 2	108 participants (Anticipated)	Interventional	2013-06-30	Recruiting
A Study of Almonertinib With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer [NCT04646824]	Phase 2	10 participants (Anticipated)	Interventional	2020-11-19	Active, not recruiting
A Phase II, Open-Label, Multicenter, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous Non-small Cell Lung Cancer [NCT04507217]	Phase 2	36 participants (Actual)	Interventional	2020-09-15	Completed
Pemetrexed for Previously Treated Patients With Metastatic Gastric Cancer: a Prospective Phase II Study [NCT01953419]	Phase 2	34 participants (Actual)	Interventional	2010-09-30	Completed
Phase I Study of Thoracic Radiotherapy and Concurrent Chemotherapy With Soy Isoflavones in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients [NCT01958372]	Phase 1	11 participants (Actual)	Interventional	2014-08-31	Completed
A Phase IIIb, Randomized, Multicenter, Open-label Study to Assess the Efficacy of Durvalumab Plus Tremelimumab Versus Pembrolizumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients [NCT06008093]	Phase 3	280 participants (Anticipated)	Interventional	2023-12-29	Not yet recruiting
A Randomized, Double-Blind Phase 2/3 Study of Fianlimab (Anti-LAG-3 Antibody), Cemiplimab (Anti-PD-1 Antibody), and Chemotherapy Versus Cemiplimab and Chemotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Irresp [NCT05800015]	Phase 2/Phase 3	950 participants (Anticipated)	Interventional	2023-08-08	Recruiting
A Phase 2 Platform Study Evaluating the Safety and Efficacy of Novel Treatment Combinations in Patients With Lung Cancer (VELOCITY-Lung) [NCT05633667]	Phase 2	397 participants (Anticipated)	Interventional	2023-03-16	Recruiting
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer [NCT05198830]	Phase 2	78 participants (Anticipated)	Interventional	2022-12-15	Recruiting
A Phase I Trial Targeting Mitochondrial Metabolism With Papaverine in Combination With Chemoradiation for Stage II-III Non-Small Cell Lung Cancer [NCT05136846]	Phase 1	28 participants (Anticipated)	Interventional	2021-12-06	Recruiting
A Phase II, Randomized, Open-label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First-line Therapy for Unresectable Pleural Mesothelioma in Chinese Participants [NCT05136677]	Phase 2	100 participants (Anticipated)	Interventional	2022-01-25	Recruiting
A Phase Ib Clinical Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Cisplatin and Pemetrexed in Treatment-naive Participants With Advanced Malignant Pleural Mesothelioma (KEYNOTE-A17). [NCT04153565]	Phase 1	19 participants (Actual)	Interventional	2019-12-09	Completed
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin: a Randomized, PhaseⅢ and Open Clinical Study of Non-small Cell Lung Cancer in PhaseⅠB [NCT02001168]	Phase 3	392 participants (Anticipated)	Interventional	2013-10-31	Active, not recruiting
Maintenance Pemetrexed Therapy After Induction Chemotherapy Versus Pemetrexed at Progression in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study [NCT02004184]	Phase 3	230 participants (Actual)	Interventional	2013-12-31	Terminated(stopped due to Poor enrollment due to the introduction of immunotherapy)
A Multicentre Phase II, Open-label, Non-randomized Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/- Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressin [NCT04042558]	Phase 2	149 participants (Anticipated)	Interventional	2019-09-26	Recruiting
Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin With Concurrent Thoracic Radiotherapy, in Patients With Unresectable, Locally Advanced, Stage III, Nonsquamous Non-Small Cell Lung Cancer [NCT01000480]	Phase 2	90 participants (Actual)	Interventional	2009-10-31	Completed
EGFR-TKIs Combine Chemotherapy as First-line Therapy for Patients With Advanced EGFR Mutation-positive NSCLC [NCT02886195]	Phase 3	120 participants (Anticipated)	Interventional	2016-07-31	Enrolling by invitation
A Phase II Randomized Trial Evaluating the Use of Proton Pump Inhibitors (PPIs) in Conjunction With Chemotherapy, in Patients With Recurrent Unresectable or Metastatic Cancers of the Head and Neck [NCT02013453]	Phase 2	0 participants (Actual)	Interventional	2013-12-31	Withdrawn(stopped due to Lack of funding)
A Phase 1/Randomized Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed and Cisplatin in Patients With Stage IV Non-small Cell Lung Cancer [NCT01139775]	Phase 1/Phase 2	76 participants (Actual)	Interventional	2011-02-28	Completed
A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination With a Platinum-Containing Doublet in Chemotherapy-Naive Subjects With Stage IV Adenocarcinoma of the Lung (FLAIR) [NCT01218516]	Phase 2	130 participants (Actual)	Interventional	2011-06-27	Completed
BATTLE-FL: A Biomarker-Integrated Study in Patients With Advanced Non-Small Cell Lung Cancer Treated in the Front-Line (FL) Setting [NCT01263782]	Phase 2	64 participants (Actual)	Interventional	2011-05-17	Completed
Phase 3, Randomized, Open-label Study Of The Efficacy And Safety Of Pf-02341066 Versus Standard Of Care Chemotherapy (Pemetrexed Or Docetaxel) In Patients With Advanced Non-small Cell Lung Cancer (Nsclc) Harboring A Translocation Or Inversion Event Involv [NCT00932893]	Phase 3	347 participants (Actual)	Interventional	2009-09-30	Completed
Phase I/II Study of Two Different Schedules of Pemetrexed (ALIMTA) and Erlotinib (TARCEVA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC) [NCT00387322]	Phase 1/Phase 2	42 participants (Actual)	Interventional	2005-03-31	Completed
Efficacy and Safety of Tislelizumab With Platinum Doublet Chemotherapy as Neoadjuvant Therapy for Participants With Initially Unresectable Stage III Non-small Cell Lung Cancer: A Single-arm, Phase II Trial [NCT05611879]	Phase 2	30 participants (Anticipated)	Interventional	2023-03-12	Recruiting
A Phase 1 Clinical Study to Evaluate the Bioavailability of Pembrolizumab Via Subcutaneous Injection of MK-3475A, a Formulation of Pembrolizumab With MK-5180, in Participants With Advanced Solid Tumors [NCT05017012]	Phase 1	72 participants (Anticipated)	Interventional	2021-09-21	Recruiting
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO) [NCT04267848]	Phase 3	1,210 participants (Anticipated)	Interventional	2020-06-16	Recruiting
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature [NCT03793179]	Phase 3	600 participants (Anticipated)	Interventional	2019-04-05	Recruiting
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) [NCT02194738]		8,300 participants (Anticipated)	Interventional	2014-09-26	Recruiting
Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma [NCT00715611]	Phase 2	65 participants (Actual)	Interventional	2008-10-11	Active, not recruiting
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to [NCT04611776]	Phase 2	0 participants (Actual)	Interventional	2021-07-01	Withdrawn(stopped due to The positive results from IMpower010 demonstrated benefit by adding atezolizumab as adjuvant therapy in early stage NSCLC. These results raised ethical concerns of enrolling pts to best supportive care over checkpoint inhibition in this setting.)
A Two Arm Phase I Trial of Sorafenib in Combination With Cisplatin/Etoposide or Carboplatin/Pemetrexed in Patients With Solid Tumors [NCT00573690]	Phase 1	31 participants (Actual)	Interventional	2007-09-30	Completed
Almonertinib Plus Pemetrexed and Carboplatin Versus Almonertinib Alone in Advanced NSCLC With EGFR T790M After First- or Second-generation TKIs Therapy: a Randomized, Controlled, Open-label, Phase 2 Study [NCT04592666]	Phase 2	226 participants (Anticipated)	Interventional	2020-10-09	Not yet recruiting
Dynamic Positron Emission Tomography/Computed Tomography Evaluated the Response of Neoadjuvant Anti-programmed Cell Death Protein 1 Combination With Chemotherapy for Stage Ⅱa-Ⅲb Non-small Cell Lung Cancer [NCT04586465]	Phase 2	23 participants (Anticipated)	Interventional	2020-10-10	Recruiting
A Phase II Evaluation of Pemetrexed (Alimta) in the Treatment of Recurrent Carcinoma of the Cervix [NCT00190983]	Phase 2	29 participants (Actual)	Interventional	2005-02-28	Completed
A Phase 1/2 Dose-Escalating Study of ALIMTA and Cyclophosphamide Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer [NCT00190671]	Phase 1/Phase 2	103 participants (Actual)	Interventional	2005-06-30	Completed
Open Multicenter Phase II Study in Second-Line Metastatic Colorectal Cancer Patients: Combination of ALIMTA and Irinotecan Administered Every Two-Weeks [NCT00191984]	Phase 2	46 participants (Actual)	Interventional	2004-06-30	Completed
Phase 2 Study of Pemetrexed in Combination With Carboplatin or Cisplatin and Cetuximab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck [NCT01087970]	Phase 2	69 participants (Actual)	Interventional	2010-08-31	Completed
Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients With Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy [NCT01085630]	Phase 2	72 participants (Actual)	Interventional	2010-04-30	Completed
Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma [NCT00251550]	Phase 1/Phase 2	12 participants	Interventional	2005-10-31	Completed
Efficacy of Targeted Therapy Combined Chemotherapy in Advanced EGFR Positive NSCLC Patients With Concurrent Driver Gene Mutations [NCT04552613]		110 participants (Anticipated)	Interventional	2020-09-30	Recruiting
A Phase I Study of Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma [NCT02639767]	Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Lack of accrual)
A Pilot Study of Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage Non-Small Cell Lung Cancer (NSCLC) [NCT04530227]	Phase 2	30 participants (Anticipated)	Interventional	2020-09-25	Recruiting
A Phase Ib, Open-label, Single-center Study to Assess the Safety of Cancer-immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment of Locally Advanced NSCLC. [NCT04287894]	Phase 1	34 participants (Anticipated)	Interventional	2018-12-28	Recruiting
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer [NCT05624996]	Phase 3	474 participants (Anticipated)	Interventional	2023-05-10	Recruiting
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating Efficacy and Safety of Inupadenant in Combination With Carboplatin and Pemetrexed in Adults With Nonsquamous Non-small Cell Lung Cancer Who Have Progressed on Immunotherapy [NCT05403385]	Phase 2	192 participants (Anticipated)	Interventional	2022-08-26	Recruiting
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation [NCT05118854]	Phase 2	27 participants (Anticipated)	Interventional	2022-03-30	Recruiting
A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib [NCT04410796]	Phase 2	571 participants (Anticipated)	Interventional	2020-05-28	Recruiting
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2) [NCT03519971]	Phase 3	328 participants (Actual)	Interventional	2018-03-29	Active, not recruiting
AdvanTIG-306: A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Ociperlimab (WCD118/BGB-A1217) Combined With Tislelizumab (VDT482/BGB-A317) Plus Platinum-based Doublet Chemotherapy Versus Placebo Combine [NCT05791097]	Phase 3	0 participants (Actual)	Interventional	2023-07-28	Withdrawn(stopped due to Business decision, not driven by safety concerns; no new safety signals have been observed in the ociperlimab program.)
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patient [NCT05687266]	Phase 3	1,000 participants (Anticipated)	Interventional	2022-12-29	Recruiting
A Pilot Study Evaluating Pemetrexed in ECOG Performance Status 3 Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [NCT02426658]	Phase 2	16 participants (Actual)	Interventional	2015-05-31	Completed
"A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)" [NCT02439450]	Phase 1/Phase 2	121 participants (Actual)	Interventional	2015-04-15	Completed
A Phase II Study of Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab in Unresectable, Locally Advanced Lung Adenocarcinoma [NCT01588704]	Phase 2	42 participants (Actual)	Interventional	2012-04-30	Completed
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small [NCT05984277]	Phase 3	900 participants (Anticipated)	Interventional	2023-10-24	Recruiting
Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection [NCT03158129]	Phase 2	101 participants (Actual)	Interventional	2017-06-09	Active, not recruiting
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies [NCT02419495]	Phase 1	221 participants (Actual)	Interventional	2015-06-26	Active, not recruiting
A Two Arm Phase I Dose Escalation Trial of Vinflunine With Erlotinib or Pemetrexed in Refractory Solid Tumors [NCT00320073]	Phase 1	41 participants (Actual)	Interventional	2006-08-31	Completed
A Phase 1 Trial of MK-7684 as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors [NCT02964013]	Phase 1	492 participants (Anticipated)	Interventional	2016-12-13	Active, not recruiting
A Multicenter Randomized Phase II Study of the Combination of Irinotecan/Cisplatin Versus Pemetrexed/Cisplatin as Second-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) [NCT00614965]	Phase 2	124 participants (Anticipated)	Interventional	2006-11-30	Completed
A Randomized Phase II Study to Evaluate Efficacy and Safety of DCVAC/LuCa Added to Chemotherapy With Carboplatin and Pemetrexed vs Chemotherapy Alone in Patients With Stage IV Non-small Cell Lung Cancer [NCT02669719]	Phase 2	70 participants (Anticipated)	Interventional	2016-01-31	Recruiting
BIBW 2992 Phase I Combination With Pemetrexed in Advanced Solid Tumours [NCT01169675]	Phase 1	53 participants (Actual)	Interventional	2010-07-31	Completed
A Phase I/II Study of Continuous, Concomitant Oral Treatment With BIBF 1120 and Pemetrexed - a Phase I, Open-label, Dose-escalation Study & a Phase II, 2 Arm, Randomized, Double-blind, Placebo-controlled Study in Japanese Patients With Stage IIIB/IV or Re [NCT00979576]	Phase 1	19 participants (Actual)	Interventional	2009-10-31	Terminated
A Single-Arm, Phase 2 Trial of Pemetrexed, Cisplatin,and Bevacizumab as Induction, Followed by Pemetrexed and Bevacizumab as Maintenance, in First-Line Treatment of Nonsquamous Advanced NSCLC [NCT01004250]	Phase 2	109 participants (Actual)	Interventional	2009-10-31	Completed
An Open-label, Multicenter, Randomized, Phase 2 Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, IMC-1121B in Combination With Platinum-based Chemotherapy Versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients With Recu [NCT01160744]	Phase 2	280 participants (Actual)	Interventional	2010-09-30	Completed
Open-label Study of Bevacizumab (Avastin®) in Combination With Pemetrexed or Pemetrexed and Carboplatin as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer [NCT00976456]	Phase 3	271 participants (Actual)	Interventional	2009-09-30	Completed
A Randomized Phase II Study of S1 Plus Carboplatin Followed by Maintenance S1versus Pemetrexed Plus Carboplatin Followed by Maintenance Pemetrexed in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer [NCT02631460]	Phase 2	470 participants (Anticipated)	Interventional	2015-12-31	Recruiting
A Phase 1b Study of LY573636-sodium in Combination With Alimta (Pemetrexed) in Patients With Solid Tumors [NCT01215916]	Phase 1	39 participants (Actual)	Interventional	2008-02-29	Completed
Phase 2 Pharmacological Study of Pemetrexed Administered With Cisplatin and a Vitamin Supplement in Patients With Nonresectable Pleural Mesothelioma [NCT00541073]	Phase 2	60 participants (Anticipated)	Interventional	2007-06-30	Completed
Phase II Randomized Controlled Trial of Neoadjuvant Pembrolizumab or Pembrolizumab With Histology-Specific Chemotherapy for Operable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) [NCT04638582]	Phase 2	44 participants (Anticipated)	Interventional	2022-08-28	Recruiting
Multicenter Phase III Study of Gefitinib Mono-therapy or Gefitinib Combined With Chemotherapy in Patients With Brain Metastases From Non-small Cell Lung Cancer Harboring EGFR Mutation [NCT01951469]	Phase 3	160 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Phase I Study of PTK/ZK in Combination With Pemetrexed Disodium (ALIMTA) [NCT00390000]	Phase 1	29 participants (Actual)	Interventional	2007-01-25	Completed
A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Endometrial Carcinoma [NCT00087100]	Phase 2	51 participants (Anticipated)	Interventional	2006-05-31	Completed
Phase II Study of the Combination of Bevacizumab Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Malignant Pleural Mesothelioma [NCT00407459]	Phase 2	77 participants (Actual)	Interventional	2007-09-30	Completed
A Phase I Study of Pemetrexed (LY231514, Alimta) in Children and Adolescents With Recurrent Solid Tumors [NCT00070473]	Phase 1	33 participants (Actual)	Interventional	2003-10-31	Completed
A Phase II Trial of Pemetrexed (ALIMTA®, LY231514, IND #40061) as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Tumor [NCT00096187]	Phase 2	55 participants (Anticipated)	Interventional	2005-07-31	Terminated
Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC): a Phase I Trial to Identify a Dose of Dacomitinib in Combination With Pemetrexed That is Safe and Tolerated as Determined by the Incidence of Dose Limitin [NCT01918761]	Phase 1	5 participants (Actual)	Interventional	2013-07-30	Terminated(stopped due to poor accrual)
Single Agent Alimta in Poor Performance Status in Patients With Non-Small Cell Lung Cancer (NSCLC) [NCT00508144]	Phase 2	64 participants (Actual)	Interventional	2005-09-30	Completed
Phase 1/2 Study of Pemetrexed (Alimta) Plus Carboplatin, or Pemetrexed Plus Cisplatin With Concurrent Radiation Therapy Followed by Every-21-Day Pemetrexed Consolidation in Patients With Favorable-Prognosis Inoperable Stage IIIA/B Non-Small-Cell Lung Canc [NCT00482014]	Phase 1/Phase 2	120 participants (Actual)	Interventional	2007-05-31	Completed
Phase II Trial of Preoperative Pemetrexed and Carboplatin in Patients With Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer [NCT00906282]	Phase 2	46 participants (Actual)	Interventional	2009-06-30	Completed
A Randomized Phase 3 Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin as First-Line Treatment in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer. [NCT01005680]	Phase 3	256 participants (Actual)	Interventional	2009-11-30	Completed
Randomized Phase II Study of Pemetrexed and Cisplatin as Either Induction or Adjuvant Chemotherapy in Stage IB-II Non-Small Cell Lung Cancer (NSCLC) [NCT00389688]	Phase 2	13 participants (Actual)	Interventional	2006-08-31	Terminated(stopped due to low accrual)
Phase I Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile Of Lenalidomide (Revlimid®, CC-5013) With Pemetrexed In Subjects With Advanced Non-Small Cell Lung Cancer [NCT00179699]	Phase 1	40 participants	Interventional	2005-09-30	Terminated
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRAS G12C Mutant Advanced Solid Tumors [NCT05067283]	Phase 1	450 participants (Anticipated)	Interventional	2021-12-17	Recruiting
A Phase 3, Randomized, Double-Blind, Multicenter Study of Talabostat and Pemetrexed vs. Pemetrexed and Placebo in Patients With Advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy [NCT00290017]	Phase 3	400 participants (Anticipated)	Interventional	2006-02-28	Terminated(stopped due to FDA Hold May 2007)
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous [NCT03631199]	Phase 3	673 participants (Actual)	Interventional	2018-12-21	Active, not recruiting
Phase 1/2 Study of Oral MKC-1 Administered Twice Daily for 14 Consecutive Days Every 3 Weeks in Combination With Pemetrexed [NCT00408226]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2006-10-31	Completed
Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations [NCT04695925]	Phase 3	291 participants (Anticipated)	Interventional	2021-01-04	Not yet recruiting
Phase II Study of Pemetrexed Plus Cisplatin in the Treatment of Patients With Extensive Small Cell Lung Cancer [NCT00475657]	Phase 2	5 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Terminated due to lack of efficacy)
Phase I/II Clinical Trial of Bortezomib (Velcade) + Pemetrexed (Alimta) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer [NCT00516100]	Phase 1/Phase 2	62 participants (Anticipated)	Interventional	2006-01-31	Active, not recruiting
Advanced Metastatic Non-small Cell Lung Cancer Patients Aged or PS Score 2 Points for First Line Application Pemetrexed/Carboplatin Chemotherapy Regimens Sequential Pemetrexed Single Drug Maintenance Treatment of Clinical Research and Related Predictive B [NCT01860508]		94 participants (Anticipated)	Interventional	2013-02-28	Recruiting
ALIMTA Plus Gemcitabine as Front-line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase II Clinical Trial [NCT00061451]	Phase 2	48 participants	Interventional	2002-12-31	Completed
Clinical and Radiographic Evaluation of Pulpotomies in Primary Molars Using Tricalcium Silicate Cements. [NCT04902495]		61 participants (Anticipated)	Interventional	2017-01-12	Recruiting
An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of Cisplatin and Pemetrexed With or Without Cixutumumab as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small Cell Lung Carcinoma [NCT01232452]	Phase 2	172 participants (Actual)	Interventional	2011-04-30	Completed
A Phase I-IIa Dose-Ranging Study of Pemetrexed (Alimta) Plus Cetuximab (Erbitux) in Patients With Recurrent Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN04-79 [NCT00216203]	Phase 1/Phase 2	36 participants (Actual)	Interventional	2005-05-31	Completed
Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response [NCT03656549]	Phase 2	23 participants (Anticipated)	Interventional	2019-02-01	Recruiting
Randomized, OpenLabel, Phase 3 Trial of Nivolumab Plus Ipilimumab or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Early Stage NSCLC [NCT02998528]	Phase 3	505 participants (Actual)	Interventional	2017-03-04	Active, not recruiting
Phase I Trial of BKM120 in Combination With Carboplatin and Pemetrexed in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [NCT01723800]	Phase 1	9 participants (Actual)	Interventional	2013-07-31	Completed
Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for1st Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer [NCT03402048]	Phase 3	567 participants (Anticipated)	Interventional	2012-07-31	Recruiting
A Prospective Phase 2 Study of PEmetrexed in Combination With Cisplatin in Patients With Advanced UrotheLIal CAnceR [NCT01490437]	Phase 2	42 participants (Actual)	Interventional	2008-07-31	Completed
A Phase II Randomized Trial Assessing the Combination of Gemcitabine and Pemetrexed in the First Line Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00434135]	Phase 2	180 participants (Anticipated)	Interventional	2006-05-31	Completed
A Multicenter Randomized Phase III Study of Pemetrexed Versus Erlotinib in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC) [NCT00440414]	Phase 3	320 participants (Anticipated)	Interventional	2006-04-30	Completed
A Phase II Study of Alimta as First Line Chemotherapy for Advanced or Metastatic Breast Cancer [NCT00106002]	Phase 2	37 participants (Actual)	Interventional	2005-04-30	Completed
A Multicenter Phase 2 Randomized Trial of Single-Agent ALIMTA or ALIMTA With Sequentially Administered GEMZAR as First-Line Chemotherapy in Elderly Patients or Patients Who Are Not Eligible for Platinum-Based Chemotherapy With Advanced NSCLC [NCT00489983]	Phase 2	91 participants (Actual)	Interventional	2003-07-31	Completed
A Phase 2 Trial of ALIMTA in Pretreated Patients With Unresectable or Metastatic Cancer of the Pancreas [NCT00490373]	Phase 2	52 participants (Actual)	Interventional	2003-10-31	Completed
Disposition of [14C]LY2603618 Following Intravenous Administration in Patients With Advanced and/or Metastatic Solid Tumors [NCT01296568]	Phase 1	3 participants (Actual)	Interventional	2011-02-28	Completed
A Randomized Multicenter Phase II Study Of Induction Therapy With Pemetrexed And Cisplatin Followed By Chemoradiation With Pemetrexed Versus Chemoradiation With Pemetrexed Followed By Consolidation Therapy With Pemetrexed And Cisplatin In Patients With St [NCT00497315]	Phase 2	30 participants (Actual)	Interventional	2006-02-28	Completed
Phase II Study of Pembrolizumab in Combination With Cisplatin or Carboplatin and Pemetrexed as Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) [NCT06155279]	Phase 2	40 participants (Anticipated)	Interventional	2024-06-30	Not yet recruiting
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study) [NCT05456256]	Phase 2	90 participants (Anticipated)	Interventional	2022-08-12	Recruiting
A Phase 1 First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Malignant Tumors [NCT05298592]	Phase 1	154 participants (Anticipated)	Interventional	2022-03-31	Recruiting
An Open Label, Multicentre, Long-Term Extension Study of Tislelizumab- Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies [NCT04164199]	Phase 3	300 participants (Anticipated)	Interventional	2019-12-19	Enrolling by invitation
A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer [NCT03215706]	Phase 3	719 participants (Actual)	Interventional	2017-08-24	Active, not recruiting
A Phase I Dose Escalation Study of Pemetrexed in Patients With Advanced Head and Neck Squamous Cell Cancer [NCT00507858]	Phase 1	36 participants (Actual)	Interventional	2005-09-30	Completed
Chemotherapy Plus Gefitinib Versus Gefitinib Alone as First-line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial [NCT02951637]	Phase 2	300 participants (Anticipated)	Interventional	2016-12-31	Not yet recruiting
Feasibility Trial on Combination of Platinum Doublets and Hypofractionated Radiotherapy for Locally-advanced Stage and / or Inoperable Non-small Cell Lung Carcinoma [NCT02947113]	Phase 2	0 participants (Actual)	Interventional	2017-11-30	Withdrawn(stopped due to New studies available with immunotherapy so recruitment is no longer acceptable.)
Application of Detecting Circulating Tumor Cells in the Accurate Diagnosis and Treatment of Early Stage Lung Adenocarcinoma [NCT02951897]		120 participants (Anticipated)	Interventional	2016-04-30	Recruiting
[NCT02940990]	Phase 2	50 participants (Anticipated)	Interventional	2016-11-30	Not yet recruiting
A Single-arm, Two-stage Phase II Study of Lapatinib and Pemetrexed in the Second Line Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00528281]	Phase 1	18 participants (Actual)	Interventional	2007-09-20	Completed
Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase [NCT02919462]	Phase 2	2 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to low recruitement rate)
A Randomized, Phase 3, Open-label Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Versus Intravenous Pembrolizumab, Administered With Platinum Doublet Chemotherapy, in the First-Line Treatment of Participants With Metast [NCT04956692]	Phase 3	531 participants (Actual)	Interventional	2021-08-05	Active, not recruiting
A Phase 3, Randomized, Double-blind Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Resection and Adjuvant Treatment With Nivolumab or Placebo for Participants With Resectable Stage II-II [NCT04025879]	Phase 3	452 participants (Anticipated)	Interventional	2019-11-05	Active, not recruiting
Phase 1 Dose Escalation Study of LY2090314 in Patients With Advanced or Metastatic Cancer in Combination With Pemetrexed and Carboplatin [NCT01287520]	Phase 1	41 participants (Actual)	Interventional	2007-11-30	Completed
Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors [NCT02921984]	Phase 1	20 participants (Actual)	Interventional	2013-09-30	Completed
A Prospective, Single-arm, Single-center Clinical Trial of Envafolimab as First-line Replacement Maintenance in Advanced NSCLC [NCT05465733]	Phase 2	25 participants (Anticipated)	Interventional	2022-08-01	Not yet recruiting
Pilot Study Targeting Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer As Part of Adjuvant Therapy and Preventive Strategy [NCT01209520]		6 participants (Actual)	Interventional	2009-07-31	Completed
A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed F [NCT03775486]	Phase 2	401 participants (Actual)	Interventional	2018-12-21	Active, not recruiting
A Randomized, Phase 2 Trial of Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy (CHAMELEON) [NCT06020989]	Phase 2	129 participants (Anticipated)	Interventional	2023-09-30	Not yet recruiting
An Open-label, Multicenter, Phase Ib/II Study of AK104, Combined Chemotherapy as First-line Therapy to Treat Locally Advanced or Metastatic Non-small Cell Lung Carcinoma [NCT04647344]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2020-11-24	Active, not recruiting
Study of Chinese Medicine Plus Chemotherapy Maintenance Versus Chemotherapy Maintenance in Advanced Non Small Cell Lung Cancer: A Randomized Double-blind Controlled Clinical Trial [NCT02900742]	Phase 3	71 participants (Actual)	Interventional	2013-03-31	Completed
Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance [NCT02930954]	Phase 2	180 participants (Anticipated)	Interventional	2016-11-30	Not yet recruiting
A Phase 1b/2 Trial of AMG 386 in Combination With Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer [NCT01666977]	Phase 1/Phase 2	36 participants (Actual)	Interventional	2012-08-31	Completed
A Phase 1 First-in-Human Dose Study of LY3023414 in Patients With Advanced Cancer [NCT01655225]	Phase 1	156 participants (Actual)	Interventional	2012-07-31	Completed
An Open-label, Randomized Phase IIB/III Active Control Study of Second-line Tergenpumatucel-L (Hyper-Acute(R)-Lung ) Immunotherapy Versus Docetaxel in Progressive or Relapsed Non-Small Cell Lung Cancer [NCT01774578]	Phase 2/Phase 3	135 participants (Actual)	Interventional	2013-02-28	Terminated
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC [NCT04585490]	Phase 3	48 participants (Anticipated)	Interventional	2021-08-25	Recruiting
A Phase II Two Cohorts Prospective Study to Evaluate the Efficacy and Safety of Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in Non-squamous NSCLC With EGFR Sensitizing Mutation Who Failed EGFR TKI Therapy [NCT04405674]	Phase 2	120 participants (Anticipated)	Interventional	2020-07-15	Recruiting
Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as First Line Treatment in Patients With Stage IV Non-squamous Non Small Cell Lung Cancer (NSCLC) [NCT00942825]	Phase 2	195 participants (Actual)	Interventional	2009-04-30	Completed
A Phase Ib, Open-label, Dose Escalation Trial Investigating Different Doses and Schedules of Sym004 in Combination With Platinum-doublets in Subjects With Stage IV Non-small Cell Lung Cancer [NCT02083679]	Phase 1	15 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Sponsor the return rights of the compound to the collaboration partner for further clinical development)
A Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of KN046 in Patients With Advanced Non-small Cell Lung Cancer [NCT03838848]	Phase 2	120 participants (Actual)	Interventional	2019-05-05	Terminated(stopped due to Cohort A,B,C end enrollments. Cohort D and E were considered to have no significant clinical benefit at the SMC meeting and decided to terminate enrollment.)
Adjuvant Chemotherapy With Pemetrexed and Cisplatin vs. Vinorelbine and Cisplatin in NSCLC IB, IIA, IIB, T3N1: a Randomized Phase II Study [NCT00349089]	Phase 2	132 participants (Actual)	Interventional	2006-09-26	Completed
Maintenance Immunotherapy With Autologous Cytokine-induced Killer Cells for Stage IIIb/IV Nonsquamous Non-small Cell Lung Cancer [NCT01481259]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2010-01-31	Recruiting
A Phase II Study of Pemetrexed in Patients With Advanced Neuroendocrine Tumors [NCT00424723]	Phase 2	32 participants (Anticipated)	Interventional	2005-12-31	Completed
Phase II Study of Carboplatin and Pemetrexed in Patients With Recurrent Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Cancer [NCT00230542]	Phase 2	44 participants (Actual)	Interventional	2005-09-30	Completed
A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC [NCT00251524]	Phase 2	69 participants (Actual)	Interventional	2005-11-30	Completed
A Phase 2 Study of ALIMTA Plus Doxorubicin Administered Every 21 Days in Patients With Advanced Breast Cancer [NCT00102219]	Phase 2	77 participants (Actual)	Interventional	2004-10-31	Completed
A Phase II Study of Pemetrexed Disodium (ALIMTA®) Plus Bevacizumab in Patients With Stage IIIB Pleural Effusion or Stage IV Non-Small Cell Lung Cancer (Second-Line Treatment) [NCT00268489]	Phase 2	48 participants (Actual)	Interventional	2006-05-31	Completed
A Two-Cohort Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin in Patients With Advanced Non-Small Cell Lung Cancers and Malignant Pleural Mesotheliomas [NCT00281125]	Phase 1/Phase 2	20 participants	Interventional	2006-01-31	Terminated(stopped due to Suspended due to data issues revealed at DSMB meeting. Planned amendment but was never submitted. Study was then closed.)
A Randomized Phase 3 Study of Two Doses of Alimta in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed a Prior Platinum-Containing Chemotherapy [NCT00078260]	Phase 3	589 participants (Actual)	Interventional	2003-12-31	Completed
A Phase II Evaluation Of Pemetrexed (ALIMTA LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma [NCT00087087]	Phase 2	51 participants (Anticipated)	Interventional	2004-07-31	Completed
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative：A Multi-center, Single-arm, Phase II Study [NCT06001151]	Phase 2	49 participants (Anticipated)	Interventional	2023-08-07	Recruiting
A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab (Anti-PD-1 Humanized Monoclonal Antibody Injection) and Chemotherapy in Previously Untreated Advanced Non-smal [NCT05787613]	Phase 2	60 participants (Anticipated)	Interventional	2023-07-10	Recruiting
Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line MK-3475 (Pembrolizumab)+/- Chemotherapy (Oncologist's/Patient's Choice) [NCT04533451]	Phase 2	101 participants (Actual)	Interventional	2020-10-01	Active, not recruiting
A Phase Ib/II, Open-Label Study of M7824 in Combination With Chemotherapy in Participants With Stage IV Non-small Cell Lung Cancer [NCT03840915]	Phase 1/Phase 2	70 participants (Actual)	Interventional	2019-04-02	Completed
A Phase II Trial to Evaluate Combination Therapy With Pemetrexed and Avelumab in Previously Treated Patients With MTAP-Deficient Advanced Urothelial Cancer [NCT03744793]	Phase 2	18 participants (Actual)	Interventional	2019-04-11	Active, not recruiting
A Phase 3 Trial of Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer After Platinum-Based Chemotherapy (BRAVA) [NCT04943627]	Phase 3	0 participants (Actual)	Interventional	2021-08-02	Withdrawn(stopped due to Strategic Business Decision)
Phase IV Randomized Trial of Pemetrexed Followed by Docetaxel or in Reverse Sequence in Non-small-cell Lung Cancer Patients Failed Previous Chemotherapy [NCT01442909]	Phase 4	44 participants (Actual)	Interventional	2008-03-31	Completed
Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study [NCT04897386]	Phase 2	30 participants (Anticipated)	Interventional	2021-06-01	Not yet recruiting
A Phase II Evaluation Of Pemetrexed (ALIMTA, LY231517, IND #40061) In the Treatment Of Recurrent Carcinoma Of The Cervix [NCT00087113]	Phase 2	0 participants	Interventional	2004-08-31	Completed
A Phase Ib/II Clinical Trial of AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer [NCT05904379]	Phase 1/Phase 2	148 participants (Anticipated)	Interventional	2023-07-13	Recruiting
Neoadjuvant Chemotherapy and Extrapleural Pneumonectomy of Malignant Pleural Mesothelioma (MPM) With or Without Hemithoracic Radiotherapy. A Randomized Multicenter Phase II Trial [NCT00334594]	Phase 2	153 participants (Actual)	Interventional	2005-11-14	Completed
Binimetinib, Pemetrexed and Cisplatin, Followed by Maintenance With Binimetinib and Pemetrexed, in Patients With Advanced Non-small Cell Lung Cancer NSCLC With KRAS Mutations. A Multicenter Phase IB Trial. [NCT02964689]	Phase 1	18 participants (Actual)	Interventional	2017-04-12	Completed
A Phase 1, Open Label Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2171 and Selected Chemotherapy Regimens When Given in Combination to Patients With Advanced Solid Tumors [NCT00502567]	Phase 1	104 participants (Actual)	Interventional	2005-01-31	Completed
Clinical Observation of the Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium in Patients With Non-small Cell Lung Cancer [NCT05273827]		81 participants (Actual)	Observational	2022-03-22	Active, not recruiting
A Phase II/III Multicenter Study Evaluating the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Actionable Somatic Mutations Detected in Blood (B-FAST: [NCT03178552]	Phase 2/Phase 3	1,000 participants (Anticipated)	Interventional	2017-09-22	Recruiting
Random Open Exploratory Clinical Research of Sequential Gefitinib With Pemetrexed/Platinum Compare With Pemetrexed/Platinum Treatment for Advanced Non-small Cell Lung Cancer Exploratory Clinical Research [NCT01769066]	Phase 2/Phase 3	117 participants (Actual)	Interventional	2009-12-31	Completed
A Phase II Trial to Evaluate Pemetrexed Clinical Responses in Relation to Tumor MTAP Gene Status in Patients With Previously Treated Metastatic Urothelial Carcinoma [NCT02693717]	Phase 2	7 participants (Actual)	Interventional	2017-05-09	Terminated(stopped due to The trial was closed due to the changing efficacy of treatments for metastatic urothelial cancer.)
Phase 2 Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514) [NCT00410904]	Phase 2	60 participants (Actual)	Interventional	2006-10-31	Completed
A Phase II Trial of Pemetrexed, Gemcitabine, and Bevacizumab Every Two Weeks in Chemotherapy-Naive Patients With Stages IIIB/IV Non- Squamous, Non-Small Cell Lung Cancer (NSCLC) [NCT00438204]	Phase 2	39 participants (Actual)	Interventional	2006-05-31	Terminated(stopped due to All data collection has completed.)
A Randomized, Phase II Study of Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed and Carboplatin (PC) for Metastatic Non-Squamous NSCLC [NCT04163432]	Phase 2	84 participants (Anticipated)	Interventional	2020-06-16	Recruiting
A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies [NCT02983045]	Phase 1/Phase 2	557 participants (Actual)	Interventional	2016-12-19	Completed
Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage. [NCT01705184]	Phase 2	120 participants (Actual)	Interventional	2012-12-31	Completed
A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) [NCT00651456]	Phase 2/Phase 3	448 participants (Actual)	Interventional	2008-02-29	Completed
A Phase II-III Randomized Trial Evaluating Maintenance Pembrolizumab (± Pemetrexed) Until Progression Versus Observation (± Pemetrexed) After 6 Months of Platinum-based Doublet Chemotherapy Plus Pembrolizumab Induction Treatment in Patients With Stage IV [NCT05255302]	Phase 2/Phase 3	1,360 participants (Anticipated)	Interventional	2022-05-02	Recruiting
A Randomised Phase 2 Trial of Pemetrexed and Gefitinib Versus Gefitinib as First Line Treatment for Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations [NCT01469000]	Phase 2	195 participants (Actual)	Interventional	2012-02-29	Completed
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients With Advanced Non-small Cell Lung Cancer [NCT01783834]	Phase 2	95 participants (Actual)	Interventional	2008-02-29	Completed
A Phase IB Dose-Escalation Study of Pemetrexed and AUY922 in Previously-Treated Patients With Metastatic Non-Squamous, Non-Small Cell Lung Cancer [NCT01784640]	Phase 1	13 participants (Actual)	Interventional	2014-01-31	Completed
A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA No [NCT02486718]	Phase 3	1,280 participants (Actual)	Interventional	2015-10-31	Active, not recruiting
A Randomized Phase II Trial of Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced EGFR Wild-Type and EGFR FISH-Positive Lung Adenocarcinoma [NCT01565538]	Phase 2	123 participants (Actual)	Interventional	2008-12-31	Completed
Phase II Trial of Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS) [NCT05786430]	Phase 2	87 participants (Anticipated)	Interventional	2023-03-31	Not yet recruiting
A Phase 1 Study of MK-5890 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors [NCT03396445]	Phase 1	202 participants (Anticipated)	Interventional	2018-02-18	Active, not recruiting
Pemetrexed (Alimta) in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study (LUN04-78) [NCT00216216]	Phase 2	43 participants (Actual)	Interventional	2005-01-31	Terminated(stopped due to The results from the interim analysis were not favorable to continue this trial.)
A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Canc [NCT01454102]	Phase 1	472 participants (Actual)	Interventional	2011-12-16	Completed
Pemetrexed Plus Gemcitabine Or Carboplatin In Patients With Advanced Malignant Mesothelioma: A Randomized Phase II Trial [NCT00101283]	Phase 2	32 participants (Actual)	Interventional	2006-02-23	Completed
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of INCMGA00012, an Anti-PD-1 Antibody, in Combination With Chemoradiation in Participants With Unresectable, Stage III Non-Small Cell Lung Cancer (POD1UM-301) [NCT04203511]	Phase 3	0 participants (Actual)	Interventional	2020-07-31	Withdrawn(stopped due to Sponsor Strategic/Business Decision)
Multicenter Phase II Study With Pemetrexed in Patients With Pre-Treated Metastatic Soft Tissue Sarcomas [NCT00427466]	Phase 2	54 participants (Actual)	Interventional	2007-01-31	Completed
A Phase I Study Investigating the Combination of Everolimus With Pemetrexed in Patients With Advanced Non Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy [NCT00434174]	Phase 1	48 participants (Actual)	Interventional	2006-12-31	Completed
A Phase I Study of ALIMTA Plus Oxaliplatin Administered Every Other Week in the Treatment of Patients With Metastatic Cancer [NCT00470405]	Phase 1	25 participants (Actual)	Interventional	2004-05-31	Completed
A Randomized (PhaseII), Double-blind, Multicenter Phase I/II Trial of Pemetrexed, Carboplatin Plus or Minus Sorafenib in the First-line Treatment of Patients With Stage IIIb or IV Non-Small Cell Lung Cancer [NCT00473486]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Sorafenib administered in the combination with pemetrexed-carboplatin appears to enhance thrombocytopenia compared to historical data.)
Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib：A Multicenter, Prospective, Phase II Clinical Study [NCT04517526]	Phase 2	60 participants (Anticipated)	Interventional	2020-11-01	Not yet recruiting
A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable [NCT05555732]	Phase 3	975 participants (Anticipated)	Interventional	2023-01-11	Recruiting
A Phase I, Open-Label Study to Assess the Safety and Tolerability of ZD6474 in Combination With Pemetrexed (Alimta) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer After Failure of Prior Chemotherapy. [NCT00506051]	Phase 1	21 participants (Actual)	Interventional	2005-07-31	Completed
A Randomized, Open Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Pemetrexed Until Progression Versus Pemetrexed Alone Until Progression in Non-small Cell Lung Cancer Patients Who Have Progressed on First Line Epidermal Growth Facto [NCT03050437]	Phase 2	96 participants (Anticipated)	Interventional	2013-03-31	Recruiting
A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Patients With Locally Advanced or Metastatic Tumors [NCT02794571]	Phase 1	518 participants (Actual)	Interventional	2016-05-23	Active, not recruiting
A Phase 1b Study of Ensartinib in Combination With Platinum-Based Chemotherapy and Bevacizumab in ALK-Positive Non-Small Cell Lung Cancer (NSCLC) [NCT04837716]	Phase 1	12 participants (Anticipated)	Interventional	2021-03-18	Active, not recruiting
A Phase I Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced NSCLC Patients [NCT01531790]	Phase 1	19 participants (Actual)	Interventional	2011-09-30	Completed
Sintilimab Plus Bevacizumab and Platinum-Based Doublet Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single-center, Single-Arm Trial [NCT05648071]	Phase 3	60 participants (Anticipated)	Interventional	2021-12-01	Recruiting
Beamion LUNG-2: A Phase III, Open-label, Randomized, Active-controlled, Multi-centre Trial Evaluating Orally Administered BI 1810631 Compared With Standard of Care as First-line Treatment in Patients With Unresectable, Locally Advanced or Metastatic Nonsq [NCT06151574]	Phase 3	270 participants (Anticipated)	Interventional	2024-01-15	Not yet recruiting
A Two Steps Phase I Trial of Pazopanib or Pemetrexed in Combination With Crizotinib Followed by the Triplet, Crizotinib Plus Pazopanib Plus Pemetrexed in Patients With Advanced Malignancies [NCT01548144]	Phase 1	178 participants (Actual)	Interventional	2012-04-30	Terminated(stopped due to PI request)
Afatinib Sequenced With Concurrent Chemotherapy and Radiation in EGFR-Mutant Non-Small Cell Lung Tumors: The ASCENT Trial [NCT01553942]	Phase 2	30 participants (Anticipated)	Interventional	2012-04-30	Recruiting
Phase I/II Study of Gemzar and Platinol Followed by Alimta and Gemzar in Patients With Advanced or Metastatic Bladder Cancer [NCT00101842]	Phase 1/Phase 2	61 participants	Interventional	2004-12-31	Completed
Phase II Trial of Pemetrexed for Advanced Chondrosarcomas [NCT00107419]	Phase 2	75 participants (Actual)	Interventional	2005-09-30	Completed
A Randomized, Double-Blind Phase 2 Study of Two Doses of Pemetrexed in the Treatment of Platinum-Resistant, Epithelial Ovarian or Primary Peritoneal Cancer [NCT00109096]	Phase 2	100 participants (Anticipated)	Interventional	2005-06-30	Completed
Clinical Study of Neoadjuvant Anti-PD-1 Drug Toripalimab Combined With Chemotherapy in the Treatment of Locally Advanced Epithelial or Mixed Tissue Malignant Pleural Mesothelioma [NCT04713761]	Phase 2	15 participants (Anticipated)	Interventional	2021-02-01	Not yet recruiting
[NCT00034606]	Phase 2	0 participants	Interventional		Completed
A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. [NCT00035035]	Phase 3	0 participants	Interventional		Completed
A Phase II Clinical Trial of Tiragolumab in Combination With Carboplatin, Pemetrexed, and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases [NCT05746481]	Phase 2	35 participants (Anticipated)	Interventional	2023-08-08	Recruiting
[NCT00055432]	Phase 2	0 participants	Interventional		Terminated
ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma: A Phase II Clinical Trial [NCT00061477]	Phase 2	48 participants	Interventional	2002-12-31	Completed
Study of Two Doses of ALIMTA (Pemetrexed) as First Line Chemotherapy for Advanced Breast Cancer [NCT00065533]	Phase 2	92 participants (Actual)	Interventional	2003-05-31	Completed
A Phase II Study of Alimta and Carboplatin in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer [NCT00072865]	Phase 2	50 participants	Interventional	2003-06-30	Completed
A Phase 1/2 Study of the Highly Selective EGFR Inhibitor, BLU-701, in Patients With EGFR-Mutant Non-Small Cell Lung Cancer [NCT05153408]	Phase 1	20 participants (Actual)	Interventional	2022-01-13	Terminated(stopped due to Lack of efficacy)
A Prospective,Multi-center, Open-labeled Phase 2 Randomized and Comparative Clinical Study of First Line Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in ⅢB/IV Non Small Cell Lung Ca [NCT03151161]	Phase 2	118 participants (Anticipated)	Interventional	2015-12-31	Not yet recruiting
A Phase II Trial of Alimta (Pemetrexed) in Patients With Recurrent Malignant Gliomas, Primary Central Nervous System Lymphoma, and Brain Metastases [NCT00276783]	Phase 2	31 participants (Actual)	Interventional	2005-11-30	Active, not recruiting
A Master Protocol of Phase 1/2 Studies of Nivolumab in Advanced NSCLC Using Nivolumab as Maintenance After Induction Chemotherapy or as First-line Treatment Alone or in Combination With Standard of Care Therapies (CheckMate 370: CHECKpoint Pathway and niv [NCT02574078]	Phase 1/Phase 2	341 participants (Actual)	Interventional	2015-11-23	Completed
A Phase 1b Study of the Dual MDMX/MDM2 Inhibitor, ALRN-6924, for the Prevention of Chemotherapy-induced Myelosuppression [NCT04022876]	Phase 1	35 participants (Actual)	Interventional	2019-09-03	Terminated(stopped due to With a favorable safety profile the difference between treatment groups for the primary composite endpoint was not sufficient to generate statistically significant results with the targeted sample size)
[NCT00035061]	Phase 2	0 participants	Interventional		Completed
A Phase I Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer. [NCT00846443]	Phase 1	12 participants (Anticipated)	Interventional	2009-01-31	Recruiting
A Phase III, Open Label, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Compared With a Platinum Agent (Cisplatin or Carboplatin) in Combination With Either Pemetrexed or Gemcitabine for PD-L1-Selected, Chemotherapy-Naive Patients With Stage IV No [NCT02409342]	Phase 3	572 participants (Actual)	Interventional	2015-07-20	Completed
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial [NCT05766800]	Phase 2	100 participants (Anticipated)	Interventional	2023-03-14	Recruiting
A Phase II Clinical Trial Evaluating Three Schedules Of ALIMTA Plus Gemcitabine As Frontline Chemotherapy For Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer [NCT00022646]	Phase 2	157 participants (Actual)	Interventional	2001-08-31	Completed
Phase I/II Trial Of Gemcitabine And ALIMTA In Patients With Measurable Or Evaluable, Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Or Vater) And Gallbladder Carcinoma [NCT00059865]	Phase 1/Phase 2	68 participants (Actual)	Interventional	2004-01-31	Completed
ALIMTA Plus Gemcitabine as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase II Clinical Trial [NCT00061464]	Phase 2	48 participants	Interventional	2003-02-28	Completed
Phase 1/2 Dose-Escalating Study of Biweekly Alimta and Gemcitabine in Patients With Advanced Cancer [NCT00071136]	Phase 1/Phase 2	48 participants	Interventional	2003-12-31	Completed
A Phase II Study of Nivolumab in Combination With Carboplatin and Pemetrexed, or Nivolumab in Combination With Ipilimumab, in Patients With Advanced, EGFR-mutant or ALK-rearranged, Non-Small Cell Lung Cancer [NCT03256136]	Phase 2	9 participants (Actual)	Interventional	2017-11-22	Completed
[NCT00040625]		0 participants	Expanded Access		Approved for marketing
Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma [NCT00402766]	Phase 1	19 participants (Actual)	Interventional	2006-08-31	Completed
An Open-label, Randomized, Multicenter Trial of Intrathecal-pemetrexed Combined With Concurrent Involved-field Radiotherapy and Intrathecal-pemetrexed Alone in Patients With Leptomeningeal Metastasis From Solid Tumors [NCT05305885]		100 participants (Anticipated)	Interventional	2022-08-19	Recruiting
A Randomized Phase 2 Trial of ALIMTA Plus a Comparator Versus Leucovorin Modulated Fluorouracil Plus a Comparator in First Line Treatment of Locally Advanced or Metastatic Colorectal Cancer [NCT00079872]	Phase 2	120 participants	Interventional	2004-02-29	Completed
A Randomized Phase 3 Trial Comparing ALIMTA Plus Best Supportive Care Versus Best Supportive Care Alone in Previously Treated Patients With Locally Advanced or Metastatic Malignant Pleural Mesothelioma [NCT00190762]	Phase 3	240 participants	Interventional	2001-10-31	Completed
Open-Label Single-Arm Phase 2 Study of ALIMTA Plus Cisplatin in Korean Patients With Advanced Gastric Carcinoma [NCT00190801]	Phase 2	50 participants	Interventional	2003-09-30	Completed
Open-Label Single-Arm Phase 2 Study of ALIMTA in Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy [NCT00190840]	Phase 2	186 participants	Interventional	2003-09-30	Completed
A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor [NCT00190918]	Phase 2	50 participants (Anticipated)	Interventional	2006-07-31	Completed
A Phase II Study of Biweekly Pemetrexed and Gemcitabine in Patients With Metastatic Breast Cancer [NCT00191347]	Phase 2	30 participants	Interventional	2004-10-31	Completed
Open-Label Single-Arm Phase II Study of ALIMTA in Combination With Oxaliplatin as First-Line Therapy in Advanced Gastric Carcinoma [NCT00192088]	Phase 2	43 participants	Interventional	2004-05-31	Completed
A Randomized Phase 2 Study Comparing Erlotinib-Pemetrexed, Pemetrexed Alone, and Erlotinib Alone, as Second-Line Treatment for Non-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer [NCT00550173]	Phase 2	247 participants (Actual)	Interventional	2007-11-30	Completed
Feasibility and Safety of Neoadjuvant Nivolumab and Chemotherapy for Resectable Malignant Pleural Mesothelioma [NCT04162015]	Phase 1	35 participants (Anticipated)	Interventional	2019-11-12	Recruiting
Adaptive-Dose to Mediastinum With Immunotherapy (Durvalumab MEDI4736) and Radiation in Locally-Advanced Non-Small Cell Lung Cancer [NCT04372927]	Phase 2	1 participants (Actual)	Interventional	2021-12-10	Terminated(stopped due to Terminated due to slow accrual)
Phase II Study of the Combination of Paclitaxel Poliglumex (CT-2103, Xyotax) and Pemetrexed (Alimta) for the Treatment of Patients With Advanced Non-small Cell Lung Cancer. [NCT00487669]	Phase 2	14 participants (Actual)	Interventional	2006-10-31	Completed
A Phase 2 Randomized Open-label Study of Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer [NCT01395758]	Phase 2	96 participants (Actual)	Interventional	2011-07-31	Completed
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) [NCT04623775]	Phase 2	420 participants (Anticipated)	Interventional	2021-02-17	Active, not recruiting
A Phase II Study of Pemetrexed and Gemcitabine Plus Bevacizumab as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV Non-Small Cell Lung Cancer [NCT00517595]	Phase 2	48 participants (Actual)	Interventional	2007-08-31	Completed
Phase I Study of the Non-receptor Kinase Inhibitor Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors [NCT03023319]	Phase 1	6 participants (Actual)	Interventional	2019-12-10	Completed
A Multicenter Phase II Trial of Neo-Adjuvant Pemetrexed (Alimta) Plus Cisplatin Followed by Surgery and Radiation for Pleural Mesothelioma [NCT00087698]	Phase 2	77 participants (Actual)	Interventional	2003-09-30	Completed
A Phase I Dose-Escalating Study of Induction Gemcitabine/Pemetrexed Followed by Pemetrexed and Concurrent Upper Abdominal Radiation Therapy in Patients With Locally Advanced Pancreatic Cancer [NCT00310050]	Phase 1	4 participants (Actual)	Interventional	2005-10-31	Terminated(stopped due to slow accrual)
Phase I/II Clinical Trial of Combined Pre-Irradiation With Pemetrexed and Erlotinib Followed by Maintenance Erlotinib for Recurrent and Second Primary Squamous Cell Carcinoma of the Head and Neck [NCT00573989]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2008-03-31	Terminated(stopped due to Drug Supply Issue)
A Study of the Effect of Anlotinib, Pemetrexed or the Combination As Maintenance Therapy for Patients With Non-Squamous Non-Small Cell Lung Cancer. [NCT04453423]	Phase 2	90 participants (Anticipated)	Interventional	2020-07-01	Not yet recruiting
Association Between Proton Pump Inhibitors and the Incidence of Hematologic Toxicity of Pemetrexed: a Prospective, Multicenter, Observational and Longitudinal Study Among Patients Treated by a Pemetrexed-based Chemotherapy [NCT03537833]		172 participants (Actual)	Observational	2018-05-02	Completed
Phase I Open Label Trial of Alimta® Plus Cisplatin and Paclitaxel Given Intraperitoneally (IP) as First Line Treatment for Women With Stage III Ovarian Cancer [NCT00702299]	Phase 1	15 participants (Actual)	Interventional	2007-09-30	Completed
A Single-arm, Open-label, and Multicenter Phase Ⅱ Study Designed to Evaluate the Efficacy and Safety of Rulonilimab Combined With Chemotherapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) [NCT05741021]	Phase 2	84 participants (Anticipated)	Interventional	2023-03-01	Not yet recruiting
A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab and With Standard Chemotherapy in Patients With Advanced Lun [NCT05664971]	Phase 1/Phase 2	240 participants (Anticipated)	Interventional	2023-02-09	Recruiting
Alimta Plus Gemcitabine as Chemotherapy for Patients With Advanced Sarcoma: A Phase II Clinical [NCT00860015]	Phase 2	12 participants (Actual)	Interventional	2005-08-31	Completed
Use of Mineral Trioxide Aggregate in the Treatment of Traumatized Permanent Teeth With Necrotic Pulps and Chronic Periapical Lesions [NCT02625298]	Phase 2	24 participants (Actual)	Interventional	2010-09-30	Completed
Phase II, A Study of Lung-Sparing Combined Modality Protocol for the Treatment for Malignant Pleural Mesothelioma: The Columbia Protocol [NCT00859495]	Phase 2	9 participants (Actual)	Interventional	2008-02-29	Terminated
A Phase II Randomized, Open-Labelled, Multicenter Study of Safety & Efficacy of Combination Brigatinib and Carboplatin-Pemetrexed Therapy or Brigatinib Monotherapy as First-Line Treatment in Advanced ALK-Positive Non-Small Cell Lung Cancer [NCT05200481]	Phase 2	110 participants (Anticipated)	Interventional	2022-05-18	Recruiting
A Phase II Study of Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the C [NCT04367311]	Phase 2	100 participants (Anticipated)	Interventional	2020-05-22	Recruiting
Phase II Multi-center Study of Pembrolizumab in Combination With Platinum-based Doublet Chemotherapy in NSCLC (Non-small Cell Lung Cancer) Patients With Targetable Genetic Alterations in Their Tumor Previously Treated With Appropriate Targeted Agents With [NCT03242915]	Phase 2	33 participants (Actual)	Interventional	2017-10-03	Active, not recruiting
S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy [NCT02134912]	Phase 2	1 participants (Actual)	Interventional	2014-08-31	Terminated(stopped due to science has moved forward and there is no intent to complete the study)
Phase 2 Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative Breast Cancer [NCT02624700]	Phase 2	13 participants (Actual)	Interventional	2016-01-28	Terminated
Phase I Clinical Study of Tislelizumab in Combination With Bevacizumab and Pemetrexed for the First-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients [NCT05273814]	Phase 1	30 participants (Anticipated)	Interventional	2022-08-01	Not yet recruiting
A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma [NCT05335941]	Phase 2	20 participants (Anticipated)	Interventional	2023-06-13	Recruiting
Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma [NCT00198133]	Phase 2	27 participants (Actual)	Interventional	2005-01-31	Completed
A Phase II Feasibility Trial of Induction Chemotherapy Followed by Extrapleural Pneumonectomy and Postoperative Radiotherapy in Patients With Malignant Pleural Mesothelioma [NCT00227630]	Phase 2	59 participants (Actual)	Interventional	2005-07-31	Completed
Molecular Profiling and Safety Study of Operable Lung Cancer Patients Treated With Alimta Combined With Cisplatin as Neoadjuvant Chemotherapy [NCT00191308]	Phase 2	30 participants (Actual)	Interventional	2005-05-31	Completed
LY231514 500 mg/m2 and LY231514 1000 mg/m2 in Patients With Advanced Non-Small Cell Lung Cancer Who Were Previously Treated With Prior Systemic Anti Cancer Therapy: A Randomized Phase II Trial [NCT00191191]	Phase 2	226 participants (Actual)	Interventional	2004-10-31	Completed
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM) [NCT03760575]	Phase 1	20 participants (Anticipated)	Interventional	2023-01-10	Recruiting
Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Randomized Phase II Study [NCT04422392]	Phase 2	93 participants (Actual)	Interventional	2020-07-13	Terminated(stopped due to since the CheckMate816 study is published in NEJM, enrolling patients becomes difficult)
An Open-label, Phase II Study of KN046 Evaluating the Efficacy and Safety of KN046 Plus Platinum-based Doublet Chemotherapy as First Line Therapy in Advanced Non-small Cell Lung Cancer Subjects. [NCT04054531]	Phase 2	50 participants (Anticipated)	Interventional	2019-09-04	Recruiting
A Phase III, Randomized, Double-blinded, Parallel Group, Multi-centre Study to Assess the Efficacy and Safety of ZD6474 (ZACTIMA™) in Combination With Pemetrexed (Alimta®) Versus Pemetrexed Alone in Patients With Locally-Advanced or Metastatic NSCLC [NCT00418886]	Phase 3	698 participants (Actual)	Interventional	2007-01-31	Completed
A Phase I Study of Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies [NCT00315861]	Phase 1	15 participants (Anticipated)	Interventional	2006-03-31	Completed
A Phase I/II Trial of Temsirolimus and Pemetrexed in Recurrent/Refractory Non Small Cell Lung Cancer (NSCLC) [NCT00921310]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2009-09-30	Terminated(stopped due to Withdrawal of funding from sponsor)
A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) [NCT03509012]	Phase 1	105 participants (Actual)	Interventional	2018-05-02	Active, not recruiting
A Phase I Trial of Cetuximab (C225) and Pemetrexed With Concurrent Radiation in Head and Neck Cancer [NCT00291707]	Phase 1	40 participants (Anticipated)	Interventional	2006-03-31	Completed
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Metmab Vs. Placebo in Combination With Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum in Patients With Untreated Stage I [NCT01496742]	Phase 2	259 participants (Actual)	Interventional	2012-04-30	Completed
A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer [NCT00383266]	Phase 2	9 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to Low accrual)
A Randomized Placebo-controlled Phase II Study of Intercalated Administration of Pemetrexed/Cisplatin With Iressa® (Gefitinib) or Placebo as First-line Treatment of Stage IIIB/IV Lung Adenocarcinoma in Never-smokers [NCT01502202]	Phase 2	162 participants (Anticipated)	Interventional	2012-03-31	Recruiting
Molecular and Genetic Changes in Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) Following Neoadjuvant Chemotherapy With Cisplatin and Alimta - Phase II Study [NCT00248495]	Phase 2	38 participants (Actual)	Interventional	2005-06-08	Completed
Phase III Study Evaluating Two Strategies of Maintenance, One With Pemetrexed in Continuous Strategy and One According to the Response of Induction Chemotherapy, in Non Squamous Non Small Cell Lung Cancer of Advanced Stage [NCT01631136]	Phase 3	932 participants (Actual)	Interventional	2012-07-31	Completed
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2) [NCT05061550]	Phase 2	350 participants (Anticipated)	Interventional	2022-04-14	Recruiting
A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (Anti-PD-L1 Antibody) Administered With Bevacizumab and/or Chemotherapy in Patients With Advanced Solid Tumors [NCT01633970]	Phase 1	240 participants (Actual)	Interventional	2012-07-11	Completed
A Phase I Open-label Dose Escalation Study of Intravenous BI 2536 Together With Pemetrexed in Previously Treated Patients With Non-small-cell Lung Cancer [NCT02211833]	Phase 1	41 participants (Actual)	Interventional	2006-10-31	Completed
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors [NCT01803282]	Phase 1	236 participants (Actual)	Interventional	2013-03-29	Completed
Phase I Dose Escalation Study of Carboplatin, Pemetrexed and Exemestane in Post-menopausal Women With Metastatic Non-squamous NSCLC [NCT01664754]	Phase 1	8 participants (Actual)	Interventional	2012-09-07	Completed
A Phase 2 Multi-Center Randomized Trial to Assess Early Intervention With Adjuvant Nivolumab in Non-Small Cell Lung Cancer Participants With ctDNA-detected Minimal Residual Disease After Surgical Resection [NCT03770299]	Phase 2	0 participants (Actual)	Interventional	2021-01-15	Withdrawn(stopped due to Business objectives have changed)
Phase I Dose Escalation Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab in Stage IV Non-Squamous Non-Small Cell Lung Cancer [NCT01700400]	Phase 1	13 participants (Actual)	Interventional	2012-09-30	Completed
Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples. [NCT01703910]	Phase 2	29 participants (Actual)	Interventional	2012-11-30	Completed
A Phase I-II Evaluation of the Safety and Efficacy of the Oral HSP90 Inhibitor Debio 0932 in Combination With Standard of Care in first-and Second-line Therapy of Patients With Stage IIIb or IV Non-small Cell Lung Cancer-the HALO Study (HSP90 Inhibition A [NCT01714037]	Phase 1	82 participants (Actual)	Interventional	2012-08-31	Terminated
Non-small Cell Lung Cancer: The Impact of Ethnic Origin on Patients Being Treated Second Line With Pemetrexed - An Observational Study [NCT00497770]		434 participants (Actual)	Observational	2007-02-28	Completed
Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed Versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell Lung Cancer (NSCLC) [NCT01742767]	Phase 2	0 participants	Interventional	2012-11-30	Recruiting
A Phase Ⅱ Randomized Controlled Trial to Compare Chemotherapy Sequenced by EGFR-TKIs and Chemotherapy Combined With EGFR-TKIs for Advanced or Metastatic NSCLC Patients Failed to EGFR-TKIs Therapy [NCT01746277]	Phase 2	60 participants (Anticipated)	Interventional	2012-10-31	Recruiting
Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer [NCT06109402]	Phase 2	160 participants (Anticipated)	Interventional	2023-12-20	Not yet recruiting
A Phase 2 Trial of Combination Therapies With Adagrasib in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation [NCT05609578]	Phase 2	90 participants (Anticipated)	Interventional	2022-07-29	Recruiting
SiCARIO (Split Course Adaptive Radioimmunotherapy) for the Treatment of Oligometastatic Non-Small Cell Lung Cancer (NSCLC) Using Biologically-Adaptive Radiotherapy - A Phase I/II Study [NCT05501665]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2023-05-09	Recruiting
A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy With or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer [NCT04929041]	Phase 2/Phase 3	427 participants (Anticipated)	Interventional	2022-10-07	Recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients With EGFRm, Locally Advanced or Metastatic NSCLC Who Have Progr [NCT04765059]	Phase 3	80 participants (Anticipated)	Interventional	2021-09-12	Recruiting
A Phase 3 Study of Pembrolizumab (MK-3475) in Combination With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants With Unresectable, Locally Adva [NCT04380636]	Phase 3	870 participants (Anticipated)	Interventional	2020-07-06	Active, not recruiting
A Multi-center Phase II Randomized Study of Customized Neoadjuvant Therapy Versus Standard Chemotherapy in Non-small Cell Lung Cancer (NSLC) Patients With Resectable Stage IIIA (N2) Disease (CONTEST-TRIAL) [NCT01784549]	Phase 2	168 participants (Anticipated)	Interventional	2012-07-31	Recruiting
A Phase II/III Clinical Trial to Evaluate the Efficacy and Safety of PM8002(Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With EGFR-mutant Advanced Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment [NCT05756972]	Phase 2/Phase 3	374 participants (Anticipated)	Interventional	2023-06-26	Recruiting
A Phase 1/2 Study Evaluating the Safety and Efficacy of ABT 751 in Combination With Pemetrexed Versus Pemetrexed Alone in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00297089]	Phase 1/Phase 2	165 participants (Actual)	Interventional	2006-11-30	Completed
Phase I Study of Pemetrexed and Sorafenib in Advanced Malignancy [NCT01450384]	Phase 1	37 participants (Actual)	Interventional	2011-10-31	Completed
A Pilot Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2 [NCT04297605]	Phase 1	28 participants (Anticipated)	Interventional	2020-05-15	Recruiting
Neoadjuvant Chemotherapy for Non-metastatic Non-small Cell Lung Cancer [NCT01860040]	Phase 2	1 participants (Actual)	Interventional	2013-04-30	Terminated(stopped due to Poor accrual, no data to analyze)
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）：A Prospective, Randomized, Open-Label, Single-Center Phase 2 Trial [NCT04459611]	Phase 2	60 participants (Actual)	Interventional	2020-07-01	Active, not recruiting
A Prospective, Single Center, Single Arm, Phase II Clinical Trial of Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment of Patients With HER2 Mutant or Amplified Recurrent / Metastatic Non-small Cell Lung Cancer [NCT04706949]	Phase 2	26 participants (Anticipated)	Interventional	2020-12-07	Recruiting
A Phase I, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer ( [NCT01809210]	Phase 1	55 participants (Actual)	Interventional	2013-04-04	Completed
Atezolizumab/Carboplatin/Nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in Metastatic TTF-1 Negative Lung Adenocarcinoma [NCT05689671]	Phase 4	136 participants (Anticipated)	Interventional	2023-12-06	Recruiting
A Phase 1b/2, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) [NCT04185883]	Phase 1/Phase 2	1,143 participants (Anticipated)	Interventional	2019-12-17	Recruiting
A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer [NCT04105270]	Phase 2	82 participants (Anticipated)	Interventional	2022-11-30	Recruiting
Phase II Study to Evaluate the Role of Postoperative Radiotherapy for Low Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer [NCT02977169]	Phase 2	300 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Efficacy of Intrathecal Pemetrexed Combined With Tyrosine Kinase Inhibitor for Treating Leptomeningeal Metastasis in EGFR-Mutant NSCLC After Failure of Osimertinib [NCT05805631]	Phase 2	23 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
A Randomized Phase II Study of Carboplatin and Pemetrexed w/ or w/o Selpercatinib in Participants With Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study) [NCT05364645]	Phase 2	74 participants (Anticipated)	Interventional	2022-07-25	Recruiting
EORTC Randomized Phase II Study of Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage Malignant Pleural Mesothelioma [NCT02436733]	Phase 2	64 participants (Anticipated)	Interventional	2016-09-20	Active, not recruiting
A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma [NCT01445392]	Phase 1	24 participants (Actual)	Interventional	2007-11-14	Terminated
Apatinib Mesylate Combined With Pemetrexed in the Treatment of Pretreated Advanced Non-squamous Non-small Cell Lung Cancer ：Single Arm Exploratory Study [NCT02974933]	Phase 2	48 participants (Anticipated)	Interventional	2016-11-30	Recruiting
A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 Versus Pemetrexed (Alimta®) in Patients With Non-small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen [NCT00372788]	Phase 2	88 participants (Actual)	Interventional	2006-08-31	Completed
Phase 1b/2a Safety and Tolerability Study of Bemcentinib With Pembrolizumab/Carboplatin/Pemetrexed in Subjects With Untreated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Without/With a STK11 Mutation [NCT05469178]	Phase 1/Phase 2	64 participants (Anticipated)	Interventional	2022-12-14	Recruiting
A Phase II/III Study Comparing HX008 (a Humanized Monoclonal Antibody Against PD-1) Plus Chemotherapy With Pembrolizumab Plus Chemotherapy as the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer. [NCT04750083]	Phase 2/Phase 3	700 participants (Anticipated)	Interventional	2020-09-25	Recruiting
A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer [NCT01041781]	Phase 3	313 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to DSMB recommendation)
A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer [NCT02337530]	Phase 2	62 participants (Actual)	Interventional	2015-02-05	Completed
Influence of Resin Cement Composition on the Longevity of Intraradicular Post in the Rehabilitation of Endodontically Treated Teeth - Randomized Clinical Trials [NCT03491527]		20 participants (Anticipated)	Interventional	2018-05-01	Not yet recruiting
Efficacy and Safety of Tislelizumab Combined With Bevacizumab and Platinum Plus Pemetrexed for Untreated EGFR+ and High PD-L1 Expression Non-squamous NSCLC :a Phase II, Single-center, Single Arm Study [NCT05394233]	Phase 2	20 participants (Anticipated)	Interventional	2022-06-01	Not yet recruiting
Neoadjuvant Osimertinib Plus Chemotherapy for EGFR-mutant Stage III N2 Non-squamous Non-small Cell Lung Cancer [NCT05011487]	Phase 2	30 participants (Anticipated)	Interventional	2021-08-13	Recruiting
Randomized Phase II Trial of Pemetrexed Plus Vinorelbine Versus Vinorelbine in Patients With Recurrent or Metastatic Breast Cancer Previously Treated With or Resistant to Anthracycline and Taxane [NCT03242616]	Phase 2	125 participants (Anticipated)	Interventional	2017-02-17	Recruiting
A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer [NCT02535325]	Phase 1	17 participants (Actual)	Interventional	2015-09-30	Completed
A Phase II Study of Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-139 [NCT03713944]	Phase 2	30 participants (Actual)	Interventional	2018-11-15	Terminated(stopped due to Extreme toxicity, thromboembolic events)
A Randomized Phase II Study of Progression Free Survival Comparing Gemcitabine (1000 mg/m2 Infusion) Versus Carboplatin (AUC5 Infusion) Plus Alimta (500 mg/m2 Infusion) as First-line Chemotherapy in Elderly Patients With Locally Advanced (Stage IIIb) or M [NCT00754364]	Phase 2	108 participants (Actual)	Interventional	2008-10-31	Terminated(stopped due to low enrollment rate)
A Phase I Pharmacokinetic Trial of LY231514 Administered Intravenously Every 3 Weeks in Advanced Cancer Patients With Varying Degrees of Renal Function [NCT00003706]	Phase 1	50 participants (Actual)	Interventional	1998-04-30	Completed
A Randomized Phase II Study of Radiation Therapy, Pemetrexed and Carboplatin With or Without Cetuximab in Stage III Non-Small Cell Lung Cancer [NCT00117962]	Phase 2	109 participants (Actual)	Interventional	2005-09-30	Completed
Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery [NCT04177953]	Phase 2	92 participants (Actual)	Interventional	2019-02-04	Active, not recruiting
A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma [NCT01878617]	Phase 2	660 participants (Actual)	Interventional	2013-06-23	Active, not recruiting
Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer [NCT02117167]	Phase 2	999 participants (Actual)	Interventional	2014-04-23	Active, not recruiting
Phase II Trial of Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer (SCCHN) [NCT00394147]	Phase 2	17 participants (Actual)	Interventional	2006-10-31	Terminated(stopped due to stopped for lack of efficacy)
Sintilimab Combined With Anlotinib Hydrochloride and Standard Platinum-Containing Dual-Agent Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) as First-Line Treatment: A Single-Arm, Prospective and Exploratory Clinical Study [NCT04846452]	Phase 2	40 participants (Anticipated)	Interventional	2021-06-01	Recruiting
Adjuvant Toripalimab Versus Placebo Combined With Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) Non-small-cell Lung Cancer (LungMate-008): a Randomised, Double-blind, Controlled, Phase 3 Trial [NCT04772287]	Phase 3	341 participants (Anticipated)	Interventional	2021-03-31	Not yet recruiting
A Phase 1/2 Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer [NCT04430933]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2021-12-06	Withdrawn(stopped due to Upon reviewing current available combo studies, the sponsor decided to prioritize different combo study.)
Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy and Crizotinib [NCT02604342]	Phase 3	119 participants (Actual)	Interventional	2015-11-03	Completed
A Randomized, Open Label, Phase III Study of Overall Survival Comparing Pembrolizumab (MK-3475) Versus Platinum Based Chemotherapy in Treatment Naïve Subjects With PD-L1 Positive Advanced or Metastatic Non-Small Cell Lung Cancer (Keynote 042) [NCT02220894]	Phase 3	1,274 participants (Actual)	Interventional	2014-10-30	Completed
Alimta (Pemetrexed) and Cisplatin Treatment as Neoadjuvant Therapy in Non Small Cell Lung Cancer [NCT00259285]	Phase 2	10 participants (Actual)	Interventional	2005-11-30	Terminated(stopped due to Trial was stopped early due to low enrollment.)
Phase II Trial of Bevacizumab in Combination With Pemetrexed as Second Line Therapy in Patients With Stable Brain Metastases From Non-small Cell Lung Cancer (NSCLC) (Excluding Squamous Cell Carcinoma) [NCT00227019]	Phase 2	16 participants (Actual)	Interventional	2006-03-31	Completed
Phase II Study of Neoadjuvant Chemotherapy With Gemcitabine and Pemetrexed in Resectable Non-Small-Cell Lung Cancer (NSCLC) With Pharmacogenomic Correlates. [NCT00226577]	Phase 2	52 participants (Actual)	Interventional	2004-02-29	Completed
A Multicenter Phase II Trial of Pemetrexed Plus Carboplatin With or Without Apatinib in Patients With Advanced Non-small Cell Lung Cancer Without EGFR Mutation, ALK Gene Rearrangement, and ROS1 Gene Rearrangement [NCT03164694]	Phase 2	128 participants (Anticipated)	Interventional	2017-05-20	Recruiting
Induction Therapy With Chemoimmunotherapy Followed by Surgery for Unresectable Stage III Non-small Cell Lung Cancer: a Single-center, Single-arm, Prospective Clinical Study [NCT04943029]	Phase 2	30 participants (Anticipated)	Interventional	2021-08-20	Recruiting
Phase II Trial of Lazertinib and Pemetrexed/Carboplatin Combination in Patients With EGFR Positive, Metastatic NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of Osimertinib [NCT05477615]	Phase 2	28 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
A Single Arm, Open Label, Exploratory Study of Pemetrexed and S-1 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy [NCT03843853]	Phase 2	0 participants (Actual)	Interventional	2019-05-01	Withdrawn(stopped due to cooperation terminated)
QL1706 Combined With Platinum-based Chemotherapy Versus Placebo Combined With Platinum-based Chemotherapy as Adjuvant Therapy for Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection: a Randomized, Double-blind, Multicenter Phase III [NCT05487391]	Phase 3	632 participants (Anticipated)	Interventional	2022-10-01	Not yet recruiting
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of P [NCT02489903]	Phase 2	139 participants (Actual)	Interventional	2015-06-30	Completed
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial [NCT04334759]	Phase 3	214 participants (Actual)	Interventional	2021-02-18	Active, not recruiting
A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation [NCT01836341]	Phase 1	0 participants (Actual)	Interventional	2013-04-30	Withdrawn
Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2 [NCT01836575]	Phase 3	228 participants (Actual)	Interventional	2008-04-30	Completed
A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients With Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC) [NCT00950365]	Phase 2	79 participants (Actual)	Interventional	2006-04-30	Completed
An Open-label, Safety and Tolerability Phase 1b Trial of CAN04, a Fully Humanized Anti-IL1RAP Monoclonal Antibody, and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors [NCT04452214]	Phase 1	19 participants (Actual)	Interventional	2020-09-24	Completed
Phase 2 Study of Erlotinib Plus Pemetrexed/Cisplatin Treating Lung Adenocarcinoma With Brain Metastases [NCT01578668]	Phase 2	69 participants (Actual)	Interventional	2012-01-31	Completed
An Open Label, Randomized, Multicenter, Phase II Study to Compare Efficacy and Safety of Gefitinib/ Pemetrexed With Pemetrexed Alone as Maintenance Therapy in Patients With Advanced (Stage IV) EGFR Mutation Negative or T790M Single Mutation Nonsquamous NS [NCT01579630]	Phase 2/Phase 3	52 participants (Actual)	Interventional	2011-03-31	Active, not recruiting
A Randomized, Open-label, Phase III Study Comparing Pemetrexed With and Without Carboplatin in Elderly Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer [NCT01593293]	Phase 3	266 participants (Anticipated)	Interventional	2012-03-31	Recruiting
Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum Doublet Chemotherapy and Other Immunooncology Agents in PD-L1 Unselected, Metastatic NSCLS Patients (ElevatION:NSCLC-101 Trial) [NCT03064854]	Phase 1	111 participants (Actual)	Interventional	2017-05-24	Terminated(stopped due to Recruitment halted prematurely due to competitive landscape for lung cancer therapies)
A Randomized Open-Label Phase II Trial of Pemetrexed and a Platinum (Carboplatin or Cisplatin) With or Without Erlotinib in Patients With Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations and Acquired Resistance to [NCT01928160]	Phase 2	0 participants (Actual)	Interventional	2014-06-30	Withdrawn(stopped due to study not accruing)
Phase II Trial of Alimta (Pemetrexed) and Gemzar (Gemcitabine) in Metastatic Breast Cancer Patients Who Have Received Prior Taxane Therapy [NCT00063570]	Phase 2	73 participants (Actual)	Interventional	2003-07-31	Completed
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC: a Multicenter, Open-label, Phase II Randomized Controlled Trial [NCT04455594]	Phase 2	168 participants (Anticipated)	Interventional	2020-10-31	Not yet recruiting
A Phase III, Randomized, Open-Label Study of Pralsetinib Versus Standard of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer [NCT04222972]	Phase 3	226 participants (Anticipated)	Interventional	2020-07-24	Recruiting
A Phase II Study of Pemetrexed/Carboplatin/Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer [NCT00402883]	Phase 2	5 participants (Actual)	Interventional	2006-11-30	Terminated(stopped due to Terminated due to bevacizumab and chemoradiotherapy toxicity)
A Phase I Trial of Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas [NCT02120807]	Phase 1	30 participants (Actual)	Interventional	2014-04-15	Completed
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors (AMBER) [NCT02817633]	Phase 1	475 participants (Anticipated)	Interventional	2016-07-08	Recruiting
A Single-Blind Randomized Phase III Trial of MTA Plus Cisplatin Versus Cisplatin in Patients With Malignant Pleural Mesothelioma [NCT00005636]	Phase 3	0 participants	Interventional	1999-11-30	Completed
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy and Safety of Neoadjuvant Treatment With Tislelizumab (BGB-A317, Anti-PD-1 Antibody) or Placebo Plus Platinum-Based Doublet Chemotherapy Followed By Adjuvant Tislelizuma [NCT04379635]	Phase 3	453 participants (Actual)	Interventional	2020-05-29	Active, not recruiting
A Multicenter, Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations Who Have Progressed on Prior EGFR TKI Treatment [NCT01646125]	Phase 2	59 participants (Actual)	Interventional	2012-11-23	Terminated(stopped due to An interim analysis was conducted in May-2014. Upon review of the data, the committee recommended study termination due to futility.)
A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small C [NCT02367781]	Phase 3	723 participants (Actual)	Interventional	2015-04-16	Completed
A Pilot Trial of Platinum, Gemcitabine, or Pemetrexed Single- or Multi-Agent Therapy With Serial Tumor Specimen Collection in Patients With Advanced Non-Small-Cell Lung Cancer [NCT02145078]		4 participants (Actual)	Interventional	2014-06-30	Terminated(stopped due to Slow accrual.)
A Randomized, Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB, Stage IV, or Recurrent [NCT02119650]	Phase 2	76 participants (Actual)	Interventional	2014-02-11	Terminated(stopped due to The study was terminated as other related studies of ruxolitinib did not provide sufficient efficacy to warrant continuation.)
A Phase II Study of AZD1775 Plus Pemetrexed and Carboplatin Followed by a Randomised Comparison of Pemetrexed and Carboplatin With or Without AZD1775 in Patients With Previously Untreated Stage IV Non-Squamous Non-Small-Cell Lung Cancer [NCT02087241]	Phase 2	22 participants (Actual)	Interventional	2014-03-31	Terminated(stopped due to The sponsor decided to terminate the study.)
An Open-label, Randomized, Phase IIIb Trial Evaluating the Efficacy and Safety of Standard of Care +/- Continuous Bevacizumab Treatment Beyond Progression of Disease (PD) in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) After Firs [NCT01351415]	Phase 3	485 participants (Actual)	Interventional	2011-06-25	Completed
A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents With and Without Chemotherapy Agents in First-line Treatment of Patients With Advanced or Metastatic Non-squamous N [NCT04686305]	Phase 1	168 participants (Anticipated)	Interventional	2021-03-09	Recruiting
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer [NCT02041533]	Phase 3	541 participants (Actual)	Interventional	2014-03-27	Completed
Phase II Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer [NCT00365183]	Phase 2	74 participants (Actual)	Interventional	2006-06-30	Terminated
A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab [NCT03559049]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2018-12-24	Active, not recruiting
An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Advanced nsqNSCLC Patients With High EGFR Expression [NCT05215925]	Phase 2	60 participants (Anticipated)	Interventional	2023-02-01	Not yet recruiting
A Randomized, Three-Arm, Open-Label Phase 3b Clinical Trial of Aumolertinib, Versus Aumolertinib With Chemotherapy, Versus Osimertinib for Patients With Metastatic NSCLC and an EGFR Mutation (TREBLE) [NCT05493501]	Phase 3	8 participants (Actual)	Interventional	2022-12-14	Terminated(stopped due to The study is being closed based on corporate changes at EQRx and is not related to any efficacy or safety issues with aumolertinib.)
Phase II Investigation of Use of CNS Active Pembrolizumab and Chemotherapy for Asymptomatic Brain Metastasis From Non-small Cell Lung Cancer (NSCLC) [NCT04964960]	Phase 2	45 participants (Anticipated)	Interventional	2022-05-19	Recruiting
A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer [NCT03846310]	Phase 1	77 participants (Actual)	Interventional	2019-04-01	Active, not recruiting
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789) [NCT03515837]	Phase 3	492 participants (Actual)	Interventional	2018-06-29	Completed
A 2-Arm Phase 2 Double-Blind Randomized Study of Carboplatin, Pemetrexed Plus Placebo Versus Carboplatin, Pemetrexed Plus Truncated Demcizumab as First-Line Treatment in Subjects With Stage IV Non-Squamous Non-Small Cell Lung Cancer [NCT02259582]	Phase 2	82 participants (Actual)	Interventional	2015-02-28	Completed
Phase II Clinical Trial to Evaluate the Preliminary Efficacy, Safety and Pharmacokinetic Characteristics of PM8002 Injection Combined With Standard Chemotherapy in the First-line Treatment of Subjects With Inoperable Malignant Mesothelioma [NCT05918107]	Phase 2	55 participants (Anticipated)	Interventional	2022-08-13	Recruiting
First-in-Human Dose Study of IOA-244 Alone and in Combination With Pemetrexed/Cisplatin in Patients With Advanced or Metastatic Cancers [NCT04328844]	Phase 1	210 participants (Anticipated)	Interventional	2020-02-25	Active, not recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Clinical Study on Toripalimab Combined With Platinum-Based Doublet Drug Chemotherapy for Resectable, Stage II-III, Non-Small Cell Lung Cancer [NCT04158440]	Phase 3	501 participants (Actual)	Interventional	2020-04-07	Active, not recruiting
A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination With Platinum Doublet Chemotherapy and Radiotherapy for Participants With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799) [NCT03631784]	Phase 2	217 participants (Actual)	Interventional	2018-10-19	Active, not recruiting
A Phase I Trial of LY231514 With Irinotecan Administered Intravenously Every 21 Days in Patients With Metastatic Cancer [NCT00003711]	Phase 1	0 participants	Interventional	1997-09-30	Completed
Alvopem® (Pemetrexed) Safety Assessment in Patients With Non-small Cell Lung Cancer and Malignant Pleural Mesothelioma [NCT04843007]		199 participants (Actual)	Observational	2016-10-05	Completed
a Clinical Trial Phase II Prospective, Single-arm Study of Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced Non-small Cell Lung Cancer [NCT05448781]	Phase 2	38 participants (Anticipated)	Interventional	2022-07-20	Not yet recruiting
Efficacy and Safety of Postoperative Adjuvant Chemotherapy Combined With Camrelizumab for Patients With ⅡA -ⅢA Non-small Cell Lung Cancer：a Phase II , Single-arm Clinical Study [NCT05825443]	Phase 2	57 participants (Anticipated)	Interventional	2023-04-10	Recruiting
From Liquid Biopsy to Cure: Using ctDNA Detection of Minimal Residual Disease to Identify Patients for Curative Therapy After Lung Cancer Resection [NCT04966663]	Phase 2	66 participants (Anticipated)	Interventional	2022-03-28	Recruiting
A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies [NCT02383212]	Phase 1	398 participants (Actual)	Interventional	2015-02-02	Completed
A Feasibility Study of Pemetrexed Single Agent and Folic Acid Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer [NCT00330915]	Phase 2	37 participants (Actual)	Interventional	2006-06-30	Completed
A Phase II Trial of Cisplatin, Pemetrexed and Bevacizumab in Untreated Malignant Mesothelioma [NCT00295503]	Phase 2	53 participants (Actual)	Interventional	2006-02-28	Completed
Phase II Study of Dose Attenuated Chemotherapy in Patients With Lung Cancer and Age > 70 and/or Comorbidities [NCT05800587]	Phase 2	280 participants (Anticipated)	Interventional	2023-02-22	Recruiting
Neoadjuvant Toripalimab Combined With Chemotherapy in Rare Mutations Stage IIB-IIIB NSCLC [NCT05800340]	Phase 2	30 participants (Anticipated)	Interventional	2023-04-04	Recruiting
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations [NCT05767892]	Phase 3	350 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) [NCT02659059]	Phase 2	324 participants (Actual)	Interventional	2016-02-15	Completed
Phase I/II Trial of Bevacizumab, Pemetrexed and Erlotinib in the First-Line Treatment of Elderly Patients With Advanced (Stage IIIB(With Malignant Pleural Effusion) or IV) Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [NCT00351039]	Phase 1/Phase 2	8 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to slow accrual)
Phase I/II Study of Two Different Schedules of Bortezomib (VELCADE, PS-341) and Pemetrexed (ALIMTA) in Advanced Solid Tumors, With Emphasis on Non-Small Cell Lung Cancer (NSCLC) [NCT00389805]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2005-03-31	Completed
Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed After Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study [NCT01473563]	Phase 2	52 participants (Actual)	Interventional	2011-12-31	Completed
A Phase III Randomised, Double Blind, Placebo Controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of Continuing IRESSA 250 mg in Addition to Chemotherapy Versus Chemotherapy Alone in Patients Who Have Epidermal Growth Factor Receptor [NCT01544179]	Phase 3	265 participants (Actual)	Interventional	2012-03-15	Completed
A Single Arm, Prospective, and Exploratory Clinical Study of Camrelizumab Combined With Pemetrexed and Carboplatin in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutation Who Failed EGFR-TKI Treatment [NCT04970043]		58 participants (Anticipated)	Interventional	2021-07-31	Not yet recruiting
A Randomized, Parallel Control, Exploratory Trial to Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in Subjects With Advanced or Metastatic of the Non-small Cell Lung Cancer (NSCLC) [NCT03256721]	Phase 2	37 participants (Actual)	Interventional	2017-08-16	Terminated(stopped due to Due to the enrollment was slow and exceeded the expected enrollment time)
Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer After Concurrent Chemotherapy and Radiotherapy. A Single-arm, Single-center, Phase II Clinical Study [NCT04828395]	Phase 2	65 participants (Anticipated)	Interventional	2021-03-01	Recruiting
A Phase II, Prospective, Single-center, Randomized, Controlled Study to Investigate the Efficacy and Safety of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cance [NCT03863483]	Phase 2	70 participants (Anticipated)	Interventional	2019-03-26	Recruiting
A Phase II, Prospective, Single-center, Randomized, Controlled Study to Investigate the Efficacy and Safety of Sintilimab Compared With Docetaxel or Pemetrexed as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With [NCT03830411]	Phase 2	76 participants (Anticipated)	Interventional	2019-03-13	Recruiting
SUNRAY-01, A Global Pivotal Study in Participants With KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in Those With PD-L1 Expression ≥5 [NCT06119581]	Phase 3	1,016 participants (Anticipated)	Interventional	2024-01-03	Not yet recruiting
Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy [NCT04253964]	Phase 2	80 participants (Anticipated)	Interventional	2020-07-01	Recruiting
A Phase 1b Study of LY2835219 in Combination With Multiple Single Agent Options for Patients With Stage IV NSCLC [NCT02079636]	Phase 1	142 participants (Actual)	Interventional	2014-03-28	Completed
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC [NCT02576574]	Phase 3	1,214 participants (Actual)	Interventional	2015-10-29	Active, not recruiting
Intrathecal Pemetrexed for Recurrent Leptomeningeal Metastasis From Non-small Cell Lung Cancer: A Prospective Pilot Clinical Trial [NCT03101579]	Phase 1	13 participants (Actual)	Interventional	2017-03-01	Completed
A Randomized, Double-blind, Phase III Trial to Compare the Efficacy and Safety of AK104 Combined With Chemotherapy to Tislelizumab Combined With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer (NSCLC) [NCT05990127]	Phase 3	642 participants (Anticipated)	Interventional	2023-11-14	Not yet recruiting
A Pilot Window of Opportunity Study Evaluating Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy Followed by Evaluation of Durvalumab (MEDI4736) in Combination With Platinum Doublet Chemotherapy and Abequolixron (RGX-104) in Non-smal [NCT05911308]	Phase 1	24 participants (Anticipated)	Interventional	2023-11-30	Not yet recruiting
Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases [NCT05012254]	Phase 2	71 participants (Anticipated)	Interventional	2021-11-18	Recruiting
A Phase II Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC [NCT04736823]	Phase 2	296 participants (Anticipated)	Interventional	2021-02-01	Recruiting
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations [NCT04512430]	Phase 2	26 participants (Anticipated)	Interventional	2020-12-02	Recruiting
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer [NCT04364048]	Phase 2	10 participants (Actual)	Interventional	2020-06-18	Active, not recruiting
[NCT01454934]	Phase 3	540 participants (Actual)	Interventional	2011-12-09	Completed
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung Cancer [NCT01126736]	Phase 1/Phase 2	98 participants (Actual)	Interventional	2010-06-10	Completed
Phase II Trial Of Pemetrexed Disodium And Gemcitabine In Advanced Urothelial Cancer [NCT00053209]	Phase 2	46 participants (Actual)	Interventional	2004-08-10	Completed
Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for EGFR Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection: A Multicenter, Randomized Controlled, Open-label [NCT04762459]	Phase 3	606 participants (Anticipated)	Interventional	2021-08-01	Enrolling by invitation
Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer [NCT02031601]	Phase 4	250 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Phase I/II Trial of Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM) [NCT00604461]	Phase 1/Phase 2	13 participants (Actual)	Interventional	2007-10-31	Terminated(stopped due to Slow Accrual)
A Phase 1, Pharmacologic and Pharmacodynamic Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors [NCT01447225]	Phase 1	43 participants (Actual)	Interventional	2011-10-31	Completed
Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Systemic Chemotherapy Versus Systemic Chemotherapy Alone as 1st-line Treatment of Malignant Peritoneal Mesothelioma [NCT03875144]	Phase 2	66 participants (Anticipated)	Interventional	2020-08-14	Recruiting
Serial [18F]Fluorothymidine (FLT)PET/CT as a Biomarker of Therapeutic Response in Pemetrexed Therapy for Non-Small Cell Lung Cancer [NCT02274038]		3 participants (Actual)	Interventional	2015-03-31	Terminated(stopped due to Poor Accrual)
A Phase 3，Randomized，Open，Parallel Controlled, Multi-center Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab as a First-line Treatment on Patient With Advanced N [NCT05346952]	Phase 3	390 participants (Anticipated)	Interventional	2022-01-25	Recruiting
A Phase 2 Study to Evaluate LY2603618 in Combination With Pemetrexed in Patients With Advanced or Metastatic Non-small Cell Lung Cancer [NCT00988858]	Phase 2	55 participants (Actual)	Interventional	2009-11-30	Completed
A Randomized, Open-Label, Phase 2 Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Subjects With Recurrent/Stage IV Non-Squamous, Non-Small Cell Lung Cancer Who Have Not Progressed After Four Cycles of a Platinum-Based First Line Chemotherapy [NCT01471197]	Phase 2	9 participants (Actual)	Interventional	2012-07-31	Terminated(stopped due to Administrative reasons)
A Randomized Phase 2, Double-blind, Placebo-controlled, Multi-center Study Comparing Pemetrexed in Combination With TH-302 vs. Pemetrexed in Combination With Placebo as Second-line Chemotherapy for Advanced Non-Squamous, Non-Small Cell Lung Cancer [NCT02093962]	Phase 2	265 participants (Actual)	Interventional	2014-06-30	Terminated(stopped due to At the interim analysis, the futility boundary was not met and the study was stopped due to insufficient efficacy.)
An Open-label, Multi-center, Clinical Study to Evaluate Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer [NCT05841472]	Phase 2	60 participants (Anticipated)	Interventional	2023-08-23	Recruiting
A Phase III, Randomised, Controlled, Multi-center, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination With Chemotherapy Versus Standard of Care Chemotherapy Alone for the Treatment of Patients With Epidermal Growth Factor Receptor Mut [NCT04351555]	Phase 3	328 participants (Anticipated)	Interventional	2020-12-16	Recruiting
A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer [NCT04061590]	Phase 2	0 participants (Actual)	Interventional	2020-05-29	Withdrawn(stopped due to Low Accrual)
Phase I/II Trial of Abraxane® (ABI-007) and Alimta® (Pemetrexed) in Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer (NSCLC) and Breast Cancer [NCT00470548]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2007-04-30	Terminated(stopped due to Practice patterns with pemetrexed have evolved.)
Open-Label, Randomized Trial of Nivolumab (BMS-936558) Plus Pemetrexed/Platinum or Nivolumab Plus Ipilimumab (BMS-734016) vs Pemetrexed Plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects With Epidermal Growth Factor Recepto [NCT02864251]	Phase 3	367 participants (Actual)	Interventional	2017-03-17	Completed
A Phase I Study of MK-3475 Alone in Subjects With Advanced Solid Tumors and in Combination With Platinum-Doublet Chemotherapy or Immunotherapy in Subjects With Advanced Non-Small Cell Lung Cancer/Extensive-Disease Small Cell Lung Cancer. [NCT01840579]	Phase 1	57 participants (Actual)	Interventional	2013-04-26	Completed
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma [NCT00700336]	Phase 1/Phase 2	69 participants (Actual)	Interventional	2008-05-31	Completed
Clinical, Radiographic, and Histologic Outcome of Sodium Hypoclorite as an Antibacterial Agent Prior to Calcium Hydroxide and Mineral Trioxide Aggregate Pulpotomies in Primary Teeth [NCT04270318]		64 participants (Actual)	Interventional	2012-09-30	Completed
A Randomized Phase II Study of Itraconazole and Pemetrexed in Patients With Previously Treated Non-Squamous Non-Small Cell Lung Cancer [NCT00769600]	Phase 2	23 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Low accrual.)
A Randomized Phase II Trial of Cytotoxic Chemotherapy With or Without Epigenetic Priming in Patients With Advanced Non-Small Cell Lung Cancer [NCT01935947]	Phase 2	17 participants (Actual)	Interventional	2013-05-31	Terminated
Randomized, Double-blind, Placebo-controlled, Multi-center Study of Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients of NSCLC With Brain Metastases of Driven Gene-negative and Not Received Systemic Chemotherapy [NCT04768075]	Phase 3	200 participants (Anticipated)	Interventional	2021-03-05	Not yet recruiting
TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV [NCT01674738]	Phase 2	0 participants (Actual)	Interventional		Withdrawn(stopped due to Decision of the Sponsor, as the funding of the study was no longer guaranteed.)
Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma [NCT05765084]	Phase 1/Phase 2	15 participants (Anticipated)	Interventional	2023-02-24	Recruiting
A Phase II Trial of Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type Non-Small-Cell Lung Cancer [NCT01042288]	Phase 2	70 participants (Actual)	Interventional	2010-06-30	Completed
Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study [NCT03086538]	Phase 2	29 participants (Actual)	Interventional	2017-05-30	Completed
A Prospective Study to Evaluate the Safety of Concurrent Durvalumab (MEDI4736) With Chemoradiation Therapy（CRT）Followed by Durvalumab for Chinese Unresectable Stage III Non Small Cell Lung Cancer（NSCLC） [NCT04982549]	Phase 2	35 participants (Anticipated)	Interventional	2021-01-21	Recruiting
Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive Non-small Cell Lung Cancer Patients With Asymptomatic Brain Metastases [NCT04967417]	Phase 2	50 participants (Anticipated)	Interventional	2021-10-31	Not yet recruiting
A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma [NCT01675765]	Phase 1	60 participants (Actual)	Interventional	2014-09-03	Completed
A Phase 3, Randomized Double-blind, Placebo-controlled, Multicenter Study of SHR-1701 in Combination With Bevacizumab and Chemotherapy in Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer With EGFR Mutation After Failure of TKIs [NCT05132413]	Phase 3	561 participants (Anticipated)	Interventional	2021-12-30	Not yet recruiting
Phase I Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas [NCT02838745]	Phase 1	7 participants (Actual)	Interventional	2016-09-30	Terminated(stopped due to Change in research plan.)
A Platform Study of RAS(ON) Inhibitor Combinations in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC) [NCT06162221]	Phase 1/Phase 2	352 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination With Carboplatin Plus Pemetrexed Versus Platinum Plus Pemetrexed or Nivolumab Plus Ipilimumab in Participants With Unresectable Pleural Mesothelioma (e [NCT06097728]	Phase 3	600 participants (Anticipated)	Interventional	2023-11-09	Recruiting
An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) [NCT05112965]	Phase 3	100 participants (Anticipated)	Interventional	2021-12-01	Recruiting
A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) [NCT03971474]	Phase 2	166 participants (Actual)	Interventional	2019-05-28	Active, not recruiting
An Open-Label, Multicenter, First-in-Human, Phase 1 Dose-Escalation and Multicohort Expansion Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas [NCT03715933]	Phase 1	240 participants (Anticipated)	Interventional	2018-10-10	Recruiting
Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial [NCT03137771]	Phase 2	218 participants (Actual)	Interventional	2017-04-07	Active, not recruiting
Single Cell Analysis of CXCL13+PD1+ CD8 T Cell in Association With Resistance to Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC [NCT05894889]	Phase 2	70 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
"Neoadjuvant Tislelizumab and Platinum-Based Doublet Chemotherapy in Stage II-IIIB EGFR-Mutated Lung Adenocarcinoma With PD-L1 Positive Expression -- A Phase II Study (DuoVitality)" [NCT05527808]		28 participants (Anticipated)	Interventional	2022-08-01	Recruiting
LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Pl [NCT01907100]	Phase 2/Phase 3	545 participants (Actual)	Interventional	2013-09-19	Terminated
Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated FGF Pathway Signaling [NCT01868022]	Phase 1	65 participants (Actual)	Interventional	2013-10-09	Completed
Phase 2 Trial of Neoadjuvant Nivolumab + Platinum-based Chemotherapy + Certolizumab in Patients With Resectable Stages II-III Lung Cancers [NCT04991025]	Phase 2	60 participants (Anticipated)	Interventional	2022-10-19	Recruiting
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer [NCT02662634]	Phase 2	0 participants (Actual)	Interventional	2016-03-31	Withdrawn
Phase II Trial of Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN) [NCT01443078]	Phase 2	42 participants (Actual)	Interventional	2011-10-31	Completed
Phase II Randomized Trial of Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer [NCT00703976]	Phase 2	80 participants (Actual)	Interventional	2008-10-31	Completed
An Open-Label, Phase 1/2 Study of ORIC-114 as a Single Agent or in Combination With Chemotherapy, in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration [NCT05315700]	Phase 1/Phase 2	280 participants (Anticipated)	Interventional	2022-03-10	Recruiting
Neoadjuvant Soft Tissue Ablation Utilizing Aliya™ Pulsed Electric Fields With Systemic Therapy in Early-Stage Resectable Non-Small Cell Lung Cancer (NSCLC) [NCT05583188]	Phase 4	15 participants (Anticipated)	Interventional	2023-02-01	Recruiting
A Single Arm, Open Label, Exploratory Study of Pemetrexed and TAS-102 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy [NCT04683965]	Phase 2	27 participants (Anticipated)	Interventional	2021-01-01	Active, not recruiting
Alternating Treatment Plans for Participants With Advanced Thoracic/Head & Neck Cancers (ATATcH) [NCT05358548]	Phase 2	150 participants (Anticipated)	Interventional	2022-04-28	Recruiting
The Phase Three Trials of Pemetrexed/Cisplatin Intercalating Gefitinib vs Pemetrexed/Cisplatin Treating EGFR Wild NSCLC(Non Squamous Cell Carcinoma) [NCT03374280]	Phase 2	178 participants (Anticipated)	Interventional	2016-12-01	Recruiting
A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. [NCT03381066]	Phase 3	225 participants (Anticipated)	Interventional	2018-04-10	Recruiting
Phase Ib Study to Evaluate the Efficacy, Safety and Tolerability of IBI188 Combination Therapy in Subjects With Advanced Malignancies [NCT04861948]	Phase 1	9 participants (Actual)	Interventional	2021-05-25	Terminated(stopped due to No signs of efficacy in solid tumors)
MEK114375: A Rollover Study to Provide Continued Treatment With GSK1120212 to Subjects With Solid Tumors or Leukemia [NCT01376310]	Phase 2	159 participants (Actual)	Interventional	2010-11-02	Terminated(stopped due to Company Decision)
Emulation of a Comparative Effectiveness Study of Pembrolizumab and Chemotherapy vs. Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer [NCT05908799]		1,854 participants (Actual)	Observational	2023-06-05	Completed
A Phase 3, Randomized, Open-label, Multicenter Study to Assess the Efficacy and Safety of HS-10241 Combined With Almonertinib Versus Pemetrexed Combined With Platinum in Metastatic or Locally Advanced NSCLC With MET Amplification After Failure of the Prio [NCT06110663]	Phase 3	314 participants (Anticipated)	Interventional	2023-12-30	Not yet recruiting
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Chemotherapy in the Treatment of EGFR WT and ALK WT Recurrent and Metastatic Non-small Cell Lung Cancer [NCT05020457]	Phase 2	60 participants (Anticipated)	Interventional	2021-12-07	Recruiting
A Randomised Non-comparative Open Label Phase II Trial of Atezolizumab Plus Bevacizumab, With Carboplatin-paclitaxel or Pemetrexed, in EGFR-mutant Non-small Cell Lung Carcinoma With Acquired Resistance [NCT04245085]	Phase 2	95 participants (Actual)	Interventional	2020-09-29	Active, not recruiting
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer [NCT04697628]	Phase 3	556 participants (Anticipated)	Interventional	2021-02-22	Recruiting
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer [NCT03774732]	Phase 3	327 participants (Anticipated)	Interventional	2019-03-21	Recruiting
Phase 2 Study of Platinum-Based Chemotherapy in Combination With Durvalumab (MEDI 4736) for NSCLC in Patients With a Poor Performance Status and the Elderly [NCT04262869]	Phase 2	0 participants (Actual)	Interventional	2020-03-27	Withdrawn(stopped due to Due to accrual issues)
Phase II Multicenter Trial of Neoadjuvant Cisplatin and Nab-paclitaxel for (N2) Defined Stage IIIA Non-Small Cell Lung Cancer (NSCLC) [NCT02276560]	Phase 2	1 participants (Actual)	Interventional	2015-01-31	Terminated(stopped due to This study was terminated due to lack of funding.)
A Phase 2 Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy for Patients With Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) [NCT05386888]	Phase 2	65 participants (Actual)	Interventional	2022-09-09	Active, not recruiting
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of Cemiplimab (Anti-PD-1) and Other Agents in Japanese Patients With Advanced Malignancies [NCT03233139]	Phase 1	145 participants (Anticipated)	Interventional	2017-06-21	Recruiting
A Phase II, Single-Arm, Prospective Study of Neoadjuvant Icotinib With Chemotherapy for the Treatment of Patients With Epidermal Growth Factor Receptor Mutation Positive, Resectable for Stage II to IIIB(N2) Non-small Cell Lung Cancer [NCT05104788]	Phase 2	27 participants (Anticipated)	Interventional	2021-10-25	Recruiting
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study [NCT04339218]	Phase 3	214 participants (Anticipated)	Interventional	2020-08-28	Recruiting
Phase II Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma [NCT03809637]	Phase 2	37 participants (Actual)	Interventional	2017-01-10	Active, not recruiting
A Phase 2, Multicenter, Randomized Study to Evaluate the Safety and Efficacy of Viagenpumatucel-L (HS-110) in Combination With Low Dose (Metronomic) Cyclophosphamide Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Adenocarcinoma After Failu [NCT02117024]	Phase 2	66 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Sponsor Decision; strategic - based on changing treatment landscape)
An Open Label, Multicenter, Phase Ib/II Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors [NCT05794477]	Phase 1/Phase 2	132 participants (Anticipated)	Interventional	2023-04-28	Recruiting
A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Double [NCT01828112]	Phase 3	231 participants (Actual)	Interventional	2013-06-28	Completed
Predictive Biomarker for the Efficacy and Safety of the Combination of Chemotherapy and Tislelizumab in Non Small Cell Lung Cancer：a Multicentre Prospective Clinical Trial [NCT05244837]	Phase 2	100 participants (Anticipated)	Interventional	2020-12-22	Recruiting
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma [NCT02357147]	Phase 2	124 participants (Actual)	Interventional	2015-11-03	Terminated(stopped due to Due to business reasons)
A Phase II Study of Lenvatinib (E7080/MK-7902) in Combination With Carboplatin Pemetrexed and Pembrolizumab (MK-3475) for Patients With Pretreated Advanced Non-squamous Non-small Cell Lung Cancer Harboring EGFR Mutations [NCT05258279]	Phase 2	30 participants (Anticipated)	Interventional	2022-07-01	Active, not recruiting
A Open-label, Single Center, Phase II Study of Surufatinib Combined With Toripalimab and Chemotherapy in Patients With Advanced Non-squamous Non-small-cell Lung Cancer [NCT05003037]	Phase 2	106 participants (Anticipated)	Interventional	2021-12-08	Recruiting
A Randomized Phase II Trial Comparing Cetuximab With Concurrent Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer Refractory to Primary Treatment [NCT00203931]	Phase 2	55 participants (Actual)	Interventional	2005-03-31	Terminated(stopped due to Slow accrual and evidence from other studies showing benefit of early initiation of pemetrexed after first-line therapy)
A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression [NCT03193788]	Phase 3	74 participants (Anticipated)	Interventional	2017-01-31	Recruiting
A Phase II Study of Pemetrexed (Alimta) as Second-Line Therapy for Hormone Refractory Prostate Cancer: Hoosier Oncology Group GU03-67 [NCT00216099]	Phase 2	49 participants (Actual)	Interventional	2005-02-28	Completed
Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer [NCT02974426]	Phase 3	1,094 participants (Anticipated)	Interventional	2016-11-30	Recruiting
FurmOnertinib Mesylate With or Without Chemotherapy +/- bevacizUmab as firSt Line Treatment in Advanced Non-small Cell Lung Cancer Patients With Uncleared Epidermal Growth Factor Receptor (EGFR) Mutation Positive Circulating Tumor Cell DNA [NCT05334277]	Phase 2	280 participants (Anticipated)	Interventional	2022-05-06	Recruiting
TIGER-3: A Phase 3, Open-label, Multicenter, Randomized Study of Oral Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC) After Failure of at Least 1 Previous EGFR-di [NCT02322281]	Phase 3	149 participants (Actual)	Interventional	2015-02-28	Terminated(stopped due to Sponsor discontinued development of CO-1686 for NSCLC)
A Randomized, Open-Label, Multicenter, Phase 3 Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-S [NCT02264990]	Phase 3	595 participants (Actual)	Interventional	2014-09-30	Completed
A Randomized, Open-Label, Phase 3 Study of Cosibelimab (CK-301) in Combination With Platinum+Pemetrexed Chemotherapy in Subjects With First-Line Metastatic Non-squamous Non-Small Cell Lung Cancer [NCT04786964]	Phase 3	25 participants (Actual)	Interventional	2021-12-08	Terminated(stopped due to Regional political conflict)
PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF CRIZOTINIB VERSUS PEMETREXED/CISPLATIN OR PEMETREXED/CARBOPLATIN IN PREVIOUSLY UNTREATED EAST ASIAN PATIENTS WITH NON-SQUAMOUS CARCINOMA OF THE LUNG HARBORING A TRANSLOCATION OR INVERSION [NCT01639001]	Phase 3	207 participants (Actual)	Interventional	2012-09-29	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00063570 (5) [back to overview]	Overall Tumor Response
NCT00063570 (5) [back to overview]	Time to Treatment Failure
NCT00063570 (5) [back to overview]	Time to Progressive Disease
NCT00063570 (5) [back to overview]	Overall Survival
NCT00063570 (5) [back to overview]	Duration of (Confirmed) Complete Response or Partial Response
NCT00087698 (6) [back to overview]	Pathological Complete Response
NCT00087698 (6) [back to overview]	Time to Progressive Disease
NCT00087698 (6) [back to overview]	Overall Tumor Response
NCT00087698 (6) [back to overview]	The 1 and 2 Year Disease-Free Survival Rate (Percentage)
NCT00087698 (6) [back to overview]	Time to Treatment Failure
NCT00087698 (6) [back to overview]	Overall Survival Time
NCT00095199 (8) [back to overview]	Duration of Overall Response (OR)
NCT00095199 (8) [back to overview]	Overall Survival (OS)
NCT00095199 (8) [back to overview]	Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities
NCT00095199 (8) [back to overview]	Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)
NCT00095199 (8) [back to overview]	Progression Free Survival (PFS)
NCT00095199 (8) [back to overview]	Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)
NCT00095199 (8) [back to overview]	Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])
NCT00095199 (8) [back to overview]	Time to Symptomatic Progression
NCT00101283 (3) [back to overview]	Overall Survival
NCT00101283 (3) [back to overview]	Best Overall Response by RECIST Criteria (Version 1.0)
NCT00101283 (3) [back to overview]	Progression-Free Survival
NCT00102804 (7) [back to overview]	Time to Worsening of Symptoms (TWS)
NCT00102804 (7) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00102804 (7) [back to overview]	Maximum Improvement Over Baseline in Individual Symptom Scores and Quality of Life Using the LCSS
NCT00102804 (7) [back to overview]	Time to Objective Progressive Disease (TPD)
NCT00102804 (7) [back to overview]	Progression-Free Survival (PFS) Time
NCT00102804 (7) [back to overview]	Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate)
NCT00102804 (7) [back to overview]	Overall Survival (OS) Time
NCT00106002 (5) [back to overview]	Duration of Tumor Response
NCT00106002 (5) [back to overview]	Overall Survival Time
NCT00106002 (5) [back to overview]	Progression-Free Survival Time
NCT00106002 (5) [back to overview]	Overall Tumor Response
NCT00106002 (5) [back to overview]	Toxicity Profile: Adverse Events (Common Terminology Criteria for Adverse Events, Grade 3 and 4, Present in >5% of Participants)
NCT00106626 (2) [back to overview]	Safety and Tolerability as Measured by the Number of Participants With Disease Progression
NCT00106626 (2) [back to overview]	Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level
NCT00111839 (5) [back to overview]	Number of Participants With Objective Response Assessed by Independent Review Committee
NCT00111839 (5) [back to overview]	Duration of Objective Response Assessed by Independent Review Committee
NCT00111839 (5) [back to overview]	Overall Survival (OS)
NCT00111839 (5) [back to overview]	Change From Baseline to Cycle 2 in Global Quality of Life (QoL), as Assessed Using Lung Cancer Symptom Scale (LCSS)
NCT00111839 (5) [back to overview]	Progression-Free Survival (PFS)
NCT00117962 (4) [back to overview]	Overall Survival
NCT00117962 (4) [back to overview]	Number of Participants With Overall Tumor Response
NCT00117962 (4) [back to overview]	Failure-free Survival
NCT00117962 (4) [back to overview]	18 Month Survival
NCT00149214 (5) [back to overview]	Number of Patients With Histologically Negative Axillary Lymph Node Status at Surgery
NCT00149214 (5) [back to overview]	Disease-free Survival
NCT00149214 (5) [back to overview]	Number of Participants With a Pathological Complete Response
NCT00149214 (5) [back to overview]	Number of Participants With a Clinical Tumor Response After the Second Sequence of Chemotherapy
NCT00149214 (5) [back to overview]	Number of Participants With a Clinical Tumor Response After the First Sequence of Chemotherapy
NCT00190671 (8) [back to overview]	Pharmacokinetics - Maximum Observed Drug Concentration (Cmax)
NCT00190671 (8) [back to overview]	Pharmacokinetics - Half-Life (t½)
NCT00190671 (8) [back to overview]	Pharmacokinetics - Clearance (CL)
NCT00190671 (8) [back to overview]	Pharmacokinetics - Area Under the Curve (AUC)
NCT00190671 (8) [back to overview]	Time to Progressive Disease
NCT00190671 (8) [back to overview]	Best Tumor Response
NCT00190671 (8) [back to overview]	Pharmacokinetics - Volume of Distribution
NCT00190671 (8) [back to overview]	Progression Free Survival
NCT00190983 (4) [back to overview]	Tumor Response
NCT00190983 (4) [back to overview]	Progression-Free Survival
NCT00190983 (4) [back to overview]	Overall Survival
NCT00190983 (4) [back to overview]	Duration of Response
NCT00191191 (5) [back to overview]	Duration of Response
NCT00191191 (5) [back to overview]	Best Overall Response
NCT00191191 (5) [back to overview]	Change From Baseline to 3 Months in Quality of Life Questionnaire for Cancer Patients Treated With Anticancer Drugs (QOL-ACD)
NCT00191191 (5) [back to overview]	Change From Baseline to 3 Months in Functional Assessment of Cancer Therapy for Lung Cancer (FACT-L) Lung Cancer Subscale (LCS)
NCT00191191 (5) [back to overview]	Progression-Free Survival (PFS)
NCT00191308 (4) [back to overview]	Overall Survival (OS)
NCT00191308 (4) [back to overview]	Disease Free Survival (DFS)
NCT00191308 (4) [back to overview]	Duration of Response
NCT00191308 (4) [back to overview]	Percentage of Participants With Objective Tumor Response (Response Rate)
NCT00191984 (5) [back to overview]	Overall Survival
NCT00191984 (5) [back to overview]	Best Overall Tumor Response
NCT00191984 (5) [back to overview]	Time to Treatment Failure
NCT00191984 (5) [back to overview]	Progression-Free Survival (PFS)
NCT00191984 (5) [back to overview]	Duration of Response
NCT00193414 (3) [back to overview]	Progression-free Survival (PFS)
NCT00193414 (3) [back to overview]	Overall Survival (OS)
NCT00193414 (3) [back to overview]	Overall Response Rate
NCT00198133 (3) [back to overview]	Duration of Remission
NCT00198133 (3) [back to overview]	Grade 3/4 Treatment Related Adverse Events
NCT00198133 (3) [back to overview]	Objective Response Rate (Complete and Partial Response)
NCT00203931 (5) [back to overview]	Progression-free Survival Based on Serum Biomarker Status
NCT00203931 (5) [back to overview]	Progression-free Survival Based on Rash Development
NCT00203931 (5) [back to overview]	Progression-free Survival
NCT00203931 (5) [back to overview]	Overall Survival
NCT00203931 (5) [back to overview]	Objective Response Rate
NCT00216099 (8) [back to overview]	Overall Survival
NCT00216099 (8) [back to overview]	Rate of Clinical Benefit
NCT00216099 (8) [back to overview]	Time to Progression
NCT00216099 (8) [back to overview]	Safety and Tolerability
NCT00216099 (8) [back to overview]	Time to Prostate-Specific Antigen (PSA)/Serological Progression
NCT00216099 (8) [back to overview]	Best Overall PSA Response
NCT00216099 (8) [back to overview]	OBJECTIVE Overall Response Rate
NCT00216099 (8) [back to overview]	RFC1 G80A Genotype
NCT00216203 (4) [back to overview]	Toxicity and Safety Profile
NCT00216203 (4) [back to overview]	Median Survival Time
NCT00216203 (4) [back to overview]	Time To Progression (TTP)
NCT00216203 (4) [back to overview]	Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cetuximab
NCT00222729 (4) [back to overview]	Disease Control Rate (DCR)
NCT00222729 (4) [back to overview]	Time-to-progression (TTP)
NCT00222729 (4) [back to overview]	Objective Response Rate (ORR)
NCT00222729 (4) [back to overview]	Overall Survival (OS)
NCT00226577 (5) [back to overview]	Toxicity
NCT00226577 (5) [back to overview]	Survival - Overall
NCT00226577 (5) [back to overview]	Disease Response - Radiographic
NCT00226577 (5) [back to overview]	Disease Response - Pathologic
NCT00226577 (5) [back to overview]	Survival - Disease Free
NCT00227019 (3) [back to overview]	Incidence of Central Nervous System (CNS) Hemorrhagic Events
NCT00227019 (3) [back to overview]	Overall Survival (OS)
NCT00227019 (3) [back to overview]	Progression-free Survival (PFS)
NCT00227539 (3) [back to overview]	Safety of Neoadjuvant Chemotherapy
NCT00227539 (3) [back to overview]	Positron Emission Tomography as a Predictor of Response Measured by the Decrease in Standard Uptake Variable (SUV) After 1 Course of Therapy
NCT00227539 (3) [back to overview]	Efficacy of Neoadjuvant Chemotherapy as Measured by Radiologic Response Rate
NCT00234052 (7) [back to overview]	Overall Survival Rate at 6, 12, 18, and 24 Months
NCT00234052 (7) [back to overview]	Overall Survival Rate
NCT00234052 (7) [back to overview]	Overall Response Rate
NCT00234052 (7) [back to overview]	Duration of Response
NCT00234052 (7) [back to overview]	Median Progression Free Survival
NCT00234052 (7) [back to overview]	Toxicity of Carboplatin, Pemetrexed and Bevacizumab Combination Treatment
NCT00234052 (7) [back to overview]	Progression Free Survival at 6, 12, 18, 24 Months
NCT00248495 (4) [back to overview]	Percent Change in SUV Level Between Pre and Post Chemotherapy
NCT00248495 (4) [back to overview]	Pathologically Complete Response
NCT00248495 (4) [back to overview]	Overall Survival
NCT00248495 (4) [back to overview]	Disease Free Survival
NCT00259285 (2) [back to overview]	Treatment Response
NCT00259285 (2) [back to overview]	Pathologic Remissions After Surgery
NCT00265785 (4) [back to overview]	Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
NCT00265785 (4) [back to overview]	Response (Confirmed and Unconfirmed, Complete and Partial)
NCT00265785 (4) [back to overview]	Progression-free Survival
NCT00265785 (4) [back to overview]	Overall Survival
NCT00268437 (2) [back to overview]	Pathologic Complete Response Rate
NCT00268437 (2) [back to overview]	Overall Survival
NCT00269152 (5) [back to overview]	The Feasibility of Post-Surgery Chemotherapy
NCT00269152 (5) [back to overview]	Overall Survival at 6 Years
NCT00269152 (5) [back to overview]	Grade III/IV Adverse Events
NCT00269152 (5) [back to overview]	Overall Survival at 3 Years
NCT00269152 (5) [back to overview]	3 Year Disease-Free Survival: Probability of Disease-Free Survival at 3 Years
NCT00280748 (4) [back to overview]	Neurological Function by Radiation Oncology Group (RTOG) Neurological Function Classification
NCT00280748 (4) [back to overview]	Neurological Function by Mini Mental State Examination
NCT00280748 (4) [back to overview]	Estimate the Overall Survival of Patients Treated With This Regimen.
NCT00280748 (4) [back to overview]	Number of Subjects Experiencing Adverse Events
NCT00293579 (4) [back to overview]	Overall Response Rate
NCT00293579 (4) [back to overview]	Impact of Pemetrexed Chemotherapy on Quality of Life
NCT00293579 (4) [back to overview]	Toxicities of Pemetrexed,in Poor Risk Cases With Poor Performance Status and Advanced, Metastatic, or Recurrent Head and Neck Cancer
NCT00293579 (4) [back to overview]	Overall Survival
NCT00295503 (3) [back to overview]	Progression Free Survival Rate at 6 Months
NCT00295503 (3) [back to overview]	Overall Survival
NCT00295503 (3) [back to overview]	Response Rate
NCT00301808 (4) [back to overview]	Safety Outcomes
NCT00301808 (4) [back to overview]	Overall Survival
NCT00301808 (4) [back to overview]	Probability of Overall Survival at One Year
NCT00301808 (4) [back to overview]	Progression-free Survival
NCT00308750 (8) [back to overview]	Duration of CR or PR (Duration of Response)
NCT00308750 (8) [back to overview]	Change From Baseline in Total Functional Assessment of Cancer Therapy -Taxane (FACT-Taxane) Scale
NCT00308750 (8) [back to overview]	Overall Survival (OS)
NCT00308750 (8) [back to overview]	Time to Disease Progression
NCT00308750 (8) [back to overview]	Number of Participants With Adverse Events (AEs) or Deaths
NCT00308750 (8) [back to overview]	Time-to-Treatment Failure (TTF)
NCT00308750 (8) [back to overview]	Change From Baseline in Total Functional Assessment of Cancer Therapy-Lung (FACT-L) Scale
NCT00308750 (8) [back to overview]	Number of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response]
NCT00310050 (3) [back to overview]	Patterns of Response
NCT00310050 (3) [back to overview]	Qualitative Dose-limiting Toxicities of Pemetrexed in Combination With Radiation Therapy
NCT00310050 (3) [back to overview]	Number of Participants That Survived
NCT00316225 (6) [back to overview]	Pemetrexed Population Pharmacokinetics (PK): Clearance
NCT00316225 (6) [back to overview]	Overall Tumor Response
NCT00316225 (6) [back to overview]	Overview of Adverse Events
NCT00316225 (6) [back to overview]	Pemetrexed Population Pharmacokinetics: Volume of Distribution
NCT00316225 (6) [back to overview]	Discontinuations Due to Adverse Events
NCT00316225 (6) [back to overview]	Number of Participants With Common Toxicity Criteria - National Cancer Institute Grade 3 and Grade 4 Toxicities
NCT00320515 (4) [back to overview]	Objective Best Tumor Response
NCT00320515 (4) [back to overview]	Progression Free Survival
NCT00320515 (4) [back to overview]	Overall Survival
NCT00320515 (4) [back to overview]	Duration of Response
NCT00324805 (2) [back to overview]	Disease-free Survival
NCT00324805 (2) [back to overview]	Overall Survival
NCT00325234 (6) [back to overview]	Time To Treatment Failure (TTTF)
NCT00325234 (6) [back to overview]	Time to Response
NCT00325234 (6) [back to overview]	Time to Progressive Disease (PD)
NCT00325234 (6) [back to overview]	Duration of Response (DOR)
NCT00325234 (6) [back to overview]	Tumor Response Rate
NCT00325234 (6) [back to overview]	Number of Participants With Adverse Events (AE)
NCT00330915 (4) [back to overview]	Number of Participants With Complete Tumor Resection
NCT00330915 (4) [back to overview]	Number of Participants Receiving Sphincter Saving Surgery
NCT00330915 (4) [back to overview]	Pathological Complete Response (pCR)
NCT00330915 (4) [back to overview]	Feasibility of Pemetrexed Prior to Surgery
NCT00350792 (5) [back to overview]	Estimated Probability of One Year Progression-free Survival
NCT00350792 (5) [back to overview]	Overall Survival
NCT00350792 (5) [back to overview]	Percentage of Participants With a Complete or Partial Tumor Response (Overall Tumor Response)
NCT00350792 (5) [back to overview]	Time to Treatment Failure
NCT00350792 (5) [back to overview]	Time to Treatment Failure
NCT00351039 (1) [back to overview]	Number of Participants With Grade 3 and Grade 4 Adverse Events
NCT00356525 (2) [back to overview]	Objective Tumor Response
NCT00356525 (2) [back to overview]	Overall Survival
NCT00363415 (5) [back to overview]	Overall Survival
NCT00363415 (5) [back to overview]	Progression Free Survival
NCT00363415 (5) [back to overview]	Change From Baseline to Each Cycle in Functional Assessment of Cancer Therapy - Lung (FACT-L)
NCT00363415 (5) [back to overview]	Number of Participants in Subgroups: LDH<=Upper Limit of Normal and History of Brain Metastases=Yes
NCT00363415 (5) [back to overview]	Overall Survival (Subgroups)
NCT00369629 (1) [back to overview]	Maximum Tolerated Dose as Measured by the Number of Dose Limiting Toxicities Seen in Cohort.
NCT00370292 (3) [back to overview]	Mean Deoxycytidine Kinase (dCK) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3
NCT00370292 (3) [back to overview]	Mean Human Equilibrative Nucleoside Transporter 1 (hENT) Expression Evaluated at Cycle 1, Cycle 2, and Cycle 3
NCT00370292 (3) [back to overview]	Best Objective Tumor Response
NCT00374868 (8) [back to overview]	Duration of Response
NCT00374868 (8) [back to overview]	Duration of Stable Disease
NCT00374868 (8) [back to overview]	Progression-Free Survival
NCT00374868 (8) [back to overview]	Overall Survival
NCT00374868 (8) [back to overview]	Time to Progressive Disease
NCT00374868 (8) [back to overview]	Best Overall Tumor Response
NCT00374868 (8) [back to overview]	Time to Treatment Failure (TTF)
NCT00374868 (8) [back to overview]	Time to Response
NCT00377520 (2) [back to overview]	Tumor Response
NCT00377520 (2) [back to overview]	Number of Participants With Adverse Events by Grade (Measures of Toxicity)
NCT00380718 (7) [back to overview]	Duration of Response
NCT00380718 (7) [back to overview]	Proportion of Participants With a Complete or Partial Response (Objective Response Rate [ORR])
NCT00380718 (7) [back to overview]	Overall Survival
NCT00380718 (7) [back to overview]	Progression-Free Survival (PFS)
NCT00380718 (7) [back to overview]	Proportion of Participants With a Best Overall Response of Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate [DCR])
NCT00380718 (7) [back to overview]	Time to Tumor Progression
NCT00380718 (7) [back to overview]	Time to Treatment Failure
NCT00383266 (6) [back to overview]	Overall Survival Rate
NCT00383266 (6) [back to overview]	Overall Survival Rate
NCT00383266 (6) [back to overview]	Toxicities
NCT00383266 (6) [back to overview]	Overall Survival (OS)
NCT00383266 (6) [back to overview]	Time to Disease Progression
NCT00383266 (6) [back to overview]	Overall Response Rate (ORR)
NCT00383331 (3) [back to overview]	Progression Free Survival
NCT00383331 (3) [back to overview]	Overall Survival
NCT00383331 (3) [back to overview]	Best Overall Tumor Response
NCT00389805 (5) [back to overview]	Number of Patients With Grade ≥ 3 Toxicity (Phase I)
NCT00389805 (5) [back to overview]	Number of Patients With Toxicity by NCI CTC v3.0 (Phase I)
NCT00389805 (5) [back to overview]	Number of Patients Experiencing a Dose-limiting Toxicity (Phase I)
NCT00389805 (5) [back to overview]	Number of Participants Who Experience Adverse Events (Phase I)
NCT00389805 (5) [back to overview]	Maximum Tolerated Dose of Bortezomib in Combination With Pemetrexel (Phase I)
NCT00391274 (5) [back to overview]	Pharmacology Toxicity
NCT00391274 (5) [back to overview]	Overall Survival
NCT00391274 (5) [back to overview]	Progression-Free Survival (PFS)
NCT00391274 (5) [back to overview]	Number of Patients With Disease Progression
NCT00391274 (5) [back to overview]	Overall Tumor Response
NCT00391586 (1) [back to overview]	Toxicity Profile
NCT00394147 (3) [back to overview]	Overall Survival
NCT00394147 (3) [back to overview]	Time to Progression
NCT00394147 (3) [back to overview]	Objective Response Rate
NCT00402051 (5) [back to overview]	Percentage of Participants Surviving Progression-Free at 6 Months (Progression Free Survival [PFS] Rate)
NCT00402051 (5) [back to overview]	Time to Treatment Failure (TTF)
NCT00402051 (5) [back to overview]	Number of Participants With Tumor Response (as Basis for Response Rate)
NCT00402051 (5) [back to overview]	Overall Survival
NCT00402051 (5) [back to overview]	Pharmacology Toxicities
NCT00407550 (4) [back to overview]	Number of Patients With Confirmed Responses
NCT00407550 (4) [back to overview]	Adverse Event
NCT00407550 (4) [back to overview]	Overall Survival
NCT00407550 (4) [back to overview]	Progression-free Survival
NCT00409006 (4) [back to overview]	Percentage of Participants Who Died During the Study
NCT00409006 (4) [back to overview]	Number of Participants With Tumor Response
NCT00409006 (4) [back to overview]	Duration of Response for Responders
NCT00409006 (4) [back to overview]	Progression-Free Survival (PFS)
NCT00410904 (3) [back to overview]	Response Rate (Complete and Partial) 2 Separate Cohorts of Relapsed NSCLC Cohort A: Pts Who Have Received Prior Chemo w/o Ever Having Received Bevacizumab. Cohort B: Pts Who Have Received Prior Bevacizumab.
NCT00410904 (3) [back to overview]	Progression-free Survival
NCT00410904 (3) [back to overview]	Overall Survival
NCT00415168 (7) [back to overview]	Percentage of Participants With Objective Response (Objective Response Rate)
NCT00415168 (7) [back to overview]	Number of Participants With Pharmacology Toxicity - Grade 3 or 4 Non-Laboratory Toxicity Possibly Related to Study Therapy
NCT00415168 (7) [back to overview]	Number of Participants With Pharmacology Toxicity - Grade 3 or 4 Laboratory Toxicity Possibly Related to Study Therapy
NCT00415168 (7) [back to overview]	Number of Participants Who Died During the Study
NCT00415168 (7) [back to overview]	Progression Free Survival (PFS)
NCT00415168 (7) [back to overview]	Overall Survival
NCT00415168 (7) [back to overview]	Duration of Response
NCT00415194 (5) [back to overview]	Time to Treatment Worsening in Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-H&N) Total Score
NCT00415194 (5) [back to overview]	Progression-free Survival (PFS)
NCT00415194 (5) [back to overview]	Percent of Participants With a Tumor Response (Response Rate)
NCT00415194 (5) [back to overview]	Overall Survival (OS)
NCT00415194 (5) [back to overview]	Duration of Response (DoR)
NCT00415636 (4) [back to overview]	Pharmacokinetic (PK) Parameter: Area Under the IC83/LY2603618 Plasma Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞])
NCT00415636 (4) [back to overview]	Pharmacokinetic (PK) Parameter: Maximum Observed Plasma Concentration (Cmax) of IC83/LY2603618
NCT00415636 (4) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00415636 (4) [back to overview]	Percentage of Participants With Best Overall Response
NCT00418886 (10) [back to overview]	Objective Response Rate (ORR)
NCT00418886 (10) [back to overview]	Time to Deterioration of Disease-related Symptoms (TDS) by Lung Cancer Symptom Scale (LCSS) Total Score
NCT00418886 (10) [back to overview]	Time to Deterioration of Disease-related Symptoms (TDS) by Average Symptom Burden Index (ASBI) Score
NCT00418886 (10) [back to overview]	Progression-Free Survival (PFS) in the Overall Population
NCT00418886 (10) [back to overview]	Overall Survival (OS)
NCT00418886 (10) [back to overview]	Progression-Free Survival (PFS) in the Female Population
NCT00418886 (10) [back to overview]	Longitudinal Analysis of Average Symptom Burden Index (ASBI) Score
NCT00418886 (10) [back to overview]	Duration of Response (DoR)
NCT00418886 (10) [back to overview]	Disease Control Rate (DCR)
NCT00418886 (10) [back to overview]	Longitudinal Analysis of Lung Cancer Symptom Scale (LCSS) Total Score
NCT00438204 (5) [back to overview]	Time to Treatment Failure
NCT00438204 (5) [back to overview]	Overall Survival
NCT00438204 (5) [back to overview]	Progression-free Survival (PFS)
NCT00438204 (5) [back to overview]	Number of Participants With Grade 3 or Grade 4 Toxicity
NCT00438204 (5) [back to overview]	Number of Participants With Response
NCT00447057 (7) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00447057 (7) [back to overview]	Time to Treatment Failure (TTTF)
NCT00447057 (7) [back to overview]	Percentage of Participants With Best Response of Complete Response (CR) or Partial Response (PR) (Response Rate)
NCT00447057 (7) [back to overview]	Percentage of Participants With Best Response of Stable Disease (SD), Partial Response (PR) or Complete Response (CR) (Disease Control Rate)
NCT00447057 (7) [back to overview]	Progression Free Survival (PFS)
NCT00447057 (7) [back to overview]	Overall Survival (OS)
NCT00447057 (7) [back to overview]	Percentage of Participants Surviving at 1 Year
NCT00454194 (6) [back to overview]	Time to Treatment Failure
NCT00454194 (6) [back to overview]	Confirmed Response Rate (Complete Response and Partial Response) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00454194 (6) [back to overview]	Progression-free Survival
NCT00454194 (6) [back to overview]	Overall Survival
NCT00454194 (6) [back to overview]	Number of Participants With at Least One Grade 3 or Above Adverse Events Assessed by NCI CTCAE v4.0
NCT00454194 (6) [back to overview]	Duration of Response
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Gemcitabine
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Paclitaxel
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Pemetrexed
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Axitinib (AG-013736)
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Capecitabine
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Cisplatin
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Docetaxel
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Carboplatin
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Cisplatin
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Gemcitabine
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Gemcitabine
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Paclitaxel
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Pemetrexed
NCT00454649 (34) [back to overview]	Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy
NCT00454649 (34) [back to overview]	Percentage of Participants With Objective Response
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Carboplatin
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Docetaxel
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Cisplatin
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Carboplatin
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Pemetrexed
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Paclitaxel
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Docetaxel
NCT00454649 (34) [back to overview]	Apparent Oral Clearance (CL/F) for Axitinib (AG-013736)
NCT00454649 (34) [back to overview]	Apparent Oral Clearance (CL/F) for Capecitabine
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Carboplatin
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Docetaxel
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Gemcitabine
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Paclitaxel
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Pemetrexed
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Axitinib (AG-013736)
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Capecitabine
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Time 8 Hours [AUC (0-8)] for Cisplatin
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Capecitabine
NCT00456261 (3) [back to overview]	Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death
NCT00456261 (3) [back to overview]	Time to Progression (TTP), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease
NCT00456261 (3) [back to overview]	Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment
NCT00461786 (5) [back to overview]	Duration of Response
NCT00461786 (5) [back to overview]	Tumor Response
NCT00461786 (5) [back to overview]	Number of Participants With Adverse Events by Grade
NCT00461786 (5) [back to overview]	Progression-Free Survival
NCT00461786 (5) [back to overview]	Overall Survival
NCT00470548 (7) [back to overview]	Duration of Overall Survival
NCT00470548 (7) [back to overview]	Number of Participants With Complete Response
NCT00470548 (7) [back to overview]	Number of Participants With Disease Control
NCT00470548 (7) [back to overview]	Number of Participants With Dose Limiting Toxicities
NCT00470548 (7) [back to overview]	Number of Participants With Stable Disease
NCT00470548 (7) [back to overview]	Number of Patients With Toxicities
NCT00470548 (7) [back to overview]	Number of Participants With Partial Response
NCT00482014 (9) [back to overview]	Phase 1 - Percentage of Participants With Complete Response or Partial Response (Response Rate)
NCT00482014 (9) [back to overview]	Phase 1 - Pharmacology Toxicity: Number of Participants With Dose Limiting Toxicities (DLTs)
NCT00482014 (9) [back to overview]	Phase 1 - Maximum Tolerated Dose (MTD) of Cisplatin
NCT00482014 (9) [back to overview]	Phase 2 - Median Survival
NCT00482014 (9) [back to overview]	Phase 2 - Survival Probability at 2 Years
NCT00482014 (9) [back to overview]	Phase 2 - Percentage of Participants With Complete Response or Partial Response (Response Rate)
NCT00482014 (9) [back to overview]	Phase 2 - Pharmacology Toxicity: Number of Participants With Adverse Events
NCT00482014 (9) [back to overview]	Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin
NCT00482014 (9) [back to overview]	Phase 2 - Time to Progression
NCT00487669 (3) [back to overview]	To Evaluate the Overall Response Rate (Complete Plus Partial Responses by RECIST Criteria) to the Combination of Paclitaxel Poliglumex and Pemetrexed as Therapy in Patients With Advanced NSCLC.
NCT00487669 (3) [back to overview]	Time to Progression
NCT00487669 (3) [back to overview]	Overall Survival
NCT00489359 (12) [back to overview]	Phase 1 - Number of Participants With Adverse Events (Toxicity)
NCT00489359 (12) [back to overview]	Phase 1 - Number of Participants With Tumor Response
NCT00489359 (12) [back to overview]	Phase 2 - Number of Participants With Adverse Events (Toxicity)
NCT00489359 (12) [back to overview]	Phase 2 - Percentage of Participants With Overall Tumor Response (Response Rate)
NCT00489359 (12) [back to overview]	Phase 2 - Progression-Free Survival
NCT00489359 (12) [back to overview]	Phase 2 - Time to Disease Progression
NCT00489359 (12) [back to overview]	Phase 2 - Time to Response (TTR)
NCT00489359 (12) [back to overview]	Phase 1 - Number of Dose-Limiting Toxicities (DLTs)
NCT00489359 (12) [back to overview]	Phase 1 - Recommended Area Under the Curve (AUC) Dose of Carboplatin for Phase 2
NCT00489359 (12) [back to overview]	Phase 1 - Recommended Dose of Pemetrexed for Phase 2
NCT00489359 (12) [back to overview]	Phase 2 - Time to Treatment Failure
NCT00489359 (12) [back to overview]	Phase 2 - Duration of Response (DOR)
NCT00491075 (1) [back to overview]	Overall Response
NCT00494026 (1) [back to overview]	Pharmacology Toxicity
NCT00497770 (11) [back to overview]	Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Drive or Use Public Transportation
NCT00497770 (11) [back to overview]	Percentage of Participants With a Best Overall Disease Control Response (Disease Control Rate)
NCT00497770 (11) [back to overview]	Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Prepare and Take Medications
NCT00497770 (11) [back to overview]	Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Handle Personal Finances
NCT00497770 (11) [back to overview]	Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Operate the Telephone
NCT00497770 (11) [back to overview]	Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to do the Act of Shopping
NCT00497770 (11) [back to overview]	Progression Free Survival
NCT00497770 (11) [back to overview]	Overall Survival
NCT00497770 (11) [back to overview]	Functional Status Based on Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Plan and Prepare Meals
NCT00497770 (11) [back to overview]	Functional Status Based on the Older Americans Resources and Services Instrumental Activities of Daily Living Scale(OARS-IADL), Ability to Perform Housework Activities
NCT00497770 (11) [back to overview]	Symptom Score Associated With Treatment as Measured by the M.D. Anderson Symptom Inventory - LC(MDASI-LC)
NCT00503997 (1) [back to overview]	Patient Response to Treatment Measured by RECIST Criteria
NCT00508144 (1) [back to overview]	Objective Response Rate (OR) Where OR=CR+PR: Number of Participants With Responses of Complete Response (CR) and Partial Response (PR)
NCT00509366 (3) [back to overview]	1-year Progression Free Survival Rate in Chemo-naive Select Stage IIIB or Stage IV NSCLC Patients
NCT00509366 (3) [back to overview]	Mean Change From Baseline to Follow-up Cycle in Quality of Life - Functional Assessment of Cancer Therapy-Lung (FACT-L)
NCT00509366 (3) [back to overview]	Median Time to Progressive Disease
NCT00517595 (6) [back to overview]	Overall Survival (OS)
NCT00517595 (6) [back to overview]	Progression Free Survival (PFS) by Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status
NCT00517595 (6) [back to overview]	Progression Free Survival (PFS)
NCT00517595 (6) [back to overview]	Time to Progression (TTP)
NCT00517595 (6) [back to overview]	Overall Response
NCT00517595 (6) [back to overview]	Overall Survival (OS) by Baseline Eastern Cooperative Oncology Group (ECOG) Performance Status
NCT00520676 (8) [back to overview]	Progression-free Survival (PFS)
NCT00520676 (8) [back to overview]	Survival Without Clinically Important Grade 3 or 4 Toxicity
NCT00520676 (8) [back to overview]	Survival Without Grade 3 or 4 Toxicity
NCT00520676 (8) [back to overview]	Survival Without Grade 4 Toxicity
NCT00520676 (8) [back to overview]	Overall Survival (OS)
NCT00520676 (8) [back to overview]	Percentage of Participants With Tumor Response (Response Rate)
NCT00520676 (8) [back to overview]	Duration of Response
NCT00520676 (8) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00520845 (3) [back to overview]	Time to Progression
NCT00520845 (3) [back to overview]	Overall Response Rate
NCT00520845 (3) [back to overview]	Median Survival
NCT00520936 (2) [back to overview]	Number of Patients With Adverse Events, Discontinuations, or Deaths Possibly Due to Study Drug
NCT00520936 (2) [back to overview]	Percentage of Participants With Overall Tumor Response (Response Rate)
NCT00523419 (5) [back to overview]	Duration of Response
NCT00523419 (5) [back to overview]	Progression-Free Survival (PFS)
NCT00523419 (5) [back to overview]	Overall Survival (OS) Time
NCT00523419 (5) [back to overview]	Number of Participants With Adverse Events (Pharmacology Toxicity)
NCT00523419 (5) [back to overview]	Percentage of Participants With Tumor Response
NCT00529100 (9) [back to overview]	Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year
NCT00529100 (9) [back to overview]	Phase 2: Time to Progressive Disease (PD)
NCT00529100 (9) [back to overview]	Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy
NCT00529100 (9) [back to overview]	Phase 1: Number of Participants With Adverse Events (AE; Toxicity)
NCT00529100 (9) [back to overview]	Phase 2: Site of Progressive Disease (PD)
NCT00529100 (9) [back to overview]	Phase 2: Percentage of Participants With Progression Free Survival (PFS)
NCT00529100 (9) [back to overview]	Phase 2: Percentage of Participants With Overall Survival (OS) at 2 Years and 3 Years
NCT00529100 (9) [back to overview]	Progression Free Survival (PFS)
NCT00529100 (9) [back to overview]	Phase 2: Percentage of Participants With Objective Tumor Response (Response Rate)
NCT00530621 (8) [back to overview]	Progression-Free Survival (PFS)
NCT00530621 (8) [back to overview]	Number of Participants Who Died During the 30 Days After Treatment Discontinuation
NCT00530621 (8) [back to overview]	Number of Participants Who Died During the Study Treatment
NCT00530621 (8) [back to overview]	Tumor Biomarkers
NCT00530621 (8) [back to overview]	Time-to-Worsening (TW) in Lung Cancer Symptom Scale (LCSS) - Health Related Quality of Life (HRQoL) Subscale
NCT00530621 (8) [back to overview]	Duration of Disease Control (DDC)
NCT00530621 (8) [back to overview]	Overall Survival (OS)
NCT00530621 (8) [back to overview]	Percentage of Participants With Complete Response or Partial Response (Tumor Response Rate)
NCT00533429 (6) [back to overview]	Duration of Response (DoR)
NCT00533429 (6) [back to overview]	Overall Survival (OS)
NCT00533429 (6) [back to overview]	Pharmacology Toxicity and Adverse Events (AEs)
NCT00533429 (6) [back to overview]	Time to Progressive Disease (TTPD)
NCT00533429 (6) [back to overview]	Progression-Free Survival (PFS)
NCT00533429 (6) [back to overview]	Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Response Rate)
NCT00538681 (2) [back to overview]	Part 1: Evaluate Safety [Toxicity, Serious Adverse Events (SAEs) and Reasons for Participant's Discontinuation]
NCT00538681 (2) [back to overview]	Part 2: To Evaluate the Safety and Toxicity Profile of Study Treatments
NCT00545948 (3) [back to overview]	Percentage of Patients With Completely Resected NSCLC Tumors That Can Be Analyzed and Used to Direct Adjuvant Chemotherapy
NCT00545948 (3) [back to overview]	2-Year Progression-Free Survival Rate in Patients With Completely Resected Stage IB, II, or IIIA NSCLC
NCT00545948 (3) [back to overview]	2-Year Overall Survival in Patients Treated for NSCLC
NCT00550173 (8) [back to overview]	Number of Participants With Adverse Events
NCT00550173 (8) [back to overview]	Number of Participants With Mutated or Non-Mutated Epidermal Growth Factor Receptor (EGFR) Genotype Status
NCT00550173 (8) [back to overview]	Overall Survival (OS)
NCT00550173 (8) [back to overview]	Time to Worsening of Symptoms (TWS) on Lung Cancer Symptoms Scale (LCSS)
NCT00550173 (8) [back to overview]	Percentage of Participants With a Tumor Response of Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]
NCT00550173 (8) [back to overview]	Percentage of Participants With CR, PR, and Stable Disease (SD) - Disease Control Rate (DCR)
NCT00550173 (8) [back to overview]	Progression-Free Survival (PFS)
NCT00550173 (8) [back to overview]	Probability of OS at 12 Months
NCT00560573 (16) [back to overview]	Recommended Phase 2 Dose (RP2D)
NCT00560573 (16) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Figitumumab
NCT00560573 (16) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Cisplatin
NCT00560573 (16) [back to overview]	Percentage of Participants With Blood Anti-drug Antibody (ADA) Specific for Figitumumab
NCT00560573 (16) [back to overview]	Progression-Free Survival (PFS)
NCT00560573 (16) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Gemcitabine
NCT00560573 (16) [back to overview]	Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Pemetrexed
NCT00560573 (16) [back to overview]	Concentration at the End of Infusion (Cinf) for Figitumumab
NCT00560573 (16) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Cisplatin
NCT00560573 (16) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Gemcitabine
NCT00560573 (16) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Pemetrexed
NCT00560573 (16) [back to overview]	Maximum Tolerated Dose (MTD)
NCT00560573 (16) [back to overview]	Minimum Observed Plasma Trough Concentration (Cmin) for Figitumumab
NCT00560573 (16) [back to overview]	Number of Participants With Dose-limiting Toxicities (DLT)
NCT00560573 (16) [back to overview]	Percentage of Participants With Objective Response or Prolonged Stabilization
NCT00560573 (16) [back to overview]	Serum Total Circulating Insulin-like Growth Factor (IGF-1) Levels
NCT00573989 (10) [back to overview]	Overall Survival
NCT00573989 (10) [back to overview]	Median Overall Survival
NCT00573989 (10) [back to overview]	Maximum Tolerated Dose of Erlotinib Hydrochloride (Phase I)
NCT00573989 (10) [back to overview]	Progression-free Survival (PFS) at 1 Year (Phase II)
NCT00573989 (10) [back to overview]	Change in Quality of Life- FACT H&N
NCT00573989 (10) [back to overview]	Objective Tumor Response
NCT00573989 (10) [back to overview]	Evaluation of Acute and Chronic Toxicity
NCT00573989 (10) [back to overview]	Median Progression Free Survival
NCT00573989 (10) [back to overview]	Change in Quality of Life: MDADI
NCT00573989 (10) [back to overview]	Change in Quality of Life: PSS-HN
NCT00577707 (1) [back to overview]	Number of Patients With Pathologic Complete Response Rate
NCT00589667 (2) [back to overview]	Median Overall Survival
NCT00589667 (2) [back to overview]	Overall Objective Response
NCT00604461 (2) [back to overview]	Number of Participants With Partial Response (PR) of Target Lesions
NCT00604461 (2) [back to overview]	Number of Months of Progression Free Survival (PFS)
NCT00606021 (6) [back to overview]	Progression Free Survival During Overall Period (Induction Phase [IP] + Maintenance Phase [MP])
NCT00606021 (6) [back to overview]	Tumor Response Rate and Disease Control Rate After Induction Phase (IP)
NCT00606021 (6) [back to overview]	Number of Participants With Adverse Events (AEs) During Overall Period
NCT00606021 (6) [back to overview]	Progression Free Survival During Maintenance Phase
NCT00606021 (6) [back to overview]	Overall Survival During Overall Period (IP + MP)
NCT00606021 (6) [back to overview]	Overall Survival During Maintenance Phase
NCT00609518 (4) [back to overview]	Progression-free Survival (PFS)
NCT00609518 (4) [back to overview]	Safety: Number of Participants With Drug-Related Grade 3 or 4 Toxicity
NCT00609518 (4) [back to overview]	Overall Survival
NCT00609518 (4) [back to overview]	Proportion of Participants With Best Overall Tumor Response (Response Rate)
NCT00614822 (4) [back to overview]	Progression Free Survival
NCT00614822 (4) [back to overview]	Overall Survival
NCT00614822 (4) [back to overview]	Number of Participants With Complete and Partial Tumor Responses
NCT00614822 (4) [back to overview]	Number of Participants With Adverse Events
NCT00660816 (4) [back to overview]	Disease Stabilization Rate (e.g., Complete Response, Partial Response, and Stable Disease)
NCT00660816 (4) [back to overview]	Overall Survival
NCT00660816 (4) [back to overview]	Progression-free Survival
NCT00660816 (4) [back to overview]	Response Rate
NCT00686959 (7) [back to overview]	Survival Rates at 1, 2, and 3 Years
NCT00686959 (7) [back to overview]	First Site of Disease Failure in Terms of Relapse
NCT00686959 (7) [back to overview]	Adverse Events: The Number of Deaths Per Treatment Group
NCT00686959 (7) [back to overview]	Progression-free Survival (PFS)
NCT00686959 (7) [back to overview]	Overall Survival
NCT00686959 (7) [back to overview]	Objective Response Rate (Complete Response [CR] + Partial Response [PR])
NCT00686959 (7) [back to overview]	Percentage of Participants With a Post Baseline Swallowing Diary Score >=4
NCT00691301 (4) [back to overview]	Progression-free Survival
NCT00691301 (4) [back to overview]	Duration of Overall Survival
NCT00691301 (4) [back to overview]	Frequency and Severity of Observed Adverse Effects
NCT00691301 (4) [back to overview]	Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0
NCT00698815 (4) [back to overview]	18 Week Progression-free Survival (PFS) Rate
NCT00698815 (4) [back to overview]	Overall Response Rate
NCT00698815 (4) [back to overview]	PFS
NCT00698815 (4) [back to overview]	Overall Survival (OS)
NCT00700336 (1) [back to overview]	4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin
NCT00702299 (6) [back to overview]	Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2)
NCT00702299 (6) [back to overview]	Overall Survival
NCT00702299 (6) [back to overview]	Pharmacokinetics (Mean Cmax, ug/mL)for Different Dosages of Pemetrexed
NCT00702299 (6) [back to overview]	Patients That Completed at Least 6 Courses of Therapy of Pemetrexed Along With Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2)at the Determined Maximum Tolerated Dose
NCT00702299 (6) [back to overview]	Patients Experienced Grade >=3 Toxicity at Dose Level 5 (1,000 mg/m2 IP Pemetrexed)
NCT00702299 (6) [back to overview]	Progression-free Survival at 18 Months as Assessed by Cancer Antigen 125
NCT00703976 (2) [back to overview]	2-year Progression-free Survival (PFS)
NCT00703976 (2) [back to overview]	2-year Overall Survival (OS)
NCT00732303 (1) [back to overview]	Assess Safety and Toxicity
NCT00732992 (11) [back to overview]	Maximum Concentration of Pemetrexed Following Continuous Daily Dosing of Sunitinib 37.5 mg/Day in Combination With Pemetrexed 500 mg/m^2 at Cycle 2 Day 1
NCT00732992 (11) [back to overview]	Terminal Phase Elimination Half-Life (T1/2) of Pemetrexed Following Continuous Daily Dosing of Sunitinib 37.5 mg/Day in Combination With Pemetrexed 500 mg/m^2 at Cycle 2 Day 1
NCT00732992 (11) [back to overview]	"Sunitinib Relative Dose Intensity in the Sunitinib 37.5 mg/Day Continuous Daily Dosing Treatment Arm"
NCT00732992 (11) [back to overview]	AUC 0-24 of Sunitinib, SU012662, and Total Drug (Sunitinib + SU012662) Following Continuous Daily Dosing of Sunitinib 37.5 mg/Day in Combination With Pemetrexed 500 mg/m^2 at Cycle 2 Day 1
NCT00732992 (11) [back to overview]	"Sunitinib Relative Dose Intensity in the Sunitinib 50 mg/Day Schedule-2/1 Treatment Arm"
NCT00732992 (11) [back to overview]	Number of Participants With Adverse Events
NCT00732992 (11) [back to overview]	Summary of Best Overall Response According to Response Evaluation Criteria in Solid Tumors (RECIST): Number of Participants
NCT00732992 (11) [back to overview]	Tmax of Sunitinib, SU012662, and Total Drug (Sunitinib + SU012662) Following Continuous Daily Dosing of Sunitinib 37.5 mg/Day in Combination With Pemetrexed 500 mg/m^2 at Cycle 2 Day 1
NCT00732992 (11) [back to overview]	Trough and Maximum Concentration of Sunitinib, SU012662, and Total Drug (Sunitinib + SU012662) Following Continuous Daily Dosing of Sunitinib 37.5 mg/Day in Combination With Pemetrexed 500 mg/m^2 at Cycle 2 Day 1
NCT00732992 (11) [back to overview]	Trough Concentrations of Sunitinib, SU012662, and Total Drug (Sunitinib + SU012662) After Coadministration of Sunitinib 50 mg/Day and Pemetrexed 500 mg/m^2 (Cycle 1 Day 1), Followed by Sunitinib 50 mg/Day on Schedule-2/1 at Cycle 1 Day 14 or 15
NCT00732992 (11) [back to overview]	AUC0-∞ of Pemetrexed Following Continuous Daily Dosing of Sunitinib 37.5 mg/Day in Combination With Pemetrexed 500 mg/m^2 at Cycle 2 Day 1
NCT00738582 (7) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) as a Measure of Safety and Tolerability of Amatuximab
NCT00738582 (7) [back to overview]	Number of Participants With Progression Free Survival (PFS) Responders and Non-responders at Month 6
NCT00738582 (7) [back to overview]	Time to Tumor Response (TTR)
NCT00738582 (7) [back to overview]	Overall Survival (OS)
NCT00738582 (7) [back to overview]	Overall Response Rate (ORR)
NCT00738582 (7) [back to overview]	Duration of Response (DR)
NCT00738582 (7) [back to overview]	Overall Progression Free Survival
NCT00738881 (1) [back to overview]	Progression-free Survival (PFS)
NCT00745875 (2) [back to overview]	Time to Death
NCT00745875 (2) [back to overview]	Progression-free Survival
NCT00762034 (28) [back to overview]	Time to Progressive Disease
NCT00762034 (28) [back to overview]	Translational Research: Overall Survival (OS) Based on Nuclear Thyroid Transcription Factor-1 (TTF-1) Expression Regardless of Study Treatment
NCT00762034 (28) [back to overview]	Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - Lung (FACT-L)
NCT00762034 (28) [back to overview]	Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group- Neurotoxicity (FACT/GOG-Ntx)
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Total (Bound and Unbound) Platinum and Unbound Platinum
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Elimination Half-life (t1/2) for Total (Bound and Unbound) Platinum and Unbound Platinum
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Total (Bound and Unbound) Platinum and Unbound Platinum
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Platinum Clearance (CL) for Total (Bound and Unbound) and Unbound Forms
NCT00762034 (28) [back to overview]	Translational Research: Number of Participants With Epidermal Growth Factor Receptor (EGFR) Mutations
NCT00762034 (28) [back to overview]	Translational Research: Overall Survival (OS) Based on Cytoplasmic and Membrane Folate Receptor Alpha (FR-α) Expression
NCT00762034 (28) [back to overview]	Translational Research: Overall Survival (OS) Based on Cytoplasmic and Nuclear Thymidylate Synthase (TS) Expression
NCT00762034 (28) [back to overview]	Safety and Toxicity Profile of Study Treatments
NCT00762034 (28) [back to overview]	Change From Baseline in Participant Reported Outcomes as Assessed by the Functional Assessment of Cancer Therapy - General (FACT-G)
NCT00762034 (28) [back to overview]	Duration of Hospitalizations Per Participant
NCT00762034 (28) [back to overview]	Number of Participants Receiving Concomitant Medication
NCT00762034 (28) [back to overview]	Number of Participants Who Received a Transfusion
NCT00762034 (28) [back to overview]	Overall Survival
NCT00762034 (28) [back to overview]	Percentage of Participants With a Complete Response (CR) and Partial Response (PR) (Overall Response Rate)
NCT00762034 (28) [back to overview]	Percentage of Participants With a Complete Response (CR), Partial Response (PR), and Stable Disease (SD) (Disease Control Rate)
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) Bevacizumab
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Area Under the Concentration Time Curve From Zero to Infinity (AUC(0-∞)) for Pemetrexed
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Bevacizumab Clearance (CL)
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Elimination Half-life (t1/2) for Bevacizumab
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Elimination Half-life (t1/2) for Pemetrexed
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Bevacizumab
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) for Pemetrexed
NCT00762034 (28) [back to overview]	Pharmacokinetics (PK): Pemetrexed Clearance (CL)
NCT00762034 (28) [back to overview]	Progression Free Survival Time
NCT00768755 (6) [back to overview]	Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Severity Score
NCT00768755 (6) [back to overview]	Change From Baseline in Monroe Dunaway (MD) Anderson Symptom Inventory (MDASI) Symptom Interference Score
NCT00768755 (6) [back to overview]	Duration of Response (DR)
NCT00768755 (6) [back to overview]	Overall Survival (OS)
NCT00768755 (6) [back to overview]	Percentage of Participants With Objective Response (OR)
NCT00768755 (6) [back to overview]	Progression-Free Survival (PFS)
NCT00769600 (3) [back to overview]	RECIST Response
NCT00769600 (3) [back to overview]	Progression Free Survival as Measured by Number of Days Without Disease Progression
NCT00769600 (3) [back to overview]	Overall Survival
NCT00771953 (1) [back to overview]	Progression Free Survival
NCT00789373 (12) [back to overview]	Percentage of Participants With Independently-Assessed Objective Tumor Response (Response Rate) During Maintenance Phase Up to Primary Data Cut-Off
NCT00789373 (12) [back to overview]	Percentage of Participants With Serious Adverse Events During Maintenance Phase
NCT00789373 (12) [back to overview]	Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score
NCT00789373 (12) [back to overview]	Percentage of Participants With a Non-Serious Adverse Event (AE) During Maintenance Phase
NCT00789373 (12) [back to overview]	Overall Survival (OS)
NCT00789373 (12) [back to overview]	Percentage of Participants With Objective Tumor Response (Response Rate) During Maintenance Phase of Study up to Primary Data Cut-Off
NCT00789373 (12) [back to overview]	Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)
NCT00789373 (12) [back to overview]	Change From Baseline in EuroQol Instrument (EQ-5D) Visual Analog Scale (VAS)
NCT00789373 (12) [back to overview]	Change From Baseline in the EuroQol Instrument (EQ-5D) Index Score
NCT00789373 (12) [back to overview]	Percentage of Participants With Hospitalizations Due to Adverse Events or Requiring Transfusion (Resource Utilization)
NCT00789373 (12) [back to overview]	Independently-assessed Objective Progression-free Survival (PFS)
NCT00789373 (12) [back to overview]	Investigator-assessed Objective Progression-free Survival (PFS)
NCT00794417 (14) [back to overview]	Phase 1 and 2: Terminal Half-Life (t1/2) of Aflibercept
NCT00794417 (14) [back to overview]	Phase 1 and 2: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
NCT00794417 (14) [back to overview]	Phase 1 and 2: Number of Participants With Positive Anti-drug Antibody (ADA) of Aflibercept
NCT00794417 (14) [back to overview]	Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Pemetrexed
NCT00794417 (14) [back to overview]	Phase 1 and 2: Terminal Half-Life (t1/2) of Pemetrexed
NCT00794417 (14) [back to overview]	Phase 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Aflibercept and Pemetrexed
NCT00794417 (14) [back to overview]	Phase 1 and 2: Number of Participants With All Grade Hematology Abnormalities
NCT00794417 (14) [back to overview]	Phase 2: Progression-free Survival (PFS)
NCT00794417 (14) [back to overview]	Phase 2: Objective Response Rate
NCT00794417 (14) [back to overview]	Phase 1: Recommended Dose of Aflibercept for Phase 2
NCT00794417 (14) [back to overview]	Phase 1 and 2: Total Body Clearance of Pemetrexed
NCT00794417 (14) [back to overview]	Phase 1 and 2: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Aflibercept
NCT00794417 (14) [back to overview]	Phase 1 and 2: Total Body Clearance of Aflibercept
NCT00794417 (14) [back to overview]	Phase 1 and 2: Number of Participants With All Grade Glucose Abnormalities
NCT00798603 (17) [back to overview]	Change From Baseline to Cycle 3 in Fatigue Assessed by Treatment-specific Adverse Events Scale
NCT00798603 (17) [back to overview]	Change From Baseline to Cycle 5 in Fatigue Assessed by Treatment-specific Adverse Events Scale
NCT00798603 (17) [back to overview]	Change From Baseline to Cycle 3 in Neuropathy Assessed by Treatment-specific Adverse Events Scale
NCT00798603 (17) [back to overview]	Change From Baseline to Cycle 3 in Overall Quality of Life Assessed by Linear Analogue Self Assessment (LASA)
NCT00798603 (17) [back to overview]	Change From Baseline to Cycle 3 in Nausea Assessed by Treatment-specific Adverse Events Scale
NCT00798603 (17) [back to overview]	Number of Grade 3 or Higher Adverse Events Occurring in >=10% of Patients
NCT00798603 (17) [back to overview]	Proportion of Confirmed Tumor Response Defined as an Objective Status of Complete Response or Partial Response on Two Consecutive Evaluations
NCT00798603 (17) [back to overview]	Time to Treatment Failure
NCT00798603 (17) [back to overview]	Progression-free Survival at 6 Months
NCT00798603 (17) [back to overview]	Progression-free Survival
NCT00798603 (17) [back to overview]	Change From Baseline to Cycle 3 in Quality of Life (QOL) as Assessed by the Lung Cancer Symptom Scale
NCT00798603 (17) [back to overview]	Overall Survival
NCT00798603 (17) [back to overview]	Duration of Response
NCT00798603 (17) [back to overview]	Change From Baseline to Cycle 5 in Quality of Life (QOL) as Assessed by the Lung Cancer Symptom Scale
NCT00798603 (17) [back to overview]	Change From Baseline to Cycle 5 in Overall Quality of Life Assessed by Linear Analogue Self Assessment (LASA)
NCT00798603 (17) [back to overview]	Change From Baseline to Cycle 5 in Neuropathy Assessed by Treatment-specific Adverse Events Scale
NCT00798603 (17) [back to overview]	Change From Baseline to Cycle 5 in Nausea Assessed by Treatment-specific Adverse Events Scale
NCT00806819 (14) [back to overview]	Overall Survival (Key Secondary Endpoint)
NCT00806819 (14) [back to overview]	Duration of Disease Control
NCT00806819 (14) [back to overview]	Incidence and Intensity of Adverse Events
NCT00806819 (14) [back to overview]	Objective Tumor Response
NCT00806819 (14) [back to overview]	Duration of Confirmed Objective Tumour Response
NCT00806819 (14) [back to overview]	Progression Free Survival (PFS) as Assessed by Central Independent Review
NCT00806819 (14) [back to overview]	Clinical Improvement.
NCT00806819 (14) [back to overview]	Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Central Independent Review
NCT00806819 (14) [back to overview]	Follow-up Analysis of Progression Free Survival (PFS) as Assessed by Investigator
NCT00806819 (14) [back to overview]	Quality of Life (QoL)
NCT00806819 (14) [back to overview]	Time to Confirmed Objective Tumour Response
NCT00806819 (14) [back to overview]	Dose Normalised Predose Plasma Concentration at Steady State (Cpre,ss,Norm) of Nintedanib and of Its Metabolites BIBF 1202 and BIBF 1202 Glucuronide
NCT00806819 (14) [back to overview]	Disease Control
NCT00806819 (14) [back to overview]	Change From Baseline in Tumour Size
NCT00807573 (1) [back to overview]	Objective Response Rate (CR + PR by RECIST) Paclitaxel, Pemetrexed, and Bevacizumab in Patients With Advanced Non-Small Lung Cancer Who Have Received no Prior Treatment for Metastatic Disease.
NCT00824408 (13) [back to overview]	Duration of Overall Response
NCT00824408 (13) [back to overview]	Objective Tumor Response, Defined as Complete Response (CR), and Partial Response (PR), Evaluated According to RECIST Criteria.
NCT00824408 (13) [back to overview]	Cmax of Volasertib
NCT00824408 (13) [back to overview]	CL of Pemetrexed
NCT00824408 (13) [back to overview]	Cmax of Pemetrexed
NCT00824408 (13) [back to overview]	Occurence of DLT
NCT00824408 (13) [back to overview]	Frequency of Patients With Possible Clinically Significant Abnormalities
NCT00824408 (13) [back to overview]	Occurrence and Intensity of AEs Graded According to CTCAE.
NCT00824408 (13) [back to overview]	Vss of Volasertib
NCT00824408 (13) [back to overview]	Overall Survival (OS)
NCT00824408 (13) [back to overview]	Progression Free Survival (PFS) Time From the Date of Randomization to Date of Disease Progression or Death, Whichever Occurred First.
NCT00824408 (13) [back to overview]	Total Clearance (CL) of Volasertib
NCT00824408 (13) [back to overview]	Vss of Pemetrexed
NCT00859495 (1) [back to overview]	Number of Subjects Who Were Able to Complete Trimodal Therapy (Combination of Surgery, Intrapleural and Systemic Chemotherapy and P-32 Radiotherapy).
NCT00860015 (1) [back to overview]	Tumor Best Response Rate
NCT00864513 (4) [back to overview]	Objective Response
NCT00864513 (4) [back to overview]	Number of Participants With Adverse Events
NCT00864513 (4) [back to overview]	CA 19-9 Response
NCT00864513 (4) [back to overview]	Progression-free Survival
NCT00867009 (4) [back to overview]	The Percentage of Participants Still Living at One Year (One Year Survival Rate)
NCT00867009 (4) [back to overview]	Progression-free Survival (PFS)
NCT00867009 (4) [back to overview]	Percentage of Participants With a Tumor Response (Objective Tumor Response Rate)
NCT00867009 (4) [back to overview]	The Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) (Disease Control Rate [DCR])
NCT00868192 (10) [back to overview]	Overall Survival (OS)
NCT00868192 (10) [back to overview]	Overall Response Rate
NCT00868192 (10) [back to overview]	Overall Survival (OS)
NCT00868192 (10) [back to overview]	Progression-free Survival (PFS)
NCT00868192 (10) [back to overview]	Progression-free Survival (PFS)
NCT00868192 (10) [back to overview]	CA-125 Response
NCT00868192 (10) [back to overview]	Distribution of Overall Survival (OS)
NCT00868192 (10) [back to overview]	Distribution of Progression-free Survival (PFS)
NCT00868192 (10) [back to overview]	Toxicity Associated With Bevacizumab and Pemetrexed
NCT00868192 (10) [back to overview]	Frequency of Clinical Response
NCT00871403 (3) [back to overview]	Best Overall Response, Assessed as the Number of Participants With the Indicated Tumor Response: Investigator Assessed Only
NCT00871403 (3) [back to overview]	Progression-free Survival (PFS)
NCT00871403 (3) [back to overview]	Percentage of Participants With a Complete Response or a Partial Response
NCT00887549 (4) [back to overview]	Percentage of Participants With Concordance Between Local and Central Histological Diagnosis
NCT00887549 (4) [back to overview]	Percentage of Participants With Tumor Response (Tumor Response Rate)
NCT00887549 (4) [back to overview]	Progression Free Survival (PFS)
NCT00887549 (4) [back to overview]	Percentage of Participants Surviving at 18 Months (Overall Survival Rate)
NCT00892710 (6) [back to overview]	Overall Survival (OS)
NCT00892710 (6) [back to overview]	Time to Treatment Failure (TTTF)
NCT00892710 (6) [back to overview]	6-month and 12-month Overall Survival Probability
NCT00892710 (6) [back to overview]	Time to Progression (TTP)
NCT00892710 (6) [back to overview]	Progression Free Survival (PFS)
NCT00892710 (6) [back to overview]	Overall Response Rate (ORR), the Number of Patients Who Experience an Objective Benefit From Treatment
NCT00906282 (5) [back to overview]	Rate of Residual Disease as an Assessment of Pathological Partial Response (pPR)
NCT00906282 (5) [back to overview]	3-Year Overall Survival Rate
NCT00906282 (5) [back to overview]	Objective Tumor Response
NCT00906282 (5) [back to overview]	Complete Resection Rate
NCT00906282 (5) [back to overview]	Pathologic Response Rate
NCT00921310 (6) [back to overview]	Phase I Only: Maximum Tolerated Dose (MTD) of Pemetrexed That Could be Administered Weekly in Combination With Temsirolimus
NCT00921310 (6) [back to overview]	Phase I Only: Maximum Tolerated Dose (MTD) of Temsirolimus That Could be Administered Weekly in Combination With Pemetrexed
NCT00921310 (6) [back to overview]	Phase I Only: Number of Participants Who Experience Dose-limiting Toxicities (DLT) of Temsirolimus and Pemetrexed
NCT00921310 (6) [back to overview]	Phase 2 Only: Progression-free Survival (PFS)
NCT00921310 (6) [back to overview]	Phase I and Phase II: Overall Response Rate (Complete Response + Partial Response)
NCT00921310 (6) [back to overview]	Phase 2 Only: Survival Rate
NCT00923273 (4) [back to overview]	Phase II: Clinical Response Rate
NCT00923273 (4) [back to overview]	Number of Participants With Serious and Non-Serious Adverse Events
NCT00923273 (4) [back to overview]	Phase I: Maximum Tolerated Dose (MTD) of Sirolimus
NCT00923273 (4) [back to overview]	Phase I: Maximum Tolerated Dose (MTD) of Pemetrexed
NCT00932893 (15) [back to overview]	Percentage of Participants With Objective Response (OR)
NCT00932893 (15) [back to overview]	Progression-Free Survival (PFS)
NCT00932893 (15) [back to overview]	Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, and Cough
NCT00932893 (15) [back to overview]	Percentage of Participants With Disease Control at Week 12
NCT00932893 (15) [back to overview]	Time to Tumor Response (TTR)
NCT00932893 (15) [back to overview]	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30)
NCT00932893 (15) [back to overview]	European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire-Supplement Module for Lung Cancer (EORTC QLQ-LC13)
NCT00932893 (15) [back to overview]	European Quality of Life - 5 Dimensional (EQ-5D) Visual Analog Scale (VAS)
NCT00932893 (15) [back to overview]	Number of Participants With Categorical Maximum QTcF for Crizotinib
NCT00932893 (15) [back to overview]	Duration of Response (DR)
NCT00932893 (15) [back to overview]	Overall Survival (OS)
NCT00932893 (15) [back to overview]	Overall Survival Probability at Months 6 and 12
NCT00932893 (15) [back to overview]	Plasma Concentration of Crizotinib
NCT00932893 (15) [back to overview]	Plasma Concentration of Soluble c-Met Ectodomain and Hepatocyte Growth Factor Scatter Proteins
NCT00932893 (15) [back to overview]	Percentage of Participants With Disease Control at Week 6
NCT00942825 (1) [back to overview]	The Primary Efficacy Endpoint is Progression Free Survival, Analyzed in the Treated Population. PFS is Assessed From Randomization Until Either Tumor Progression, as Per RECIST Criteria, or Until Death Due to Any Reason.
NCT00948675 (5) [back to overview]	Percentage of Participants With Complete Response or Partial Response (Overall Tumor Response Rate)
NCT00948675 (5) [back to overview]	Overall Survival (OS)
NCT00948675 (5) [back to overview]	Disease Control Rates Defined as Complete Response (CR), Partial Response (PR), and Stable Disease (SD)
NCT00948675 (5) [back to overview]	Progression Free Survival (PFS)
NCT00948675 (5) [back to overview]	Progression Free Survival Without Grade 4 Toxicity (G4PFS) as Measured by the Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
NCT00949650 (13) [back to overview]	Trough Plasma Concentrations of Afatinib at Day 29
NCT00949650 (13) [back to overview]	Trough Plasma Concentrations of Afatinib at Day 22
NCT00949650 (13) [back to overview]	Progression-Free Survival (PFS) Time
NCT00949650 (13) [back to overview]	Percentage of Patients With Objective Response (OR)
NCT00949650 (13) [back to overview]	Percentage of Participants With Disease Control (DC)
NCT00949650 (13) [back to overview]	HRQOL: Time to Deterioration in Pain
NCT00949650 (13) [back to overview]	HRQOL: Time to Deterioration in Dyspnoea
NCT00949650 (13) [back to overview]	Health Related Quality of Life (HRQOL): Time to Deterioration in Coughing
NCT00949650 (13) [back to overview]	Overall Survival (OS) Time
NCT00949650 (13) [back to overview]	Trough Plasma Concentrations of Afatinib at Day 43
NCT00949650 (13) [back to overview]	Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
NCT00949650 (13) [back to overview]	Change From Baseline in Body Weight
NCT00949650 (13) [back to overview]	Tumour Shrinkage
NCT00950365 (3) [back to overview]	PFS (Progression Free Survival)
NCT00950365 (3) [back to overview]	Overall Survival
NCT00950365 (3) [back to overview]	Objective Response Rate (CR +PR) Evaluated Using RECIST
NCT00961415 (8) [back to overview]	Number of Participants With Marked Laboratory Abnormalities
NCT00961415 (8) [back to overview]	Duration of Response During Maintenance Treatment Phase
NCT00961415 (8) [back to overview]	Duration of Disease Control During Maintenance Treatment Phase
NCT00961415 (8) [back to overview]	Overall Survival During Maintenance Treatment Phase
NCT00961415 (8) [back to overview]	Progression Free Survival During Maintenance Treatment Phase
NCT00961415 (8) [back to overview]	Best Overall Response Rate During Maintenance Treatment Phase
NCT00961415 (8) [back to overview]	Incidence of Adverse Events and Serious Adverse Event
NCT00961415 (8) [back to overview]	Quality of Life
NCT00976456 (2) [back to overview]	Overall Survival
NCT00976456 (2) [back to overview]	Progression Free Survival
NCT00979576 (10) [back to overview]	AUC0-inf of Pemetrexed
NCT00979576 (10) [back to overview]	Adverse Events According to Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 for All Courses
NCT00979576 (10) [back to overview]	Duration of Disease Control
NCT00979576 (10) [back to overview]	Dose Limiting Toxicities
NCT00979576 (10) [back to overview]	AUC0-inf of Nintedanib
NCT00979576 (10) [back to overview]	Disease Control Rate
NCT00979576 (10) [back to overview]	Cmax of Nintedanib
NCT00979576 (10) [back to overview]	Overall Response Rate
NCT00979576 (10) [back to overview]	Number of Participants With Clinically Relevant Abnormalities in Laboratory Parameters
NCT00979576 (10) [back to overview]	Cmax of Pemetrexed
NCT00982111 (10) [back to overview]	Pharmacokinetics (PK): Minimum Concentration (Cmin) of Necitumumab
NCT00982111 (10) [back to overview]	Overall Survival Time (OS)
NCT00982111 (10) [back to overview]	Progression-Free Survival (PFS)
NCT00982111 (10) [back to overview]	Time to Treatment Failure (TTF)
NCT00982111 (10) [back to overview]	Percentage of Participants Who Achieve Best Overall Tumor Response of Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate [ORR])
NCT00982111 (10) [back to overview]	Percentage of Participants With EGFR Measured by IHC
NCT00982111 (10) [back to overview]	Number of Participants With Serum Anti-Necitumumab Antibody Assessment (Immunogenicity)
NCT00982111 (10) [back to overview]	Epidermal Growth Factor Hormone (EGFR) Protein Expression Measured by Immunohistochemistry (IHC)
NCT00982111 (10) [back to overview]	Mean Change From Baseline in Patient Reported Outcomes (PRO) Using the European Quality of Life-5 Dimensions (EQ-5D)
NCT00982111 (10) [back to overview]	Mean Change From Baseline in PRO as Measured Using the Lung Cancer Symptom Scale (LCSS)
NCT00988858 (9) [back to overview]	Duration of Response
NCT00988858 (9) [back to overview]	Overall Tumor Response - Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
NCT00988858 (9) [back to overview]	Percentage of Participants Who Achieved a Best Response of Complete Response (CR), Partial Response (PR), or Stable Disease (SD) (Clinical Benefit Rate)
NCT00988858 (9) [back to overview]	Progression-free Survival (PFS)
NCT00988858 (9) [back to overview]	Pharmacokinetics (PK): Maximum Plasma Concentration (Cmax) of LY2603618
NCT00988858 (9) [back to overview]	PK: Area Under the Plasma Concentration vs. Time Curve From Time Zero to Infinity [AUC(0-∞)] of LY2603618
NCT00988858 (9) [back to overview]	Change in Symptom Burden Scores of Lung Cancer Symptom Scale (LCSS)
NCT00988858 (9) [back to overview]	PK: Maximum Plasma Concentration (Cmax) of Pemetrexed
NCT00988858 (9) [back to overview]	PK: Area Under the Plasma Concentration vs. Time Curve From Time Zero to Infinity [AUC(0-∞)] of Pemetrexed
NCT01000480 (3) [back to overview]	Number of Participants With an Objective Tumor Response
NCT01000480 (3) [back to overview]	Overall Survival
NCT01000480 (3) [back to overview]	1 Year Progression Free Survival
NCT01001910 (3) [back to overview]	Progression-free Interval
NCT01001910 (3) [back to overview]	Incidence of Toxicities
NCT01001910 (3) [back to overview]	Overall Survival (OS)
NCT01004250 (5) [back to overview]	Percentage of Participants With Confirmed Complete Response or Partial Response During the Maintenance Therapy Only
NCT01004250 (5) [back to overview]	Percentage of Participants With Confirmed Complete Response or Partial Response During Study Treatment (Induction and Maintenance)
NCT01004250 (5) [back to overview]	Overall Survival
NCT01004250 (5) [back to overview]	Progression-Free Survival
NCT01004250 (5) [back to overview]	Percentage of Participants With Confirmed Response Complete or Partial Response During the Induction Treatment Only
NCT01005680 (9) [back to overview]	Time to Treatment Failure (TtTF)
NCT01005680 (9) [back to overview]	Time to Progressive Disease (TtPD)
NCT01005680 (9) [back to overview]	Tumor Response Rate
NCT01005680 (9) [back to overview]	Survival Without Toxicity (SWT)
NCT01005680 (9) [back to overview]	Risk/Benefit Ratio
NCT01005680 (9) [back to overview]	Progression Free Survival (PFS)
NCT01005680 (9) [back to overview]	Overall Survival (OS)
NCT01005680 (9) [back to overview]	Duration of Response (DoR)
NCT01005680 (9) [back to overview]	Disease Control Rate (DCR)
NCT01017874 (7) [back to overview]	Time to Progressive Disease (TtPD)
NCT01017874 (7) [back to overview]	Time to Worsening of Health-Related Quality of Life (TWQ) Using the Participant-Rated Lung Cancer Symptom Scale (LCSS)
NCT01017874 (7) [back to overview]	Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Tumor Response Rate (TRR)]
NCT01017874 (7) [back to overview]	Percentage of Participants With Complete Response (CR), Partial Response (PR) or Stable Disease (SD) [Disease Control Rate (DCR)]
NCT01017874 (7) [back to overview]	Progression Free Survival (PFS)
NCT01017874 (7) [back to overview]	Overall Survival (OS)
NCT01017874 (7) [back to overview]	Duration of Tumor Response
NCT01020786 (9) [back to overview]	Overall Survival (OS) During the Maintenance Therapy Period
NCT01020786 (9) [back to overview]	Percentage of Participants Who Achieved a Complete Response (CR) or Partial Response (PR) During the Induction and Maintenance Therapy Periods
NCT01020786 (9) [back to overview]	Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Maintenance Therapy Period
NCT01020786 (9) [back to overview]	Progression Free Survival (PFS) During the Maintenance Therapy Period
NCT01020786 (9) [back to overview]	Percentage of Participants Who Achieve a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Induction and Maintenance Therapy Periods
NCT01020786 (9) [back to overview]	Overall Survival (OS) During the Induction and Maintenance Therapy Periods
NCT01020786 (9) [back to overview]	Percentage of Participants Who Achieve a Complete Response (CR) or a Partial Response (PR) During the Induction Therapy Period
NCT01020786 (9) [back to overview]	Percentage of Participants Who Observe a Complete Response (CR), Partial Response (PR), or Stable Disease (SD) During the Induction Therapy Period
NCT01020786 (9) [back to overview]	Progression Free Survival (PFS) During the Induction and Maintenance Therapy Periods
NCT01041781 (7) [back to overview]	Incidence of Toxicities as Assessed by NCI CTCAE v. 4.0
NCT01041781 (7) [back to overview]	Prognostic Value of Urinary Prostaglandin Metabolites (PGE-M) Levels for Worse PFS for Patients Who Had Baseline Urinary PGE-M Above/Below the Median Quartile (Q2)
NCT01041781 (7) [back to overview]	Prognostic Value of Urinary Prostaglandin Metabolites (PGE-M) Levels for Worse PFS for Patients Who Had Baseline Urinary PGE-M Above/Below the Third Quartile (Q3)
NCT01041781 (7) [back to overview]	Progression-free Survival
NCT01041781 (7) [back to overview]	Prognostic Value of Urinary Prostaglandin Metabolites (PGE-M) Levels for Worse PFS for Patients Who Had Baseline Urinary PGE-M Above/Below the First Quartile (Q1)
NCT01041781 (7) [back to overview]	Response Rate
NCT01041781 (7) [back to overview]	Overall Survival
NCT01042288 (5) [back to overview]	Median Overall Survival (OS)
NCT01042288 (5) [back to overview]	Median Progression-free Survival (PFS)
NCT01042288 (5) [back to overview]	Median Time to Progression (TTP)
NCT01042288 (5) [back to overview]	Frequency of Adverse Events and Severity as a Measure of Toxicity
NCT01042288 (5) [back to overview]	Objective Response Rate
NCT01057589 (6) [back to overview]	Progression Free Survival (PFS)
NCT01057589 (6) [back to overview]	Percent of Participants With a Partial Response (PR) or a Complete Response (CR)
NCT01057589 (6) [back to overview]	Change From Baseline in Performance Status Scale for Head and Neck Cancer Patients (PSS-HNC)
NCT01057589 (6) [back to overview]	Change From Baseline in Participant Reported European-Quality of Life 5 Dimension Instrument (EQ-5D) Visual Analog Scale (VAS) at End of Triplet Combination Therapy and End of Maintenance Therapy
NCT01057589 (6) [back to overview]	Overall Survival (OS)
NCT01057589 (6) [back to overview]	Change From Baseline in Participant Reported EQ-5D Utility Score at End of Triplet Combination Therapy and End of Maintenance Therapy
NCT01063283 (2) [back to overview]	Response Rate
NCT01063283 (2) [back to overview]	Change in 24 Hour Diastolic Blood Pressure (DBP)
NCT01064648 (9) [back to overview]	Response Rate by Modified RECIST (Phase II)
NCT01064648 (9) [back to overview]	Overall Survival (Phase II)
NCT01064648 (9) [back to overview]	Maximum Tolerated Dose of Cediranib in Combination With Cisplatin and Pemetrexed (Phase I)
NCT01064648 (9) [back to overview]	Disease Control Rate by RECIST 1.1 (Phase II)
NCT01064648 (9) [back to overview]	(Phase I) Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT01064648 (9) [back to overview]	(Phase II) Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT01064648 (9) [back to overview]	Progression-free Survival (Phase II)
NCT01064648 (9) [back to overview]	Disease Control Rate by Modified RECIST (Phase II)
NCT01064648 (9) [back to overview]	Response Rate by RECIST1.1 (Phase II)
NCT01085630 (4) [back to overview]	Overall Survival
NCT01085630 (4) [back to overview]	Progression-free Survival
NCT01085630 (4) [back to overview]	Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (v4)
NCT01085630 (4) [back to overview]	Response Rate
NCT01087970 (6) [back to overview]	Overall Survival (OS)
NCT01087970 (6) [back to overview]	Percentage of Participants Having a Confirmed Partial Response (PR) or Complete Response (CR)
NCT01087970 (6) [back to overview]	Progression-Free Survival (PFS)
NCT01087970 (6) [back to overview]	Change From Baseline in Performance Status Scale for Head and Neck Cancer (PSS-HNC)
NCT01087970 (6) [back to overview]	Number of Participants Who Died While on Treatment and Died During 30-Day Post-Treatment Discontinuation Follow-Up (FU)
NCT01087970 (6) [back to overview]	Change From Baseline in Participant-Reported European-Quality of Life-5 Dimension Instrument-3 Levels (EQ-5D-3L)
NCT01107626 (3) [back to overview]	Response Rate
NCT01107626 (3) [back to overview]	Overall Survival
NCT01107626 (3) [back to overview]	Progression-free Survival
NCT01126736 (4) [back to overview]	Phase 2: Percentage of Participants Who Experienced TEAEs
NCT01126736 (4) [back to overview]	Phase 1b: Percentage of Participants With Grade 3 or Higher Treatment Emergent Adverse Events (TEAEs)
NCT01126736 (4) [back to overview]	Phase 2: Progression-free Survival (PFS)
NCT01126736 (4) [back to overview]	Phase 1b: Number of Participants With Dose-Limiting Toxicity (DLTs)
NCT01139775 (15) [back to overview]	Phase 1: Document Any Antitumor Activity Per Radiological Scans and/or Tumor Markers
NCT01139775 (15) [back to overview]	Deaths
NCT01139775 (15) [back to overview]	Phase 2: Progression-Free Survival Time
NCT01139775 (15) [back to overview]	Phase 2: Pharmacokinetic: Cmax (LY2603618)
NCT01139775 (15) [back to overview]	Phase 1: Pharmacokinetic: Area Under the Plasma Concentration Versus Time Curve (AUC) (LY2603618)
NCT01139775 (15) [back to overview]	Phase 2: Overall Survival
NCT01139775 (15) [back to overview]	Phase 1: Pharmacokinetic: AUC (Pemetrexed and Cisplatin)
NCT01139775 (15) [back to overview]	Phase 1: Pharmacokinetic: Cmax (Pemetrexed and Cisplatin)
NCT01139775 (15) [back to overview]	Phase 2: Clinical Benefit Rate: Percentage of Participant Who Achieved a Response of Stable Disease (SD), Partial Response (PR), or Complete Response (CR)
NCT01139775 (15) [back to overview]	Phase 2: Change in Tumor Size
NCT01139775 (15) [back to overview]	Phase 1: Recommended Phase 2 Dose of LY2603618
NCT01139775 (15) [back to overview]	Phase 1: Pharmacokinetic: Maximum Plasma Concentration (Cmax) (LY2603618)
NCT01139775 (15) [back to overview]	Phase 2: Change From Baseline to Long-term Follow up in Lung Cancer Symptom Scale (LCSS)
NCT01139775 (15) [back to overview]	Phase 2: Pharmacokinetic: AUC (LY2603618)
NCT01139775 (15) [back to overview]	Phase 2: Overall Tumor Response Rate: Percentage of Participants Who Achieved a Confirmed Best Response of Completed Response (CR) or Partial Response (PR)
NCT01160744 (7) [back to overview]	Change in Tumor Size (CTS)
NCT01160744 (7) [back to overview]	Duration of Response (DOR)
NCT01160744 (7) [back to overview]	Overall Survival (OS)
NCT01160744 (7) [back to overview]	Percentage of Participants With Best Overall Response of Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]
NCT01160744 (7) [back to overview]	Percentage of Participants With CR, PR, or Stable Disease (SD) [Disease Control Rate (DCR)]
NCT01160744 (7) [back to overview]	Progression-Free Survival (PFS)
NCT01160744 (7) [back to overview]	Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) and Who Died
NCT01165021 (5) [back to overview]	Overall Survival (OS)
NCT01165021 (5) [back to overview]	Percentage of Participants With Complete Response (CR) or Partial Response (PR) [Overall Response Rate (ORR)]
NCT01165021 (5) [back to overview]	Percentage of Participants With No Viable Tumor Cells in Resected Lung Tissue [Pathological Complete Remission (pCR)]
NCT01165021 (5) [back to overview]	Progression-Free Survival (PFS)
NCT01165021 (5) [back to overview]	Percentage of Participants Who Exhibit a Downward Shift in Tumor Extent From Stage IIIAN2 to Stages IIIA, II, I, or Stage 0
NCT01169675 (6) [back to overview]	Disease Control
NCT01169675 (6) [back to overview]	Objective Response (OR)
NCT01169675 (6) [back to overview]	Tumour Shrinkage
NCT01169675 (6) [back to overview]	Progression Free Survival (PFS)
NCT01169675 (6) [back to overview]	Investigator Defined Dose Limiting Toxicity (DLT) During First Course of Treatment, Treated Set
NCT01169675 (6) [back to overview]	Investigator Defined Dose Limiting Toxicity (DLT) During All Courses of Treatment, Treated Set
NCT01215916 (4) [back to overview]	Percentage of Participants With a Tumor Response
NCT01215916 (4) [back to overview]	Number of Participants With Clinically Significant Effects
NCT01215916 (4) [back to overview]	Pharmacokinetics, Area Under the Curve (AUC) of LY573636
NCT01215916 (4) [back to overview]	Pharmacokinetics, Concentration Maximum (Cmax) of LY573636
NCT01218516 (5) [back to overview]	Progression-free Survival (PFS)
NCT01218516 (5) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
NCT01218516 (5) [back to overview]	Overall Response Rate (ORR)
NCT01218516 (5) [back to overview]	Overall Survival (OS)
NCT01218516 (5) [back to overview]	Duration of Response (DR)
NCT01232452 (10) [back to overview]	Pharmacokinetics (PK): Maximum Serum Concentration (Cmax) of Cixutumumab, Cycle 1 (First Infusion) and Cycle 4 (Fourth Infusion)
NCT01232452 (10) [back to overview]	Time to Worsening of Symptoms as Measured by Lung Cancer Symptom Scale (LCSS) Score
NCT01232452 (10) [back to overview]	PK: Area Under the Concentration Time Curve (AUC[0-inf]) of Cixutumumab, Cycle 1 (i.e. First Infusion)
NCT01232452 (10) [back to overview]	Percentage of Participants Achieving an Objective Response Rate (ORR)
NCT01232452 (10) [back to overview]	Overall Survival (OS)
NCT01232452 (10) [back to overview]	Duration of Response (DOR)
NCT01232452 (10) [back to overview]	Change in Tumor Size (CTS)
NCT01232452 (10) [back to overview]	Time to Progressive Disease (TTPS)
NCT01232452 (10) [back to overview]	Progression-free Survival (PFS)
NCT01232452 (10) [back to overview]	PK: Area Under the Concentration Time Curve During 1 Dosing Interval (i.e. 504 hr, AUC(0-tau) of Cixutumumab, Cycle 4 (i.e. Fourth Infusion)
NCT01263782 (2) [back to overview]	Overall Response Rate
NCT01263782 (2) [back to overview]	Progression Free Survival
NCT01287520 (10) [back to overview]	PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314
NCT01287520 (10) [back to overview]	PK Parameter: AUC0-∞ of Free Carboplatin (Carb)
NCT01287520 (10) [back to overview]	PK Parameter: Cmax of Free Carboplatin
NCT01287520 (10) [back to overview]	Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of Pemetrexed (Pem)
NCT01287520 (10) [back to overview]	Pharmacokinetic (PK) Parameter: Area Under the Concentration-Time Curve From Time 0 Hour to Infinity (AUC0-∞) of LY2090314
NCT01287520 (10) [back to overview]	PK Parameter: Maximum Plasma Concentration (Cmax) of Pemetrexed (Pem)
NCT01287520 (10) [back to overview]	PK Parameter: AUC0-∞ of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)
NCT01287520 (10) [back to overview]	Number of Participants With Best Overall Tumor Response
NCT01287520 (10) [back to overview]	Recommended LY2090314 Dose for Phase 2 Studies (Maximum Tolerated Dose [MTD])
NCT01287520 (10) [back to overview]	PK Parameter: Maximum Plasma Concentration (Cmax) of LY2090314 Coadministered With Pemetrexed (Pem) and Carboplatin (Carb)
NCT01296568 (10) [back to overview]	Plasma Pharmacokinetics of LY2603618: Area Under the Concentration Time Curve From Time Zero to Infinity [AUC(0-infinity)]
NCT01296568 (10) [back to overview]	Relative Abundance of LY2603618 and the Metabolites of LY2603618 in Feces
NCT01296568 (10) [back to overview]	Plasma Pharmacokinetics of LY2603618: Maximum Observed Drug Concentration (Cmax)
NCT01296568 (10) [back to overview]	Plasma Pharmacokinetics of LY2603618: Area Under the Concentration Time Curve From Time Zero to Time t [AUC(0-tlast)]
NCT01296568 (10) [back to overview]	Relative Abundance of LY2603618 and the Metabolites of LY2603618 in Urine
NCT01296568 (10) [back to overview]	The Number of Participants With a Tumor Response
NCT01296568 (10) [back to overview]	Plasma Pharmacokinetics of Radioactivity: Area Under the Concentration Time Curve From Time Zero to Infinity [AUC(0-infinity)]
NCT01296568 (10) [back to overview]	Plasma Pharmacokinetics of Radioactivity: Area Under the Concentration Time Curve From Time Zero to Time t [AUC(0-tlast)]
NCT01296568 (10) [back to overview]	Plasma Pharmacokinetics of Radioactivity: Maximum Observed Drug Concentration (Cmax)
NCT01296568 (10) [back to overview]	Urinary and Fecal Excretion of LY2603618 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
NCT01313663 (14) [back to overview]	Number of Participants With the Indicated Changes From Baseline Value in Lactate Dehydrogenase (LDH)
NCT01313663 (14) [back to overview]	Number of Participants With Any On-therapy AE (Serious or Non-serious) Leading to Dose Reductions (DRs) or Interruptions/Delays in the Study
NCT01313663 (14) [back to overview]	Number of Participants With Any Non-serious On-therapy Adverse Event (AE: Occurring in >=5% Participants in Any Treatment Arm) and Serious Adverse Event (SAE)
NCT01313663 (14) [back to overview]	Number of Participants With a Change From Baseline Grade to Grade 3 and 4 for the Indicated Clinical Laboratory Parameters
NCT01313663 (14) [back to overview]	Number of Participants (Par.) With the Indicated Best Overall Response
NCT01313663 (14) [back to overview]	Time on Study Treatment (Pazopanib), as a Measure of Extent of Exposure
NCT01313663 (14) [back to overview]	Number of Participants With Any AE (Serious or Non-serious) Leading to Withdrawal From Study Treatment
NCT01313663 (14) [back to overview]	Average Dose of Pemetrexed for All Cycles, as a Measure of Extent of Exposure
NCT01313663 (14) [back to overview]	Mean Daily Dose, as a Measure of Extent of Exposure
NCT01313663 (14) [back to overview]	Number of Participants With the Indicated Worst-case Change From Baseline in Blood Pressure
NCT01313663 (14) [back to overview]	Progression Free Survival (PFS)
NCT01313663 (14) [back to overview]	Mean Number of Pemetrexed Dosing Cycles, as a Measure of Extent of Exposure
NCT01313663 (14) [back to overview]	Number of Participants With a Increase From Baseline in Bazett's QTc at the Indicated Time Points
NCT01313663 (14) [back to overview]	Number of Participants With the Indicated Grade Changes From Baseline Grade in Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk. Phos.), and Total Bilirubin (TB)
NCT01338792 (3) [back to overview]	Time to Disease Progression and Overall Survival
NCT01338792 (3) [back to overview]	Best Overall Response
NCT01338792 (3) [back to overview]	Number of Participants With Serious Adverse Events (SAEs)
NCT01344824 (3) [back to overview]	Overall Survival
NCT01344824 (3) [back to overview]	Subjects Experiencing Toxicity
NCT01344824 (3) [back to overview]	Progression-free Survival
NCT01351415 (8) [back to overview]	Overall Survival (OS)
NCT01351415 (8) [back to overview]	Percentage of Participants With Disease Control According to RECIST v1.1
NCT01351415 (8) [back to overview]	Percentage of Participants With Objective Response According to RECIST v1.1
NCT01351415 (8) [back to overview]	Percentage of Participants Who Are Alive at Month 6, 12, and 18
NCT01351415 (8) [back to overview]	Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01351415 (8) [back to overview]	Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
NCT01351415 (8) [back to overview]	Time to Progression (TTP) According to RECIST v1.1
NCT01351415 (8) [back to overview]	Duration of Response (DoR) According to RECIST v1.1
NCT01358968 (7) [back to overview]	Number of Participants With a Tumor Response
NCT01358968 (7) [back to overview]	Plasma Pharmacokinetics of LY2603618: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)]
NCT01358968 (7) [back to overview]	Plasma Pharmacokinetics of LY2603618: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Observed Plasma Concentration of LY2603618 [AUC(0-tlast)]
NCT01358968 (7) [back to overview]	Plasma Pharmacokinetics of LY2603618: the Maximum Concentration of LY2603618 in the Plasma (Cmax)
NCT01358968 (7) [back to overview]	Plasma Pharmacokinetics of Desipramine: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to Infinity [AUC(0-∞)]
NCT01358968 (7) [back to overview]	Plasma Pharmacokinetics of Desipramine: the Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Observed Plasma Concentration of Desipramine [AUC(0-tlast)]
NCT01358968 (7) [back to overview]	Plasma Pharmacokinetics of Desipramine: the Maximum Concentration of Desipramine in the Plasma (Cmax)
NCT01376310 (1) [back to overview]	Number of Participants With Adverse Events
NCT01395758 (4) [back to overview]	ORR Among Subjects in the Crossover Period Treated With Erlotinib Plus Tivantinib
NCT01395758 (4) [back to overview]	Overall Survival (OS) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy.
NCT01395758 (4) [back to overview]	Objective Response Rate (ORR) Among All Eligible Subjects (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Chemotherapy.
NCT01395758 (4) [back to overview]	Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent Chemotherapy.
NCT01443078 (2) [back to overview]	PERCIST Partial Metabolic Response
NCT01443078 (2) [back to overview]	Pathologic Response Rate
NCT01447225 (11) [back to overview]	To Determine the Maximum Tolerated Dose (MTD) of MM-121 in Combination With Anticancer Therapies: MM-121 Doses
NCT01447225 (11) [back to overview]	Immunogenicity
NCT01447225 (11) [back to overview]	Objective Response Rate
NCT01447225 (11) [back to overview]	Pharmacokinetics
NCT01447225 (11) [back to overview]	Pharmacokinetics (AUClast)
NCT01447225 (11) [back to overview]	To Characterize Dose-limiting Toxicities (DLTs) Associated With the Combination of MM-121 With Anticancer Therapies
NCT01447225 (11) [back to overview]	To Determine the Maximum Tolerated Dose (MTD) of MM-121 in Combination With Anticancer Therapies: Carboplatin
NCT01447225 (11) [back to overview]	To Determine the Maximum Tolerated Dose (MTD) of MM-121 in Combination With Anticancer Therapies: Cabazitaxel
NCT01447225 (11) [back to overview]	To Determine the Maximum Tolerated Dose (MTD) of MM-121 in Combination With Anticancer Therapies: Gemcitabine
NCT01447225 (11) [back to overview]	To Determine the Maximum Tolerated Dose (MTD) of MM-121 in Combination With Anticancer Therapies: Pemetrexed
NCT01447225 (11) [back to overview]	To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Anticancer Therapies
NCT01454102 (6) [back to overview]	Number of Participants With Abnormalities in Selected Hepatic Clinical Laboratory Tests
NCT01454102 (6) [back to overview]	Number of Participants With Abnormalities in Selected Thyroid Clinical Laboratory Tests
NCT01454102 (6) [back to overview]	Objective Response Rate (ORR)
NCT01454102 (6) [back to overview]	Progression-Free Survival Rate (PFSR) at Week 24
NCT01454102 (6) [back to overview]	Number of Participants Who Experienced Selected Adverse Events
NCT01454102 (6) [back to overview]	Number of Participants Who Experienced Serious Adverse Events (SAE), Adverse Events (AE) Leading to Discontinuation, or Death
NCT01454934 (3) [back to overview]	Overall Survival (OS)
NCT01454934 (3) [back to overview]	Progression Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST)
NCT01454934 (3) [back to overview]	Objective Response Rate (ORR)
NCT01469000 (7) [back to overview]	Time to Worsening of Symptom (TWS) as Per Lung Cancer Symptom Scale (LCSS)
NCT01469000 (7) [back to overview]	Time To Progressive Disease (TTPD)
NCT01469000 (7) [back to overview]	Overall Survival (OS)
NCT01469000 (7) [back to overview]	Duration of Response (DoR)
NCT01469000 (7) [back to overview]	Progression Free Survival (PFS)
NCT01469000 (7) [back to overview]	Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR])
NCT01469000 (7) [back to overview]	Percentage of Participants With CR, PR, and Stable Disease (SD) (Disease Control Rate [DCR])
NCT01471197 (3) [back to overview]	Number of Participants Who Died Within 30 Days and 31 Days After Last Dose - All Treated Participants
NCT01471197 (3) [back to overview]	Number of Participants With Deaths, Adverse Events (AEs), Serious AEs (SAEs) and AEs Leading to Discontinuation - All Treated Participants
NCT01471197 (3) [back to overview]	Overall Survival of Participants During the Study - All Treated Participants
NCT01473563 (16) [back to overview]	Participant Satisfaction: Preferences Regarding Home and/or Hospital Treatment
NCT01473563 (16) [back to overview]	Participant Satisfaction: Regarding the Study Nurse
NCT01473563 (16) [back to overview]	Physician Satisfaction: Distant Management of Participant
NCT01473563 (16) [back to overview]	Resource Utilization: Number of Participants With an Unplanned Use of Healthcare Resources
NCT01473563 (16) [back to overview]	Overall Survival (OS) at 6 Months
NCT01473563 (16) [back to overview]	Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), or Died
NCT01473563 (16) [back to overview]	Change From Baseline in the EQ-5D Index Score
NCT01473563 (16) [back to overview]	Time to Treatment Failure (TTF)
NCT01473563 (16) [back to overview]	Resource Utilization: Duration of Health Care Visits
NCT01473563 (16) [back to overview]	Percentage of Participants Who Adhered to Treatment Administration at Home
NCT01473563 (16) [back to overview]	Participant Satisfaction: Chemotherapy at Home
NCT01473563 (16) [back to overview]	Resource Utilization: Unplanned Health Care Visits, Consultations, and Diagnostic Services
NCT01473563 (16) [back to overview]	Resource Utilization: Distances Traveled
NCT01473563 (16) [back to overview]	Participant Satisfaction: Chemotherapy at Hospital
NCT01473563 (16) [back to overview]	Change From Baseline in the European Quality of Life Instrument (EQ-5D) Visual Analogue Scale (VAS)
NCT01473563 (16) [back to overview]	Maximum Improvement Over Baseline in Individual Lung Cancer Symptoms Scale (LCSS) Item Scores
NCT01544179 (12) [back to overview]	Median Overall Survival (OS) at Time of PFS Analysis
NCT01544179 (12) [back to overview]	Median Progression-Free Survival (Site Read, Investigator Assessment)
NCT01544179 (12) [back to overview]	Objective Response Rate (ORR) (Site Read Data)
NCT01544179 (12) [back to overview]	Progression-Free Survival (Site Read, Investigator Assessment)
NCT01544179 (12) [back to overview]	Time to Worsening in FACT-L Total Score
NCT01544179 (12) [back to overview]	Time to Worsening in Lung Cancer Subscale
NCT01544179 (12) [back to overview]	Overall Survival (OS)
NCT01544179 (12) [back to overview]	Time to Worsening in Trial Outcome Index
NCT01544179 (12) [back to overview]	Disease Control Rate (DCR)
NCT01544179 (12) [back to overview]	Improvement in FACT-L Total Score
NCT01544179 (12) [back to overview]	Improvement in Trial Outcome Index
NCT01544179 (12) [back to overview]	Improvement in Lung Cancer Subscale
NCT01565538 (3) [back to overview]	Overall Survival
NCT01565538 (3) [back to overview]	Progression-Free Survival
NCT01565538 (3) [back to overview]	Best Tumor Response
NCT01639001 (21) [back to overview]	Percentage of Participants With Visual Disturbance as Assessed by Visual Symptom Assessment Questionnaire (VSAQ-ALK)
NCT01639001 (21) [back to overview]	Time to Deterioration (TTD) in Participant Reported Pain, Dyspnea, or Cough Assessed Using Quality of Life Questionnaire Supplement Module for Lung Cancer (QLQ-LC13)
NCT01639001 (21) [back to overview]	Percentage of Participants With Visual Disturbance as Assessed by Visual Symptom Assessment Questionnaire (VSAQ-ALK)
NCT01639001 (21) [back to overview]	Percentage of Participants With Treatment-Emergent AEs (Treatment Related)
NCT01639001 (21) [back to overview]	Percentage of Participants With Treatment-Emergent Adverse Events (AEs; All Causalities)
NCT01639001 (21) [back to overview]	Estimate of the Percentage of Participants Surviving at 1 Year and at 18 Months
NCT01639001 (21) [back to overview]	Change From Baseline Scores in QLQ-C30 Symptoms as Assessed by the EORTC-QLQ-C30
NCT01639001 (21) [back to overview]	Change From Baseline in Lung Cancer Symptom Scores as Assessed by the EORTC Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13)
NCT01639001 (21) [back to overview]	Change From Baseline in Functioning and Global Quality of Life (QOL) as Assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30)
NCT01639001 (21) [back to overview]	Agreement Between Central Laboratory ALK FISH and ALK IHC Test Results - Molecular Profiling Evaluable
NCT01639001 (21) [back to overview]	Time to Tumor Response (TTR) Based on IRR
NCT01639001 (21) [back to overview]	Time to Progression (TTP) Based on IRR
NCT01639001 (21) [back to overview]	Change From Baseline in General Health Status as Assessed by EuroQol 5D (EQ-5D)-Visual Analog Scale (VAS)
NCT01639001 (21) [back to overview]	Change From Baseline in General Health Status as Assessed by EQ-5D-Index
NCT01639001 (21) [back to overview]	Progression-Free Survival (PFS) Based on IRR by Treatment Arm
NCT01639001 (21) [back to overview]	Duration of Response (DR) Based on IRR
NCT01639001 (21) [back to overview]	Extracranial Time to Progression (EC-TTP) Based on IRR
NCT01639001 (21) [back to overview]	Intracranial Time to Progression (IC-TTP) Based on IRR
NCT01639001 (21) [back to overview]	Objective Response Rate (ORR) - Percentage of Participants With Objective Response Based on IRR
NCT01639001 (21) [back to overview]	Overall Survival (OS)
NCT01639001 (21) [back to overview]	Percentage of Participants With Disease Control at 12 Weeks Based on IRR
NCT01646125 (2) [back to overview]	Progression Free Survival (PFS)
NCT01646125 (2) [back to overview]	Overall Response Rate (ORR)
NCT01675765 (2) [back to overview]	Number of Subjects Reporting Adverse Events
NCT01675765 (2) [back to overview]	Objective Tumor Response
NCT01803282 (2) [back to overview]	Percentage of Participants Experiencing Treatment-Emergent Adverse Events
NCT01803282 (2) [back to overview]	Percentage of Participants Experiencing Laboratory Abnormalities
NCT01809210 (9) [back to overview]	Cmax,ss
NCT01809210 (9) [back to overview]	CL/F
NCT01809210 (9) [back to overview]	Best Percentage Change From Baseline in Target Lesion Size
NCT01809210 (9) [back to overview]	Dose Limiting Toxicity (DLT) Events in Chemotherapy in Combination With Selumetinib
NCT01809210 (9) [back to overview]	Best Objective Response
NCT01809210 (9) [back to overview]	AUC (0-tau)
NCT01809210 (9) [back to overview]	Percentage Change From Baseline at 6 Weeks in Target Lesion Size
NCT01809210 (9) [back to overview]	Objective Response Rate (ORR)
NCT01809210 (9) [back to overview]	Tmax,ss
NCT01828099 (1) [back to overview]	Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC)
NCT01828112 (1) [back to overview]	Progression Free Survival (PFS) Blinded Independent Review Committee Per Blinded Independent Review Committee (BIRC)
NCT01840579 (42) [back to overview]	Number of Participants Who Experienced Dose-limiting Toxicities (DLTs)
NCT01840579 (42) [back to overview]	Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
NCT01840579 (42) [back to overview]	Maximum Serum Concentration (Cmax) of Pembrolizumab for Cycle 8: Parts A, B, C, and E
NCT01840579 (42) [back to overview]	Maximum Serum Concentration (Cmax) of Pembrolizumab for Cycle 6: Part A
NCT01840579 (42) [back to overview]	Maximum Serum Concentration (Cmax) of Pembrolizumab for Cycle 4: Parts A and D
NCT01840579 (42) [back to overview]	Maximum Serum Concentration (Cmax) of Pembrolizumab for Cycle 18: Part A
NCT01840579 (42) [back to overview]	Number of Participants Who Experienced at Least One Adverse Event (AE)
NCT01840579 (42) [back to overview]	Maximum Serum Concentration (Cmax) of Pembrolizumab for Cycle 2: Part A
NCT01840579 (42) [back to overview]	Volume of Distribution (Vz) of Pembrolizumab Over Time for Part A Cycle 1
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 9: Part A
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 8: Part D
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 7: Parts A, B, C, and E
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 6: Part D
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 5: Parts A, B, C, and E
NCT01840579 (42) [back to overview]	Area Under the Concentration Time Curve From 0-28 Days (AUC 0-28) for Part A Cycle 1
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 4: Part D
NCT01840579 (42) [back to overview]	Clearance (CL) of Pembrolizumab Over Time for Part A Cycle 1
NCT01840579 (42) [back to overview]	Area Under the Concentration Time Curve From 0-Infinity (AUC 0-inf) for Part A Cycle 1
NCT01840579 (42) [back to overview]	Maximum Serum Concentration (Cmax) of Pembrolizumab for Cycle 1: Parts A, B, C, D, and E
NCT01840579 (42) [back to overview]	Maximum Serum Concentration (Cmax) of Pembrolizumab for Cycle 10: Part A
NCT01840579 (42) [back to overview]	Maximum Serum Concentration (Cmax) of Pembrolizumab for Cycle 12: Part A
NCT01840579 (42) [back to overview]	Maximum Serum Concentration (Cmax) of Pembrolizumab for Cycle 14: Part A
NCT01840579 (42) [back to overview]	Maximum Serum Concentration (Cmax) of Pembrolizumab for Cycle 16: Part A
NCT01840579 (42) [back to overview]	Time to Maximum Serum Concentration (Tmax) of Pembrolizumab for Cycle 8: Parts B, C, and E
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 3: Parts A, B, C, and E
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 3: Part D
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 27: Parts B, C, and E
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 23: Parts B, C, and E
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 2: Part D
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 19: Parts B, C, and E
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 17: Part A
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 16: Part D
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 15: Parts A, B, C, and E
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 14: Part D
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 13: Part A
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 12: Part D
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 11: Parts A, B, C, and E
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 10: Part D
NCT01840579 (42) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab for Cycle 1: Parts A, B, C, D, and E
NCT01840579 (42) [back to overview]	Time to Maximum Serum Concentration (Tmax) of Pembrolizumab for Cycle 4: Part D
NCT01840579 (42) [back to overview]	Time to Maximum Serum Concentration (Tmax) of Pembrolizumab for Cycle 1: Parts A, B, C, D, and E
NCT01840579 (42) [back to overview]	Terminal Half-Life (t1/2) of Pembrolizumab Over Time for Part A Cycle 1
NCT01868022 (23) [back to overview]	Number of Participants With Non-serious Adverse Events (AEs) and Serious AEs (SAEs)
NCT01868022 (23) [back to overview]	Number of Participants With the Abnormal Urinalysis Findings
NCT01868022 (23) [back to overview]	Number of Participants With Clinically Significant Findings for 12-lead Electrocardiogram (ECG)
NCT01868022 (23) [back to overview]	Change From Baseline in Heart Rate
NCT01868022 (23) [back to overview]	Change From Baseline in Temperature
NCT01868022 (23) [back to overview]	Number of Participants With Dose Delays
NCT01868022 (23) [back to overview]	Number of Participants With Dose Reduction
NCT01868022 (23) [back to overview]	Number of Participants With Dose-Limiting Toxicities (DLT)
NCT01868022 (23) [back to overview]	Number of Participants With Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD)
NCT01868022 (23) [back to overview]	Number of Participants With Overall Response Rate (ORR)
NCT01868022 (23) [back to overview]	Number of Participants Withdrew Due to AEs
NCT01868022 (23) [back to overview]	Progression Free Survival (PFS) as Assessed by Investigator
NCT01868022 (23) [back to overview]	Treatment Duration With GSK3052230
NCT01868022 (23) [back to overview]	Change From Baseline in Forced Vital Capacity (FVC) in of Arm C Participants With Malignant Pleural Mesothelioma (MPM)
NCT01868022 (23) [back to overview]	Change From Baseline in Forced Vital Capacity (FVC) in of Arm C Participants With Malignant Pleural Mesothelioma (MPM)
NCT01868022 (23) [back to overview]	Change From Baseline in Forced Vital Capacity (FVC) in of Arm C Participants With Malignant Pleural Mesothelioma (MPM)
NCT01868022 (23) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)
NCT01868022 (23) [back to overview]	Number of Participants With Abnormal Echocardiogram (ECHO) Findings
NCT01868022 (23) [back to overview]	Number of Participants With Hematology Change From Baseline With Respect to the Normal Range
NCT01868022 (23) [back to overview]	Number of Participants With Best Response
NCT01868022 (23) [back to overview]	Number of Participants With Clinical Chemistry Changes From Baseline With Respect to the Normal Range
NCT01868022 (23) [back to overview]	Number of Participants With Clinical Chemistry Changes From Baseline With Respect to the Normal Range
NCT01868022 (23) [back to overview]	Number of Participants With Clinical Chemistry Changes From Baseline With Respect to the Normal Range
NCT01907100 (4) [back to overview]	Disease Control According to Modified RECIST- Investigator Assessment
NCT01907100 (4) [back to overview]	Objective Response According to Modified RECIST- Investigator Assessment
NCT01907100 (4) [back to overview]	Overall Survival (OS)
NCT01907100 (4) [back to overview]	Progression-Free Survival (PFS)
NCT01918761 (4) [back to overview]	Overall Survival
NCT01918761 (4) [back to overview]	Progression-free Survival
NCT01918761 (4) [back to overview]	Dose Limiting Toxicities (DLTs)
NCT01918761 (4) [back to overview]	Overall Response Rate
NCT01982955 (44) [back to overview]	Phase 1b: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiograms (ECG) Findings
NCT01982955 (44) [back to overview]	Phase 1b: Number of Participants With Clinically Significant Abnormalities in Vital Signs
NCT01982955 (44) [back to overview]	Phase 1b: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2
NCT01982955 (44) [back to overview]	Phase 1b: Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]	Phase 1b: Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]	Phase 2 (Non-Randomized Part Only): Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]	Phase 2 (Non-Randomized Part Only): Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]	Phase 2 (Non-Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Independent Review Committee (IRC)
NCT01982955 (44) [back to overview]	Phase 2 (Non-Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Investigator
NCT01982955 (44) [back to overview]	Phase 2 (Randomized Part Only): Percentage of Participants With Disease Control Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]	Phase 2 (Randomized Part Only): Percentage of Participants With Objective Response Based on Tumor Response Assessment According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST v1.1) Criteria
NCT01982955 (44) [back to overview]	Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by Independent Review Committee (IRC)
NCT01982955 (44) [back to overview]	Phase 2 (Randomized Part Only): Progression-free Survival (PFS) Based on Tumor Assessment by the Investigator
NCT01982955 (44) [back to overview]	Phase 2: (Non-Randomized Part Only): Overall Survival (OS) Time
NCT01982955 (44) [back to overview]	Phase 2: (Randomized Part Only): Overall Survival (OS) Time
NCT01982955 (44) [back to overview]	Phase 2: Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status Scale Score at End of Treatment (EOT)
NCT01982955 (44) [back to overview]	Phase 2: Number of Participants With Clinically Significant Abnormalities in 12-Lead Electrocardiograms (ECG) Findings
NCT01982955 (44) [back to overview]	Phase 2: Number of Participants With Clinically Significant Abnormalities in Vital Signs
NCT01982955 (44) [back to overview]	Phase 2: Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status Score of 2 or Higher Than 2
NCT01982955 (44) [back to overview]	Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Permanent Treatment Discontinuation
NCT01982955 (44) [back to overview]	Phase 2: Time-to-Symptom Progression (TTSP)
NCT01982955 (44) [back to overview]	Phase 1b: Apparent Terminal Elimination Rate Constant Lambda(z) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Apparent Terminal Half-Life (t1/2) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Apparent Total Body Clearance From Plasma (CL/F) of Tepotinib and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Apparent Volume of Distribution (Vz/F) During the Terminal Phase of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Apparent Volume of Distribution During the Steady State (Vss/F) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Sampling Time AUC (0-t) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC 0-infinity) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Area Under the Plasma Concentration-Time Curve Within 1 Dosing Interval (AUC 0-tau) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Average Observed Plasma Concentration (Cavg) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Maximum Observed Plasma Concentration (Cmax) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Minimum Observed Plasma Concentration (Cmin) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 1b: Number of Participants With Death and Reasons
NCT01982955 (44) [back to overview]	Phase 1b: Number of Participants With Grade 3/4 Treatment-Emergent Adverse Events (TEAEs) and Grade 3/4 Treatment-Related TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version 4.03
NCT01982955 (44) [back to overview]	Phase 1b: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI-CTCAE Version 4.03 Reported as Treatment-Emergent Adverse Events (TEAEs)
NCT01982955 (44) [back to overview]	Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
NCT01982955 (44) [back to overview]	Phase 1b: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) Leading to Permanent Treatment Discontinuation
NCT01982955 (44) [back to overview]	Phase 1b: Number of Participants With Treatment-Related Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Serious TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03
NCT01982955 (44) [back to overview]	Phase 1b: Time to Reach Maximum Plasma Concentration (Tmax) of Tepotinib, Its Metabolites and Gefitinib
NCT01982955 (44) [back to overview]	Phase 2: Number of Participants With Death and Reasons
NCT01982955 (44) [back to overview]	Phase 2: Number of Participants With Greater Than or Equal to (>=) Grade 3 Treatment-Emergent Adverse Events (TEAEs) and >= Grade 3 Treatment-Related TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03
NCT01982955 (44) [back to overview]	Phase 2: Number of Participants With Laboratory Test Abnormalities of Grade 3 or Higher Severity Based on NCI-CTCAE Version 4.03 Reported as Treatment-Emergent Adverse Events (TEAEs)
NCT01982955 (44) [back to overview]	Phase 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Treatment-Related TEAEs and Treatment-Related Serious TEAEs According to National Cancer Institute Common Toxicity Criteria for Adverse Events Version 4.03
NCT01982955 (44) [back to overview]	Phase 1b: Number of Participants Experiencing at Least One Dose Limiting Toxicity (DLT)
NCT02039674 (6) [back to overview]	Part 2 Cohorts G+ and G-: Duration of Response (DOR)
NCT02039674 (6) [back to overview]	Part 2 Cohorts G+ and G-: Progression-Free Survival (PFS)
NCT02039674 (6) [back to overview]	Part 2 Cohorts G+ and G-: Overall Survival (OS)
NCT02039674 (6) [back to overview]	All Cohorts: Number of Participants Who Experienced a Dose-limiting Toxicity (DLT)
NCT02039674 (6) [back to overview]	Part 2 Cohorts D4 and H: Objective Response Rate (ORR)
NCT02039674 (6) [back to overview]	Part 2 Cohorts G+ and G-: Objective Response Rate (ORR)
NCT02041533 (6) [back to overview]	Disease-related Symptom Improvement Rate by Week 12
NCT02041533 (6) [back to overview]	Progression-Free Survival in Participants With PD-L1 Expression >= 5%
NCT02041533 (6) [back to overview]	Progression-Free Survival in All Randomized Participants
NCT02041533 (6) [back to overview]	Overall Survival in Participants With PD-L1 Expression >= 5%
NCT02041533 (6) [back to overview]	Overall Survival in All Randomized Participants
NCT02041533 (6) [back to overview]	Objective Response Rate (ORR) in Participants With PD-L1 Expression >= 5%
NCT02079636 (15) [back to overview]	Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib on Day 1 and at Steady State (Cycle 2 Day 1) in Part A , B, C, D and E
NCT02079636 (15) [back to overview]	Number of Participants With Dose-Limiting Toxicities (DLT) or DLT-equivalent in Part A, B, C, D and E
NCT02079636 (15) [back to overview]	Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) in Part A, B, C, D and E
NCT02079636 (15) [back to overview]	PK: Area Under the Concentration Curve (AUC) of Pemetrexed at Steady State in Part A
NCT02079636 (15) [back to overview]	Progression Free Survival Time in Part A, B, C, D and E
NCT02079636 (15) [back to overview]	PK: Maximum Concentration (Cmax) of Ramucirumab at 1 Hour Post-End-of-Infusion in Part C
NCT02079636 (15) [back to overview]	PK: Maximum Concentration (Cmax) of LY3023414 in Part D
NCT02079636 (15) [back to overview]	Change From Baseline in MD Anderson Symptom Inventory Scale-Lung Cancer (MDASI-LC) in Part A, B, C, D and E
NCT02079636 (15) [back to overview]	PK: Area Under the Concentration Curve (AUC) of LY3023414 in Part D
NCT02079636 (15) [back to overview]	PK: Dose-normalized Maximum Concentration (Cmax) of Active Gemcitabine Metabolite: 2',2'-Difluorodeoxyuridine (dFdU) on Day 1 and at Steady State (Cycle 2 Day 1) in Part B
NCT02079636 (15) [back to overview]	PK: Area Under the Concentration Curve (AUC) of Active Gemcitabine Metabolite: 2',2'-Difluorodeoxyuridine (dFdU) on Day 1 and at Steady State (Cycle 2 Day 1) in Part B
NCT02079636 (15) [back to overview]	PK: Area Under the Concentration Curve (AUC) of Abemaciclib in Part A, B, C, D and E
NCT02079636 (15) [back to overview]	Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib on Day 1 and at Steady State (Cycle 2 Day 1) in Part A , B, C, D and E
NCT02079636 (15) [back to overview]	PK: Area Under the Concentration Curve (AUC) of Abemaciclib in Part A, B, C, D and E
NCT02079636 (15) [back to overview]	Pharmacokinetics: Maximum Concentration (Cmax) of Pemetrexed at Steady State in Part A
NCT02083679 (2) [back to overview]	Number of Subjects With Dose Limiting Toxicities (DLTs)
NCT02083679 (2) [back to overview]	Number of Subjects With Treatment-emergent Adverse (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death
NCT02087241 (2) [back to overview]	Assess the Objective Response Rates in Each Arm
NCT02087241 (2) [back to overview]	Assess the Disease Control Rate in Each Treatment Arm
NCT02093962 (1) [back to overview]	Overall Survival
NCT02117024 (6) [back to overview]	Progression-Free Survival (PFS)
NCT02117024 (6) [back to overview]	Overall Survival (OS)
NCT02117024 (6) [back to overview]	Frequency of Adverse Events: Number of Participants With Treatment-Emergent Adverse Events (TEAE)
NCT02117024 (6) [back to overview]	Survival at 6 Months
NCT02117024 (6) [back to overview]	Survival at 12 Months
NCT02117024 (6) [back to overview]	Time to Progression (TTP)
NCT02119650 (5) [back to overview]	Progression-free Survival (PFS)
NCT02119650 (5) [back to overview]	Duration of Response
NCT02119650 (5) [back to overview]	Overall Survival (OS)
NCT02119650 (5) [back to overview]	Objective Response Rate (ORR)
NCT02119650 (5) [back to overview]	Participants With Treatment-emergent Adverse Events (TEAEs)
NCT02142738 (3) [back to overview]	Objective Response Rate (ORR)
NCT02142738 (3) [back to overview]	Overall Survival (OS) Rate
NCT02142738 (3) [back to overview]	Progression Free Survival (PFS) Rate at Month 6
NCT02145078 (2) [back to overview]	Overall Survival (OS)
NCT02145078 (2) [back to overview]	Progression-free Survival (PFS)
NCT02220894 (11) [back to overview]	Number of Participants Who Experienced At Least One Adverse Event (AE)
NCT02220894 (11) [back to overview]	Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1%
NCT02220894 (11) [back to overview]	Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20%
NCT02220894 (11) [back to overview]	Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50%
NCT02220894 (11) [back to overview]	Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20%
NCT02220894 (11) [back to overview]	Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50%
NCT02220894 (11) [back to overview]	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1%
NCT02220894 (11) [back to overview]	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20%
NCT02220894 (11) [back to overview]	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50%
NCT02220894 (11) [back to overview]	Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1%
NCT02220894 (11) [back to overview]	Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
NCT02264990 (6) [back to overview]	Progression Free Survival (PFS) in All Participants
NCT02264990 (6) [back to overview]	Overall Survival (OS) in the Lung Subtype Panel Positive Subgroup
NCT02264990 (6) [back to overview]	Overall Survival in All Participants
NCT02264990 (6) [back to overview]	Objective Response Rate (ORR) in the Lung Subtype Panel Positive Subgroup
NCT02264990 (6) [back to overview]	Objective Response Rate (ORR) in All Participants
NCT02264990 (6) [back to overview]	Progression Free Survival (PFS) in the Lung Subtype Panel Positive Subgroup
NCT02274038 (1) [back to overview]	Overall Survival
NCT02322281 (5) [back to overview]	Duration of Response (DOR) According to RECIST Version 1.1 as Determined by Investigator Assessment
NCT02322281 (5) [back to overview]	Overall Survival (OS)
NCT02322281 (5) [back to overview]	Percentage of Participants With Confirmed Response
NCT02322281 (5) [back to overview]	Progression Free Survival (PFS) According to RECIST Version 1.1 as Determined by Investigator Review (invPFS)
NCT02322281 (5) [back to overview]	Plasma PK for Patients Treated With Rociletinib Based on Sparse Sampling
NCT02337530 (1) [back to overview]	Progression Free Survival
NCT02347917 (11) [back to overview]	Overall Survival(OS)
NCT02347917 (11) [back to overview]	Phase 1 Part: Number of Participants With Dose-limiting Toxicities (DLTs)
NCT02347917 (11) [back to overview]	Phase 2 Part: Progression-free Survival (PFS)
NCT02347917 (11) [back to overview]	Phase 1 Part: Area Under the Concentration-time Curve
NCT02347917 (11) [back to overview]	Phase 1 Part: Maximum Observed Concentration (Cmax) and Minimum Observed Concentration (Cmin) of BBI608 When Administered With Pem and CDDP
NCT02347917 (11) [back to overview]	Phase 1 Part: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Drug Reactions (ADRs)
NCT02347917 (11) [back to overview]	Respiratory Function Tests (Forced Expiratory Volume in the First Second [FEV1])
NCT02347917 (11) [back to overview]	Respiratory Function Tests (Forced Expiratory Volume in the First Second [FEV1])
NCT02347917 (11) [back to overview]	Response Rate (RR) and Disease Control Rate (DCR)
NCT02347917 (11) [back to overview]	Respiratory Function Tests (Vital Capacity [VC] and Forced Vital Capacity [FVC])
NCT02347917 (11) [back to overview]	Respiratory Function Tests (Vital Capacity [VC] and Forced Vital Capacity [FVC])
NCT02357147 (1) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT02367781 (19) [back to overview]	Percentage of Participants With Adverse Events
NCT02367781 (19) [back to overview]	Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale
NCT02367781 (19) [back to overview]	Overall Survival (OS) in the ITT-WT Population
NCT02367781 (19) [back to overview]	OS as Determined by the Investigator Using Recist v1.1 in the ITT Population
NCT02367781 (19) [back to overview]	Plasma Concentrations of Nab-Paclitaxel Reported as Total Paclitaxel
NCT02367781 (19) [back to overview]	Plasma Concentrations of Carboplatin
NCT02367781 (19) [back to overview]	PFS as Determined by the Investigator Using Recist v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
NCT02367781 (19) [back to overview]	Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) to Atezolizumab
NCT02367781 (19) [back to overview]	Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT Population, PD-L1 Expression Population, and PD-L1 Expression WT Population
NCT02367781 (19) [back to overview]	OS as Determined by the Investigator Using RECIST v1.1 in the PD-L1 Expression Population and PD-L1 Expression WT Population
NCT02367781 (19) [back to overview]	Minimum Observed Serum Concentration (Cmin) of Atezolizumab Prior to Infusion in Atezolizumab+Carboplain+Nab-Paclitaxel
NCT02367781 (19) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Atezolizumab for Patients in Atezolizumab+Carboplatin+Nab-Paclitaxel Arm
NCT02367781 (19) [back to overview]	Time to Deterioration (TTD) in Patient-Reported Lung Cancer Symptoms in the ITT-WT Population
NCT02367781 (19) [back to overview]	Event Free Rate (%) at Year 1 and 2 in PD-L1 Expression Population and PD-L1 Expression WT Population
NCT02367781 (19) [back to overview]	Event Free Rate (%) at Year 1 and 2 in ITT-WT Population and ITT Population
NCT02367781 (19) [back to overview]	Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1 in ITT-WT Population, ITT Population, and PD-L1 Expression Population and PD-L1 Expression WT Population
NCT02367781 (19) [back to overview]	Change From Baseline in Patient-Reported Lung Cancer Symptoms Score Using the Symptoms in Lung Cancer (SILC) Scale
NCT02367781 (19) [back to overview]	Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population
NCT02367781 (19) [back to overview]	Percentage of Participants With an Objective Response (OR) (Complete Response [CR] or Partial Response [PR]) as Determined by the Investigator Using RECIST v1.1 in the ITT-WT Population
NCT02409342 (24) [back to overview]	Duration of Response (DOR) in the TC3 or IC3-WT Populations
NCT02409342 (24) [back to overview]	TTD as Assessed Using EORTC QLQ Supplementary Lung Cancer Module (EORTC QLQ-LC13) in the TC3 or IC3-WT Populations
NCT02409342 (24) [back to overview]	Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations
NCT02409342 (24) [back to overview]	Time to Deterioration (TTD) in Patient-reported Lung Cancer Symptoms Score as Assessed by the Symptoms in Lung Cancer (SILC) Scale Symptom Score in the TC3 or IC3-WT Populations
NCT02409342 (24) [back to overview]	Overall Survival (OS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
NCT02409342 (24) [back to overview]	Percentage of Participants Who Are Alive at 1 Year in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
NCT02409342 (24) [back to overview]	Percentage of Participants Who Are Alive at 2 Years in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
NCT02409342 (24) [back to overview]	Percentage of Participants With Anti-therapeutic Antibodies (ATAs)
NCT02409342 (24) [back to overview]	Change From Baseline in Patient-reported Lung Cancer Symptoms Score as Assessed by the SILC Scale Symptom Score in the TC3 or IC3-WT Populations
NCT02409342 (24) [back to overview]	Progression-free Survival (PFS) in the TC3 or IC3-WT Populations
NCT02409342 (24) [back to overview]	Percentage of Participants With Objective Response (ORR) in the TC3 or IC3-WT Populations
NCT02409342 (24) [back to overview]	Percentage of Participants With at Least One Adverse Event
NCT02409342 (24) [back to overview]	Percentage of Participants Who Are Alive at 2 Years in the TC3 or IC3-WT Populations
NCT02409342 (24) [back to overview]	Percentage of Participants Who Are Alive at 1 Year in the TC3 or IC3-WT Populations
NCT02409342 (24) [back to overview]	Progression-free Survival (PFS) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
NCT02409342 (24) [back to overview]	OS in Participants With PD-L1 Expression
NCT02409342 (24) [back to overview]	Minimum Observed Serum Concentration (Cmin) of Atezolizumab
NCT02409342 (24) [back to overview]	Investigator-Assessed PFS in Participants With PD-L1 Expression According to RECIST v1.1
NCT02409342 (24) [back to overview]	Investigator-Assessed PFS in Participants With bTMB According to RECIST v1.1
NCT02409342 (24) [back to overview]	OS in Participants With Blood Tumor Mutational Burden (bTMB)
NCT02409342 (24) [back to overview]	Overall Survival (OS) in the TC3 or IC3-WT Populations
NCT02409342 (24) [back to overview]	Maximum Observed Serum Concentration (Cmax) of Atezolizumab
NCT02409342 (24) [back to overview]	Percentage of Participants With Objective Response (ORR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
NCT02409342 (24) [back to overview]	Duration of Response (DOR) in the TC2/3 or IC2/3-WT and TC1/2/3 or IC1/2/3-WT Populations
NCT02426658 (5) [back to overview]	Overall Survival
NCT02426658 (5) [back to overview]	Time to Tumor Progression
NCT02426658 (5) [back to overview]	Change in Quality of Life (QOL), Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung Cancer 13-item (LC13)
NCT02426658 (5) [back to overview]	Incidence of Hematologic Toxicity, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
NCT02426658 (5) [back to overview]	Response Rate
NCT02439450 (1) [back to overview]	Phase 1b: Frequency of Treatment Emergent Adverse Events (TEAEs) as Assessed by CTCAE v4.03.
NCT02453282 (29) [back to overview]	DoR; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	DoR; FAS Population
NCT02453282 (29) [back to overview]	Ctrough_ss of Tremelimumab
NCT02453282 (29) [back to overview]	Cmax_ss of Tremelimumab
NCT02453282 (29) [back to overview]	PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy
NCT02453282 (29) [back to overview]	Serum Concentrations of Tremelimumab
NCT02453282 (29) [back to overview]	Serum Concentrations of Durvalumab
NCT02453282 (29) [back to overview]	Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
NCT02453282 (29) [back to overview]	Number of Participants With ADA Response to Tremelimumab
NCT02453282 (29) [back to overview]	Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months
NCT02453282 (29) [back to overview]	Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab
NCT02453282 (29) [back to overview]	Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population
NCT02453282 (29) [back to overview]	Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy
NCT02453282 (29) [back to overview]	PFS2; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	PFS2; FAS Population
NCT02453282 (29) [back to overview]	PFS; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	PFS; FAS Population
NCT02453282 (29) [back to overview]	Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	Percentage of Participants APF12; FAS Population
NCT02453282 (29) [back to overview]	Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population
NCT02453282 (29) [back to overview]	Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy
NCT02453282 (29) [back to overview]	OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy
NCT02453282 (29) [back to overview]	OS; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	OS; FAS Population
NCT02453282 (29) [back to overview]	ORR; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	ORR; FAS Population
NCT02453282 (29) [back to overview]	Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population
NCT02453282 (29) [back to overview]	Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab
NCT02453282 (29) [back to overview]	Duration of Response (DoR); PD-L1 (TC >=25%) Analysis Set Population
NCT02542293 (20) [back to overview]	Duration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	DoR; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
NCT02542293 (20) [back to overview]	APF12; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
NCT02542293 (20) [back to overview]	Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set
NCT02542293 (20) [back to overview]	Serum Concentrations of Durvalumab
NCT02542293 (20) [back to overview]	Time From Randomization to Second Progression or Death (PFS2); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	Serum Concentrations of Tremelimumab
NCT02542293 (20) [back to overview]	Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set
NCT02542293 (20) [back to overview]	Number of Participants With ADA Response to Tremelimumab
NCT02542293 (20) [back to overview]	Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
NCT02542293 (20) [back to overview]	ORR; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets
NCT02542293 (20) [back to overview]	OS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
NCT02542293 (20) [back to overview]	OS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	OS; Global and China Cohorts: FAS, PD-L1 Tumor Cell (TC) ≥25%, and PD-L1 TC ≥50% Analysis Sets
NCT02542293 (20) [back to overview]	OS; Global Cohort: bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, PD-L1-Negative NSCLC, bTMB <20 Mut/Mb, bTMB Non-Evaluable Population, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	Alive and Progression-Free at 12 Months (APF12); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	PFS; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets
NCT02542293 (20) [back to overview]	Progression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	PFS2; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
NCT02574078 (7) [back to overview]	Percentage of Participants With Treatment-related Adverse Events (AEs) Leading to Both Study Drugs Discontinuation, Group E Only
NCT02574078 (7) [back to overview]	Overall Survival (OS), Groups A-C Only
NCT02574078 (7) [back to overview]	Overall Survival (OS), Group D Only
NCT02574078 (7) [back to overview]	Objective Response Rate (ORR), Groups A-E
NCT02574078 (7) [back to overview]	Duration of Response (DOR), Groups A-D Only
NCT02574078 (7) [back to overview]	Progression-Free Survival (PFS), Group E Only
NCT02574078 (7) [back to overview]	Progression-Free Survival (PFS), Groups A-D Only
NCT02576574 (32) [back to overview]	Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)
NCT02576574 (32) [back to overview]	Overall Survival (OS) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)
NCT02576574 (32) [back to overview]	Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)
NCT02576574 (32) [back to overview]	Overall Survival (OS) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)
NCT02576574 (32) [back to overview]	Overall Survival (OS) in Full Analysis Set (FAS)
NCT02576574 (32) [back to overview]	Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)
NCT02576574 (32) [back to overview]	Duration of Response (DOR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)
NCT02576574 (32) [back to overview]	Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set
NCT02576574 (32) [back to overview]	Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set
NCT02576574 (32) [back to overview]	Number of Participants With At Least One Positive Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs) for Avelumab
NCT02576574 (32) [back to overview]	Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Heart Rate Increase/Decrease
NCT02576574 (32) [back to overview]	Overall Survival (OS) in Modified Full Analysis Set (mFAS)
NCT02576574 (32) [back to overview]	Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Body Temperature Increase
NCT02576574 (32) [back to overview]	Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance: Baseline Score Versus (Vs) Worst Post-baseline Score
NCT02576574 (32) [back to overview]	Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer 13 (EORTC QLQ-LC13) at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set
NCT02576574 (32) [back to overview]	Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Modified Full Analysis Set (mFAS)
NCT02576574 (32) [back to overview]	Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in Moderate and High Programmed Death Ligand 1 (PD-L1)+ Full Analysis Set (FAS)
NCT02576574 (32) [back to overview]	Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Modified Full Analysis Set (mFAS)
NCT02576574 (32) [back to overview]	Progression Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) Assessed by Independent Review Committee (IRC) in High Programmed Death Ligand 1 (PD-L1) + Full Analysis Set (FAS)
NCT02576574 (32) [back to overview]	Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Modified Full Analysis Set
NCT02576574 (32) [back to overview]	Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Systolic Blood Pressure Increase/Decrease and Maximal Diastolic Blood Pressure Increase/Decrease
NCT02576574 (32) [back to overview]	Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Weight Increase/Decrease
NCT02576574 (32) [back to overview]	Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in Moderate and High PD-L1+ Full Analysis Set
NCT02576574 (32) [back to overview]	Change From Baseline in European Quality Of Life 5-dimensions (EQ-5D-5L) Visual Analog Scale (VAS) in High PD-L1+ Health-related Quality of Life (HRQoL) Analysis Set at End of Treatment
NCT02576574 (32) [back to overview]	Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ Modified HRQoL Analysis Set
NCT02576574 (32) [back to overview]	Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life (EORTC QLQ-C30) Global Health Status at End of Treatment (EOT) in High Programmed Death Ligand 1 (PD-L1)+ HRQoL Analysis Set
NCT02576574 (32) [back to overview]	Number of Participants With Potentially Clinically Significant Abnormalities (PCSA) in Electrocardiogram (ECG) Parameters
NCT02576574 (32) [back to overview]	Number of Participants With Shift From Baseline to Greater Than or Equal to (>=) Grade 3 in Laboratory Parameter Values Based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03
NCT02576574 (32) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and AEs of Special Interest (AESIs)
NCT02576574 (32) [back to overview]	Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Modified Full Analysis Set
NCT02576574 (32) [back to overview]	Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Independent Review Committee (IRC) in High PD-L1+ Full Analysis Set
NCT02576574 (32) [back to overview]	Number of Participants With Maximal On-Treatment Changes From Baseline in Vital Signs - Maximal Respiration Rate Increase/Decrease
NCT02578680 (6) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT02578680 (6) [back to overview]	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging
NCT02578680 (6) [back to overview]	Number of Participants Who Discontinued Any Study Drug Due to an AE
NCT02578680 (6) [back to overview]	Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging
NCT02578680 (6) [back to overview]	Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging
NCT02578680 (6) [back to overview]	Overall Survival (OS)
NCT02591615 (3) [back to overview]	Overall Response Rate (ORR) Per RECIST 1.1
NCT02591615 (3) [back to overview]	Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability)
NCT02591615 (3) [back to overview]	Compare Progression-Free Survival (PFS) Per RECIST 1.1
NCT02604342 (27) [back to overview]	Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC30 Score for ITT Population
NCT02604342 (27) [back to overview]	Plasma Concentration of Alectinib
NCT02604342 (27) [back to overview]	Duration of Response for Lesions in the CNS (C-DOR) Using RECIST Version 1.1 as Assessed by IRC
NCT02604342 (27) [back to overview]	Overall Survival (OS)
NCT02604342 (27) [back to overview]	Percentage of Participants With Adverse Events (AEs)
NCT02604342 (27) [back to overview]	Percentage of Participants With CNS Objective Response Rate (ORR) With Measurable CNS Metastases at Baseline Using RECIST Version 1.1 as Assessed By IRC
NCT02604342 (27) [back to overview]	Percentage of Participants With Disease Control in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC
NCT02604342 (27) [back to overview]	Percentage of Participants With ORR in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC
NCT02604342 (27) [back to overview]	PFS Using RECIST Version 1.1 as Assessed by IRC
NCT02604342 (27) [back to overview]	Plasma Concentration of Alectinib Metabolite
NCT02604342 (27) [back to overview]	Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator
NCT02604342 (27) [back to overview]	Time to CNS Progression in C-ITT Population Using RECIST Version 1.1 as Assessed by IRC
NCT02604342 (27) [back to overview]	TTD in Composite of Three Symptoms (Cough, Dyspnea, and Chest Pain) Using EORTC QLQ-LC13 Score for C-ITT Population
NCT02604342 (27) [back to overview]	TTD in Composite of Three Symptoms (Cough, Dyspnea, and Chest Pain) Using EORTC QLQ-LC13 Score for ITT Population
NCT02604342 (27) [back to overview]	Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Over Time
NCT02604342 (27) [back to overview]	Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (EORTC QLQ-C30) Over Time
NCT02604342 (27) [back to overview]	Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer-13 (EORTC QLQ-LC13) Over Time
NCT02604342 (27) [back to overview]	Compliance of European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Lung Cancer-13 (EORTC QLQ-LC13) Over Time
NCT02604342 (27) [back to overview]	Compliance of European Quality of Life (EuroQoL) 5 Dimension 5 Levels (EQ-5D-5L) Questionnaire Over Time
NCT02604342 (27) [back to overview]	Compliance of European Quality of Life (EuroQoL) 5 Dimension 5 Levels (EQ-5D-5L) Questionnaire Over Time
NCT02604342 (27) [back to overview]	Duration of Response (DOR) Using RECIST Version 1.1 as Assessed by Investigator and IRC
NCT02604342 (27) [back to overview]	Percentage of Participants With Disease Control Using RECIST Version 1.1 as Assessed by Investigator and IRC
NCT02604342 (27) [back to overview]	Percentage of Participants With Objective Response of CR or PR Using RECIST Version 1.1 as Assessed by Investigator and IRC
NCT02604342 (27) [back to overview]	PFS in C-ITT Population Using RECIST Version 1.1 as Assessed by Investigator and IRC
NCT02604342 (27) [back to overview]	Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC13 Score for C-ITT Population
NCT02604342 (27) [back to overview]	Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC13 Score for ITT Population
NCT02604342 (27) [back to overview]	Time to Deterioration (TTD) in Lung Cancer Symptoms Using EORTC QLQ-LC30 Score for C-ITT Population
NCT02624700 (3) [back to overview]	The 2-year Survival Rate After Initial Study Treatment.
NCT02624700 (3) [back to overview]	Number of Participants at Risk and Affected by Adverse Events (AEs)
NCT02624700 (3) [back to overview]	The Duration of Progression-free Survival (PFS).
NCT02625298 (2) [back to overview]	Changes Between Initial and Post Treatment Dimensions of Periapical Lesions
NCT02625298 (2) [back to overview]	Presence of Clinical Symptoms
NCT02657434 (18) [back to overview]	Percentage of Participants With Anti-Therapeutic Antibodies (ATAs) of Atezolizumab
NCT02657434 (18) [back to overview]	Percentage of Participants With an Objective Response (Complete Response [CR] or Partial Response [PR]) Assessed by the Investigator Using RECIST V1.1
NCT02657434 (18) [back to overview]	Minimum Observed Serum Atezolizumab Concentration (Cmin)
NCT02657434 (18) [back to overview]	Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score
NCT02657434 (18) [back to overview]	Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score
NCT02657434 (18) [back to overview]	Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by European Organization for the Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Symptom Score
NCT02657434 (18) [back to overview]	Duration of Response (DOR) as Determined by the Investigator Using RECIST v1.1
NCT02657434 (18) [back to overview]	Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score
NCT02657434 (18) [back to overview]	Maximum Observed Serum Atezolizumab Concentration (Cmax)
NCT02657434 (18) [back to overview]	Overall Survival (OS)
NCT02657434 (18) [back to overview]	Overall Survival Rate at Year 1
NCT02657434 (18) [back to overview]	Overall Survival Rate Year 2
NCT02657434 (18) [back to overview]	Progression Free Survival (PFS) as Assessed by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
NCT02657434 (18) [back to overview]	Change From Baseline in Patient-Reported Lung Cancer Symptoms as Assessed by EORTC Quality-of-Life Lung Cancer Module (QLQ-LC13) Symptom Score
NCT02657434 (18) [back to overview]	Plasma Concentrations for Pemetrexed in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
NCT02657434 (18) [back to overview]	Change From Baseline in Patient-Reported Lung Cancer Symptoms as Reported Using the Symptoms in Lung Cancer (SILC) Scale Score
NCT02657434 (18) [back to overview]	Plasma Concentrations for Cisplatin in Arm A (Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
NCT02657434 (18) [back to overview]	Plasma Concentrations for Carboplatin in Arm A(Atezolizumab + Carboplatin or Cisplatin + Pemetrexed)
NCT02659059 (17) [back to overview]	Number of Participants With Laboratory Abnormalities in Hepatic Tests - Part 2
NCT02659059 (17) [back to overview]	Progression Free Survival (PFS) - Part 1
NCT02659059 (17) [back to overview]	Overall Survival (OS) - Part 2
NCT02659059 (17) [back to overview]	Overall Survival (OS) - Part 1
NCT02659059 (17) [back to overview]	Objective Response Rate (ORR) - Part 2
NCT02659059 (17) [back to overview]	Objective Response Rate (ORR) - Part 1
NCT02659059 (17) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLTs) - Part 2
NCT02659059 (17) [back to overview]	Number of Participants With Adverse Events (AEs) - Part 2
NCT02659059 (17) [back to overview]	Progression Free Survival (PFS) by Tumor Mutation Burden (TMB) Levels - Part 1
NCT02659059 (17) [back to overview]	Progression Free Survival (PFS) - Part 2
NCT02659059 (17) [back to overview]	Progression Free Survival (PFS) by PD-L1 Expression Levels - Part 1
NCT02659059 (17) [back to overview]	Overall Survival (OS) by Tumor Mutation Burden (TMB) Levels - Part 1
NCT02659059 (17) [back to overview]	Overall Survival (OS) by PD-L1 Expression Levels - Part 1
NCT02659059 (17) [back to overview]	Objective Response Rate (ORR) by Tumor Mutation Burden (TMB) Levels - Part 1
NCT02659059 (17) [back to overview]	Objective Response Rate (ORR) by PD-L1 Positive and Negative Levels - Part 1
NCT02659059 (17) [back to overview]	Objective Response Rate (ORR) by PD-L1 Expression Levels-Part 1
NCT02659059 (17) [back to overview]	Number of Participants With Laboratory Abnormalities in Thyroid Tests - Part 2
NCT02709512 (4) [back to overview]	Overall Survival
NCT02709512 (4) [back to overview]	Overall Survival Phase 3 Interim Analysis
NCT02709512 (4) [back to overview]	Progression Free Survival
NCT02709512 (4) [back to overview]	Response Rate
NCT02710396 (4) [back to overview]	Number of Subjects With NSCLC Who Achieved DCB
NCT02710396 (4) [back to overview]	Objective Response Rate (ORR)
NCT02710396 (4) [back to overview]	Progression Free Survival (PFS)
NCT02710396 (4) [back to overview]	Overall Survival (OS)
NCT02862457 (17) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab in Part B Cycles 1, 2, 4, 6, and 8
NCT02862457 (17) [back to overview]	Maximum Concentration (Cmax) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Maximum Concentration (Cmax) of Pembrolizumab in Part B Cycle 1
NCT02862457 (17) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab in Part A Cycles 1, 2, 4, 6, and 8
NCT02862457 (17) [back to overview]	Trough Concentration (Ctrough) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Trough Concentration (Ctrough) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Time to Maximum Concentration (Tmax) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Maximum Concentration (Cmax) of Pembrolizumab in Part A Cycle 1
NCT02862457 (17) [back to overview]	Time to Maximum Concentration (Tmax) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Terminal Half-Life (t1/2) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Terminal Half-Life (t1/2) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Maximum Concentration (Cmax) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Area Under the Concentration-Time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Number of Participants Who Experienced At Least One Adverse Event (AE)
NCT02862457 (17) [back to overview]	Number of Participants Who Discontinued Study Treatment Due to An Adverse Event (AE)
NCT02862457 (17) [back to overview]	Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0)
NCT02862457 (17) [back to overview]	Area Under the Concentration-Time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) of Epacadostat in Part A
NCT02864251 (6) [back to overview]	Overall Survival (OS)
NCT02864251 (6) [back to overview]	Objective Response Rate (ORR) by Blinded Independent Centralized Review (BICR)
NCT02864251 (6) [back to overview]	Duration of Response (DOR) by Blinded Independent Centralized Review (BICR)
NCT02864251 (6) [back to overview]	12 Month Progression Free Survival Rates (PFSR) by Blinded Independent Centralized Review (BICR)
NCT02864251 (6) [back to overview]	9 Month Progression Free Survival Rates (PFSR) by Blinded Independent Centralized Review (BICR)
NCT02864251 (6) [back to overview]	Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR)
NCT02899299 (7) [back to overview]	Progression Free Survival (PFS)
NCT02899299 (7) [back to overview]	Objective Response Rate (ORR) According to PD-L1 Expression Level
NCT02899299 (7) [back to overview]	Disease Control Rate (DCR)
NCT02899299 (7) [back to overview]	Objective Response Rate (ORR)
NCT02899299 (7) [back to overview]	Overall Survival (OS)
NCT02899299 (7) [back to overview]	Progression Free Survival (PFS) According to PD-L1 Expression Level
NCT02899299 (7) [back to overview]	Overall Survival (OS) According to PD-L1 Expression Level
NCT02937116 (13) [back to overview]	Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)
NCT02937116 (13) [back to overview]	The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration
NCT02937116 (13) [back to overview]	Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants
NCT02937116 (13) [back to overview]	Clearance of IBI308 in Plasma After Single Dose Administration
NCT02937116 (13) [back to overview]	DOR According to RECIST 1.1 as Assessed by Investigator
NCT02937116 (13) [back to overview]	Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants
NCT02937116 (13) [back to overview]	TTR According to RECIST 1.1 as Assessed by Investigator
NCT02937116 (13) [back to overview]	Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
NCT02937116 (13) [back to overview]	Volume of Distribution of IBI308 in Plasma After Single Dose Administration
NCT02937116 (13) [back to overview]	PFS According to RECIST 1.1 as Assessed by Investigator
NCT02937116 (13) [back to overview]	OS for Participants
NCT02937116 (13) [back to overview]	Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator
NCT02937116 (13) [back to overview]	Number of All Study Participants Who Demonstrate a Tumor Response
NCT02983045 (3) [back to overview]	Part 3 Schedule Finding: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window
NCT02983045 (3) [back to overview]	Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D)
NCT02983045 (3) [back to overview]	Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window
NCT02998528 (4) [back to overview]	Major Pathologic Response (MPR) Rate
NCT02998528 (4) [back to overview]	Event-Free Survival (EFS)
NCT02998528 (4) [back to overview]	Time to Death or Distant Metastases (TTDM)
NCT02998528 (4) [back to overview]	Pathologic Complete Response (pCR) Rate
NCT03003962 (44) [back to overview]	OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	Alive and Progression-Free at 12 Months (APF12)
NCT03003962 (44) [back to overview]	DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set
NCT03003962 (44) [back to overview]	DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set
NCT03003962 (44) [back to overview]	DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set
NCT03003962 (44) [back to overview]	APF12 in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	APF12 in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	APF12 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Time to Deterioration of EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Time to Deterioration of EORTC QLQ-LC13
NCT03003962 (44) [back to overview]	Time to Deterioration of EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Time to Deterioration of EORTC QLQ-C30
NCT03003962 (44) [back to overview]	Percentage of Participants With Antidrug Antibody (ADA) Response to Durvalumab
NCT03003962 (44) [back to overview]	Percentage of Participants With ADA Response to Durvalumab in LREM Analysis Set
NCT03003962 (44) [back to overview]	Number of Participants With ECOG Performance Status in PD-L1 TC >=25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
NCT03003962 (44) [back to overview]	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire Version 3 (QLQ-C30)
NCT03003962 (44) [back to overview]	Change From Baseline in EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Change From Baseline in EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Change From Baseline in EORTC 13-Item Lung Cancer Quality of Life Questionnaire (QLQ-LC13)
NCT03003962 (44) [back to overview]	Time From Randomization to Second Progression (PFS2)
NCT03003962 (44) [back to overview]	Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
NCT03003962 (44) [back to overview]	Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment
NCT03003962 (44) [back to overview]	Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment
NCT03003962 (44) [back to overview]	ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	OS at 18 Months
NCT03003962 (44) [back to overview]	OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	OS at 18 Months in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	OS at 24 Months
NCT03003962 (44) [back to overview]	OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	OS at 24 Months in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	PFS2 in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	PFS2 in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	PFS2 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set
NCT03003962 (44) [back to overview]	Overall Survival (OS)
NCT03003962 (44) [back to overview]	OS in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	OS in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	OS in Participants With LREM
NCT03041181 (1) [back to overview]	Number of Participants With Grade 3 or Grade 4 Adverse Events
NCT03085914 (3) [back to overview]	Phases 1 and 2: Objective Response Rate (ORR)
NCT03085914 (3) [back to overview]	Phases 1 & 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
NCT03085914 (3) [back to overview]	Phases 1 and 2: Number of Participants With Dose Limiting Toxicities (DLTs)
NCT03138889 (4) [back to overview]	Objective Response Rate (ORR) Per Blinded Independent Central Review (BICR) by RECIST 1.1 of NKTR-214 Plus Pembrolizumab for Dose Expansion Cohorts 2 and 3.
NCT03138889 (4) [back to overview]	Objective Response Rate (ORR) Per Investigator's Assessment by RECIST 1.1 of NKTR-214 at a Dose of 0.006 mg/kg With Pembrolizumab and Platinum-based Chemotherapy for Dose Expansion Cohorts 4+5.
NCT03138889 (4) [back to overview]	Number of Participants Experiencing Dose-Limiting Toxicities in Dose Optimization Cohort 1a
NCT03138889 (4) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events [Safety and Tolerability] for Dose Optimization Cohort 1a.
NCT03164616 (13) [back to overview]	PK of Tremelimumab; Peak and Trough Serum Concentrations
NCT03164616 (13) [back to overview]	Pharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations
NCT03164616 (13) [back to overview]	Number of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab
NCT03164616 (13) [back to overview]	Number of Patients With ADA Response to Tremelimumab
NCT03164616 (13) [back to overview]	Time From Randomization to Second Progression (PFS2)
NCT03164616 (13) [back to overview]	Progression-Free Survival (PFS); D + SoC Compared With SoC Alone
NCT03164616 (13) [back to overview]	PFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC
NCT03164616 (13) [back to overview]	Overall Survival (OS); D + SoC Compared With SoC Alone
NCT03164616 (13) [back to overview]	OS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC
NCT03164616 (13) [back to overview]	Duration of Response (DoR)
NCT03164616 (13) [back to overview]	Time to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-Lung Cancer Module 13 (QLQ-LC13)
NCT03164616 (13) [back to overview]	Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)
NCT03164616 (13) [back to overview]	Objective Response Rate (ORR)
NCT03215706 (8) [back to overview]	Objective Response Rate (ORR) by BICR by PD-LI Tumor Cell Expression
NCT03215706 (8) [back to overview]	Duration of Response (DoR)
NCT03215706 (8) [back to overview]	Objective Response Rate (ORR) by BICR
NCT03215706 (8) [back to overview]	Overall Survival (OS)
NCT03215706 (8) [back to overview]	Progression Free Survival (PFS) by BICR
NCT03215706 (8) [back to overview]	Time to Response (TTR)
NCT03215706 (8) [back to overview]	OS by PD-L1 Tumor Cell Expression
NCT03215706 (8) [back to overview]	PFS by BICR by PD-L1 Tumor Cell Expression
NCT03256136 (5) [back to overview]	Duration Of Response
NCT03256136 (5) [back to overview]	Progression Free Survival (PFS)
NCT03256136 (5) [back to overview]	Disease Control Rate (DCR), Presented in Numbers of Participants
NCT03256136 (5) [back to overview]	Overall Survival (OS)
NCT03256136 (5) [back to overview]	Objective Response Rate (ORR), Presented in Numbers of Participants
NCT03307785 (158) [back to overview]	Part A: Area Under the Plasma Concentration From Time Zero to Infinity (AUC[0-infinity]) of Niraparib
NCT03307785 (158) [back to overview]	Part A: AUC at Steady State (AUCss) of Niraparib
NCT03307785 (158) [back to overview]	Part A: AUC(0-infinity) of TSR-042
NCT03307785 (158) [back to overview]	Part A: Cmax of TSR-042
NCT03307785 (158) [back to overview]	Part A: Ctau of TSR-042
NCT03307785 (158) [back to overview]	Part A: Disease Control Rate
NCT03307785 (158) [back to overview]	Part A: Duration of Response
NCT03307785 (158) [back to overview]	Part A: Maximum Observed Plasma (Cmax) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Number of Participants With Dose-limiting Toxicity (DLT)
NCT03307785 (158) [back to overview]	Part A: Number of Participants With Positive Anti-TSR-042 Antibodies
NCT03307785 (158) [back to overview]	Part A: Objective Response Rate
NCT03307785 (158) [back to overview]	Part A: Observed Concentration at the End of the Dosing Interval (Ctau) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Progression-free Survival
NCT03307785 (158) [back to overview]	Part A: Time to Reach Maximum Plasma Concentration (Tmax) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Tmax of TSR-042
NCT03307785 (158) [back to overview]	Part B: AUC(0-infinity) of TSR-042
NCT03307785 (158) [back to overview]	Part B: Cmax of TSR-042
NCT03307785 (158) [back to overview]	Part B: Ctau of TSR-042
NCT03307785 (158) [back to overview]	Part B: Disease Control Rate
NCT03307785 (158) [back to overview]	Part B: Number of Participants With DLT
NCT03307785 (158) [back to overview]	Part B: Number of Participants With Positive Anti-TSR-042 Antibodies
NCT03307785 (158) [back to overview]	Part B: Objective Response Rate
NCT03307785 (158) [back to overview]	Part F: Number of Participants With Non-serious TEAEs, STEAEs and AESIs
NCT03307785 (158) [back to overview]	Part E: Number of Participants With Non-serious TEAEs, STEAEs and AESIs
NCT03307785 (158) [back to overview]	Part D: Vz of TSR-042
NCT03307785 (158) [back to overview]	Part D: Vss of TSR-042
NCT03307785 (158) [back to overview]	Part D: Tmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part D: Number of Participants With Non-serious TEAEs, STEAEs and AESIs
NCT03307785 (158) [back to overview]	Part D: Cmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part D: CL of TSR-042
NCT03307785 (158) [back to overview]	Part D: AUCss of TSR-042
NCT03307785 (158) [back to overview]	Part D: AUC0-t of TSR-042
NCT03307785 (158) [back to overview]	Part C: Vz/F of Niraparib
NCT03307785 (158) [back to overview]	Part C: Vz of TSR-042
NCT03307785 (158) [back to overview]	Part C: Vss of TSR-042
NCT03307785 (158) [back to overview]	Part C: Tmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part C: Tmax,ss of Niraparib
NCT03307785 (158) [back to overview]	Part C: Number of Participants With Non-serious TEAEs, STEAEs and AESIs
NCT03307785 (158) [back to overview]	Part C: Ctau,ss of TSR-042
NCT03307785 (158) [back to overview]	Part C: Ctau,ss of Niraparib
NCT03307785 (158) [back to overview]	Part C: Cmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part C: Cmax,ss of Niraparib
NCT03307785 (158) [back to overview]	Part C: CL/F of Niraparib
NCT03307785 (158) [back to overview]	Part C: CL of TSR-042
NCT03307785 (158) [back to overview]	Part C: AUCss of TSR-042
NCT03307785 (158) [back to overview]	Part C: AUC0-t of TSR-042
NCT03307785 (158) [back to overview]	Part C: AUC0-t of Niraparib
NCT03307785 (158) [back to overview]	Part B: Vz of TSR-042
NCT03307785 (158) [back to overview]	Part B: Vss of TSR-042
NCT03307785 (158) [back to overview]	Part B: Tmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part B: Number of Participants With Non-serious TEAEs, STEAEs and AESIs
NCT03307785 (158) [back to overview]	Part B: Ctau,ss of TSR-042
NCT03307785 (158) [back to overview]	Part B: Cmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part B: CL of TSR-042
NCT03307785 (158) [back to overview]	Part B: AUCss of TSR-042
NCT03307785 (158) [back to overview]	Part B: AUC0-t of TSR-042
NCT03307785 (158) [back to overview]	Part A: Volume of Distribution After Oral Administration (Vz/F) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Volume of Distribution After Oral Administration (Vz/F) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Volume of Distribution After Intravenous Administration (Vz) of of TSR-042
NCT03307785 (158) [back to overview]	Part A: Volume of Distribution After Intravenous Administration (Vz) of of TSR-042
NCT03307785 (158) [back to overview]	Part C: Ctau of TSR-042
NCT03307785 (158) [back to overview]	Part C: Ctau of Niraparib
NCT03307785 (158) [back to overview]	Part C: Cmax of TSR-042
NCT03307785 (158) [back to overview]	Part C: Cmax of Niraparib
NCT03307785 (158) [back to overview]	Part F: AUC0-t of TSR-042
NCT03307785 (158) [back to overview]	Part F: AUCss of TSR-042
NCT03307785 (158) [back to overview]	Part F: CL of TSR-022
NCT03307785 (158) [back to overview]	Part F: CL of TSR-042
NCT03307785 (158) [back to overview]	Part F: Cmax of TSR-022
NCT03307785 (158) [back to overview]	Part F: Cmax of TSR-042
NCT03307785 (158) [back to overview]	Part F: Cmax,ss of TSR-022
NCT03307785 (158) [back to overview]	Part C: AUCss of Niraparib
NCT03307785 (158) [back to overview]	Part C: AUC(0-infinity) of TSR-042
NCT03307785 (158) [back to overview]	Part C: AUC(0-infinity) of Niraparib
NCT03307785 (158) [back to overview]	Part B: Tmax of TSR-042
NCT03307785 (158) [back to overview]	Part B: Progression-free Survival
NCT03307785 (158) [back to overview]	Part A: Tmax at Steady State (Tmax,ss) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Tmax at Steady State (Tmax,ss) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Tmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part A: Tmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part A: Volume of Distribution After Intravenous Administration (Vss) of of TSR-042
NCT03307785 (158) [back to overview]	Part A: Volume of Distribution After Intravenous Administration (Vss) of of TSR-042
NCT03307785 (158) [back to overview]	Part F: Cmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part F: Ctau of TSR-022
NCT03307785 (158) [back to overview]	Part F: Ctau of TSR-042
NCT03307785 (158) [back to overview]	Part F: Ctau,ss of TSR-022
NCT03307785 (158) [back to overview]	Part F: Ctau,ss of TSR-042
NCT03307785 (158) [back to overview]	Part F: AUCss of TSR-022
NCT03307785 (158) [back to overview]	Part F: Disease Control Rate
NCT03307785 (158) [back to overview]	Part F: Duration of Response
NCT03307785 (158) [back to overview]	Part F: Number of Participants With DLT
NCT03307785 (158) [back to overview]	Part F: Number of Participants With Positive Anti-TSR-022 Antibodies
NCT03307785 (158) [back to overview]	Part F: Number of Participants With Positive Anti-TSR-042 Antibodies
NCT03307785 (158) [back to overview]	Part F: Objective Response Rate
NCT03307785 (158) [back to overview]	Part F: AUC0-t of TSR-022
NCT03307785 (158) [back to overview]	Part F: AUC(0-infinity) of TSR-042
NCT03307785 (158) [back to overview]	Part F: AUC(0-infinity) of TSR-022
NCT03307785 (158) [back to overview]	Part E: Vz of TSR-042
NCT03307785 (158) [back to overview]	Part E: Vss of TSR-042
NCT03307785 (158) [back to overview]	Part E: Tmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part E: Tmax of TSR-042
NCT03307785 (158) [back to overview]	Part E: Progression-free Survival
NCT03307785 (158) [back to overview]	Part E: Objective Response Rate
NCT03307785 (158) [back to overview]	Part E: Number of Participants With Positive Anti-TSR-042 Antibodies
NCT03307785 (158) [back to overview]	Part E: Number of Participants With DLT
NCT03307785 (158) [back to overview]	Part E: Duration of Response
NCT03307785 (158) [back to overview]	Part E: Disease Control Rate
NCT03307785 (158) [back to overview]	Part E: Ctau,ss of TSR-042
NCT03307785 (158) [back to overview]	Part E: Ctau of TSR-042
NCT03307785 (158) [back to overview]	Part E: Cmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part E: Cmax of TSR-042
NCT03307785 (158) [back to overview]	Part E: CL of TSR-042
NCT03307785 (158) [back to overview]	Part E: AUCss of TSR-042
NCT03307785 (158) [back to overview]	Part E: AUC0-t of TSR-042
NCT03307785 (158) [back to overview]	Part E: AUC(0-infinity) of TSR-042
NCT03307785 (158) [back to overview]	Part D: Tmax of TSR-042
NCT03307785 (158) [back to overview]	Part F: Progression-free Survival
NCT03307785 (158) [back to overview]	Part F: Tmax of TSR-022
NCT03307785 (158) [back to overview]	Part F: Tmax of TSR-042
NCT03307785 (158) [back to overview]	Part F: Tmax,ss of TSR-022
NCT03307785 (158) [back to overview]	Part F: Tmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part F: Vss of TSR-022
NCT03307785 (158) [back to overview]	Part F: Vss of TSR-042
NCT03307785 (158) [back to overview]	Part F: Vz of TSR-022
NCT03307785 (158) [back to overview]	Part F: Vz of TSR-042
NCT03307785 (158) [back to overview]	Part A: Area Under the Plasma Concentration From Time Zero to t (AUC[0-t]) of Niraparib
NCT03307785 (158) [back to overview]	Part A: AUC(0-t) of TSR-042
NCT03307785 (158) [back to overview]	Part A: AUC(0-t) of TSR-042
NCT03307785 (158) [back to overview]	Part A: AUCss of TSR-042
NCT03307785 (158) [back to overview]	Part A: AUCss of TSR-042
NCT03307785 (158) [back to overview]	Part A: Clearance After Intravenous Administration (CL) of TSR-042
NCT03307785 (158) [back to overview]	Part A: Clearance After Intravenous Administration (CL) of TSR-042
NCT03307785 (158) [back to overview]	Part A: Clearance After Oral Administration (CL/F) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Clearance After Oral Administration (CL/F) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Cmax at Steady State (Cmax,ss) of Niraparib
NCT03307785 (158) [back to overview]	Part D: Progression-free Survival
NCT03307785 (158) [back to overview]	Part D: Objective Response Rate
NCT03307785 (158) [back to overview]	Part D: Number of Participants With Positive Anti-TSR-042 Antibodies
NCT03307785 (158) [back to overview]	Part D: Number of Participants With DLT
NCT03307785 (158) [back to overview]	Part D: Disease Control Rate
NCT03307785 (158) [back to overview]	Part D: Ctau of TSR-042
NCT03307785 (158) [back to overview]	Part D: Cmax of TSR-042
NCT03307785 (158) [back to overview]	Part D: AUC(0-infinity) of TSR-042
NCT03307785 (158) [back to overview]	Part C: Tmax of TSR-042
NCT03307785 (158) [back to overview]	Part A: Cmax at Steady State (Cmax,ss) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Cmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part A: Cmax,ss of TSR-042
NCT03307785 (158) [back to overview]	Part A: Ctau at Steady State (Ctau,ss) of Niraparib
NCT03307785 (158) [back to overview]	Part A: Ctau,ss of TSR-042
NCT03307785 (158) [back to overview]	Part A: Ctau,ss of TSR-042
NCT03307785 (158) [back to overview]	Part A: Number of Participants With Non-serious Treatment-emergent Adverse Events (TEAEs), Serious TEAEs (STEAEs) and Adverse Events of Special Interest (AESIs)
NCT03307785 (158) [back to overview]	Part D: Ctau,ss of TSR-042
NCT03307785 (158) [back to overview]	Part C: Tmax of Niraparib
NCT03307785 (158) [back to overview]	Part C: Progression-free Survival
NCT03307785 (158) [back to overview]	Part C: Objective Response Rate
NCT03307785 (158) [back to overview]	Part C: Number of Participants With Positive Anti-TSR-042 Antibodies
NCT03307785 (158) [back to overview]	Part C: Number of Participants With DLT
NCT03307785 (158) [back to overview]	Part C: Disease Control Rate
NCT03317496 (13) [back to overview]	Absolute Value of Tumor Mutational Burden (TMB) in Tumor Tissue
NCT03317496 (13) [back to overview]	Duration of Response (DOR) as Per RECIST v 1.1 by Investigator Assessment
NCT03317496 (13) [back to overview]	Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) v 4.03
NCT03317496 (13) [back to overview]	Number of Participants With Treatment Related TEAEs
NCT03317496 (13) [back to overview]	Overall Survival (OS)
NCT03317496 (13) [back to overview]	Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment
NCT03317496 (13) [back to overview]	Phase 1b Lead-in: Number of Participants With Dose-Limiting Toxicities (DLT)
NCT03317496 (13) [back to overview]	Progression Free Survival (PFS) as Per RECIST v 1.1 by Investigator Assessment
NCT03317496 (13) [back to overview]	Time-to-Tumor Response (TTR) as Per RECIST v 1.1 by Investigator Assessment
NCT03317496 (13) [back to overview]	Number of Participants With Grade 3 or Higher Laboratory Abnormalities by CTCAE Grade
NCT03317496 (13) [back to overview]	Number of Participants With Programmed Death-Ligand 1 (PD-L1) Expression
NCT03317496 (13) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
NCT03317496 (13) [back to overview]	Serum Concentration of Avelumab
NCT03607539 (6) [back to overview]	Time to Response (TTR) by IRRC Assessment
NCT03607539 (6) [back to overview]	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC)
NCT03607539 (6) [back to overview]	Duration of Response (DOR) by IRRC Assessment
NCT03607539 (6) [back to overview]	Overall Survival (OS)
NCT03607539 (6) [back to overview]	Objective Response Rate (ORR) by IRRC Assessment
NCT03607539 (6) [back to overview]	Disease Control Rate (DCR) by IRRC Assessment
NCT03631784 (4) [back to overview]	Number of Participants Who Discontinued From Study Treatment Due to an AE
NCT03631784 (4) [back to overview]	Percentage of Participants Who Developed Grade 3 or Higher Pneumonitis
NCT03631784 (4) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT03631784 (4) [back to overview]	Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
NCT03664024 (6) [back to overview]	Percentage of Participants Discontinuing Study Intervention Due to an AE.
NCT03664024 (6) [back to overview]	Percentage of Participants Who Experienced One or More Adverse Events (AEs)
NCT03664024 (6) [back to overview]	Overall Survival (OS)
NCT03664024 (6) [back to overview]	Objective Response Rate
NCT03664024 (6) [back to overview]	Progression Free Survival (PFS)
NCT03664024 (6) [back to overview]	Tumor Mutation Burden (TMB) in Cell-free Circulating Tumor Deoxyribonucleic Acid (ctDNA)
NCT03713944 (5) [back to overview]	Number of Participants With Adverse Events
NCT03713944 (5) [back to overview]	Disease Control Rate
NCT03713944 (5) [back to overview]	Overall Response Rate
NCT03713944 (5) [back to overview]	Overall Survival
NCT03713944 (5) [back to overview]	Progression Free Survival
NCT03737994 (12) [back to overview]	Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria
NCT03737994 (12) [back to overview]	Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria
NCT03737994 (12) [back to overview]	Overall Survival (OS)
NCT03737994 (12) [back to overview]	Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria
NCT03737994 (12) [back to overview]	Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria
NCT03737994 (12) [back to overview]	Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria
NCT03737994 (12) [back to overview]	Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria
NCT03737994 (12) [back to overview]	Duration of Overall Response, Per Investigator Assessment Using RECIST v1.1
NCT03737994 (12) [back to overview]	Duration of Overall Response, Per Investigator Assessment Using RECIST v1.1
NCT03737994 (12) [back to overview]	Number of Participants by Highest Grade Adverse Event Reported
NCT03737994 (12) [back to overview]	Overall Survival (OS)
NCT03737994 (12) [back to overview]	Overall Survival (OS)
NCT03775486 (11) [back to overview]	Progression-free Survival
NCT03775486 (11) [back to overview]	Time to Deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13
NCT03775486 (11) [back to overview]	Time to Deterioration in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30
NCT03775486 (11) [back to overview]	Progression-free Survival in Homologous Recombination Repair Related Gene Mutation (HRRm) Population
NCT03775486 (11) [back to overview]	Presence of Anti-drug Antibodies (ADAs) for Durvalumab
NCT03775486 (11) [back to overview]	Overall Survival
NCT03775486 (11) [back to overview]	Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13
NCT03775486 (11) [back to overview]	Duration of Response
NCT03775486 (11) [back to overview]	Concentration of Durvalumab
NCT03775486 (11) [back to overview]	Change From Baseline in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30
NCT03775486 (11) [back to overview]	Number of Participants With Treatment-Related Adverse Events
NCT03840915 (7) [back to overview]	Number of Participants With Positive Antidrug Antibodies (ADA)
NCT03840915 (7) [back to overview]	Number of Participants With Dose-Limiting Toxicities (DLTs)
NCT03840915 (7) [back to overview]	Duration of Response (DOR)
NCT03840915 (7) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs
NCT03840915 (7) [back to overview]	Percentage of Participants With Confirmed Objective Response According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by Investigator (IRC)
NCT03840915 (7) [back to overview]	Overall Survival (OS)
NCT03840915 (7) [back to overview]	Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1) Assessed by Investigator
NCT03850444 (11) [back to overview]	Number of Participants Who Discontinued Study Treatment Due to an Adverse Event (AE)
NCT03850444 (11) [back to overview]	Number of Participants Who Experienced At Least One Adverse Event (AE)
NCT03850444 (11) [back to overview]	Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1%
NCT03850444 (11) [back to overview]	Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20%
NCT03850444 (11) [back to overview]	Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50%
NCT03850444 (11) [back to overview]	Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥1%
NCT03850444 (11) [back to overview]	Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥20%
NCT03850444 (11) [back to overview]	Overall Survival (OS) in Participants With a Tumor Proportion Score (TPS) of ≥50%
NCT03850444 (11) [back to overview]	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥1%
NCT03850444 (11) [back to overview]	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥20%
NCT03850444 (11) [back to overview]	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR) in Participants With a Tumor Proportion Score (TPS) of ≥50%
NCT03950674 (7) [back to overview]	Overall Response Rate (ORR) Per RECIST 1.1 as Assessed by Blinded Central Imaging
NCT03950674 (7) [back to overview]	Duration of Response (DOR) Per RECIST 1.1 as Assessed by Blinded Central Imaging
NCT03950674 (7) [back to overview]	Number of Participants Who Experienced an Adverse Event (AE)
NCT03950674 (7) [back to overview]	Overall Survival (OS)
NCT03950674 (7) [back to overview]	Progression-Free Survival (PFS) as Assessed by Investigator Immune-related RECIST (irRECIST) Response Criteria
NCT03950674 (7) [back to overview]	Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Central Imaging
NCT03950674 (7) [back to overview]	Number of Participants Who Discontinued Any Study Drug Due to an AE
NCT03971474 (8) [back to overview]	Disease Control Rate (DCR)
NCT03971474 (8) [back to overview]	Duration of Response (DOR)
NCT03971474 (8) [back to overview]	Investigator Assessed-progression-free Survival (IA-PFS)
NCT03971474 (8) [back to overview]	Overall Survival (OS), Subgroup Analysis by Stratification Factors
NCT03971474 (8) [back to overview]	Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT03971474 (8) [back to overview]	Investigator-Assessed Progression-Free Survival (IA-PFS), Subgroup Analysis by Stratification Factors
NCT03971474 (8) [back to overview]	Response Rate (RR)
NCT03971474 (8) [back to overview]	Overall Survival (OS)
NCT04012619 (1) [back to overview]	the Maximum Tolerated Dose (MTD)
NCT04372927 (4) [back to overview]	Response Rate
NCT04372927 (4) [back to overview]	Frequency and Severity of Pneumonitis
NCT04372927 (4) [back to overview]	Frequency of Adverse Events
NCT04372927 (4) [back to overview]	Overall Survival (OS)
NCT04816214 (15) [back to overview]	Run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)
NCT04816214 (15) [back to overview]	Run-in Part: Maximum Plasma Concentration (Cmax) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)
NCT04816214 (15) [back to overview]	Run-in Part: Disease Control Rate (DCR) as Per Investigator Assessment
NCT04816214 (15) [back to overview]	Run-in Part: Duration of Response (DOR) as Per Investigator Assessment
NCT04816214 (15) [back to overview]	Run-in Part: Time to Response (TTR) as Per Investigator Assessment
NCT04816214 (15) [back to overview]	Run-in Part: Median Duration of Exposure to Each Study Drug
NCT04816214 (15) [back to overview]	Run-in Part: Number of Participants With at Least One Dose Interruption and Dose Reduction of Each Study Drug
NCT04816214 (15) [back to overview]	Run-in Part: Time to Maximum Plasma Concentration (Tmax) of Capmatinib
NCT04816214 (15) [back to overview]	Run-in Part: Time to Maximum Plasma Concentration (Tmax) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)
NCT04816214 (15) [back to overview]	Run-in Part: Maximum Plasma Concentration (Cmax) of Capmatinib
NCT04816214 (15) [back to overview]	Run-in Part: Progression-Free Survival (PFS) as Per Investigator Assessment
NCT04816214 (15) [back to overview]	Run-in Part: Dose Intensity of Each Study Drug
NCT04816214 (15) [back to overview]	Run-in Part: Overall Response Rate (ORR) as Per Investigator Assessment
NCT04816214 (15) [back to overview]	Run-in Part: Area Under the Curve to the Last Measurable Concentration (AUClast) of Osimertinib and Its Metabolites (AZ5104 and AZ7550)
NCT04816214 (15) [back to overview]	Run-in Part: Area Under the Curve to the Last Measurable Concentration (AUClast) of Capmatinib

Overall Tumor Response

Best overall (confirmed) response recorded from start of treatment until disease progression/recurrence, start of other anti-tumor therapy/intervention, or end of trial, whichever comes first. Response must be confirmed at least 6 weeks from previous scans. Best overall response assignment depends on both measurement and confirmation criteria. (NCT00063570)
Timeframe: Every 6 weeks from start of treatment until documented disease progression or for 6 months from last dose of study drug, whichever occurs first. After 6 months, clinical assessment every 12 weeks and radiologic test performed as clinically indicated

Intervention	participants (Number)
	Complete Response	Partial Response	Stable Disease	Progressive Disease	Unknown
21-Day Schedule	0	5	10	6	0
Bi-Weekly Schedule	2	8	26	14	2

Intervention	percentage of participants (Mean)
	1-Year Disease-Free Rate	2-Year Disease-Free Rate
Pemetrexed	61.40	33.24

Intervention	months (Median)
Cetuximab & Pemetrexed	4.17
Pemetrexed	6.93
Cetuximab & Docetaxel	5.36
Docetaxel	5.39

Intervention	participants (Number)
Cetuximab & Pemetrexed	179
Pemetrexed	143
Cetuximab + Docetaxel	112
Docetaxel	97

Intervention	percentage of participants (Number)
Cetuximab & Pemetrexed	17.1
Pemetrexed	22.9
Cetuximab & Docetaxel	17.3
Docetaxel	13.5

Intervention	months (Median)
Cetuximab & Pemetrexed	2.89
Pemetrexed	2.76
Cetuximab & Docetaxel	2.37
Docetaxel	1.54

Intervention	proportion of participants (Number)
Cetuximab & Pemetrexed	0.522
Pemetrexed	0.480
Cetuximab & Docetaxel	0.335
Docetaxel	0.253

Intervention	proportion of participants (Number)
Cetuximab & Pemetrexed	0.066
Pemetrexed	0.043
Cetuximab & Docetaxel	0.078
Docetaxel	0.066

Intervention	eligible, treated participants (Number)
	Partial Response	Stable Disease	Progression	Unevaluable
Pemetrexed/Carboplatin	3	7	5	1
Pemetrexed/Gemcitabine	0	6	5	2

Intervention	months (Median)
	Loss of appetite	Fatigue	Cough	Dyspnea	Hemoptysis	Pain	Symptomatic distress	Interference with activity level	Global quality of life
Pemetrexed and BSC	3.78	3.06	6.05	5.36	NA	6.11	4.21	6.51	5.75
Placebo and BSC	4.40	3.09	4.67	4.40	NA	4.63	3.78	3.98	3.71

Intervention	participants (Number)
	SAEs	Other Non-Serious AEs
Pemetrexed and BSC	83	386
Placebo and BSC	31	178

Intervention	units on a scale (Mean)
	Loss of appetite (n=403, 197)	Fatigue (n=403, 197)	Cough (n=402, 197)	Dyspnea (n=400, 196)	Pain (n=401, 197)	Hemoptysis (n=402, 196)	Symptom distress (n=401, 196)	Interference with activity level (n=400, 197)	Global quality of life (n=401, 195)	ASBI (n=392, 195)	Total LCSS (n=388, 193)
Pemetrexed and BSC	7.3	10.2	7.6	7.6	5.4	1.5	6.5	10.8	10.7	3.7	4.07
Placebo and BSC	10.6	10.4	6.7	5.4	4.3	2.1	8.2	9.3	10.5	3.8	4.04

Intervention	participants (Number)
	Anaemia - Grade 3	Anaemia - Grade 4	Leukopenia - Grade 3	Leukopenia - Grade 4	Neutropenia - Grade 3	Neutropenia - Grade 4	Constipation - Grade 3	Constipation - Grade 4	Nausea - Grade 3	Nausea - Grade 4	Asthenia - Grade 3	Asthenia - Grade 4	Fatigue - Grade 3	Fatigue - Grade 4	Cellulitis - Grade 3	Cellulitis - Grade 4	Dehydration - Grade 3	Dehydration - Grade 4	Hyperglycaemia - Grade 3	Hyperglycaemia - Grade 4	Dyspnoea - Grade 3	Dyspnoea - Grade 4	Pleural effusion - Grade 3	Pleural effusion - Grade 4
Pemetrexed	5	0	4	2	8	5	2	0	3	0	3	0	5	0	2	0	2	0	3	2	4	0	2	0

Intervention	Participants (Number)
Cohort A - Vorinostat BID + Pemetrexed + Cisplatin	4
Cohort B - Vorinostat QD + Pemetrexed + Cisplatin	1
Cohort C - Vorinostat BID + Pemetrexed	9
Cohort D - Vorinostat QD + Pemetrexed	10

Intervention	Participants (Number)
	Number (#) of DLT	# Participants treated at a dose level	# Participants treated at a dose level =MTD	# Participants treated at a dose level >MTD
Dose Level A.1	1	0	6	0
Dose Level A.2	3	0	0	7
Dose Level B.1	0	0	3	0
Dose Level B.2	2	0	0	6
Dose Level C.1	1	7	0	0
Dose Level C.2	0	4	0	0
Dose Level C.3	0	0	3	0
Dose Level D.1	1	0	9	0
Dose Level D.2	2	0	0	7

Intervention	participants (Number)
Pemetrexed Alone	2
Pemetrexed Plus Matuzumab 800 mg Per Week	8
Pemetrexed Plus Matuzumab 1600 mg Every 3 Weeks	1

Intervention	months (Median)
Pemetrexed Alone	7.9
Pemetrexed Plus Matuzumab 800 mg Per Week	12.4
Pemetrexed Plus Matuzumab 1600 mg Every 3 Weeks	5.9

Intervention	units on a scale (Mean)
	Baseline	Change at Cycle 2
Pemetrexed Alone	35.9	3.5
Pemetrexed Plus Matuzumab 1600 mg Every 3 Weeks	35.8	15.7
Pemetrexed Plus Matuzumab 800 mg Per Week	31.1	0.8

Intervention	months (Median)
Std Tx + Pemetrexed	21.2
Std Tx + Pemetrexed and Cetuximab	25.2

Intervention	months (Median)
Std Tx + Pemetrexed	12.6
Std Tx + Pemetrexed and Cetuximab	12.3

Intervention	participants (Number)
Pemetrexed Plus Doxorubicin, Followed by Docetaxel	64
Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel	63

pemetrexed

Description

Cross-References

Synonyms (90)

Research Excerpts

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (5)

Drug Classes (2)

Protein Targets (25)

Potency Measurements

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (90)

Molecular Functions (44)

Ceullar Components (24)

Bioassays (511)

Research

Studies (2,414)

Market Indicators

Research Demand Index: 84.76

Study Types

Clinical Trials (964)

Trial Overview

Trial Outcomes

Overall Tumor Response

Time to Treatment Failure

Time to Progressive Disease

Overall Survival

Duration of (Confirmed) Complete Response or Partial Response

Pathological Complete Response

Time to Progressive Disease

Overall Tumor Response

The 1 and 2 Year Disease-Free Survival Rate (Percentage)

Time to Treatment Failure

Overall Survival Time

Duration of Overall Response (OR)

Overall Survival (OS)

Number of Participants With Common Toxicity Criteria (CTC) Grade 3 or 4 Toxicities

Percentage of Participants With Symptomatic Response (Symptom Response Rates) Using the Lung Cancer Subscale (LCS) Scores of Functional Assessment of Cancer Therapy for Participants With Lung Cancer (FACT-L)

Progression Free Survival (PFS)

Proportion of Randomized Participants With Best Overall Response (OR) of Partial Response (PR), Complete Response (CR), or Stable Disease (SD)

Proportion of Randomized Participants With the Best Overall Response (OR) of Partial Response (PR) or Complete Response (CR) (Overall Response Rate [ORR])

Time to Symptomatic Progression

Overall Survival

Best Overall Response by RECIST Criteria (Version 1.0)

Progression-Free Survival

Time to Worsening of Symptoms (TWS)

Number of Participants With Adverse Events (AEs)

Maximum Improvement Over Baseline in Individual Symptom Scores and Quality of Life Using the LCSS

Time to Objective Progressive Disease (TPD)

Progression-Free Survival (PFS) Time

Percentage of Participants With a Complete Response (CR) or Partial Response (PR) (Objective Tumor Response Rate)

Overall Survival (OS) Time

Duration of Tumor Response

Overall Survival Time

Progression-Free Survival Time

Overall Tumor Response

Toxicity Profile: Adverse Events (Common Terminology Criteria for Adverse Events, Grade 3 and 4, Present in >5% of Participants)

Safety and Tolerability as Measured by the Number of Participants With Disease Progression

Maximum Tolerated Dose (MTD) Status as Determined by Number of Participants With Dose Limiting Toxicity (DLT) at Each Dose Level

Number of Participants With Objective Response Assessed by Independent Review Committee

Duration of Objective Response Assessed by Independent Review Committee

Overall Survival (OS)

Change From Baseline to Cycle 2 in Global Quality of Life (QoL), as Assessed Using Lung Cancer Symptom Scale (LCSS)

Progression-Free Survival (PFS)

Overall Survival

Number of Participants With Overall Tumor Response

Failure-free Survival

18 Month Survival

Number of Patients With Histologically Negative Axillary Lymph Node Status at Surgery

Disease-free Survival

Number of Participants With a Pathological Complete Response

Number of Participants With a Clinical Tumor Response After the Second Sequence of Chemotherapy

Number of Participants With a Clinical Tumor Response After the First Sequence of Chemotherapy

Pharmacokinetics - Maximum Observed Drug Concentration (Cmax)

Intervention	participants (Number)
	Pathological Complete Response	Tumor Cells Still Present	Not evaluable
Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel	24	89	6
Pemetrexed Plus Doxorubicin, Followed by Docetaxel	21	99	7

Intervention	participants (Number)
	Complete Tumor Response	Partial Tumor Response	Stable Disease	Progressive Disease	Unknown	Not Done
Cyclophosphamide Plus Doxorubicin, Followed by Docetaxel	21	60	24	1	10	3
Pemetrexed Plus Doxorubicin, Followed by Docetaxel	19	59	35	2	9	7

Intervention	Liters (Geometric Mean)
	Central Volume of Distribution (V1)	Peripheral Volume of Distribution (V2)
Pemetrexed 1800mg/m2	8.14	3.33
Pemetrexed 600mg/m2	7.46	3.58

Intervention	participants (Number)
	Complete Response (CR)	Partial Response (PR)	Stable Disease (SD)	Progressive Disease (PD)
Pemetrexed 1000 mg/m2	0	16	34	58
Pemetrexed 500 mg/m2	0	20	40	48

Intervention	units on a scale (Mean)
	Functional Baseline (n=107, n=107)	Functional Change from Baseline (n=58, n=60)	Physical Baseline (n=107, n=107)	Physical Change from Baseline (n=58, n=60)	Emotional Baseline (n=107, n=107)	Emotional Change from Baseline (n=58, n=60)	Sociality Baseline (n=107, n=107)	Sociality Change from Baseline (n=58, n=60)	Face Scale Baseline (n=107, n=107)	Face Scale Change from Baseline (n=58, n=60)
Pemetrexed 1000 mg/m2	75.0	-3.7	73.9	-3.5	62.1	0.3	46.1	1.6	59.3	-2.1
Pemetrexed 500 mg/m2	77.0	-1.5	78.9	-1.6	67.2	-1.7	45.9	1.6	59.3	-1.3

Intervention	units on a scale (Mean)
	Baseline (n=107, n=107)	Change from Baseline (n=58, n=60)
Pemetrexed 1000 mg/m2	69.6	0.4
Pemetrexed 500 mg/m2	71.5	3.0

Intervention	percentage of participatns (Number)
	>50% decline in PSA	Stable PSA	PSA progression
Pemetrexed 500mg/m^2	8	20	65

Intervention	percentage of participants (Number)
	Participants with PR with meas. dis. per RECIST	participants with SD maintained at 12 weeks
Pemetrexed 500mg/m^2	8	39

Intervention	participants (Number)
	A/A Genotype	A/G Genotype	G/G Genotype
Pemetrexed 500mg/m^2	6	22	18

Intervention	percentage of particpants (Number)
	Acne-like rash: Phase I - Any Grade	Acne-like rash: Phase I - Grade 3/4	Acne-like rash: Phase II - Any Grade	Acne-like rash: Phase II - Grade 3/4	ALT elevation: Phase I - Any Grade	ALT elevation: Phase I - Grade 3/4	ALT elevation: Phase II - Any Grade	ALT elevation: Phase II - Grade 3/4	Anemia: Phase I - Any Grade	Anemia: Phase I - Grade 3/4	Anemia: Phase II - Any Grade	Anemia: Phase II - Grade 3/4	Thrombocytopenia: Phase I - Any Grade	Thrombocytopenia: Phase I - Grade 3/4	Thrombocytopenia: Phase II - Any Grade	Thrombocytopenia: Phase II - Grade 3/4	Neutropenia: Phase I - Any Grade	Neutropenia: Phase I - Grade 3/4	Neutropenia: Phase II - Any Grade	Neutropenia: Phase II - Grade 3/4	Febrile Neutropenia: Phase I - Any Grade	Febrile Neutropenia: Phase I - Grade 3/4	Febrile Neutropenia: Phase II - Any Grade	Febrile Neutropenia: Phase II - Grade 3/4	Dizziness: Phase I - Any Grade	Dizziness: Phase I - Grade 3/4	Dizziness: Phase II - Any Grade	Dizziness: Phase II - Grade 3/4	Dyspnea: Phase I - Any Grade	Dyspnea: Phase I - Grade 3/4	Dyspnea: Phase II - Any Grade	Dyspnea: Phase II - Grade 3/4	Cough: Phase I - Any Grade	Cough: Phase I - Grade 3/4	Cough: Phase II - Any Grade	Cough: Phase II - Grade 3/4	Fatigue: Phase I - Any Grade	Fatigue: Phase I - Grade 3/4	Fatigue: Phase II - Any Grade	Fatigue: Phase II - Grade 3/4	Anorexia: Phase I - Any Grade	Anorexia: Phase I - Grade 3/4	Anorexia: Phase II - Any Grade	Anorexia: Phase II - Grade 3/4	Mucositis: Phase I - Any Grade	Mucositis: Phase I - Grade 3/4	Mucositis: Phase II - Any Grade	Mucositis: Phase II - Grade 3/4	Nausea: Phase I - Any Grade	Nausea: Phase I - Grade 3/4	Nausea: Phase II - Any Grade	Nausea: Phase II - Grade 3/4	Diarrhea: Phase I - Any Grade	Diarrhea: Phase I - Grade 3/4	Diarrhea: Phase II - Any Grade	Diarrhea: Phase II - Grade 3/4	Constipation: Phase I - Any Grade	Constipation: Phase I - Grade 3/4	Constipation: Phase II - Any Grade	Constipation: Phase II - Grade 3/4	Fever(no neutropenia): Phase I - Any Grade	Fever(no neutropenia): Phase I - Grade 3/4	Fever(no neutropenia): Phase II - Any Grade	Fever(no neutropenia): Phase II - Grade 3/4	Headache: Phase I - Any Grade	Headache: Phase I - Grade 3/4	Headache: Phase II - Any Grade	Headache: Phase II - Grade 3/4	Hypomagnesmia: Phase I - Any Grade	Hypomagnesmia: Phase I - Grade 3/4	Hypomagnesmia: Phase II - Any Grade	Hypomagnesmia: Phase II - Grade 3/4	Vomiting: Phase I - Any Grade	Vomiting: Phase I - Grade 3/4	Vomiting: Phase II - Any Grade	Vomiting: Phase II - Grade 3/4
Pemetrexed + Cetuximab	58.3	16.7	57	23.8	33.3	16.7	0	0	0	0	14.3	0	8.3	0	14.3	0	8.3	0	4.8	4.8	8.3	8.3	0	0	8.3	8.3	19	4.8	25	8.3	33.3	0	25	0	28.6	0	33.3	0	76	4.8	33.3	0	19	4.8	41.7	0	38	4.8	33.3	0	28.6	0	33.3	0	33.3	9.5	16.7	0	23.8	4.8	8.3	0	19	4.8	50	0	23.8	0	0	0	19	4.8	16.7	0	23.8	4.8